Mutational landscape and significance across 12 major c

Nature

502, 333-339

DOI: 10.1038/nature12634

Citation Report

#	Article	IF	Citations
1	Combs for molecules. Nature, 2013, 502, 307-308.	13.7	4
2	Comparisons across cancers. Nature, 2013, 502, 306-307.	13.7	10
3	A panoramic view of cancer. Nature Reviews Genetics, 2013, 14, 750-750.	7.7	2
4	Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. Nature Communications, 2013, 4, 2730.	5.8	104
5	Drugging cancer genomes. Nature Reviews Drug Discovery, 2013, 12, 889-890.	21.5	47
6	First FDA Authorization for Next-Generation Sequencer. New England Journal of Medicine, 2013, 369, 2369-2371.	13.9	178
7	A panoramic view of cancer. Nature Reviews Cancer, 2013, 13, 755-755.	12.8	0
8	Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications. Genome Medicine, 2013, 5, 101.	3.6	38
9	Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets. PLoS ONE, 2014, 9, e98293.	1.1	105
10	53BP1 Mediates the Fusion of Mammalian Telomeres Rendered Dysfunctional by DNA-PKcs Loss or Inhibition. PLoS ONE, 2014, 9, e108731.	1.1	7
12	Role of MTDH, FOXM1 and microRNAs in Drug Resistance in Hepatocellular Carcinoma. Diseases (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10	1.0	2
13	Toward a systematic understanding of cancers: a survey of the pan-cancer study. Frontiers in Genetics, 2014, 5, 194.	1.1	22
14	Mechanisms of Base Substitution Mutagenesis in Cancer Genomes. Genes, 2014, 5, 108-146.	1.0	49
15	Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism. Oncotarget, 2014, 5, 8879-8892.	0.8	90
16	Overview of the biochemical and genetic processes in malignant mesothelioma. Jornal Brasileiro De Pneumologia, 2014, 40, 429-442.	0.4	11
18	Clinical Interpretation and Implications of Whole Genome Sequencing. Journal of Next Generation Sequencing & Applications, 2014, 01, .	0.3	2
20	The role of mRNA splicing in prostate cancer. Asian Journal of Andrology, 2014, 16, 515.	0.8	21
21	Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells. Oncotarget, 2014, 5, 11365-11380.	0.8	37

#	Article	IF	Citations
23	Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases. Oncotarget, 2014, 5, 12440-12447.	0.8	64
24	Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis. Breast Cancer Research, 2014, 16, 501.	2.2	27
25	The translational significance of epithelialâ€•mesenchymal transition in head and neck cancer. Clinical and Translational Medicine, 2014, 3, 60.	1.7	18
26	Time to individualize treatment for adrenocortical cancer?. Nature Reviews Endocrinology, 2014, 10, 76-78.	4.3	10
27	Novel prediction of anticancer drug chemosensitivity in cancer cell lines: Evidence of moderation by microRNA expressions. , 2014, 2014, 4780-6.		9
28	HotSpotter: efficient visualization of driver mutations. BMC Genomics, 2014, 15, 1044.	1.2	8
29	A PTCH1 Homolog Transcriptionally Activated by p53 Suppresses Hedgehog Signaling. Journal of Biological Chemistry, 2014, 289, 33020-33031.	1.6	29
30	The Genome of the Chicken DT40 Bursal Lymphoma Cell Line. G3: Genes, Genomes, Genetics, 2014, 4, 2231-2240.	0.8	25
31	Overview of Genetically Engineered Mouse Models of Colorectal Carcinoma to Enable Translational Biology and Drug Development. Current Protocols in Pharmacology, 2014, 65, 14.29.1-10.	4.0	2
32	Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor. Cancer Cell International, 2014, 14, 115.	1.8	38
33	Biobank Bootstrapping: Is Biobank Sustainability Possible Through Cost Recovery?. Biopreservation and Biobanking, 2014, 12, 374-380.	0.5	40
34	Clinical update on cancer: molecular oncology of head and neck cancer. Cell Death and Disease, 2014, 5, e1018-e1018.	2.7	160
35	ASXL1 and DNMT3A mutation in a cytogenetically normal B3 thymoma. Oncogenesis, 2014, 3, e111-e111.	2.1	13
36	TALEN-mediated genetic tailoring as a tool to analyze the function of acquired mutations in multiple myeloma cells. Blood Cancer Journal, 2014, 4, e210-e210.	2.8	14
37	A combinatorial approach for analyzing intra-tumor heterogeneity from high-throughput sequencing data. Bioinformatics, 2014, 30, i78-i86.	1.8	100
38	Proteomic signatures associated with p53 mutational status in lung adenocarcinoma. Proteomics, 2014, 14, 2750-2759.	1.3	20
39	Human germline and pan-cancer variomes and their distinct functional profiles. Nucleic Acids Research, 2014, 42, 11570-11588.	6.5	22
40	cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?. Expert Opinion on Therapeutic Targets, 2014, 18, 999-1009.	1.5	24

#	Article	IF	Citations
41	Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial. Frontiers in Genetics, 2014, 5, 152.	1.1	72
42	Attempt at a systemic outlook on aging and carcinogenesis. Bio-Algorithms and Med-Systems, 2014, 10, 101-115.	1.0	1
43	microRNA expression patterns across seven cancers are highly correlated and dominated by evolutionarily ancient families. Biomedical Reports, 2014, 2, 384-387.	0.9	7
44	Protein Conservation and Variation Suggest Mechanisms of Cell Type-Specific Modulation of Signaling Pathways. PLoS Computational Biology, 2014, 10, e1003659.	1.5	28
45	ContrastRank: a new method for ranking putative cancer driver genes and classification of tumor samples. Bioinformatics, 2014, 30, i572-i578.	1.8	22
46	RidgeRace: ridge regression for continuous ancestral character estimation on phylogenetic trees. Bioinformatics, 2014, 30, i527-i533.	1.8	28
47	OncodriveROLE classifies cancer driver genes in loss of function and activating mode of action. Bioinformatics, 2014, 30, i549-i555.	1.8	49
48	Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders. Frontiers in Pharmacology, 2014, 5, 252.	1.6	34
49	Genetic-based prediction of disease traits: prediction is very difficult, especially about the futureÃ¢â‚¬Â. Frontiers in Genetics, 2014, 5, 162.	1.1	53
50	Naturally Occurring Cancers in Dogs: Insights for Translational Genetics and Medicine. ILAR Journal, 2014, 55, 16-45.	1.8	62
51	The H3K27me3 demethylase UTX in normal development and disease. Epigenetics, 2014, 9, 658-668.	1.3	109
52	Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17947-17952.	3.3	273
53	Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma. Clinical Cancer Research, 2014, 20, 6582-6592.	3.2	493
54	Integrated Omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. Nature Communications, 2014, 5, 5469.	5.8	93
55	Cancer beyond organ and tissue specificity: Nextâ€generationâ€sequencing gene mutation data reveal complex genetic similarities across major cancers. International Journal of Cancer, 2014, 135, 2362-2369.	2.3	36
56	TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood, 2014, 123, 3305-3315.	0.6	89
57	The river blindness drug <scp>I</scp>vermectin and related macrocyclic lactones inhibit <scp>WNT</scp>â€<scp>TCF</scp> pathway responses in human cancer. EMBO Molecular Medicine, 2014, 6, 1263-1278.	3.3	103
58	Integration of Genomic Data Enables Selective Discovery of Breast Cancer Drivers. Cell, 2014, 159, 1461-1475.	13.5	77

#	Article	IF	Citations
59	MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 2014, 515, 558-562.	13.7	2,109
60	Tumors with a more complex genome have a higher frequency of <scp>HLA</scp> class I total loss: a unifying panâ€cancer hypothesis. Tissue Antigens, 2014, 83, 286-289.	1.0	2
61	Present and future of cancer biomarkers. Clinical Chemistry and Laboratory Medicine, 2014, 52, 791-4.	1.4	33
62	Sequencing the head and neck cancer genome: implications for therapy. Annals of the New York Academy of Sciences, 2014, 1333, 33-42.	1.8	38
63	Not just g RAS ping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers. Cancer Science, 2014, 105, 499-505.	1.7	19
64	DOTS-Finder: a comprehensive tool for assessing driver genes in cancer genomes. Genome Medicine, 2014, 6, 44.	3.6	25
65	Neuregulin 1â€“activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration. Science Signaling, 2014, 7, ra116.	1.6	153
66	A global assessment of cancer genomic alterations in epigenetic mechanisms. Epigenetics and Chromatin, 2014, 7, 29.	1.8	64
67	An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer. Journal of Experimental and Clinical Cancer Research, 2014, 33, 94.	3.5	28
68	Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations. Genome Biology, 2014, 15, 484.	3.8	117
69	MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis. Genome Biology, 2014, 15, 489.	3.8	54
70	Predictive Biomarkers and Companion Diagnostics. The Future of Immunohistochemistry. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 555-561.	0.6	48
71	Aberrant transcriptional regulations in cancers: genome, transcriptome and epigenome analysis of lung adenocarcinoma cell lines. Nucleic Acids Research, 2014, 42, 13557-13572.	6.5	102
72	The Cancer Genome Atlas findings in head and neck cancer. Current Opinion in Oncology, 2014, 26, 245-246.	1.1	5
73	Practicing Pathology in the Era of Big Data and Personalized Medicine. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 1-9.	0.6	47
74	Carcinoma of Unknown Primary Site. New England Journal of Medicine, 2014, 371, 2039-2040.	13.9	20
75	Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers. European Urology, 2014, 66, 936-948.	0.9	141
76	Mesothelin expression is associated with poor outcomes in breast cancer. Breast Cancer Research and Treatment, 2014, 147, 675-684.	1.1	42

#	Article	IF	Citations
77	h5vc: scalable nucleotide tallies with HDF5. Bioinformatics, 2014, 30, 1464-1466.	1.8	4
78	PARP-1 inhibitors and radiotherapy sensitivity: future prospects for therapy?. Breast Cancer Management, 2014, 3, 281-296.	0.2	3
79	Genetic mutations in head and neck cancer: utilizing existing treatments. Pharmacogenomics, 2014, 15, 1553-1555.	0.6	2
80	Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of UNC5C and Prognostic Importance of DNA Repair Gene Mutations on Survival. Clinical Cancer Research, 2014, 20, 6605-6617.	3.2	77
81	A Pan-Cancer Modular Regulatory Network Analysis to Identify Common and Cancer-Specific Network Components. Cancer Informatics, 2014, 13s5, CIN.S14058.	0.9	18
82	Towards identification of true cancer biomarkers. BMC Medicine, 2014, 12, 156.	2.3	30
83	Bypass of the pre-60S ribosomal quality control as a pathway to oncogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5640-5645.	3.3	71
84	Structure-based predictions broadly link transcription factor mutations to gene expression changes in cancers. Nucleic Acids Research, 2014, 42, 12973-12983.	6.5	5
85	Common progenitor cells in mature B-cell malignancies. Current Opinion in Hematology, 2014, 21, 333-340.	1.2	17
86	The epigenetic landscape of T-cell acute lymphoblastic leukemia. International Journal of Biochemistry and Cell Biology, 2014, 53, 547-557.	1.2	20
87	The genome-wide molecular signature of transcription factors in leukemia. Experimental Hematology, 2014, 42, 637-650.	0.2	13
88	Lymphohematopoietic cancers induced by chemicals and other agents and their implications for risk evaluation: An overview. Mutation Research - Reviews in Mutation Research, 2014, 761, 40-64.	2.4	30
89	von Hippel-Lindau Exonic Methylation Analysis Using MALDI-TOF Mass Spectrometry. Journal of Urology, 2014, 192, 1528-1533.	0.2	5
90	Evolution of the Cancer Stem Cell Model. Cell Stem Cell, 2014, 14, 275-291.	5.2	1,825
91	Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature, 2014, 506, 328-333.	13.7	1,241
92	Exploiting epigenetic vulnerabilities for cancer therapeutics. Trends in Pharmacological Sciences, 2014, 35, 136-145.	4.0	57
93	Enhancer Malfunction in Cancer. Molecular Cell, 2014, 53, 859-866.	4.5	156
94	Mutant p53 in Cancer: New Functions and Therapeutic Opportunities. Cancer Cell, 2014, 25, 304-317.	7.7	1,226

#	Article	IF	Citations
95	Locus-Specific Databases in Cancer: What Future in a Post-Genomic Era? The TP53 LSDB paradigm. Human Mutation, 2014, 35, 643-653.	1.1	15
96	Genome-wide screening and identification of long noncoding RNAs and their interaction with protein coding RNAs in bladder urothelial cell carcinoma. Cancer Letters, 2014, 349, 77-86.	3.2	37
97	The forkhead transcription factor FOXK2 acts as a chromatin targeting factor for the BAP1-containing histone deubiquitinase complex. Nucleic Acids Research, 2014, 42, 6232-6242.	6.5	66
98	Individualized Medicine from Prewomb to Tomb. Cell, 2014, 157, 241-253.	13.5	247
99	The 'omics' of adrenocortical tumours for personalized medicine. Nature Reviews Endocrinology, 2014, 10, 215-228.	4.3	41
101	Prion-like aggregation of mutant p53 in cancer. Trends in Biochemical Sciences, 2014, 39, 260-267.	3.7	167
102	MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia. Cancer Cell, 2014, 25, 652-665.	7.7	274
103	Wnt of the Two Horizons: Putting Stem Cell Self-Renewal and Cell Fate Determination into Context. Stem Cells and Development, 2014, 23, 1975-1990.	1.1	9
104	TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade. Human Mutation, 2014, 35, 672-688.	1.1	294
105	Recommendations for Analyzing and ReportingTP53Gene Variants in the High-Throughput Sequencing Era. Human Mutation, 2014, 35, 766-778.	1.1	29
106	Colorectal cancer risk and patientsâ€™ survival: influence of polymorphisms in genes somatically mutated in colorectal tumors. Cancer Causes and Control, 2014, 25, 759-769.	0.8	15
107	Integrated analysis of germline and somatic variants in ovarian cancer. Nature Communications, 2014, 5, 3156.	5.8	253
108	Genomics, drug approval, and optimal treatment duration. Nature Reviews Clinical Oncology, 2014, 11, 71-72.	12.5	5
109	Discovery and saturation analysis of cancer genes across 21 tumour types. Nature, 2014, 505, 495-501.	13.7	2,586
110	Onco-proteogenomics: cancer proteomics joins forces with genomics. Nature Methods, 2014, 11, 1107-1113.	9.0	118
111	Section I: Integrating laboratory medicine with tissue specimens. Current Problems in Cancer, 2014, 38, 144-158.	1.0	4
112	Analytical tools and current challenges in the modern era of neuroepigenomics. Nature Neuroscience, 2014, 17, 1476-1490.	7.1	100
113	Comprehensive characterization of complex structural variations in cancer by directly comparing genome sequence reads. Nature Biotechnology, 2014, 32, 1106-1112.	9.4	74

#	Article	IF	Citations
114	Enhancer alterations in cancer: a source for a cell identity crisis. Genome Medicine, 2014, 6, 77.	3.6	47
115	Evolutionary triage governs fitness in driver and passenger mutations and suggests targeting never mutations. Nature Communications, 2014, 5, 5499.	5.8	71
116	p53 as a target for the treatment of cancer. Cancer Treatment Reviews, 2014, 40, 1153-1160.	3.4	187
117	Androgen-regulated metabolism and biosynthesis in prostate cancer. Endocrine-Related Cancer, 2014, 21, T57-T66.	1.6	61
118	ATP-Dependent Chromatin Remodeling Complexes as Novel Targets for Cancer Therapy. Advances in Cancer Research, 2014, 121, 183-233.	1.9	44
119	Interferon regulatory factor 8 functions as a tumor suppressor in renal cell carcinoma and its promoter methylation is associated with patient poor prognosis. Cancer Letters, 2014, 354, 227-234.	3.2	32
120	Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nature Medicine, 2014, 20, 1472-1478.	15.2	1,533
121	The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact. Annals of Oncology, 2014, 25, 1889-1900.	0.6	79
122	Tumor Suppression by the Fbw7ÂUbiquitin Ligase: Mechanisms and Opportunities. Cancer Cell, 2014, 26, 455-464.	7.7	303
123	CARM1 and BAF155: an example of how chromatin remodeling factors can be relocalized and contribute to cancer. Breast Cancer Research, 2014, 16, 307.	2.2	1
124	Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Medicine, 2014, 6, 5.	3.6	186
125	The translation of cancer genomics: time for a revolution in clinical cancer care. Genome Medicine, 2014, 6, 22.	3.6	13
126	Cancer genomics: one cell at a time. Genome Biology, 2014, 15, 452.	3.8	264
127	Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biology, 2014, 15, 453.	3.8	180
128	Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations. Cancer Research, 2014, 74, 7181-7184.	0.4	53
129	miRNAs in tumor radiation response: bystanders or participants?. Trends in Molecular Medicine, 2014, 20, 529-539.	3.5	40
131	Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases. Nature Communications, 2014, 5, 3981.	5.8	18
132	PALB2: The hub of a network of tumor suppressors involved in DNA damage responses. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 263-275.	3.3	52

#	Article	IF	Citations
133	Chemical biology approaches to target validation in cancer. Current Opinion in Pharmacology, 2014, 17, 87-100.	1.7	36
134	Translational genomics and head and neck cancer: toward precision medicine. Clinical Genetics, 2014, 86, 412-421.	1.0	21
135	Studying Tumorigenesis through Network Evolution and Somatic Mutational Perturbations in the Cancer Interactome. Molecular Biology and Evolution, 2014, 31, 2156-2169.	3.5	79
136	Translating Genomics for Precision Cancer Medicine. Annual Review of Genomics and Human Genetics, 2014, 15, 395-415.	2.5	63
137	Non-small-cell lung cancers: a heterogeneous set of diseases. Nature Reviews Cancer, 2014, 14, 535-546.	12.8	1,375
138	Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature, 2014, 512, 155-160.	13.7	911
139	Medicinal properties of Hericium erinaceus and its potential to formulate novel mushroom-based pharmaceuticals. Applied Microbiology and Biotechnology, 2014, 98, 7661-7670.	1.7	44
140	Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. Genes and Diseases, 2014, 1, 75-86.	1.5	78
141	Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data. Cancer Research, 2014, 74, 3902-3912.	0.4	34
142	Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science, 2014, 345, 570-573.	6.0	573
143	Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells. Molecular Cancer Research, 2014, 12, 1140-1155.	1.5	27
144	A 3â€²-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Annals of Oncology, 2014, 25, 2230-2236.	0.6	36
145	Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell, 2014, 158, 929-944.	13.5	1,242
146	Lentiviral Vector-based Insertional Mutagenesis Identifies Genes Involved in the Resistance to Targeted Anticancer Therapies. Molecular Therapy, 2014, 22, 2056-2068.	3.7	16
147	ACVR1 Mutations in DIPG: Lessons Learned from FOP. Cancer Research, 2014, 74, 4565-4570.	0.4	76
148	The Genomic and Epigenomic Landscapes of AML. Seminars in Hematology, 2014, 51, 259-272.	1.8	12
149	Epigenetic regulation of hematopoietic stem cell aging. Experimental Cell Research, 2014, 329, 192-199.	1.2	55
150	Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer. Physiological Genomics, 2014, 46, 699-724.	1.0	26

#	Article	IF	Citations
151	Is target validation all we need?. Current Opinion in Pharmacology, 2014, 17, 81-86.	1.7	5
152	Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer. Genome Biology, 2014, 15, 429.	3.8	179
153	A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening. Genome Medicine, 2014, 6, 57.	3.6	101
154	The `dnetâ€™ approach promotes emerging research on cancer patient survival. Genome Medicine, 2014, 6, 64.	3.6	52
155	Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer. Clinical Cancer Research, 2014, 20, 4935-4948.	3.2	101
156	Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. Breast Cancer Research and Treatment, 2014, 147, 227-235.	1.1	19
157	Role of the Keap1â€“Nrf2 Pathway in Cancer. Advances in Cancer Research, 2014, 122, 281-320.	1.9	134
158	Where cancer genomics should go next: a clinician's perspective. Human Molecular Genetics, 2014, 23, R69-R75.	1.4	13
159	Cohesin mutations in myeloid malignancies: underlying mechanisms. Experimental Hematology and Oncology, 2014, 3, 13.	2.0	54
160	The ecology of cancer from an evolutionary game theory perspective. Interface Focus, 2014, 4, 20140019.	1.5	68
161	Toxicogenomics and Cancer Susceptibility: Advances with Next-Generation Sequencing. Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews, 2014, 32, 121-158.	2.9	32
162	Expanding the computational toolbox for mining cancer genomes. Nature Reviews Genetics, 2014, 15, 556-570.	7.7	166
163	Tumor antigen discovery through translation of the cancer genome. Immunologic Research, 2014, 58, 292-299.	1.3	13
164	Patterns and processes of somatic mutations in nine major cancers. BMC Medical Genomics, 2014, 7, 11.	0.7	57
165	Squamous Cell Carcinoma of the Oral Tongue in Young Non-Smokers Is Genomically Similar to Tumors in Older Smokers. Clinical Cancer Research, 2014, 20, 3842-3848.	3.2	124
166	Translational research in oncologyâ€”10 years of progress and future prospects. Nature Reviews Clinical Oncology, 2014, 11, 649-662.	12.5	65
167	Use of next generation sequencing in head and neck squamous cell carcinomas: A review. Oral Oncology, 2014, 50, 1035-1040.	0.8	21
168	e-Driver: a novel method to identify protein regions driving cancer. Bioinformatics, 2014, 30, 3109-3114.	1.8	116

#	Article	IF	Citations
171	Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance. Cell Stem Cell, 2014, 14, 329-341.	5.2	172
172	The Structural Basis of PI3K Cancer Mutations: From Mechanism to Therapy. Cancer Research, 2014, 74, 641-646.	0.4	55
173	Examining the impact of gene variants on histone lysine methylation. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2014, 1839, 1463-1476.	0.9	29
174	Molecular Analysis for Therapy Choice: NCI MATCH. Seminars in Oncology, 2014, 41, 297-299.	0.8	161
175	Mutational Context and Diverse Clonal Development in Early and Late Bladder Cancer. Cell Reports, 2014, 7, 1649-1663.	2.9	128
176	Consequences of feedback in signal transduction for targeted therapies. Biochemical Society Transactions, 2014, 42, 770-775.	1.6	15
179	Do physicians think genomic medicine will be useful for patient care?. Personalized Medicine, 2014, 11, 425-433.	0.8	21
180	The potential of genome-wide analyses to improve non-small-cell lung cancer care. Lung Cancer Management, 2014, 3, 383-396.	1.5	0
181	Leveraging the new with the old: providing a framework for the integration of historic microarray studies with next generation sequencing. BMC Bioinformatics, 2014, 15, S3.	1.2	1
182	Revealing the inherent heterogeneity of human malignancies by variant consensus strategies coupled with cancer clonal analysis. BMC Bioinformatics, 2014, 15, S9.	1.2	5
183	Cancer genomics: new software tools making sequencing more accessible. Personalized Medicine, 2014, 11, 127-130.	0.8	0
184	Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities. Expert Reviews in Molecular Medicine, 2015, 17, e17.	1.6	51
185	Oncolytic Viruses: Exploiting Cancer's Deal with the Devil. Trends in Cancer, 2015, 1, 266-277.	3.8	73
186	From drug response profiling to target addiction scoring in cancer cell models. DMM Disease Models and Mechanisms, 2015, 8, 1255-1264.	1.2	13
187	Inferring regulatory element landscapes and transcription factor networks from cancer methylomes. Genome Biology, 2015, 16, 105.	13.9	178
188	Mouse models of colorectal cancer as preclinical models. BioEssays, 2015, 37, 909-920.	1.2	59
189	Using somatic mutation data to test tumors for clonal relatedness. Annals of Applied Statistics, 2015, 9, 1533-1548.	0.5	23
190	Whole Exome Sequencing Identifies Frequent Somatic Mutations in Cell-Cell Adhesion Genes in Chinese Patients with Lung Squamous Cell Carcinoma. Scientific Reports, 2015, 5, 14237.	1.6	51

#	Article	IF	Citations
191	NEK9-dependent proliferation of cancer cells lacking functional p53. Scientific Reports, 2014, 4, 6111.	1.6	15
192	dbEMT: an epithelial-mesenchymal transition associated gene resource. Scientific Reports, 2015, 5, 11459.	1.6	117
194	Dysregulation of the Keap1â€“Nrf2 pathway in cancer. Biochemical Society Transactions, 2015, 43, 645-649.	1.6	72
195	Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. Blood, 2015, 125, 133-139.	0.6	86
196	Ribosomopathies and the paradox of cellular hypo- to hyperproliferation. Blood, 2015, 125, 1377-1382.	0.6	83
197	Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood, 2015, 126, 2491-2501.	0.6	180
198	On the Verge: Immunotherapy for Colorectal Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 970-978.	2.3	9
199	Cancer typeâ€dependent genetic interactions between cancer driver alterations indicate plasticity of epistasis across cell types. Molecular Systems Biology, 2015, 11, 824.	3.2	54
200	Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization. Journal of Circulating Biomarkers, 2015, 4, 3.	0.8	103
201	Efficient Test and Visualization of Multi-Set Intersections. Scientific Reports, 2015, 5, 16923.	1.6	306
202	Mutated NPM1 in combination with overexpression of Meis1 or Hoxa9 is not sufficient to induce acute myeloid leukemia. Experimental Hematology and Oncology, 2015, 5, 25.	2.0	2
203	Regulation rewiring analysis reveals mutual regulation between STAT1 and miR-155-5p in tumor immunosurveillance in seven major cancers. Scientific Reports, 2015, 5, 12063.	1.6	19
204	A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men. EBioMedicine, 2015, 2, 1957-1964.	2.7	61
205	Computational methods and resources for the interpretation of genomic variants in cancer. BMC Genomics, 2015, 16, S7.	1.2	18
206	Identification of genomic features in the classification of loss- and gain-of-function mutation. BMC Medical Informatics and Decision Making, 2015, 15, S6.	1.5	10
207	A multilevel pan-cancer map links gene mutations to cancer hallmarks. Chinese Journal of Cancer, 2015, 34, 439-49.	4.9	38
208	TGFÎ² isoforms and receptors mRNA expression in breast tumours: prognostic value and clinical implications. BMC Cancer, 2015, 15, 1010.	1.1	25
209	Neuron navigator 2 overexpression indicates poor prognosis of colorectal cancer and promotes invasion through the SSH1L/cofilin-1 pathway. Journal of Experimental and Clinical Cancer Research, 2015, 34, 117.	3.5	27

#	Article	IF	Citations
210	Chromatin interaction analysis reveals changes in small chromosome and telomere clustering between epithelial and breast cancer cells. Genome Biology, 2015, 16, 214.	3.8	206
211	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesisâ€generating study. Journal of Pathology, 2015, 237, 166-178.	2.1	53
212	Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics. British Journal of Haematology, 2015, 170, 305-322.	1.2	36
213	Parameter optimization for constructing competing endogenous RNA regulatory network in glioblastoma multiforme and other cancers. BMC Genomics, 2015, 16, S1.	1.2	43
214	Dysregulated transcription across diverse cancer types reveals the importance of RNA-binding protein in carcinogenesis. BMC Genomics, 2015, 16, S5.	1.2	58
215	Network-based stratification analysis of 13 major cancer types using mutations in panels of cancer genes. BMC Genomics, 2015, 16, S7.	1.2	27
216	Oncogenes and tumor suppressor genes: comparative genomics and network perspectives. BMC Genomics, 2015, 16, S8.	1.2	41
217	Can Petoâ€™s paradox be used as the null hypothesis to identify the role of evolution in natural resistance to cancer? A critical review. BMC Cancer, 2015, 15, 792.	1.1	17
218	DNA methylation subgroups in melanoma are associated with proliferative and immunological processes. BMC Medical Genomics, 2015, 8, 73.	0.7	29
219	Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study. World Journal of Surgical Oncology, 2015, 13, 128.	0.8	18
220	Cis-regulatory somatic mutations and gene-expression alteration in B-cell lymphomas. Genome Biology, 2015, 16, 84.	3.8	36
221	Impact of alleleâ€specific peptides in proteome quantification. Proteomics - Clinical Applications, 2015, 9, 432-436.	0.8	4
222	Whole-genome sequencing of a malignant granular cell tumor with metabolic response to pazopanib. Journal of Physical Education and Sports Management, 2015, 1, a000380.	0.5	23
223	Generating a focused view of disease ontology cancer terms for pan-cancer data integration and analysis. Database: the Journal of Biological Databases and Curation, 2015, 2015, bav032-bav032.	1.4	40
224	Categorization of cancer through genomic complexity could guide research and management strategies. Journal of Pathology, 2015, 236, 397-402.	2.1	4
226	New and emerging factors in tumorigenesis: an overview. Cancer Management and Research, 2015, 7, 225.	0.9	27
227	Exploiting the Fanconi Anemia Pathway for Targeted Anti-Cancer Therapy. Molecules and Cells, 2015, 38, 669-676.	1.0	23
228	Immunotherapy and Radiation â€“ A New Combined Treatment Approach for Bladder Cancer?. Bladder Cancer, 2015, 1, 15-27.	0.2	19

#	Article	IF	Citations
229	Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget, 2015, 6, 24750-24779.	0.8	115
230	Circulating Cell-Free Tumour DNA in the Management of Cancer. International Journal of Molecular Sciences, 2015, 16, 14122-14142.	1.8	104
231	Bioinformatics Mining and Modeling Methods for the Identification of Disease Mechanisms in Neurodegenerative Disorders. International Journal of Molecular Sciences, 2015, 16, 29179-29206.	1.8	47
232	Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer. Frontiers in Oncology, 2015, 5, 149.	1.3	52
233	Exome Sequencing of an Adult Pituitary Atypical Teratoid Rhabdoid Tumor. Frontiers in Oncology, 2015, 5, 236.	1.3	17
234	Putative Breast Cancer Driver Mutations in TBX3 Cause Impaired Transcriptional Repression. Frontiers in Oncology, 2015, 5, 244.	1.3	18
235	Mutant p53: One, No One, and One Hundred Thousand. Frontiers in Oncology, 2015, 5, 289.	1.3	71
236	Novel Insights into Chk1 Regulation by Phosphorylation. Cell Structure and Function, 2015, 40, 43-50.	0.5	28
237	Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy. PLoS ONE, 2015, 10, e0123967.	1.1	27
238	Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Wspolczesna Onkologia, 2015, 1A, 68-77.	0.7	2,410
239	A Dual Model for Prioritizing Cancer Mutations in the Non-coding Genome Based on Germline and Somatic Events. PLoS Computational Biology, 2015, 11, e1004583.	1.5	17
240	Distinctive Behaviors of Druggable Proteins in Cellular Networks. PLoS Computational Biology, 2015, 11, e1004597.	1.5	43
241	Identification of Distinct Tumor Subpopulations in Lung Adenocarcinoma via Single-Cell RNA-seq. PLoS ONE, 2015, 10, e0135817.	1.1	54
242	p53mutations in colorectal cancer- molecular pathogenesis and pharmacological reactivation. World Journal of Gastroenterology, 2015, 21, 84.	1.4	248
243	Pervasive transcription read-through promotes aberrant expression of oncogenes and RNA chimeras in renal carcinoma. ELife, 2015, 4, .	2.8	114
244	Classification of Cancer Primary Sites Using Machine Learning and Somatic Mutations. BioMed Research International, 2015, 2015, 1-9.	0.9	20
245	Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. ELife, 2015, 4, e06907.	2.8	140
246	Targeting the PI3K/AKT/mTOR Pathway in Cancer Cells. , 0, , .		7

#	Article	IF	Citations
247	Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. Journal of Clinical Investigation, 2015, 125, 3981-3991.	3.9	328
248	Aberrant RSPO3-LGR4 signaling in Keap1-deficient lung adenocarcinomas promotes tumor aggressiveness. Oncogene, 2015, 34, 4692-4701.	2.6	59
249	Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nature Reviews Cancer, 2015, 15, 334-346.	12.8	486
250	Outlook on PI3K/AKT/mTOR inhibition in acute leukemia. Molecular and Cellular Therapies, 2015, 3, 2.	0.2	101
251	Actinomycin D and nutlin-3a synergistically promote phosphorylation of p53 on serine 46 in cancer cell lines of different origin. Cellular Signalling, 2015, 27, 1677-1687.	1.7	22
252	Simultaneous Inference of Cancer Pathways and Tumor Progression from Cross-Sectional Mutation Data. Journal of Computational Biology, 2015, 22, 510-527.	0.8	28
253	Epigenetic Control of Stem Cell Potential during Homeostasis, Aging, and Disease. Cell Stem Cell, 2015, 16, 613-625.	5.2	144
254	Association between Morphologic CT Imaging Traits and Prognostically Relevant Gene Signatures in Women with High-Grade Serous Ovarian Cancer: A Hypothesis-generating Study. Radiology, 2015, 274, 742-751.	3.6	50
255	OH, the Places Youâ€™ll Go! Hydroxylation, Gene Expression, and Cancer. Molecular Cell, 2015, 58, 729-741.	4.5	67
256	Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site. JAMA Oncology, 2015, 1, 40.	3.4	199
257	Malignant Transformation ofÂCraniopharyngioma. , 2015, , 511-533.		0
258	Molecular Biology of Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 191-203.	0.9	30
259	Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer. Clinical Cancer Research, 2015, 21, 3667-3677.	3.2	130
260	ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM. Molecular Cancer Research, 2015, 13, 1206-1217.	1.5	44
261	Personalized Therapy of Cancer. , 2015, , 199-381.		1
262	The somatic autosomal mutation matrix in cancer genomes. Human Genetics, 2015, 134, 851-864.	1.8	16
263	TP53: an oncogene in disguise. Cell Death and Differentiation, 2015, 22, 1239-1249.	5.0	227
264	Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer. Frontiers in Oncology, 2015, 5, 97.	1.3	39

#	Article	IF	Citations
265	Application of Machine-Learning Methods to Understand Gene Expression Regulation. Genetic and Evolutionary Computation, 2015, , 1-15.	1.0	2
266	Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia. Expert Opinion on Therapeutic Targets, 2015, 19, 1187-1202.	1.5	16
268	From Mutational Mechanisms in Single Cells to Mutational Patterns in Cancer Genomes. Cold Spring Harbor Symposia on Quantitative Biology, 2015, 80, 117-137.	2.0	11
269	Targeting the immune system in head and neck cancer. Current Opinion in Oncology, 2015, 27, 157-158.	1.1	1
270	Progress of cancer genomics. Thoracic Cancer, 2015, 6, 557-560.	0.8	1
271	A thesaurus of genetic variation for interrogation of repetitive genomic regions. Nucleic Acids Research, 2015, 43, e68-e68.	6.5	5
272	A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nature Communications, 2015, 6, 10001.	5.8	266
273	Stem cells and healthy aging. Science, 2015, 350, 1199-1204.	6.0	268
274	Mitochondrial dysfunction and longevity in animals: Untangling the knot. Science, 2015, 350, 1204-1207.	6.0	213
275	Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. Cancer Research, 2015, 75, 5341-5354.	0.4	130
276	Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations. Epigenomics, 2015, 7, 687-690.	1.0	14
277	Novel Targeted Agents in Head and Neck Squamous Cell Carcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 993-1009.	0.9	2
278	Intercellular Communication in Cancer. , 2015, , .		4
279	Update on recurrent genetic aberrations in acute myeloid leukemia. International Journal of Hematologic Oncology, 2015, 4, 179-190.	0.7	1
280	Patterns and functional implications of rare germline variants across 12 cancer types. Nature Communications, 2015, 6, 10086.	5.8	243
281	Efficient exploration of pan-cancer networks by generalized covariance selection and interactive web content. Nucleic Acids Research, 2015, 43, e98-e98.	6.5	16
282	Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. Journal of the National Cancer Institute, 2015, 108, djv427.	3.0	164
283	Mitochondrial Genome Acquisition Restores Respiratory Function and Tumorigenic Potential of Cancer Cells without Mitochondrial DNA. Cell Metabolism, 2015, 21, 81-94.	7.2	582

#	Article	IF	Citations
284	Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science, 2015, 347, 78-81.	6.0	1,561
285	Enhancer Sequence Variants and Transcription-Factor Deregulation Synergize to Construct Pathogenic Regulatory Circuits in B-Cell Lymphoma. Immunity, 2015, 42, 186-198.	6.6	64
286	The mutational landscape of endometrial cancer. Current Opinion in Genetics and Development, 2015, 30, 25-31.	1.5	35
287	Runx3 at the interface of immunity, inflammation and cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 131-143.	3.3	69
288	An assessment of computational methods for estimating purity and clonality using genomic data derived from heterogeneous tumor tissue samples. Briefings in Bioinformatics, 2015, 16, 232-241.	3.2	67
289	Interaction of p53 with prolyl isomerases: Healthy and unhealthy relationships. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 2048-2060.	1.1	24
290	Targeting histone lysine methylation in cancer. , 2015, 150, 1-22.		164
291	Metabolic modulation of cancer: a new frontier with great translational potential. Journal of Molecular Medicine, 2015, 93, 127-142.	1.7	27
292	Somatic Diseases (Cancer). , 2015, , 343-360.		0
293	Cooperation between Noncanonical Ras Network Mutations. Cell Reports, 2015, 10, 307-316.	2.9	26
294	Systematical analyses of variants in CTCF-binding sites identified a novel lung cancer susceptibility locus among Chinese population. Scientific Reports, 2015, 5, 7833.	1.6	16
295	Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. Clinical Chemistry, 2015, 61, 544-553.	1.5	85
296	DNMT3A in haematological malignancies. Nature Reviews Cancer, 2015, 15, 152-165.	12.8	379
297	DNA Replication Stress as a Hallmark of Cancer. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 425-448.	9.6	593
298	Rb and FZR1/Cdh1 determine CDK4/6-cyclin D requirement in C. elegans and human cancer cells. Nature Communications, 2015, 6, 5906.	5.8	62
299	The role of DNA damage responses in p53 biology. Archives of Toxicology, 2015, 89, 501-517.	1.9	138
300	Deubiquitinases and the new therapeutic opportunities offered to cancer. Endocrine-Related Cancer, 2015, 22, T35-T54.	1.6	111
301	ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells. Molecular Cancer Therapeutics, 2015, 14, 877-888.	1.9	55

#	Article	IF	Citations
302	Critical roles of non-histone protein lysine methylation in human tumorigenesis. Nature Reviews Cancer, 2015, 15, 110-124.	12.8	299
303	The emerging roles of YAP and TAZ in cancer. Nature Reviews Cancer, 2015, 15, 73-79.	12.8	928
304	Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity. Cell, 2015, 160, 48-61.	13.5	2,948
305	The butterfly effect in cancer: A single base mutation can remodel the cell. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1131-1136.	3.3	62
306	Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution. Cancer Cell, 2015, 27, 15-26.	7.7	923
307	KEAP1 Genetic Polymorphisms Associate with Breast Cancer Risk and Survival Outcomes. Clinical Cancer Research, 2015, 21, 1591-1601.	3.2	37
308	The landscape of long noncoding RNAs in the human transcriptome. Nature Genetics, 2015, 47, 199-208.	9.4	2,410
309	A comprehensively characterized large panel of head and neck cancer patientâ€derived xenografts identifies the m<scp>TOR</scp> inhibitor everolimus as potential new treatment option. International Journal of Cancer, 2015, 136, 2940-2948.	2.3	53
310	Breast Cancer Genomics From Microarrays to Massively Parallel Sequencing: Paradigms and New Insights. Journal of the National Cancer Institute, 2015, 107, .	3.0	80
311	AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation. Angiogenesis, 2015, 18, 151-162.	3.7	110
312	Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas. Scientific Reports, 2015, 5, 8829.	1.6	73
313	Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients. British Journal of Cancer, 2015, 112, 1411-1420.	2.9	51
314	Targeting the Tumor Stroma in Breast Cancer. Current Breast Cancer Reports, 2015, 7, 71-79.	0.5	0
315	Identification of novel mutations by exome sequencing in African American colorectal cancer patients. Cancer, 2015, 121, 34-42.	2.0	36
316	Broad, Hybrid Captureâ€"Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clinical Cancer Research, 2015, 21, 3631-3639.	3.2	236
317	Translational Implications of Tumor Heterogeneity. Clinical Cancer Research, 2015, 21, 1258-1266.	3.2	424
318	Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity. DNA Repair, 2015, 28, 107-115.	1.3	55
319	Seek and Destroy: Relating Cancer Drivers to Therapies. Cancer Cell, 2015, 27, 319-321.	7.7	5

#	Article	IF	Citations
320	The Cancer Stem Cell Niche: How Essential Is the Niche in Regulating Stemness of Tumor Cells?. Cell Stem Cell, 2015, 16, 225-238.	5.2	1,195
321	Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer. Scientific Reports, 2015, 5, 8542.	1.6	66
322	Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma. Cancer Cell, 2015, 27, 327-341.	7.7	316
323	In Silico Prescription of Anticancer Drugs to Cohorts of 28 Tumor Types Reveals Targeting Opportunities. Cancer Cell, 2015, 27, 382-396.	7.7	290
324	PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas. Gynecologic Oncology, 2015, 137, 321-328.	0.6	15
325	The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas. Oral Oncology, 2015, 51, 423-430.	0.8	39
326	Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway. Clinical Cancer Research, 2015, 21, 5360-5370.	3.2	68
327	DBC1 Functions as a Tumor Suppressor by Regulating p53 Stability. Cell Reports, 2015, 10, 1324-1334.	2.9	56
328	Personalised medicine in veterinary oncology: One to cure just one. Veterinary Journal, 2015, 205, 128-135.	0.6	17
329	SUMO-2 Orchestrates Chromatin Modifiers in Response to DNA Damage. Cell Reports, 2015, 10, 1778-1791.	2.9	117
330	Baseline caspase activity predicts progression free survival of temsirolimus-treated head neck cancer patients. European Journal of Cancer, 2015, 51, 1596-1602.	1.3	9
331	HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment. Cancer Discovery, 2015, 5, 832-841.	7.7	250
332	Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. European Urology, 2015, 68, 959-967.	0.9	395
333	p53 family members â€“ important messengers in cell death signaling in photodynamic therapy of cancer?. Photochemical and Photobiological Sciences, 2015, 14, 1390-1396.	1.6	26
334	Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data. Bioinformatics, 2015, 31, 3561-3568.	1.8	55
335	Histone profiles in cancer. , 2015, 154, 87-109.		6
336	Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas. Gynecologic Oncology, 2015, 138, 323-331.	0.6	19
337	Helicobacter pylori Infection Causes Characteristic DNA Damage Patterns in Human Cells. Cell Reports, 2015, 11, 1703-1713.	2.9	114

#	Article	IF	Citations
338	Novel Agents and Associated Toxicities of Inhibitors of the PI3K/Akt/mTOR Pathway for the Treatment of Breast Cancer. Current Oncology, 2015, 22, 33-48.	0.9	95
339	Mutation-induced protein interaction kinetics changes affect apoptotic network dynamic properties and facilitate oncogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4046-54.	3.3	31
340	Genomic landscape of cutaneous T cell lymphoma. Nature Genetics, 2015, 47, 1011-1019.	9.4	347
341	BAP1,PBRM1andSETD2in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Expert Review of Molecular Diagnostics, 2015, 15, 1201-1210.	1.5	78
342	Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer. Clinical Cancer Research, 2015, 21, 4709-4718.	3.2	52
343	Precision medicine for metastatic breast cancerâ€"limitations and solutions. Nature Reviews Clinical Oncology, 2015, 12, 693-704.	12.5	272
344	Activation-Induced Cytidine Deaminase Contributes to Pancreatic Tumorigenesis by Inducing Tumor-Related Gene Mutations. Cancer Research, 2015, 75, 3292-3301.	0.4	22
345	MEMCover: integrated analysis of mutual exclusivity and functional network reveals dysregulated pathways across multiple cancer types. Bioinformatics, 2015, 31, i284-i292.	1.8	87
346	Understanding next generation sequencing in oncology: A guide for oncologists. Critical Reviews in Oncology/Hematology, 2015, 96, 463-474.	2.0	38
347	The cancer COMPASS: navigating the functions of MLL complexes in cancer. Cancer Genetics, 2015, 208, 178-191.	0.2	122
348	Genomic heterogeneity in multiple myeloma. Current Opinion in Genetics and Development, 2015, 30, 56-65.	1.5	31
349	Exploring the Mechanisms of Gastrointestinal Cancer Development Using Deep Sequencing Analysis. Cancers, 2015, 7, 1037-1051.	1.7	7
350	G1/S Inhibitors and the SWI/SNF Complex Control Cell-Cycle Exit during Muscle Differentiation. Cell, 2015, 162, 300-313.	13.5	93
351	A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer. Hormones and Cancer, 2015, 6, 214-224.	4.9	30
352	Roles of Nrf2 in cell proliferation and differentiation. Free Radical Biology and Medicine, 2015, 88, 168-178.	1.3	189
353	Genomic alterations in lung adenocarcinoma. Lancet Oncology, The, 2015, 16, e342-e351.	5.1	302
354	ESR1 mutationsâ€"a mechanism for acquired endocrine resistance in breast cancer. Nature Reviews Clinical Oncology, 2015, 12, 573-583.	12.5	458
355	Replication stress and cancer. Nature Reviews Cancer, 2015, 15, 276-289.	12.8	755

#	Article	IF	Citations
356	Re-annotation of presumed noncoding disease/trait-associated genetic variants by integrative analyses. Scientific Reports, 2015, 5, 9453.	1.6	13
357	Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nature Reviews Clinical Oncology, 2015, 12, 344-357.	12.5	243
358	Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest. Radiotherapy and Oncology, 2015, 115, 120-127.	0.3	47
359	Pan-cancer transcriptome analysis reveals long noncoding RNAs with conserved function. RNA Biology, 2015, 12, 628-642.	1.5	85
360	Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN). Oral Oncology, 2015, 51, 399-408.	0.8	19
361	An essential passenger with p53. Nature, 2015, 520, 626-627.	13.7	19
362	Molecular characterization and testing in acute myeloid leukemia. Journal of Hematopathology, 2015, 8, 177-189.	0.2	3
363	Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Science Translational Medicine, 2015, 7, 283ra54.	5.8	589
364	Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. Expert Review of Molecular Diagnostics, 2015, 15, 647-664.	1.5	40
365	Emerging drugs for head and neck cancer. Expert Opinion on Emerging Drugs, 2015, 20, 313-329.	1.0	39
366	Synthetic epigeneticsâ€"towards intelligent control of epigenetic states and cell identity. Clinical Epigenetics, 2015, 7, 18.	1.8	59
367	Somatic cancer mutations in the MLL3-SET domain alter the catalytic properties of the enzyme. Clinical Epigenetics, 2015, 7, 36.	1.8	36
368	The next steps in next-gen sequencing of cancer genomes. Journal of Clinical Investigation, 2015, 125, 462-468.	3.9	34
369	Thed_J/d_SRatio Test Reveals Hundreds of Novel Putative Cancer Drivers. Molecular Biology and Evolution, 2015, 32, 2181-2185.	3.5	7
370	Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing InÂVivo. Cancer Cell, 2015, 27, 631-643.	7.7	259
371	A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nature Genetics, 2015, 47, 668-671.	9.4	311
372	Cancer3D: understanding cancer mutations through protein structures. Nucleic Acids Research, 2015, 43, D968-D973.	6.5	46
373	Ribosomal proteins: functions beyond the ribosome. Journal of Molecular Cell Biology, 2015, 7, 92-104.	1.5	522

#	Article	IF	Citations
374	Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1724-33.	3.3	57
375	Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas. Cancer Research, 2015, 75, 2017-2028.	0.4	27
376	Molecular Pathways: Aspirin and Wnt Signalingâ€"A Molecularly Targeted Approach to Cancer Prevention and Treatment. Clinical Cancer Research, 2015, 21, 1543-1548.	3.2	74
377	Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial. Journal of Clinical Oncology, 2015, 33, 1000-1007.	0.8	206
378	Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. Nature Communications, 2015, 6, 6336.	5.8	100
379	Textbook of Personalized Medicine. , 2015, , .		27
380	Wholeâ€exome <scp>DNA</scp> sequence analysis of Brca2â€•and Trp53â€deficient mouse mammary gland tumours. Journal of Pathology, 2015, 236, 186-200.	2.1	14
381	Epigenetic modifiers in normal and malignant hematopoiesis. Epigenomics, 2015, 7, 301-320.	1.0	23
382	TP53 hot spot mutations in ovarian cancer: Selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas. Gynecologic Oncology, 2015, 138, 159-164.	0.6	21
383	Hitting cancersâ€™ weak spots: vulnerabilities imposed by p53 mutation. Trends in Cell Biology, 2015, 25, 486-495.	3.6	80
384	Molecularly Targeted Therapies in Nonâ€“Small-Cell Lung Cancer Annual Update 2014. Journal of Thoracic Oncology, 2015, 10, S1-S63.	0.5	119
385	Big Data Biology: Between Eliminative Inferences and Exploratory Experiments. Philosophy of Science, 2015, 82, 198-218.	0.5	27
386	CMPD: cancer mutant proteome database. Nucleic Acids Research, 2015, 43, D849-D855.	6.5	13
387	How the environment shapes cancer genomes. Current Opinion in Oncology, 2015, 27, 71-77.	1.1	31
388	The opposing roles of <scp>NOTCH</scp> signalling in head and neck cancer: a mini review. Oral Diseases, 2015, 21, 850-857.	1.5	67
389	Development of Lung Adenocarcinomas with Exclusive Dependence on Oncogene Fusions. Cancer Research, 2015, 75, 2264-2271.	0.4	38
390	Distinct novel quinazolinone exhibits selective inhibition in MGC-803 cancer cells by dictating mutant p53 function. European Journal of Medicinal Chemistry, 2015, 95, 377-387.	2.6	27
391	Genotyping concordance in DNA extracted from formalinâ€fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. Molecular Oncology, 2015, 9, 1868-1876.	2.1	29

#	Article	IF	Citations
392	The first five years of single-cell cancer genomics and beyond. Genome Research, 2015, 25, 1499-1507.	2.4	324
393	Targeting HER (ERBB) signaling in head and neck cancer: An essential update. Molecular Aspects of Medicine, 2015, 45, 74-86.	2.7	22
394	Genetics and genomics of psychiatric disease. Science, 2015, 349, 1489-1494.	6.0	337
395	Somatic mutation in cancer and normal cells. Science, 2015, 349, 1483-1489.	6.0	996
396	Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes. Cell Cycle, 2015, 14, 2219-2221.	1.3	60
397	Bone Metastases in Lung Cancer. Potential Novel Approaches to Therapy. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 799-809.	2.5	26
398	Intron retention is a widespread mechanism of tumor-suppressor inactivation. Nature Genetics, 2015, 47, 1242-1248.	9.4	322
399	Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacologica Sinica, 2015, 36, 1219-1227.	2.8	193
400	RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell, 2015, 28, 666-676.	7.7	700
401	The dynamics of Rho GTPase signaling and implications for targeting cancer and the tumor microenvironment. Small GTPases, 2015, 6, 123-133.	0.7	37
402	Establishing the Role of PPARÎ²/Î´ in Carcinogenesis. Trends in Endocrinology and Metabolism, 2015, 26, 595-607.	3.1	69
403	The Personalization of Therapy: Molecular Profiling Technologies and Their Application. Seminars in Oncology, 2015, 42, 775-787.	0.8	6
404	The enemy of my enemy is my friend. Nature, 2015, 527, 170-171.	13.7	47
405	Between Pathways and Networks Lies Context: Implications for Precision Medicine. Science Progress, 2015, 98, 253-263.	1.0	0
406	Tumor characterization and stratification by integrated molecular profiles reveals essential pan-cancer features. BMC Genomics, 2015, 16, 503.	1.2	32
407	Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia. Best Practice and Research in Clinical Haematology, 2015, 28, 90-97.	0.7	10
408	Conditional inactivation of the mouse von Hippelâ€“Lindau tumor suppressor gene results in wide-spread hyperplastic, inflammatory and fibrotic lesions in the kidney. Oncogene, 2015, 34, 2631-2639.	2.6	44
409	Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. Annals of Oncology, 2015, 26, 2367-2374.	0.6	40

#	Article	IF	Citations
410	Massive interstitial copy-neutral loss-of-heterozygosity as evidence for cancer being a disease of the DNA-damage response. BMC Medical Genomics, 2015, 8, 42.	0.7	21
411	Novel delivery approaches for cancer therapeutics. Journal of Controlled Release, 2015, 219, 248-268.	4.8	127
412	Genomic landscape of adenoid cystic carcinoma of the breast. Journal of Pathology, 2015, 237, 179-189.	2.1	133
413	The functional relevance of somatic synonymous mutations in melanoma and other cancers. Pigment Cell and Melanoma Research, 2015, 28, 673-684.	1.5	47
414	EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. Molecular Cell, 2015, 60, 307-318.	4.5	161
415	Systematic analysis of somatic mutations impacting gene expression in 12 tumour types. Nature Communications, 2015, 6, 8554.	5.8	102
417	Cancer Genetics and Implications for Clinical Management. Surgical Clinics of North America, 2015, 95, 919-934.	0.5	6
418	The dynamic control of signal transduction networks in cancer cells. Nature Reviews Cancer, 2015, 15, 515-527.	12.8	282
419	Multi-institutional Validation of the Predictive Value of Ki-67 in Patients with High Grade Urothelial Carcinoma of the Upper Urinary Tract. Journal of Urology, 2015, 193, 1486-1493.	0.2	38
420	Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer. Journal of the National Cancer Institute, 2015, 107, djv246.	3.0	63
421	Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. Nature Structural and Molecular Biology, 2015, 22, 703-711.	3.6	72
422	The mRNA related ceRNAâ€“ceRNA landscape and significance across 20 major cancer types. Nucleic Acids Research, 2015, 43, 8169-8182.	6.5	170
424	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. New England Journal of Medicine, 2015, 373, 1733-1747.	13.9	281
425	LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential. Cancer Biology and Therapy, 2015, 16, 821-833.	1.5	83
426	Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape. Cell Reports, 2015, 12, 1300-1313.	2.9	37
427	Yeast as Models of Mitotic Fidelity. Recent Results in Cancer Research, 2015, 200, 143-164.	1.8	2
428	Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer. Cell Stem Cell, 2015, 17, 260-271.	5.2	328
429	Gene mutations in gastric cancer: a review of recent next-generation sequencing studies. Tumor Biology, 2015, 36, 7385-7394.	0.8	46

#	Article	IF	Citations
430	Genetically altered cancer epigenome. , 2015, , 265-289.		1
431	Low-frequency KRAS mutations are prevalent in lung adenocarcinomas. Personalized Medicine, 2015, 12, 83-98.	0.8	19
432	LEDGF/p75 interacts with mRNA splicing factors and targets HIV-1 integration to highly spliced genes. Genes and Development, 2015, 29, 2287-2297.	2.7	90
433	Cancerâ€™s Fuel Choice: New Flavors for a Picky Eater. Molecular Cell, 2015, 60, 514-523.	4.5	120
434	Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6496-505.	3.3	313
435	Selecting causal genes from genome-wide association studies via functionally coherent subnetworks. Nature Methods, 2015, 12, 154-159.	9.0	96
436	Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nature Genetics, 2015, 47, 106-114.	9.4	830
437	ATM and ATR as therapeutic targets in cancer. , 2015, 149, 124-138.		487
438	Snowball: resampling combined with distance-based regression to discover transcriptional consequences of a driver mutation. Bioinformatics, 2015, 31, 84-93.	1.8	5
439	Modelling bladder cancer in mice: opportunities and challenges. Nature Reviews Cancer, 2015, 15, 42-54.	12.8	114
440	Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation. Nature Structural and Molecular Biology, 2015, 22, 37-43.	3.6	121
441	SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia. Oncogene, 2015, 34, 631-638.	2.6	47
442	Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature, 2015, 518, 552-555.	13.7	685
443	The use of molecular markers in predicting dysplasia and guiding treatment. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 113-124.	1.0	9
444	Pharmacogenomic biomarkers for personalized cancer treatment. Journal of Internal Medicine, 2015, 277, 201-217.	2.7	57
445	Vanno: A Visualization-Aided Variant Annotation Tool. Human Mutation, 2015, 36, 167-174.	1.1	6
446	Neurofibromatosis type 1 molecular diagnosis: what can NGS do for you when you have a large gene with loss of function mutations?. European Journal of Human Genetics, 2015, 23, 596-601.	1.4	97
447	Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy. Antioxidants and Redox Signaling, 2015, 23, 51-65.	2.5	44

#	Article	IF	Citations
448	Synthetic Lethal Vulnerabilities of Cancer. Annual Review of Pharmacology and Toxicology, 2015, 55, 513-531.	4.2	38
449	Driver and Passenger Mutations in Cancer. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 25-50.	9.6	291
450	Uveal melanoma hepatic metastases mutation spectrum analysis using targeted next-generation sequencing of 400 cancer genes. British Journal of Ophthalmology, 2015, 99, 437-439.	2.1	31
451	A DNA methylationâ€based definition of biologically distinct breast cancer subtypes. Molecular Oncology, 2015, 9, 555-568.	2.1	156
452	Pharmacogenetics of Cancer Drugs. Annual Review of Medicine, 2015, 66, 65-81.	5.0	51
453	Emerging biomarkers in head and neck cancer in the era of genomics. Nature Reviews Clinical Oncology, 2015, 12, 11-26.	12.5	264
454	Novel Targets in Head and Neck Cancer: Should We Be Optimistic?. Clinical Cancer Research, 2015, 21, 495-497.	3.2	3
455	Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications. Leukemia, 2015, 29, 269-278.	3.3	38
456	Challenges and opportunities for next-generation sequencing in companion diagnostics. Expert Review of Molecular Diagnostics, 2015, 15, 193-209.	1.5	12
457	Immunotherapy in Colorectal Cancer. , 2016, , .		0
458	Redefining Androgen Receptor Function: Clinical Implications in Understanding Prostate Cancer Progression and Therapeutic Resistance. , 0, , .		0
459	Meta-dimensional data integration identifies critical pathways for susceptibility, tumorigenesis and progression of endometrial cancer. Oncotarget, 2016, 7, 55249-55263.	0.8	14
460	Genomic Instability: The Pivotal Role of Mutant P53 in Human Cancers. Chemotherapy, 2016, 05, .	0.0	0
461	Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene. Genes, 2016, 7, 50.	1.0	124
462	Histone Methylation Modifiers in Medical Therapeutics. , 2016, , 705-729.		1
463	Genomics of Colorectal Cancer in African Americans. Journal of Next Generation Sequencing & Applications, 2016, 3, .	0.3	9
464	The Emerging Epigenetic Landscape in Melanoma. , 0, , .		0
465	CASTIN: a system for comprehensive analysis of cancer-stromal interactome. BMC Genomics, 2016, 17, 899.	1.2	10

#	Article	IF	Citations
466	Targeting homologous recombination repair in cancer. , 2016, , 225-275.		3
467	Interrogating the Cancer Genome to Deliver More Precise Cancer Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e577-e583.	1.8	2
468	Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e141-e149.	1.8	63
469	Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget, 2016, 7, 3403-3415.	0.8	306
470	Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e442-e448.	1.8	8
471	Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. Oncotarget, 2016, 7, 56491-56500.	0.8	75
472	The dominant-negative interplay between p53, p63 and p73: A family affair. Oncotarget, 2016, 7, 69549-69564.	0.8	33
473	Optimizing an ion semiconductor sequencing data analysis method to identify somatic mutations in the genomes of cancer cells in clinical tissue samples . Biomedical Research, 2016, 37, 359-366.	0.3	23
474	Immunomediated Pan-cancer Regulation Networks are Dominant Fingerprints after Treatment of Cell Lines with Demethylation. Cancer Informatics, 2016, 15, CIN.S31809.	0.9	0
475	Comprehensive characterization of lncRNA-mRNA related ceRNA network across 12 major cancers. Oncotarget, 2016, 7, 64148-64167.	0.8	171
476	Multi-OMICs and Genome Editing Perspectives on Liver Cancer Signaling Networks. BioMed Research International, 2016, 2016, 1-14.	0.9	7
477	Cancer Clinical Research. , 2016, , 41-53.		3
478	The Reverse Transcriptase Encoded by LINE-1 Retrotransposons in the Genesis, Progression, and Therapy of Cancer. Frontiers in Chemistry, 2016, 4, 6.	1.8	40
479	Subpathway-LNCE: Identify dysfunctional subpathways competitively regulated by lncRNAs through integrating lncRNA-mRNA expression profile and pathway topologies. Oncotarget, 2016, 7, 69857-69870.	0.8	18
480	Computational Identification of Key Regulators in Two Different Colorectal Cancer Cell Lines. Frontiers in Genetics, 2016, 7, 42.	1.1	10
481	Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy. Frontiers in Oncology, 2016, 6, 21.	1.3	99
482	Cullin 3 Ubiquitin Ligases in Cancer Biology: Functions and Therapeutic Implications. Frontiers in Oncology, 2016, 6, 113.	1.3	66
483	Targeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and Treatment. International Journal of Molecular Sciences, 2016, 17, 1552.	1.8	27

#	Article	IF	Citations
484	Comparison between two amplicon-based sequencing panels of different scales in the detection of somatic mutations associated with gastric cancer. BMC Genomics, 2016, 17, 833.	1.2	31
485	A Multi-Method Approach for Proteomic Network Inference in 11 Human Cancers. PLoS Computational Biology, 2016, 12, e1004765.	1.5	32
486	Preferential Allele Expression Analysis Identifies Shared Germline and Somatic Driver Genes in Advanced Ovarian Cancer. PLoS Genetics, 2016, 12, e1005755.	1.5	12
487	Proteotranscriptomic Analysis Reveals Stage Specific Changes in the Molecular Landscape of Clear-Cell Renal Cell Carcinoma. PLoS ONE, 2016, 11, e0154074.	1.1	42
488	Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. PLoS ONE, 2016, 11, e0155189.	1.1	112
489	Whole Genome Pathway Analysis Identifies an Association of Cadmium Response Gene Loss with Copy Number Variation in Mutant p53 Bearing Uterine Endometrial Carcinomas. PLoS ONE, 2016, 11, e0159114.	1.1	7
490	Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis. PLoS ONE, 2016, 11, e0165089.	1.1	35
491	IDH1/2 Mutants Inhibit TET-Promoted Oxidation of RNA 5mC to 5hmC. PLoS ONE, 2016, 11, e0161261.	1.1	16
492	Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. Bladder Cancer, 2016, 2, 15-25.	0.2	29
493	AKT in cancer: new molecular insights and advances in drug development. British Journal of Clinical Pharmacology, 2016, 82, 943-956.	1.1	209
494	Cancer in Drosophila. Current Topics in Developmental Biology, 2016, 116, 181-199.	1.0	44
495	TP53Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. Human Mutation, 2016, 37, 865-876.	1.1	589
496	Tongue cancer in the young. Current Opinion in Oncology, 2016, 28, 193-194.	1.1	7
497	Integrated patient and tumor genetic testing for individualized cancer therapy. Clinical Pharmacology and Therapeutics, 2016, 99, 143-146.	2.3	14
498	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and <scp>TERT</scp> promoter hotspot mutations and TERT gene amplification as likely drivers of progression. Journal of Pathology, 2016, 238, 508-518.	2.1	102
499	The Dietary Flavonoid Fisetin Causes Cell Cycle Arrest, Caspaseâ€Dependent Apoptosis, and Enhanced Cytotoxicity of Chemotherapeutic Drugs in Tripleâ€Negative Breast Cancer Cells. Journal of Cellular Biochemistry, 2016, 117, 1913-1925.	1.2	66
500	Research Needs for Understanding the Biology of Overdiagnosis in Cancer Screening. Journal of Cellular Physiology, 2016, 231, 1870-1875.	2.0	17
501	Microglandular adenosis associated with tripleâ€negative breast cancer is a neoplastic lesion of tripleâ€negative phenotype harbouring <scp>TP53</scp> somatic mutations. Journal of Pathology, 2016, 238, 677-688.	2.1	52

#	Article	IF	Citations
502	High prevalence of discordant human papillomavirus and p16 oropharyngeal squamous cell carcinomas in an African American cohort. Head and Neck, 2016, 38, E867-72.	0.9	15
503	The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures. Cancer Drug Discovery and Development, 2016, , 109-124.	0.2	0
504	A Landscape of Pharmacogenomic Interactions in Cancer. Cell, 2016, 166, 740-754.	13.5	1,518
505	Frameshift mutations of a tumor suppressor gene <scp>ZNF</scp>292 in gastric and colorectal cancers with high microsatellite instability. Apmis, 2016, 124, 556-560.	0.9	15
506	Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19â€¯784 Diverse Solid Tumors. JAMA Oncology, 2016, 2, 1565.	3.4	195
507	Pharmacological activation of wild-type p53 in the therapy of leukemia. Experimental Hematology, 2016, 44, 791-798.	0.2	41
508	Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer. , 2016, 166, 71-83.		14
509	Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing. Histopathology, 2016, 68, 262-271.	1.6	22
510	Identifying and annotating human bifunctional RNAs reveals their versatile functions. Science China Life Sciences, 2016, 59, 981-992.	2.3	16
511	Fragile Genes That Are Frequently Altered in Cancer: Players Not Passengers. Cytogenetic and Genome Research, 2016, 150, 208-216.	0.6	31
512	Detection and Characterization of Circulating Tumour Cells in Multiple Myeloma. Journal of Circulating Biomarkers, 2016, 5, 10.	0.8	15
513	Protein kinase Msk1 physically and functionally interacts with the KMT2A/MLL1 methyltransferase complex and contributes to the regulation of multiple target genes. Epigenetics and Chromatin, 2016, 9, 52.	1.8	26
514	Survival Ensemble with Sparse Random Projections for Censored Clinical and Gene Expression Data. IPSJ Transactions on Bioinformatics, 2016, 9, 18-23.	0.2	0
515	Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. ESMO Open, 2016, 1, e000094.	2.0	126
516	Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia. Genome Biology, 2016, 17, 140.	3.8	67
517	Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types. BMC Genomics, 2016, 17, 394.	1.2	28
518	Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data. BMC Bioinformatics, 2016, 17, 341.	1.2	103
519	Cell type-specific properties and environment shape tissue specificity of cancer genes. Scientific Reports, 2016, 6, 20707.	1.6	64

#	Article	IF	Citations
520	Transfer Learning for Survival Analysis via Efficient L2,1-Norm Regularized Cox Regression. , 2016, , .		32
521	The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, nonâ€coding <scp>RNA</scp> and synonymous mutations. EMBO Molecular Medicine, 2016, 8, 442-457.	3.3	209
522	New Robust Clustering Model for Identifying Cancer Genome Landscapes. , 2016, , .		4
523	A cloud-based workflow to quantify transcript-expression levels in public cancer compendia. Scientific Reports, 2016, 6, 39259.	1.6	76
524	Divergent viral presentation among human tumors and adjacent normal tissues. Scientific Reports, 2016, 6, 28294.	1.6	60
525	Effect of vascular endothelial growth factor siRNA and wild-type p53 co-expressing plasmid in MDA-MB-231 cells. Molecular Medicine Reports, 2016, 13, 461-468.	1.1	3
526	Pan-cancer subtyping in a 2D-map shows substructures that are driven by specific combinations of molecular characteristics. Scientific Reports, 2016, 6, 24949.	1.6	21
527	BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53. Scientific Reports, 2016, 6, 39743.	1.6	29
528	iCAGES: integrated CAncer GEnome Score for comprehensively prioritizing driver genes in personal cancer genomes. Genome Medicine, 2016, 8, 135.	3.6	45
530	Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia. Scientific Reports, 2016, 6, 24057.	1.6	8
531	MicroRNA-profiles in lung adenocarcinomas. Expert Review of Precision Medicine and Drug Development, 2016, 1, 469-474.	0.4	0
532	Genomic profiling of multiple sequentially acquired tumor metastatic sites from an â€œexceptional responderâ€•lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. Journal of Physical Education and Sports Management, 2016, 2, a001263.	0.5	18
533	A novel independence test for somatic alterations in cancer shows that biology drives mutual exclusivity but chance explains most co-occurrence. Genome Biology, 2016, 17, 261.	3.8	114
534	Introduction to cancer genetic susceptibility syndromes. Hematology American Society of Hematology Education Program, 2016, 2016, 293-301.	0.9	25
535	Cancer-associated DDX3X mutations drive stress granule assembly and impair global translation. Scientific Reports, 2016, 6, 25996.	1.6	121
536	Uncovering disease mechanisms through network biology in the era of Next Generation Sequencing. Scientific Reports, 2016, 6, 24570.	1.6	29
537	Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nature Communications, 2016, 7, 12484.	5.8	523
538	Should tissue structure suppress or amplify selection to minimize cancer risk?. Biology Direct, 2016, 11, 41.	1.9	24

#	Article	IF	Citations
539	Exploration of regression models for cancer noncoding mutation recurrence. , 2016, , .		1
540	A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 681-691.	2.2	46
541	Drosophila Lung Cancer Models Identify Trametinib plus Statin as Candidate Therapeutic. Cell Reports, 2016, 14, 1477-1487.	2.9	88
542	Targeting <scp>DNA</scp> repair, <scp>DNA</scp> metabolism and replication stress as antiâ€cancer strategies. FEBS Journal, 2016, 283, 232-245.	2.2	100
543	ECGene: A Literatureâ€Based Knowledgebase of Endometrial Cancer Genes. Human Mutation, 2016, 37, 337-343.	1.1	13
544	An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer. Cancer Research, 2016, 76, 1733-1745.	0.4	20
545	A novel kinase mutation in VEGFR-1 predisposes its Î±C-helix/activation loop towards allosteric activation: Atomic insights from protein simulation. European Journal of Human Genetics, 2016, 24, 1287-1293.	1.4	4
546	Regulation of Cancer Cell Behavior by the Small GTPase Rab13. Journal of Biological Chemistry, 2016, 291, 9929-9937.	1.6	38
547	TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. Cancer Cell, 2016, 29, 846-858.	7.7	228
548	Micropapillary Variant Bladder Cancer: A Bad Apple or a New Fruit?. European Urology, 2016, 70, 621-622.	0.9	0
549	The Role of MDM2 Amplification and Overexpression in Tumorigenesis. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026336.	2.9	158
550	Hematopoiesis during development, aging, and disease. Experimental Hematology, 2016, 44, 689-695.	0.2	8
551	Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations. Gynecologic Oncology, 2016, 142, 150-157.	0.6	6
552	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nature Reviews Clinical Oncology, 2016, 13, 674-690.	12.5	1,938
553	Cancer Stem Cells: Basic Concepts and Therapeutic Implications. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 47-76.	9.6	559
554	Diagnostic Potential of lncRNAs in Cancer. EBioMedicine, 2016, 7, 7-8.	2.7	4
555	Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer. British Journal of Cancer, 2016, 114, 1395-1404.	2.9	75
556	Exploring phenotype patterns of breast cancer within somatic mutations: a modicum in the intrinsic code. Briefings in Bioinformatics, 2017, 18, bbw040.	3.2	2

#	Article	IF	Citations
557	Carcinogen-specific mutations in preferred Ras-Raf pathway oncogenes directed by strand bias. Carcinogenesis, 2016, 37, 810-816.	1.3	7
558	Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. Cancer Research, 2016, 76, 3767-3772.	0.4	124
559	PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer. Molecular Cancer Therapeutics, 2016, 15, 1669-1681.	1.9	23
560	Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors. Molecular Cancer Therapeutics, 2016, 15, 1746-1756.	1.9	45
561	Genomically Driven Tumors and Actionability across Histologies:BRAF-Mutant Cancers as a Paradigm. Molecular Cancer Therapeutics, 2016, 15, 533-547.	1.9	63
562	An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. Nature Chemical Biology, 2016, 12, 531-538.	3.9	269
563	DGIdb 2.0: mining clinically relevant drugâ€“gene interactions. Nucleic Acids Research, 2016, 44, D1036-D1044.	6.5	359
564	The Role of Cholesterol in Cancer. Cancer Research, 2016, 76, 2063-2070.	0.4	438
565	The Conundrum of Genetic â€œDriversâ€•in Benign Conditions. Journal of the National Cancer Institute, 2016, 108, djw036.	3.0	113
566	Shorter telomeres and high telomerase activity correlate with a highly aggressive phenotype in breast cancer cell lines. Tumor Biology, 2016, 37, 11917-11926.	0.8	20
567	Review: the Contribution of both Nature and Nurture to Carcinogenesis and Progression in Solid Tumours. Cancer Microenvironment, 2016, 9, 63-69.	3.1	25
568	The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. Clinical Cancer Research, 2016, 22, 1865-1874.	3.2	700
569	Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nature Genetics, 2016, 48, 675-680.	9.4	236
570	Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies. Modern Pathology, 2016, 29, 685-697.	2.9	55
571	WeSME: uncovering mutual exclusivity of cancer drivers and beyond. Bioinformatics, 2017, 33, 814-821.	1.8	79
572	Analyzing Somatic Genome Rearrangements in Human Cancers by Using Whole-Exome Sequencing. American Journal of Human Genetics, 2016, 98, 843-856.	2.6	33
573	The spectrum of renal cell carcinoma in adults. Abdominal Radiology, 2016, 41, 1052-1065.	1.0	5
574	A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 741-749.	2.2	13

#	Article	IF	Citations
575	Impacts of somatic mutations on gene expression: an association perspective. Briefings in Bioinformatics, 2017, 18, bbw037.	3.2	40
576	Genomic Approaches to Zebrafish Cancer. Advances in Experimental Medicine and Biology, 2016, 916, 125-145.	0.8	5
577	The role of the RAS pathway in iAMP21-ALL. Leukemia, 2016, 30, 1824-1831.	3.3	38
578	Clinical Implications of Genomic Discoveries in Lung Cancer. New England Journal of Medicine, 2016, 374, 1864-1873.	13.9	235
579	Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers. Oncologist, 2016, 21, 1315-1325.	1.9	64
580	Frameshift Mutation of ASPM Gene in Colorectal Cancers with Regional Heterogeneity. Pathology and Oncology Research, 2016, 22, 877-879.	0.9	5
581	Exome and Genome Sequencing and ParallelsÂinÂRadiology: Searching for Patient-Centered Management of IncidentalÂandÂSecondary Findings. Journal of the American College of Radiology, 2016, 13, 1467-1472.	0.9	7
582	Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. Cancer Letters, 2016, 382, 32-43.	3.2	25
583	Polycomb and trithorax opposition in development and disease. Wiley Interdisciplinary Reviews: Developmental Biology, 2016, 5, 659-688.	5.9	37
584	A practical approach to liver metastasis from unknown primary cancer: What surgeons need to know. Cancer Genetics, 2016, 209, 559-566.	0.2	13
585	Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 2129-2140.	0.5	70
586	CMOS biosensors for in vitro diagnosis â€“ transducing mechanisms and applications. Lab on A Chip, 2016, 16, 3664-3681.	3.1	35
587	Acute Myeloid Leukemia: How Do We Measure Success?. Current Hematologic Malignancy Reports, 2016, 11, 528-536.	1.2	8
588	Shedding Light on the 2016 World Health Organization Classification of Tumors of the Central Nervous System in the Era of Radiomics and Radiogenomics. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 741-749.	0.6	13
589	Epigenomic Consequences of Coding and Noncoding Driver Mutations. Trends in Cancer, 2016, 2, 585-605.	3.8	8
590	TET enzymes as oxygen-dependent tumor suppressors: exciting new avenues for cancer management. Epigenomics, 2016, 8, 1445-1448.	1.0	9
591	Systematic Analysis Reveals that Cancer Mutations Converge on Deregulated Metabolism of Arachidonate and Xenobiotics. Cell Reports, 2016, 16, 878-895.	2.9	21
592	Mutational and expressional alterations of ZMPSTE24, DNA damage response-related gene, in gastric and colorectal cancers. Pathology Research and Practice, 2016, 212, 1113-1118.	1.0	2

#	Article	IF	Citations
593	Dysregulation of histone methyltransferases in breast cancer â€“ Opportunities for new targeted therapies?. Molecular Oncology, 2016, 10, 1497-1515.	2.1	56
594	Epigenetics, Enhancers, and Cancer. Energy Balance and Cancer, 2016, , 29-53.	0.2	1
595	The Ecology and Evolution of Cancer: The Ultra-Microevolutionary Process. Annual Review of Genetics, 2016, 50, 347-369.	3.2	86
597	Proteogenomic Analysis of Single Amino Acid Polymorphisms in Cancer Research. Advances in Experimental Medicine and Biology, 2016, 926, 93-113.	0.8	7
598	In silicoframeworks for systematic pre-clinical screening of potential anti-leukemia therapeutics. Expert Opinion on Drug Discovery, 2016, 11, 1213-1222.	2.5	3
599	The genomic landscape of breast cancer and its interaction with host immunity. Breast, 2016, 29, 241-250.	0.9	194
600	Individual response to ionizing radiation. Mutation Research - Reviews in Mutation Research, 2016, 770, 369-386.	2.4	124
601	Geographic Pervasiveness of Cancer: Prospects of Novel Biomarker and Therapeutic Research in Developing Countries using OMICS approaches. , 2016, , 9-17.		1
602	Big Data Analytics. , 2016, , .		9
603	The Role of p53/p21/p16 in DNA-Damage Signaling and DNA Repair. , 2016, , 243-256.		15
604	The Relationship Between Checkpoint Adaptation and Mitotic Catastrophe in Genomic Changes in Cancer Cells. , 2016, , 373-389.		8
605	Epigenetics of hematopoiesis and hematological malignancies. Genes and Development, 2016, 30, 2021-2041.	2.7	125
606	Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. Clinical Cancer Research, 2016, 22, 6228-6235.	3.2	40
607	Signaling Receptors for TGF-Î² Family Members. Cold Spring Harbor Perspectives in Biology, 2016, 8, a022053.	2.3	480
608	Panobinostat for the treatment of acute myelogenous leukemia. Expert Opinion on Investigational Drugs, 2016, 25, 1117-1131.	1.9	23
609	Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. Cell, 2016, 166, 1041-1054.	13.5	206
610	Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. Modern Pathology, 2016, 29, 1292-1305.	2.9	68
611	Dosing targeted and cytotoxic twoâ€drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013. International Journal of Cancer, 2016, 139, 2135-2141.	2.3	31

#	Article	IF	Citations
612	Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nature Medicine, 2016, 22, 1056-1061.	15.2	62
613	Clinical Outcomes of TP53 Mutations in Cancers. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026294.	2.9	49
614	Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications. Cancer and Metastasis Reviews, 2016, 35, 457-474.	2.7	48
615	Molecular targets of curcumin for cancer therapy: an updated review. Tumor Biology, 2016, 37, 13017-13028.	0.8	157
616	In search for symmetries in the metabolism of cancer. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2016, 8, 23-35.	6.6	6
617	Development of a robust DNA quality and quantity assessment qPCR assay for targeted next-generation sequencing library preparation. International Journal of Oncology, 2016, 49, 1755-1765.	1.4	10
618	Enhancer deregulation in cancer and other diseases. BioEssays, 2016, 38, 1003-1015.	1.2	79
619	Evidence for a role of a lncRNA encoded from the p53 tumor suppressor gene in maintaining the undifferentiated state of human myeloid leukemias. Gene Reports, 2016, 5, 45-50.	0.4	4
620	Higher Order Chromatin Modulator Cohesin SA1 Is an Early Biomarker for Colon Carcinogenesis: Race-Specific Implications. Cancer Prevention Research, 2016, 9, 844-854.	0.7	11
621	Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genomics, 2016, 17, 525.	1.2	172
622	Studying Cancer Evolution in Barrettâ€™s Esophagus and Esophageal Adenocarcinoma. Advances in Experimental Medicine and Biology, 2016, 908, 213-236.	0.8	1
623	Cancer Biomarkers in Body Fluids. , 2016, , .		5
624	CPe-III-S Metabolism in Vitro and in Vivo and Molecular Simulation of Its Metabolites Using a p53-R273H Mutant. Journal of Agricultural and Food Chemistry, 2016, 64, 7095-7103.	2.4	3
625	Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?. Cold Spring Harbor Perspectives in Biology, 2016, 8, a023614.	2.3	70
626	H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development. Future Medicinal Chemistry, 2016, 8, 1589-1607.	1.1	37
628	Novel Approaches to Apoptosis-Inducing Therapies. Advances in Experimental Medicine and Biology, 2016, 930, 173-204.	0.8	17
629	Systems medicine in colorectal cancer: from a mathematical model toward a new type of clinical trial. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2016, 8, 314-336.	6.6	11
630	Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9846-9851.	3.3	178

#	Article	IF	Citations
631	Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Scientific Reports, 2016, 6, 26191.	1.6	162
632	Hepatocellular carcinoma cell lines retain the genomic and transcriptomic landscapes of primary human cancers. Scientific Reports, 2016, 6, 27411.	1.6	49
633	p53 Regulates Progenitor Cell Quiescence and Differentiation in the Airway. Cell Reports, 2016, 17, 2173-2182.	2.9	62
634	Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discovery, 2016, 6, 1342-1351.	7.7	168
635	Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. Npj Breast Cancer, 2016, 2, 16036.	2.3	127
636	Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes?. Cancer Research, 2016, 76, 5195-5200.	0.4	41
637	Zinc and zinc-containing biomolecules in childhood brain tumors. Journal of Molecular Medicine, 2016, 94, 1199-1215.	1.7	15
638	Adenovirus-mediated p53 and ING4 gene co-transfer elicits synergistic antitumor effects through enhancement of p53 acetylation in breast cancer. Oncology Reports, 2016, 35, 243-252.	1.2	13
639	hERG1 potassium channel in cancer cells: a tool to reprogram immortality. European Biophysics Journal, 2016, 45, 649-655.	1.2	17
640	MLL3/MLL4/COMPASS Family on Epigenetic Regulation of Enhancer Function and Cancer. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026427.	2.9	122
641	Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. Oncologist, 2016, 21, 1200-1211.	1.9	211
642	Unsupervised detection of cancer driver mutations with parsimony-guided learning. Nature Genetics, 2016, 48, 1288-1294.	9.4	52
643	Candidate driver genes involved in genome maintenance and DNA repair in SÃ©zary syndrome. Blood, 2016, 127, 3387-3397.	0.6	96
644	Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. Blood, 2016, 127, 221-232.	0.6	97
645	Implications and opportunities of precision medicine in rare malignancies. Expert Opinion on Orphan Drugs, 2016, 4, 953-960.	0.5	0
646	Small-molecule binding sites to explore proteinâ€“protein interactions in the cancer proteome. Molecular BioSystems, 2016, 12, 3067-3087.	2.9	15
647	Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study. Molecular Therapy, 2016, 24, 1697-1706.	3.7	79
648	Tumors smother their epigenome. Molecular and Cellular Oncology, 2016, 3, e1240549.	0.3	8

#	Article	IF	Citations
649	Rational design of cancer gene panels with OncoPaD. Genome Medicine, 2016, 8, 98.	3.6	5
650	Genetic alterations in fatty acid transport and metabolism genes are associated with metastatic progression and poor prognosis of human cancers. Scientific Reports, 2016, 6, 18669.	1.6	155
651	Cohesin Mutations in Cancer. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026476.	2.9	68
652	The minimal amount of starting DNA for Agilentâ€™s hybrid capture-based targeted massively parallel sequencing. Scientific Reports, 2016, 6, 26732.	1.6	37
653	Transposon mutagenesis identifies genes that cooperate with mutant Pten in breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7749-E7758.	3.3	48
654	Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation. Nature Communications, 2016, 7, 13294.	5.8	34
655	Systematic analysis of mutation distribution in three dimensional protein structures identifies cancer driver genes. Scientific Reports, 2016, 6, 26483.	1.6	20
656	Pitfalls of improperly procured adjacent non-neoplastic tissue for somatic mutation analysis using next-generation sequencing. BMC Medical Genomics, 2016, 9, 64.	0.7	14
657	Challenges in identifying cancer genes by analysis of exome sequencing data. Nature Communications, 2016, 7, 12096.	5.8	34
658	Discovery of Novel Spiro[3H-indole-3,2â€²-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2â€“p53 Interaction. Journal of Medicinal Chemistry, 2016, 59, 10147-10162.	2.9	89
659	Computational pan-genomics: status, promises and challenges. Briefings in Bioinformatics, 2018, 19, bbw089.	3.2	207
660	Big Data Analytics in Genomics. , 2016, , .		7
661	Emerging role of checkpoint inhibition in localized bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 548-555.	0.8	19
662	Deubiquitylating enzyme USP9x regulates hippo pathway activity by controlling angiomotin protein turnover. Cell Discovery, 2016, 2, 16001.	3.1	34
663	Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations. Cancer Research, 2016, 76, 6785-6794.	0.4	3
664	Computational Approaches to Accelerating Novel Medicine and Better Patient Care from Bedside to Benchtop. Advances in Protein Chemistry and Structural Biology, 2016, 102, 147-179.	1.0	2
665	SSA-ME Detection of cancer driver genes using mutual exclusivity by small subnetwork analysis. Scientific Reports, 2016, 6, 36257.	1.6	12
666	Regulation of disease-associated gene expression in the 3D genome. Nature Reviews Molecular Cell Biology, 2016, 17, 771-782.	16.1	294

#	Article	IF	Citations
667	Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer. Genome Medicine, 2016, 8, 55.	3.6	51
668	The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nature Communications, 2016, 7, 11479.	5.8	1,221
669	Quantitative Proteomics of the SMAD (Suppressor of Mothers against Decapentaplegic) Transcription Factor Family Identifies Importin 5 as a Bone Morphogenic Protein Receptor SMAD-specific Importin. Journal of Biological Chemistry, 2016, 291, 24121-24132.	1.6	15
670	Cancer driver gene discovery through an integrative genomics approach in a non-parametric Bayesian framework. Bioinformatics, 2017, 33, 483-490.	1.8	22
671	Basic Principles of Carcinogenesis. , 2016, , 1-17.		1
672	A Bioinformatics Approach for Understanding Genotypeâ€“Phenotype Correlation in Breast Cancer. , 2016, , 397-428.		1
673	Big Data and Cancer Research. , 2016, , 259-276.		1
674	Insights into cancer severity from biomolecular interaction mechanisms. Scientific Reports, 2016, 6, 34490.	1.6	21
675	Correlation between Gene Variants, Signaling Pathways, and Efficacy of Chemotherapy Drugs against Colon Cancers. Cancer Informatics, 2016, 15, CIN.S34506.	0.9	13
676	Integrating cancer genomic data into electronic health records. Genome Medicine, 2016, 8, 113.	3.6	57
677	XGR software for enhanced interpretation of genomic summary data, illustrated by application to immunological traits. Genome Medicine, 2016, 8, 129.	3.6	137
678	Investigating cellular network heterogeneity and modularity in cancer: a network entropy and unbalanced motif approach. BMC Systems Biology, 2016, 10, 65.	3.0	36
679	Cancer immunotherapy. Current Opinion in Urology, 2016, 26, 535-542.	0.9	9
680	Cancer immunotherapy. Current Opinion in Urology, 2016, 26, 556-563.	0.9	5
681	Progress in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2016, , .	0.8	6
682	Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 191-201.	1.4	12
683	Prognostic and Predictive Effect of TP53 Mutations inÂPatients with Nonâ€“Small Cell Lung Cancer from Adjuvant Cisplatinâ€“Based Therapy Randomized Trials:ÂA LACE-Bio Pooled Analysis. Journal of Thoracic Oncology, 2016, 11, 850-861.	0.5	78
684	Histone H3.5 forms an unstable nucleosome and accumulates around transcription start sites in human testis. Epigenetics and Chromatin, 2016, 9, 2.	1.8	53

#	Article	IF	Citations
685	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature Medicine, 2016, 22, 792-799.	15.2	322
686	Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nature Cell Biology, 2016, 18, 897-909.	4.6	205
687	The clinical utility of molecular genetic cancer profiling. Expert Review of Molecular Diagnostics, 2016, 16, 827-838.	1.5	6
688	Systematic interactome mapping of acute lymphoblastic leukemia cancer gene products reveals EXT-1 tumor suppressor as a Notch1 and FBWX7 common interactor. BMC Cancer, 2016, 16, 335.	1.1	15
689	Epigenetic balance of gene expression by Polycomb and COMPASS families. Science, 2016, 352, aad9780.	6.0	407
690	GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease. Cancer Letters, 2016, 376, 104-109.	3.2	22
691	Web-TCGA: an online platform for integrated analysis of molecular cancer data sets. BMC Bioinformatics, 2016, 17, 72.	1.2	140
692	The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinomaâ€"differences in histological subtypes. BMC Cancer, 2016, 16, 71.	1.1	14
693	Integrative DNA methylome analysis of pan-cancer biomarkers in cancer discordant monozygotic twin-pairs. Clinical Epigenetics, 2016, 8, 7.	1.8	32
694	Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model. Clinical Epigenetics, 2016, 8, 34.	1.8	61
695	PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. Cell Reports, 2016, 15, 2692-2704.	2.9	92
696	Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. Cancer Discovery, 2016, 6, 1006-1021.	7.7	108
697	The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice. Genetics, 2016, 203, 1601-1611.	1.2	8
698	The Somatic Nature of Cancer Allows It to Affect Highly Constrained Genes. Genome Biology and Evolution, 2016, 8, 1614-1620.	1.1	3
699	Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics. Cell Reports, 2016, 15, 2705-2718.	2.9	78
700	Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma. Clinical Cancer Research, 2016, 22, 4356-4365.	3.2	68
701	Evaluating the molecule-based prediction of clinical drug responses in cancer. Bioinformatics, 2016, 32, 2891-2895.	1.8	113
703	Malignant pheochromocytomas/paragangliomas harbor mutations in transport and cell adhesion genes. International Journal of Cancer, 2016, 138, 2201-2211.	2.3	24

#	Article	IF	Citations
704	Uterine adenosarcomas are mesenchymal neoplasms. Journal of Pathology, 2016, 238, 381-388.	2.1	94
705	The <scp>CDKN</scp>2A/p16<scp>^{INK}</scp>^{4a} 5â€²<scp>UTR</scp> sequence and translational regulation: impact of novel variants predisposing to melanoma. Pigment Cell and Melanoma Research, 2016, 29, 210-221.	1.5	9
706	The biology of circulating tumor cells. Oncogene, 2016, 35, 1216-1224.	2.6	421
707	Using high-throughput sequencing transcriptome data for INDEL detection: challenges for cancer drug discovery. Expert Opinion on Drug Discovery, 2016, 11, 257-268.	2.5	6
708	Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. European Urology, 2016, 70, 75-82.	0.9	174
709	Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs. , 2016, 162, 69-85.		27
710	Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types. Nature Communications, 2016, 7, 10499.	5.8	124
711	Assessment of Minimal Residual Disease in Standard-Risk AML. New England Journal of Medicine, 2016, 374, 422-433.	13.9	662
712	The kinome 'at large' in cancer. Nature Reviews Cancer, 2016, 16, 83-98.	12.8	226
713	Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment. Pharmacogenomics, 2016, 17, 297-307.	0.6	36
714	Defective control of preâ€“messenger RNA splicing in human disease. Journal of Cell Biology, 2016, 212, 13-27.	2.3	182
715	Frameshift Mutations of AKAP9 Gene in Gastric and Colorectal Cancers with High Microsatellite Instability. Pathology and Oncology Research, 2016, 22, 587-592.	0.9	20
716	Polymorphisms in methylenetetrahydrofolate reductase and cystathionine beta-synthase in oral cancer â€“ a caseâ€“control study in southeastern Brazilians. Brazilian Journal of Otorhinolaryngology, 2016, 82, 558-566.	0.4	2
717	Role of non-coding sequence variants in cancer. Nature Reviews Genetics, 2016, 17, 93-108.	7.7	420
718	Synergistic tumor suppression by adenovirus-mediated ING4/PTEN double gene therapy for gastric cancer. Cancer Gene Therapy, 2016, 23, 13-23.	2.2	15
719	Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. Journal of Clinical Oncology, 2016, 34, 91-101.	0.8	146
720	Systematic discovery of complex insertions and deletions in human cancers. Nature Medicine, 2016, 22, 97-104.	15.2	93
721	An integrative somatic mutation analysis to identify pathways linked with survival outcomes across 19 cancer types. Bioinformatics, 2016, 32, 1643-1651.	1.8	35

#	Article	IF	Citations
722	Microsatellite instability in pulmonary adenocarcinomas: a comprehensive study of 480 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 313-319.	1.4	60
723	The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organsâ€"Part B: Prostate and Bladder Tumours. European Urology, 2016, 70, 106-119.	0.9	1,323
724	Pharmacogenetic Predictors of Response. Advances in Experimental Medicine and Biology, 2016, 882, 191-215.	0.8	4
725	cMyc-p53 feedback mechanism regulates the dynamics of T lymphocytes in the immune response. Cell Cycle, 2016, 15, 1267-1275.	1.3	13
726	Cancer genomics: opportunities for medicinal chemistry?. Future Medicinal Chemistry, 2016, 8, 357-359.	1.1	4
727	Pan-Cancer Analyses Reveal Long Intergenic Non-Coding RNAs Relevant to Tumor Diagnosis, Subtyping and Prognosis. EBioMedicine, 2016, 7, 62-72.	2.7	33
728	Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers. Gynecologic Oncology, 2016, 141, 2-9.	0.6	40
729	The importance of p53 pathway genetics in inherited and somatic cancer genomes. Nature Reviews Cancer, 2016, 16, 251-265.	12.8	131
731	CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 692-700.	2.2	6
732	NCG 5.0: updates of a manually curated repository of cancer genes and associated properties from cancer mutational screenings. Nucleic Acids Research, 2016, 44, D992-D999.	6.5	95
733	Future directions in bladder cancer immunotherapy: towards adaptive immunity. Immunotherapy, 2016, 8, 351-365.	1.0	21
734	Regulation of epithelialâ€"mesenchymal transition in endometrial cancer: connecting PI3K, estrogen signaling, and microRNAs. Clinical and Translational Oncology, 2016, 18, 1056-1061.	1.2	26
735	Distinct Subtypes of Gastric Cancer Defined by Molecular Characterization Include Novel Mutational Signatures with Prognostic Capability. Cancer Research, 2016, 76, 1724-1732.	0.4	120
736	Noninvasive diagnosis and monitoring of mutations by deep sequencing of circulating tumor DNA in esophageal squamous cell carcinoma. Biochemical and Biophysical Research Communications, 2016, 471, 596-602.	1.0	47
737	Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2170-2175.	3.3	102
738	Whole-genome mutational burden analysis of three pluripotency induction methods. Nature Communications, 2016, 7, 10536.	5.8	109
739	Coordinating cell proliferation and differentiation: Antagonism between cell cycle regulators and cell type-specific gene expression. Cell Cycle, 2016, 15, 196-212.	1.3	417
740	Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes. Cancer Research, 2016, 76, 1975-1988.	0.4	89

#	Article	IF	Citations
741	Next-Generation Sequencing for the Analysis of Cancer Specimens. , 2016, , 911-931.		0
742	Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships. Molecular Oncology, 2016, 10, 360-370.	2.1	41
743	Cell Competition Drives the Formation of Metastatic Tumors in a Drosophila Model of Epithelial Tumor Formation. Current Biology, 2016, 26, 419-427.	1.8	90
744	Chemotherapy for Muscle-Invasive Bladder Cancer. Current Treatment Options in Oncology, 2016, 17, 6.	1.3	19
745	Autoantibody Production in Cancerâ€"The Humoral Immune Response toward Autologous Antigens in Cancer Patients. Autoimmunity Reviews, 2016, 15, 477-483.	2.5	196
746	The Genomic Landscape of Male Breast Cancers. Clinical Cancer Research, 2016, 22, 4045-4056.	3.2	119
747	Special Techniques. , 2016, , 11-44.		0
748	Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nature Reviews Genetics, 2016, 17, 284-299.	7.7	679
749	Mutation R273H confers p53 a stimulating effect on the IGF-1R-AKT pathway via miR-30a suppression in breast cancer. Biomedicine and Pharmacotherapy, 2016, 78, 335-341.	2.5	16
751	Upregulation of RNA Processing Factors in Poorly Differentiated Lung Cancer Cells. Translational Oncology, 2016, 9, 89-98.	1.7	9
752	Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. BMC Cancer, 2016, 16, 170.	1.1	30
753	HP1-Assisted Aurora B Kinase Activity Prevents Chromosome Segregation Errors. Developmental Cell, 2016, 36, 487-497.	3.1	61
755	Ratiometric Array of Conjugated Polymersâ€"Fluorescent Protein Provides a Robust Mammalian Cell Sensor. Journal of the American Chemical Society, 2016, 138, 4522-4529.	6.6	122
756	The inflammatory inception of gallbladder cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 245-254.	3.3	71
757	The impact of next-generation sequencing on the DNA methylationâ€"based translational cancer research. Translational Research, 2016, 169, 1-18.e1.	2.2	58
758	Ancestral-derived effects on the mutational landscape of laryngeal cancer. Genomics, 2016, 107, 76-82.	1.3	18
759	On the Sample Complexity of Cancer Pathways Identification. Journal of Computational Biology, 2016, 23, 30-41.	0.8	6
760	p53 as an Effector or Inhibitor of Therapy Response. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026260.	2.9	10

#	Article	IF	Citations
761	The relationship between the nucleolus and cancer: Current evidence and emerging paradigms. Seminars in Cancer Biology, 2016, 37-38, 36-50.	4.3	149
762	Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development. Advances in Experimental Medicine and Biology, 2016, 890, 1-23.	0.8	7
763	A Systems Oncology Approach Identifies NT5E as a Key Metabolic Regulator in Tumor Cells and Modulator of Platinum Sensitivity. Journal of Proteome Research, 2016, 15, 280-290.	1.8	26
764	Evolving Lessons on the Complex Role of AMPK in Normal Physiology and Cancer. Trends in Pharmacological Sciences, 2016, 37, 192-206.	4.0	104
765	TBMS1 exerts its cytotoxicity in NCI-H460 lung cancer cells through nucleolar stress-induced p53/MDM2-dependent mechanism, a quantitative proteomics study. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2016, 1864, 204-210.	1.1	16
766	BAP1/ASXL1 recruitment and activation for H2A deubiquitination. Nature Communications, 2016, 7, 10292.	5.8	149
767	CRISPR-Cas9â€“based target validation for p53-reactivating model compounds. Nature Chemical Biology, 2016, 12, 22-28.	3.9	74
768	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nature Biotechnology, 2016, 34, 155-163.	9.4	634
769	Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nature Medicine, 2016, 22, 105-113.	15.2	629
770	Exploring preferred amino acid mutations in cancer genes: Applications to identify potential drug targets. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 155-165.	1.8	28
771	The noncoding RNAs SNORD50A and SNORD50B bind K-Ras and are recurrently deleted in human cancer. Nature Genetics, 2016, 48, 53-58.	9.4	143
772	Single-cell analysis of CTCs with diagnostic precision: opportunities and challenges for personalized medicine. Expert Review of Molecular Diagnostics, 2016, 16, 25-38.	1.5	30
773	Targeting p300 Addiction inCBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation ofMYCExpression. Cancer Discovery, 2016, 6, 430-445.	7.7	129
774	Emerging strategies for targeting PI3K in gynecologic cancer. Gynecologic Oncology, 2016, 140, 333-344.	0.6	21
775	RRP12 is a crucial nucleolar protein that regulates p53 activity in osteosarcoma cells. Tumor Biology, 2016, 37, 4351-4358.	0.8	17
776	Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer. Oncogene, 2016, 35, 2357-2369.	2.6	35
777	Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene, 2016, 35, 2413-2427.	2.6	426
778	lncRNAs and microRNAs with a role in cancer development. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2016, 1859, 169-176.	0.9	449

#	Article	IF	Citations
779	Long noncoding RNAs: Re-writing dogmas of RNA processing and stability. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2016, 1859, 128-138.	0.9	182
780	Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers. Oncogene, 2016, 35, 1386-1398.	2.6	22
781	Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma. Clinical Cancer Research, 2017, 23, 283-288.	3.2	70
782	Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response. Oncogene, 2017, 36, 35-46.	2.6	85
783	Translational aspects in targeting the stromal tumour microenvironment: From bench to bedside. European Journal of Molecular and Clinical Medicine, 2017, 3, 9.	0.5	18
784	Distinct oncogenic Ras signals characterized by profound differences in flux through the RasGDP/RasGTP cycle. Small GTPases, 2017, 8, 20-25.	0.7	10
785	Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, 392-398.	0.6	7
786	Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy. Chemotherapy, 2017, 62, 43-53.	0.8	69
788	Genomic insights in gynecologic cancer. Current Problems in Cancer, 2017, 41, 8-36.	1.0	13
789	The Cellular Origin and Evolution of Breast Cancer. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a027128.	2.9	67
790	Gambogic acid potentiates the chemosensitivity of colorectal cancer cells to 5-fluorouracil by inhibiting proliferation and inducing apoptosis. Experimental and Therapeutic Medicine, 2017, 13, 662-668.	0.8	13
791	Integrated analysis of differentially expressed genes and pathways in triple-negative breast cancer. Molecular Medicine Reports, 2017, 15, 1087-1094.	1.1	10
792	Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing. Genetics in Medicine, 2017, 19, 989-997.	1.1	90
793	The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB. Clinical Cancer Research, 2017, 23, 3871-3883.	3.2	53
794	Single palindromic molecular beacon-based amplification for genetic analysis of cancers. Biosensors and Bioelectronics, 2017, 91, 692-698.	5.3	28
795	Altered Pathway Analyzer: A gene expression dataset analysis tool for identification and prioritization of differentially regulated and network rewired pathways. Scientific Reports, 2017, 7, 40450.	1.6	12
796	DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer. Nature Communications, 2017, 8, 14093.	5.8	85
797	Helicobacter pylori-Mediated Genetic Instability and Gastric Carcinogenesis. Current Topics in Microbiology and Immunology, 2017, 400, 305-323.	0.7	25

#	Article	IF	Citations
798	The Chromodomain Helicase DNA-Binding Chromatin Remodelers: Family Traits that Protect from and Promote Cancer. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026450.	2.9	54
799	Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications. Current Breast Cancer Reports, 2017, 9, 34-44.	0.5	11
800	Predicting evolution. Nature Ecology and Evolution, 2017, 1, 77.	3.4	272
801	Hidden Markov Models in Bioinformatics: SNV Inference from Next Generation Sequence. Methods in Molecular Biology, 2017, 1552, 123-133.	0.4	2
802	(+)-Strebloside-Induced Cytotoxicity in Ovarian Cancer Cells Is Mediated through Cardiac Glycoside Signaling Networks. Journal of Natural Products, 2017, 80, 659-669.	1.5	33
803	The OncoPPi network of cancer-focused proteinâ€“protein interactions to inform biological insights and therapeutic strategies. Nature Communications, 2017, 8, 14356.	5.8	151
804	Milestones in pathologyâ€”from histology to molecular biology. Memo - Magazine of European Medical Oncology, 2017, 10, 42-45.	0.3	7
805	Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast. Molecular Oncology, 2017, 11, 913-926.	2.1	11
806	B-Myb Induces APOBEC3B Expression Leading to Somatic Mutation in Multiple Cancers. Scientific Reports, 2017, 7, 44089.	1.6	26
807	Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies. Genome Medicine, 2017, 9, 16.	3.6	50
808	Functional germline variants in driver genes of breast cancer. Cancer Causes and Control, 2017, 28, 259-271.	0.8	12
809	Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. Nature Communications, 2017, 8, 14447.	5.8	22
810	Aneuploidy in Cancer: Seq-ing Answers to Old Questions. Annual Review of Cancer Biology, 2017, 1, 335-354.	2.3	65
811	The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas. Clinical Cancer Research, 2017, 23, 3859-3870.	3.2	129
812	Targeting human SET1/MLL family of proteins. Protein Science, 2017, 26, 662-676.	3.1	49
813	Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer. Journal of Surgical Research, 2017, 212, 195-204.	0.8	27
814	The evolving genomic landscape of urothelial carcinoma. Nature Reviews Urology, 2017, 14, 215-229.	1.9	89
815	Transcriptional Addiction in Cancer. Cell, 2017, 168, 629-643.	13.5	843

#	Article	IF	Citations
816	Implementing Genome-Driven Oncology. Cell, 2017, 168, 584-599.	13.5	405
817	Identification of outcome-related driver mutations in cancer using conditional co-occurrence distributions. Scientific Reports, 2017, 7, 43350.	1.6	8
818	Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Research, 2017, 77, 1250-1260.	0.4	68
819	Comprehensive characterization of genes associated with the TP53 signal transduction pathway in various tumors. Molecular and Cellular Biochemistry, 2017, 431, 75-85.	1.4	7
820	Historical Perspective on Familial Gastric Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2017, 3, 192-200.	2.3	31
821	Elevated PRC1 in gastric carcinoma exerts oncogenic function and is targeted by piperlongumine in a p53â€dependent manner. Journal of Cellular and Molecular Medicine, 2017, 21, 1329-1341.	1.6	33
822	Haploinsufficiency networks identify targetable patterns of allelic deficiency in low mutation ovarian cancer. Nature Communications, 2017, 8, 14423.	5.8	35
823	A stemness-related ZEB1â€“MSRB3 axis governs cellular pliancy and breast cancer genome stability. Nature Medicine, 2017, 23, 568-578.	15.2	131
824	High-confidence coding and noncoding transcriptome maps. Genome Research, 2017, 27, 1050-1062.	2.4	58
826	Discovery of cancer common and specific driver gene sets. Nucleic Acids Research, 2017, 45, e86-e86.	6.5	55
827	Genomics and evolution of protein phosphatases. Science Signaling, 2017, 10, .	1.6	206
828	An Expanded Association Approach for Rare Germline Variants with Copy-Number Alternation. Lecture Notes in Computer Science, 2017, , 81-94.	1.0	1
829	Potentially functional variants in lncRNAs are associated with breast cancer risk in a Chinese population. Molecular Carcinogenesis, 2017, 56, 2048-2057.	1.3	11
830	Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients. Oncologist, 2017, 22, 576-584.	1.9	39
831	Intrinsic Molecular Processes: Impact on Mutagenesis. Trends in Cancer, 2017, 3, 357-371.	3.8	4
832	Network Analysis Reveals A Signaling Regulatory Loop in the PIK3CA-mutated Breast Cancer Predicting Survival Outcome. Genomics, Proteomics and Bioinformatics, 2017, 15, 121-129.	3.0	51
833	Bisulfite-converted duplexes for the strand-specific detection and quantification of rare mutations. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4733-4738.	3.3	12
834	Computational methods to dissect gene regulatory networks in cancer. Current Opinion in Systems Biology, 2017, 2, 115-122.	1.3	8

#	Article	IF	Citations
835	Exploring background mutational processes to decipher cancer genetic heterogeneity. Nucleic Acids Research, 2017, 45, W514-W522.	6.5	65
836	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	15.2	2,473
837	TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis. Cancer Research, 2017, 77, 3181-3193.	0.4	102
838	TP53 Arg72Pro, mortality after cancer, and all-cause mortality in 105,200 individuals. Scientific Reports, 2017, 7, 336.	1.6	8
839	Single-cell template strand sequencing by Strand-seq enables the characterization of individual homologs. Nature Protocols, 2017, 12, 1151-1176.	5.5	89
840	â€˜Big dataâ€™ approaches for novel anti-cancer drug discovery. Expert Opinion on Drug Discovery, 2017, 12, 599-609.	2.5	9
841	Enrichment of PI3K-AKTâ€“mTOR Pathway Activation in Hepatic Metastases from Breast Cancer. Clinical Cancer Research, 2017, 23, 4919-4928.	3.2	74
842	Genome variation across cancers scales with tissue stiffness â€“ An invasion-mutation mechanism and implications for immune cell infiltration. Current Opinion in Systems Biology, 2017, 2, 103-114.	1.3	50
843	Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer. Clinical Cancer Research, 2017, 23, 4693-4703.	3.2	62
844	Molecular Genetics of Endometrial Carcinoma. Advances in Experimental Medicine and Biology, 2017, , .	0.8	6
845	Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS. Human Cell, 2017, 30, 140-148.	1.2	3
846	A comprehensive map of molecular drug targets. Nature Reviews Drug Discovery, 2017, 16, 19-34.	21.5	1,608
847	RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response. Leukemia, 2017, 31, 1706-1714.	3.3	49
848	CanProVar 2.0: An Updated Database of Human Cancer Proteome Variation. Journal of Proteome Research, 2017, 16, 421-432.	1.8	36
849	Next-Generation Sequencing. Advances in Experimental Medicine and Biology, 2017, 943, 119-148.	0.8	54
850	Cooperative genomic alteration network reveals molecular classification across 12 major cancer types. Nucleic Acids Research, 2017, 45, 567-582.	6.5	32
851	Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations. Clinical Cancer Research, 2017, 23, 5547-5560.	3.2	40
852	Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation. Oncogene, 2017, 36, 5885-5896.	2.6	56

#	Article	IF	Citations
853	A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. Cancer Cell, 2017, 31, 820-832.e3.	7.7	433
854	Myxoid fibroadenomas differ from conventional fibroadenomas: a hypothesisâ€generating study. Histopathology, 2017, 71, 626-634.	1.6	26
855	Targeted sequencing-based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia. British Journal of Cancer, 2017, 117, 136-143.	2.9	29
856	Immunogenomics: using genomics to personalize cancer immunotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 209-219.	1.4	7
857	Informing materials: drugs as tools for exploring cancer mechanisms and pathways. History and Philosophy of the Life Sciences, 2017, 39, 10.	0.6	11
858	Molecular regulation and pharmacological targeting of the Î²â€catenin destruction complex. British Journal of Pharmacology, 2017, 174, 4575-4588.	2.7	61
859	Recent progress in immunotherapy for urological cancer. International Journal of Urology, 2017, 24, 735-742.	0.5	12
860	MicroRNAs as Key Effectors in the p53 Network. International Review of Cell and Molecular Biology, 2017, 333, 51-90.	1.6	34
861	Translational control and the cancer cell response to stress. Current Opinion in Cell Biology, 2017, 45, 102-109.	2.6	58
862	Targeting DNA damage response systems to impact cancer care. Current Problems in Cancer, 2017, 41, 247-250.	1.0	2
863	A molecular portrait of microsatellite instability across multiple cancers. Nature Communications, 2017, 8, 15180.	5.8	480
864	MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma. Nature Communications, 2017, 8, 15770.	5.8	64
865	Semi-automated cancer genome analysis using high-performance computing. Human Mutation, 2017, 38, 1325-1335.	1.1	9
866	A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo. Nature Methods, 2017, 14, 737-742.	9.0	105
867	CD117 expression is a predictive marker for poor prognosis in patients with non-small cell lung cancer. Oncology Letters, 2017, 13, 3703-3708.	0.8	22
868	Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia. Advances in Biological Regulation, 2017, 65, 36-58.	1.4	33
869	Senescence in Health and Disease. Cell, 2017, 169, 1000-1011.	13.5	1,137
870	The promising impact of molecular profiling on treatment strategies in oral cancers. Journal of Stomatology, Oral and Maxillofacial Surgery, 2017, 118, 242-247.	0.5	13

#	Article	IF	Citations
871	Tissue-Specific Signaling Networks Rewired by Major Somatic Mutations in Human Cancer Revealed by Proteome-Wide Discovery. Cancer Research, 2017, 77, 2810-2821.	0.4	29
872	Chromatin marks shape mutation landscape at early stage of cancer progression. Npj Genomic Medicine, 2017, 2, 9.	1.7	13
873	A Direct Test of Selection in Cell Populations Using the Diversity in Gene Expression within Tumors. Molecular Biology and Evolution, 2017, 34, 1730-1742.	3.5	9
874	CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion. Nucleic Acids Research, 2017, 45, 6698-6716.	6.5	114
875	Phenotyping in Precision Medicine. , 2017, , 55-77.		4
876	Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma. Annals of Otology, Rhinology and Laryngology, 2017, 126, 334-339.	0.6	2
877	Evaluation of the use of therapeutic peptides for cancer treatment. Journal of Biomedical Science, 2017, 24, 21.	2.6	352
878	Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy. Molecular Therapy - Oncolytics, 2017, 5, 20-40.	2.0	35
879	Systematical analyses of variants in DNase I hypersensitive sites to identify hepatocellular carcinoma susceptibility loci in a Chinese population. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1887-1894.	1.4	2
880	Functional variomics and network perturbation: connecting genotype to phenotype in cancer. Nature Reviews Genetics, 2017, 18, 395-410.	7.7	84
882	Understanding cell cycle and cell death regulation provides novel weapons against human diseases. Journal of Internal Medicine, 2017, 281, 483-495.	2.7	84
883	Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility. Annals of Oncology, 2017, 28, 1625-1630.	0.6	24
884	Functional variants in DCAF4 associated with lung cancer risk in European populations. Carcinogenesis, 2017, 38, 541-551.	1.3	16
885	Perspectives of long non-coding RNAs in cancer. Molecular Biology Reports, 2017, 44, 203-218.	1.0	95
886	Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network. Scientific Reports, 2017, 7, 738.	1.6	12
887	Genetic Heterogeneity in Therapy-NaÃ¯ve Synchronous Primary Breast Cancers and Their Metastases. Clinical Cancer Research, 2017, 23, 4402-4415.	3.2	91
888	Histone Code Aberrancies in Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 599-601.	0.5	2
889	CRISPR/Cas9 editing of the genome for cancer modeling. Methods, 2017, 121-122, 130-137.	1.9	34

#	Article	IF	Citations
890	Abseq: Ultrahigh-throughput single cell protein profiling with droplet microfluidic barcoding. Scientific Reports, 2017, 7, 44447.	1.6	217
891	[10]-Gingerol, a major phenolic constituent of ginger root, induces cell cycle arrest and apoptosis in triple-negative breast cancer cells. Experimental and Molecular Pathology, 2017, 102, 370-376.	0.9	66
892	Runx3 in Immunity, Inflammation and Cancer. Advances in Experimental Medicine and Biology, 2017, 962, 369-393.	0.8	43
893	Non-autonomous cell proliferation in the mammary gland and cancer. Current Opinion in Cell Biology, 2017, 45, 55-61.	2.6	11
894	Identifying the clonal relationship model of multifocal papillary thyroid carcinoma by whole genome sequencing. Cancer Letters, 2017, 396, 110-116.	3.2	9
895	Compromised BRCA1â€“PALB2 interaction is associated with breast cancer risk. Oncogene, 2017, 36, 4161-4170.	2.6	71
896	Pan-cancer analysis distinguishes transcriptional changes of aneuploidy from proliferation. Genome Research, 2017, 27, 501-511.	2.4	52
897	Genomics, Endoscopy, and Control of Gastroesophageal Cancers: A Perspective. Cellular and Molecular Gastroenterology and Hepatology, 2017, 3, 359-366.	2.3	5
898	CTCF genetic alterations in endometrial carcinoma are pro-tumorigenic. Oncogene, 2017, 36, 4100-4110.	2.6	50
899	Identification of an atypical etiological head and neck squamous carcinoma subtype featuring the CpG island methylator phenotype. EBioMedicine, 2017, 17, 223-236.	2.7	62
900	Comparison of False Discovery Rate Control Strategies for Variant Peptide Identifications in Shotgun Proteogenomics. Journal of Proteome Research, 2017, 16, 1936-1943.	1.8	13
901	The genetic landscape of breast carcinomas with neuroendocrine differentiation. Journal of Pathology, 2017, 241, 405-419.	2.1	52
902	Gene alterations and epigenetic changes in intrahepatic cholangiocarcinoma. Expert Review of Anticancer Therapy, 2017, 17, 89-96.	1.1	3
903	Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Research, 2017, 27, 11-37.	5.7	185
904	PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias. Leukemia, 2017, 31, 1975-1986.	3.3	10
905	Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition. Annals of Oncology, 2017, 28, 547-554.	0.6	44
906	Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2â€“Positive Metastatic Bladder Cancer. Journal of Clinical Oncology, 2017, 35, 48-55.	0.8	165
907	Proteome-Scale Investigation of Protein Allosteric Regulation Perturbed by Somatic Mutations in 7,000 Cancer Genomes. American Journal of Human Genetics, 2017, 100, 5-20.	2.6	72

#	Article	IF	Citations
908	Implementation of a Multicenter Biobanking Collaboration for Nextâ€Generation Sequencingâ€Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies. Oncologist, 2017, 22, 33-40.	1.9	29
909	Integrating genomic information and signaling dynamics for efficient cancer therapy. Current Opinion in Systems Biology, 2017, 1, 38-43.	1.3	1
910	Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation. Free Radical Biology and Medicine, 2017, 103, 236-247.	1.3	117
911	Crossâ€species analysis of the canine and human bladder cancer transcriptome and exome. Genes Chromosomes and Cancer, 2017, 56, 328-343.	1.5	34
912	Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology, 2017, 49, 141-155.	0.3	112
913	E2F transcription factors associated with up-regulated genes in glioblastoma. Cancer Biomarkers, 2017, 18, 199-208.	0.8	17
914	Extracellular Matrix Remodeling and Stiffening Modulate Tumor Phenotype and Treatment Response. Annual Review of Cancer Biology, 2017, 1, 313-334.	2.3	101
915	Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma. International Journal of Cancer, 2017, 140, 1551-1563.	2.3	30
916	Splicing factor gene mutations in hematologic malignancies. Blood, 2017, 129, 1260-1269.	0.6	99
917	Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. Journal of Molecular Diagnostics, 2017, 19, 4-23.	1.2	1,267
918	Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers. Cancer Informatics, 2017, 16, 117693511769126.	0.9	16
919	Overcoming mutational complexity in acute myeloid leukemia by inhibition of critical pathways. Science Translational Medicine, 2017, 9, .	5.8	19
920	Targeting RNA helicases in cancer: The translation trap. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 510-520.	3.3	57
921	Multiple regulatory mechanisms of the biological function of NRF3 (NFE2L3) control cancer cell proliferation. Scientific Reports, 2017, 7, 12494.	1.6	61
922	Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. Journal of Pathology: Clinical Research, 2017, 3, 279-293.	1.3	70
923	Ribosomopathies: Thereâ€™s strength in numbers. Science, 2017, 358, .	6.0	343
925	Maintenance of cellular respiration indicates drug resistance in acute myeloid leukemia. Leukemia Research, 2017, 62, 56-63.	0.4	27
926	Natural (and Unnatural) Small Molecules as Pharmacological Chaperones and Inhibitors in Cancer. Handbook of Experimental Pharmacology, 2017, 245, 155-190.	0.9	10

#	Article	IF	Citations
927	Ninjurin 1 has two opposing functions in tumorigenesis in a p53-dependent manner. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 11500-11505.	3.3	40
928	The number of key carcinogenic events can be predicted from cancer incidence. Scientific Reports, 2017, 7, 12170.	1.6	35
929	Hippo Reprograms the Transcriptional Response to Ras Signaling. Developmental Cell, 2017, 42, 667-680.e4.	3.1	39
931	Revealing the Determinants of Widespread Alternative Splicing Perturbation in Cancer. Cell Reports, 2017, 21, 798-812.	2.9	51
932	Signatures of positive selection reveal a universal role of chromatin modifiers as cancer driver genes. Scientific Reports, 2017, 7, 13124.	1.6	20
933	Universal Patterns of Selection in Cancer and Somatic Tissues. Cell, 2017, 171, 1029-1041.e21.	13.5	1,085
934	Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways. Npj Breast Cancer, 2017, 3, 40.	2.3	52
935	Antioxidants in the Treatment of Cancer. Nutrition and Cancer, 2017, 69, 1099-1104.	0.9	69
936	The USP7 Inhibitor P5091 Induces Cell Death in Ovarian Cancers with Different P53 Status. Cellular Physiology and Biochemistry, 2017, 43, 1755-1766.	1.1	40
937	The genomic and epigenomic landscape in thymic carcinoma. Carcinogenesis, 2017, 38, 1084-1091.	1.3	46
938	The long noncoding RNA Malat1: Its physiological and pathophysiological functions. RNA Biology, 2017, 14, 1705-1714.	1.5	383
939	Pharmacometabolomics Informs Quantitative Radiomics for Glioblastoma Diagnostic Innovation. OMICS A Journal of Integrative Biology, 2017, 21, 429-439.	1.0	15
940	Targeted next-generation sequencing for analyzing the genetic alterations in atypical adenomatous hyperplasia and adenocarcinoma in situ. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2447-2453.	1.2	16
941	Liâ€“Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53. Trends in Pharmacological Sciences, 2017, 38, 908-927.	4.0	35
942	Implications of CRISPR-Based Germline Engineering for Cancer Survivors. Therapeutic Innovation and Regulatory Science, 2017, 51, 672-682.	0.8	1
943	Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. Cell Reports, 2017, 20, 2833-2845.	2.9	40
944	Long nonâ€coding RNAs and prostate cancer. Cancer Science, 2017, 108, 2107-2114.	1.7	107
945	Claspin functions in cell homeostasisâ€”A link to cancer?. DNA Repair, 2017, 59, 27-33.	1.3	26

#	Article	IF	Citations
946	Comprehensive analyses of somatic TP53 mutation in tumors with variable mutant allele frequency. Scientific Data, 2017, 4, 170120.	2.4	9
947	Dynamic assembly and activation of estrogen receptor Î± enhancers through coregulator switching. Genes and Development, 2017, 31, 1535-1548.	2.7	50
948	Deep Correlational Learning for Survival Prediction from Multi-modality Data. Lecture Notes in Computer Science, 2017, , 406-414.	1.0	47
949	Î±5Î²1-Integrin promotes tension-dependent mammary epithelial cell invasion by engaging the fibronectin synergy site. Molecular Biology of the Cell, 2017, 28, 2958-2977.	0.9	52
950	Unravelling the biology of chromatin in health and cancer using proteomic approaches. Expert Review of Proteomics, 2017, 14, 905-915.	1.3	5
951	Activin A more prominently regulates muscle mass in primates than does GDF8. Nature Communications, 2017, 8, 15153.	5.8	129
952	A Comprehensive Look at Oromaxillofacial and Laryngopharyngeal Cancers. , 2017, , 531-587.		0
953	A Bioinformatic Algorithm for Analyzing Cell Signaling Using Temporal Proteomic Data. Proteomics, 2017, 17, 1600425.	1.3	13
954	PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Scientific Reports, 2017, 7, 10240.	1.6	19
955	Future Clinical Trials. Surgical Oncology Clinics of North America, 2017, 26, 791-797.	0.6	4
956	IL-11 contribution to tumorigenesis in an NRF2 addiction cancer model. Oncogene, 2017, 36, 6315-6324.	2.6	46
957	The genetic landscape of endometrial clear cell carcinomas. Journal of Pathology, 2017, 243, 230-241.	2.1	168
958	The whole-genome landscape of medulloblastoma subtypes. Nature, 2017, 547, 311-317.	13.7	787
959	Targeted nextâ€generation sequencing using a multigene panel in myeloid neoplasms: Implementation in clinical diagnostics. International Journal of Laboratory Hematology, 2017, 39, 604-612.	0.7	9
960	The Evolving Genomic Landscape of Barrettâ€™s Esophagus and Esophageal Adenocarcinoma. Gastroenterology, 2017, 153, 657-673.e1.	0.6	69
961	Big data in cancer genomics. Current Opinion in Systems Biology, 2017, 4, 78-84.	1.3	12
962	The immune contexture in cancer prognosis and treatment. Nature Reviews Clinical Oncology, 2017, 14, 717-734.	12.5	1,590
963	Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. Clinical Cancer Research, 2017, 23, 6686-6696.	3.2	66

#	Article	IF	Citations
964	Binding kinetics of mutant p53R175H with wild type p53 and p63: A Surface Plasmon Resonance and Atomic Force Spectroscopy study. Biophysical Chemistry, 2017, 228, 55-61.	1.5	5
965	Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer. JAMA Oncology, 2017, 3, 1707.	3.4	129
966	p53 loss does not permit escape from BrafV600E-induced senescence in a mouse model of lung cancer. Oncogene, 2017, 36, 6325-6335.	2.6	9
967	Cross-talk between 10-gingerol and its anti-cancerous potential: a recent update. Food and Function, 2017, 8, 2635-2649.	2.1	34
968	Variation in organâ€specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas. Environmental and Molecular Mutagenesis, 2017, 58, 466-476.	0.9	16
969	The chromatin remodeling BAP complex limits tumor promoting activity of the Hippo pathway effector Yki to prevent neoplastic transformation inDrosophilaepithelia. DMM Disease Models and Mechanisms, 2017, 10, 1201-1209.	1.2	13
970	Mutant p53 as a target for cancer treatment. European Journal of Cancer, 2017, 83, 258-265.	1.3	287
971	Four <scp>PTEN</scp>â€targeting coâ€expressed mi<scp>RNA</scp>s and <scp>ACTN</scp>4â€targeting mi<scp>R</scp>â€548b are independent prognostic biomarkers in human squamous cell carcinoma of the oral tongue. International Journal of Cancer, 2017, 141, 2318-2328.	2.3	20
972	Epigenomic analysis in a cell-based model reveals the roles of H3K9me3 in breast cancer transformation. Epigenomics, 2017, 9, 1077-1092.	1.0	11
973	Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer. Cancer Research, 2017, 77, 4530-4541.	0.4	44
974	p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells. Nucleic Acids Research, 2017, 45, 11056-11069.	6.5	70
975	A pathology atlas of the human cancer transcriptome. Science, 2017, 357, .	6.0	2,570
976	p53-R273H upregulates neuropilin-2 to promote cell mobility and tumor metastasis. Cell Death and Disease, 2017, 8, e2995-e2995.	2.7	22
977	Genomic Evolution of Breast Cancer Metastasis and Relapse. Cancer Cell, 2017, 32, 169-184.e7.	7.7	534
978	AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nature Neuroscience, 2017, 20, 1329-1341.	7.1	179
979	Defining key concepts of intestinal and epithelial cancer biology through the use of mouse models. Carcinogenesis, 2017, 38, 953-965.	1.3	5
980	Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline. Expert Opinion on Emerging Drugs, 2017, 22, 347-355.	1.0	0
981	The effects of PI3K-mediated signalling on glioblastoma cell behaviour. Oncogenesis, 2017, 6, 398.	2.1	45

#	Article	IF	Citations
982	Resistance to Targeted Therapies in Breast Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2017, , .	0.1	1
983	Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast. Npj Breast Cancer, 2017, 3, 48.	2.3	63
984	OMICS, Oral Cancer Molecular Landscapes, and Clinical Practice. OMICS A Journal of Integrative Biology, 2017, 21, 689-703.	1.0	8
985	Development of a genetic sensor that eliminates p53 deficient cells. Nature Communications, 2017, 8, 1463.	5.8	15
986	Integrative Analysis of Histopathological Images and Genomic Data Predicts Clear Cell Renal Cell Carcinoma Prognosis. Cancer Research, 2017, 77, e91-e100.	0.4	109
987	The activated conformation of integrin Î²7 is a novel multiple myelomaâ€“specific target for CAR T cell therapy. Nature Medicine, 2017, 23, 1436-1443.	15.2	105
988	Molecularly targeted therapies for p53-mutant cancers. Cellular and Molecular Life Sciences, 2017, 74, 4171-4187.	2.4	72
989	A pan-cancer genome-wide analysis reveals tumour dependencies by induction of nonsense-mediated decay. Nature Communications, 2017, 8, 15943.	5.8	45
990	DNA methylation markers for diagnosis and prognosis of common cancers. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 7414-7419.	3.3	387
991	Genomic Uracil â€” Dangers and Benefits in Processing. , 2017, , 13-62.		0
992	Frameshift mutation and loss of expression of PLK2 , a serine/threonine kinase-encoding gene, in colorectal cancers. Pathology Research and Practice, 2017, 213, 1019-1020.	1.0	4
993	Scaffold Proteins in Gastrointestinal Tumors as a Shortcut to Oncoprotein Activation. Gastrointestinal Tumors, 2017, 4, 1-10.	0.3	0
994	Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastoma. Neurology: Genetics, 2017, 3, e164.	0.9	32
995	Next-Generation Sequencing in Glioblastoma Personalized Therapy. Current Cancer Research, 2017, , 161-190.	0.2	1
996	Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox. Cancer Research, 2017, 77, 4626-4638.	0.4	42
997	Biomarkers of response to PD-1/PD-L1 inhibition. Critical Reviews in Oncology/Hematology, 2017, 116, 116-124.	2.0	249
998	Histone H3 lysine 4 methyltransferase KMT2D. Gene, 2017, 627, 337-342.	1.0	201
999	ISOWN: accurate somatic mutation identification in the absence of normal tissue controls. Genome Medicine, 2017, 9, 59.	3.6	44

#	Article	IF	Citations
1000	Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition. Clinical Cancer Research, 2017, 23, 6044-6053.	3.2	27
1001	Pan-cancer analysis of systematic batch effects on somatic sequence variations. BMC Bioinformatics, 2017, 18, 211.	1.2	13
1002	Single genome retrieval of context-dependent variability in mutation rates for human germline. BMC Genomics, 2017, 18, 81.	1.2	8
1003	Revealing common disease mechanisms shared by tumors of different tissues of origin through semantic representation of genomic alterations and topic modeling. BMC Genomics, 2017, 18, 105.	1.2	2
1004	Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2017, 10, 61.	6.9	29
1005	Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells. Genome Medicine, 2017, 9, 51.	3.6	12
1006	The NF1 somatic mutational landscape in sporadic human cancers. Human Genomics, 2017, 11, 13.	1.4	203
1007	Leiomyoma with bizarre nuclei: a morphological, immunohistochemical and molecular analysis of 31 cases. Modern Pathology, 2017, 30, 1476-1488.	2.9	51
1009	RNA Editing in Pathogenesis of Cancer. Cancer Research, 2017, 77, 3733-3739.	0.4	60
1010	Integrative cancer genomics: models, algorithms and analysis. Frontiers of Computer Science, 2017, 11, 392-406.	1.6	3
1011	PhyloOncology: Understanding cancer through phylogenetic analysis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1867, 101-108.	3.3	22
1012	Neomorphic mutations create therapeutic challenges in cancer. Oncogene, 2017, 36, 1607-1618.	2.6	24
1013	Computational approaches for the identification of cancer genes and pathways. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2017, 9, e1364.	6.6	65
1015	Reconstituting regulation of the canonical Wnt pathway by engineering a minimal Î²-catenin destruction machine. Molecular Biology of the Cell, 2017, 28, 41-53.	0.9	26
1016	Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. Trends in Pharmacological Sciences, 2017, 38, 25-40.	4.0	87
1017	Do hematopoietic stem cells get old?. Leukemia, 2017, 31, 529-531.	3.3	5
1018	Modeling human MLL-AF9 translocated acute myeloid leukemia from single donors reveals RET as a potential therapeutic target. Leukemia, 2017, 31, 1166-1176.	3.3	18
1019	Natural Selection in Cancer Biology: From Molecular Snowflakes to Trait Hallmarks. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a029652.	2.9	48

#	Article	IF	Citations
1020	Targeting mutant p53 in cancer: a long road to precision therapy. FEBS Journal, 2017, 284, 837-850.	2.2	55
1021	Next-Generation Sequencing and Result Interpretation in Clinical Oncology: Challenges of Personalized Cancer Therapy. Annual Review of Medicine, 2017, 68, 113-125.	5.0	34
1022	Massive parallel sequencing of solid tumours â€“ challenges and opportunities for pathologists. Histopathology, 2017, 70, 123-133.	1.6	12
1023	Inactivation of Cancer Mutations Utilizing CRISPR/Cas9. Journal of the National Cancer Institute, 2017, 109, .	3.0	30
1024	Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes. Clinical Cancer Research, 2017, 23, 2584-2592.	3.2	15
1025	Pathology and Molecular Pathology of Breast Cancer. , 2017, , 173-231.		1
1026	The role of cancer stem cells in tumor heterogeneity and resistance to therapy. Canadian Journal of Physiology and Pharmacology, 2017, 95, 1-15.	0.7	48
1027	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. Modern Pathology, 2017, 30, 69-84.	2.9	48
1028	Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction. Oncogene, 2017, 36, 1991-2001.	2.6	54
1029	What makes oncogenes mutually exclusive?. Small GTPases, 2017, 8, 187-192.	0.7	37
1030	The epigenetic landscape of renal cancer. Nature Reviews Nephrology, 2017, 13, 47-60.	4.1	99
1031	Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy. Seminars in Cancer Biology, 2017, 42, 13-19.	4.3	54
1032	Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. Nature Genetics, 2017, 49, 65-74.	9.4	326
1033	p53: Multiple Facets of a Rubik's Cube. Annual Review of Cancer Biology, 2017, 1, 185-201.	2.3	18
1034	The p53 family orchestrates the regulation of metabolism: physiological regulation and implications for cancer therapy. British Journal of Cancer, 2017, 116, 149-155.	2.9	71
1035	Intratumoral Heterogeneity of Frameshift Mutations in MECOM Gene is Frequent in Colorectal Cancers with High Microsatellite Instability. Pathology and Oncology Research, 2017, 23, 145-149.	0.9	17
1036	The reversal of multidrug resistance in ovarian carcinoma cells by co-application of tariquidar and paclitaxel in transferrin-targeted polymeric micelles. Journal of Drug Targeting, 2017, 25, 225-234.	2.1	41
1037	Interaction with ZMYND11 mediates opposing roles of Ras-responsive transcription factors ETS1 and ETS2. Nucleic Acids Research, 2017, 45, gkx039.	6.5	14

#	Article	IF	Citations
1038	Differential network analysis via lasso penalized D-trace loss. Biometrika, 2017, 104, 755-770.	1.3	49
1039	The Dawning of Translational Breast Cancer: From Bench to Bedside. Advances in Experimental Medicine and Biology, 2017, 1026, 1-25.	0.8	0
1040	A novel and efficient algorithm for de novo discovery of mutated driver pathways in cancer. Annals of Applied Statistics, 2017, 11, 1481-1512.	0.5	12
1041	A comprehensive genomic pan-cancer classification using The Cancer Genome Atlas gene expression data. BMC Genomics, 2017, 18, 508.	1.2	145
1042	Preclinical and clinical development of neoantigen vaccines. Annals of Oncology, 2017, 28, xii11-xii17.	0.6	160
1043	<i>TBX19</i> is overexpressed in colorectal cancer and associated with lymph node metastasis. Fukushima Journal of Medical Sciences, 2017, 63, 141-151.	0.1	11
1044	Epigenetic and genetic deregulation in cancer target distinct signaling pathway domains. Nucleic Acids Research, 2017, 45, 583-596.	6.5	18
1045	WSISA: Making Survival Prediction from Whole Slide Histopathological Images. , 2017, , .		149
1046	An improved burden-test pipeline for identifying associations from rare germline and somatic variants. BMC Genomics, 2017, 18, 753.	1.2	11
1047	PMTDS: a computational method based on genetic interaction networks for Precision Medicine Targetâ€Drug Selection in cancer. Quantitative Biology, 2017, 5, 380-394.	0.3	4
1048	Cancer-mutated ribosome protein L22 (RPL22/eL22) suppresses cancer cell survival by blocking p53-MDM2 circuit. Oncotarget, 2017, 8, 90651-90661.	0.8	37
1049	Transcriptional landscape of human cancers. Oncotarget, 2017, 8, 34534-34551.	0.8	74
1050	New Developments and Challenges in Rare Genitourinary Tumors: Non-Urothelial Bladder Cancers and Squamous Cell Cancers of the Penis. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 330-336.	1.8	5
1051	Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board. JCO Precision Oncology, 2017, 1, 1-10.	1.5	18
1052	Acquired ribosomopathies in leukemia and solid tumors. Hematology American Society of Hematology Education Program, 2017, 2017, 716-719.	0.9	28
1053	Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. Blood Advances, 2017, 1, 1884-1890.	2.5	40
1054	Molecular Characterization of Somatic Alterations in Dukesâ€™ B and C Colorectal Cancers by Targeted Sequencing. Frontiers in Pharmacology, 2017, 8, 465.	1.6	8
1055	FH535 Inhibits Proliferation and Motility of Colon Cancer Cells by Targeting Wnt/Î²-catenin Signaling Pathway. Journal of Cancer, 2017, 8, 3142-3153.	1.2	32

#	Article	IF	Citations
1056	Ribosomopathies and the Quality Control of Ribosome Assembly. , 2017, , 203-224.		1
1057	Comparing the genomes of cutaneous melanoma tumors to commercially available cell lines. Oncotarget, 2017, 8, 114877-114893.	0.8	10
1058	Downregulation of ARID1A, a component of the SWI/SNF chromatin remodeling complex, in breast cancer. Journal of Cancer, 2017, 8, 1-8.	1.2	40
1059	Whole-genome sequencing identifies new genetic alterations in meningiomas. Oncotarget, 2017, 8, 17070-17080.	0.8	17
1060	G2/M-Phase Checkpoint Adaptation and Micronuclei Formation as Mechanisms That Contribute to Genomic Instability in Human Cells. International Journal of Molecular Sciences, 2017, 18, 2344.	1.8	61
1061	Modulation of Ras/ERK and Phosphoinositide Signaling by Long-Chain n-3 PUFA in Breast Cancer and Their Potential Complementary Role in Combination with Targeted Drugs. Nutrients, 2017, 9, 185.	1.7	27
1062	The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer. Cancers, 2017, 9, 81.	1.7	119
1063	New Frontiers in Melanoma Epigeneticsâ€"The More We Know, the More We Donâ€™t Know. Epigenomes, 2017, 1, 3.	0.8	6
1064	MYC Deregulation in Primary Human Cancers. Genes, 2017, 8, 151.	1.0	281
1065	The Tumor Suppressor p53 in Mucosal Melanoma of the Head and Neck. Genes, 2017, 8, 384.	1.0	10
1066	Change of Title: Microarrays Becomes High-Throughput. High-Throughput, 2017, 6, 10.	4.4	1
1067	Mutational Signatures Are Critical for Proper Estimation of Purifying Selection Pressures in Cancer Somatic Mutation Data When Using the dN/dS Metric. Frontiers in Genetics, 2017, 8, 74.	1.1	33
1068	Computational Methods for Characterizing Cancer Mutational Heterogeneity. Frontiers in Genetics, 2017, 8, 83.	1.1	27
1069	New Insight into microRNA Functions in Cancer: Oncogeneâ€"microRNAâ€"Tumor Suppressor Gene Network. Frontiers in Molecular Biosciences, 2017, 4, 46.	1.6	104
1070	The Regulation of Tumor Cell Invasion and Metastasis by Endoplasmic Reticulum-to-Mitochondrial Ca2+ Transfer. Frontiers in Oncology, 2017, 7, 171.	1.3	28
1071	Mutation Spectrum Induced by 8-Bromoguanine, a Base Damaged by Reactive Brominating Species, in Human Cells. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-11.	1.9	4
1072	Manipulation of Innate and Adaptive Immunity through Cancer Vaccines. Journal of Immunology Research, 2017, 2017, 1-7.	0.9	31
1073	Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine. BioMed Research International, 2017, 2017, 1-18.	0.9	40

#	Article	IF	Citations
1074	SPAG6 regulates cell apoptosis through the TRAIL signal pathway in myelodysplastic syndromes. Oncology Reports, 2017, 37, 2839-2846.	1.2	14
1075	Crosstalk between DNA Damage and Inflammation in the Multiple Steps of Carcinogenesis. International Journal of Molecular Sciences, 2017, 18, 1808.	1.8	185
1076	A Normalization-Free and Nonparametric Method Sharpens Large-Scale Transcriptome Analysis and Reveals Common Gene Alteration Patterns in Cancers. Theranostics, 2017, 7, 2888-2899.	4.6	12
1077	Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. Theranostics, 2017, 7, 2111-2133.	4.6	12
1079	Endometrial Cancer Genomics. , 2017, , 199-227.		0
1080	Mobile Genome Express (MGE): A comprehensive automatic genetic analyses pipeline with a mobile device. PLoS ONE, 2017, 12, e0174696.	1.1	1
1081	Stratification of clear cell renal cell carcinoma (ccRCC) genomes by gene-directed copy number alteration (CNA) analysis. PLoS ONE, 2017, 12, e0176659.	1.1	17
1082	Succinct workflows for circulating tumor cells after enrichment: From systematic counting to mutational profiling. PLoS ONE, 2017, 12, e0177276.	1.1	12
1083	Genetic basis of calcifying cystic odontogenic tumors. PLoS ONE, 2017, 12, e0180224.	1.1	50
1084	Clinical Epigenetics of Lung Cancer. , 2017, , 97-133.		3
1085	The rare nonsense mutation in p53 triggers alternative splicing to produce a protein capable of inducing apoptosis. PLoS ONE, 2017, 12, e0185126.	1.1	6
1086	Towards precision medicine: discovering novel gynecological cancer biomarkers and pathways using linked data. Journal of Biomedical Semantics, 2017, 8, 40.	0.9	19
1087	NAT10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity. BMC Cancer, 2017, 17, 605.	1.1	54
1088	A systematic analysis of FDA-approved anticancer drugs. BMC Systems Biology, 2017, 11, 87.	3.0	235
1089	Identification of trunk mutations in gastric carcinoma: a case study. BMC Medical Genomics, 2017, 10, 49.	0.7	5
1090	Next-generation sequencing: recent applications to the analysis of colorectal cancer. Journal of Translational Medicine, 2017, 15, 246.	1.8	76
1091	MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. Journal of Hematology and Oncology, 2017, 10, 133.	6.9	213
1092	Association of a novel point mutation in MSH2 gene with familial multiple primary cancers. Journal of Hematology and Oncology, 2017, 10, 158.	6.9	4

#	Article	IF	Citations
1093	Intergenic disease-associated regions are abundant in novel transcripts. Genome Biology, 2017, 18, 241.	3.8	45
1094	The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex. Genome Biology, 2017, 18, 237.	3.8	179
1095	Identification of cis-regulatory mutations generating de novo edges in personalized cancer gene regulatory networks. Genome Medicine, 2017, 9, 80.	3.6	17
1096	Differential analysis between somatic mutation and germline variation profiles reveals cancer-related genes. Genome Medicine, 2017, 9, 79.	3.6	30
1097	Novel insights into epigenetic drivers of oropharyngeal squamous cell carcinoma: role of HPV and lifestyle factors. Clinical Epigenetics, 2017, 9, 124.	1.8	33
1098	A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer. , 2017, 5, 103.		8
1099	Perspective on the dynamics of cancer. Theoretical Biology and Medical Modelling, 2017, 14, 18.	2.1	13
1100	Characterization of background noise in capture-based targeted sequencing data. Genome Biology, 2017, 18, 136.	3.8	50
1101	The 150 most important questions in cancer research and clinical oncology series: questions 50â€“56. Chinese Journal of Cancer, 2017, 36, 69.	4.9	6
1102	Investigating MicroRNA and transcription factor co-regulatory networks in colorectal cancer. BMC Bioinformatics, 2017, 18, 388.	1.2	35
1103	QuaDMutEx: quadratic driver mutation explorer. BMC Bioinformatics, 2017, 18, 458.	1.2	8
1104	Nominalism in Medicine: the case of personalized medicine or precision medicine. Italian Journal of Medicine, 2017, 11, 417.	0.2	1
1105	Biological Consequences of Priming Phosphorylation in Cancer Development. , 0, , .		5
1106	The subclonal structure and genomic evolution of oral squamous cell carcinoma revealed by ultra-deep sequencing. Oncotarget, 2017, 8, 16571-16580.	0.8	25
1107	Mutation analysis and copy number alterations of KIF23 in non-small-cell lung cancer exhibiting KIF23 over-expression. OncoTargets and Therapy, 2017, Volume 10, 4969-4979.	1.0	20
1108	Mutation-profile-based methods for understanding selection forces in cancer somatic mutations: a comparative analysis. Oncotarget, 2017, 8, 58835-58846.	0.8	11
1109	p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers. International Journal of Oncology, 2017, 50, 1721-1728.	1.4	12
1110	Advances on immunotherapy in genitourinary and renal cell carcinoma. Translational Cancer Research, 2017, 6, 17-29.	0.4	10

#	Article	IF	Citations
1111	Developing a novel dual PI3K–mTOR inhibitor from the prodrug of a metabolite. OncoTargets and Therapy, 2017, Volume 10, 5077-5087.	1.0	1
1112	Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment. Cancers, 2017, 9, 35.	1.7	85
1113	NDRG2 promotes adriamycin sensitivity through a Bad/p53 complex at the mitochondria in breast cancer. Oncotarget, 2017, 8, 29038-29047.	0.8	10
1114	Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget, 2017, 8, 91779-91794.	0.8	298
1115	A mathematical theory of the transcription repression (TR) therapy of cancer - whether and how it may work. Oncotarget, 2017, 8, 38642-38649.	0.8	3
1116	The Histone Methyltransferase Mixed Lineage Leukemia (MLL) 3 May Play a Potential Role in Clinical Dilated Cardiomyopathy. Molecular Medicine, 2017, 23, 196-203.	1.9	32
1117	Epigenetic regulation of NOTCH1 and NOTCH3 by KMT2A inhibits glioma proliferation. Oncotarget, 2017, 8, 63110-63120.	0.8	21
1119	Translational significance of multi-dimensional omics. Journal of Thoracic Disease, 2017, 9, E83-E84.	0.6	1
1120	The Molecular Biology of Head and Neck Cancer. , 2017, , 243-256.		1
1121	Genomic analysis to assess disease progression and recurrence in patients with oral squamous cell carcinoma: â€“ a preliminary study. British Journal of Oral and Maxillofacial Surgery, 2018, 56, 198-205.	0.4	2
1123	Identifying noncoding risk variants using disease-relevant gene regulatory networks. Nature Communications, 2018, 9, 702.	5.8	35
1124	A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response. Cell, 2018, 172, 1007-1021.e17.	13.5	97
1125	Insights from Large-Scale Cancer Genome Sequencing. Annual Review of Cancer Biology, 2018, 2, 429-444.	2.3	5
1126	Expression and function of immune ligand-receptor pairs in NK cells and cancer stem cells: therapeutic implications. Cellular Oncology (Dordrecht), 2018, 41, 107-121.	2.1	21
1127	Single Nucleotide Polymorphism Facilitated Down-Regulation of the Cohesin Stromal Antigen-1: Implications for Colorectal Cancer Racial Disparities. Neoplasia, 2018, 20, 289-294.	2.3	7
1128	Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma. Clinical Cancer Research, 2018, 24, 2688-2699.	3.2	45
1129	Synthesis of Triazole Derivatives of Levoglucosenone As Promising Anticancer Agents: Effective Exploration of the Chemical Space through retro-aza-Michael//aza-Michael Isomerizations. Journal of Organic Chemistry, 2018, 83, 3516-3528.	1.7	25
1130	Somatic Mutations and Intratumoral Heterogeneity of MYH11 Gene in Gastric and Colorectal Cancers. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 562-566.	0.6	15

#	Article	IF	Citations
1131	Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 342-351.	1.3	13
1132	The landscape of genomic alterations across childhood cancers. Nature, 2018, 555, 321-327.	13.7	1,068
1133	Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature, 2018, 555, 371-376.	13.7	649
1134	Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPRâ€“mediated direct in vivo screening. Science Advances, 2018, 4, eaao5508.	4.7	64
1135	Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma. Nature Communications, 2018, 9, 894.	5.8	67
1136	Pan-cancer analysis of somatic mutations across 21 neuroendocrine tumor types. Cell Research, 2018, 28, 601-604.	5.7	4
1137	APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. Cell Death and Disease, 2018, 9, 439.	2.7	182
1138	Enhancer reprogramming in tumor progression: a new route towards cancer cell plasticity. Cellular and Molecular Life Sciences, 2018, 75, 2537-2555.	2.4	26
1139	Loss of ARID1A, a component of the SWI/SNF chromatin remodeling complex, at the invasion front is related to poor outcomes in oral squamous cell carcinoma. Oral Cancer, 2018, 2, 1-5.	0.3	1
1140	A Structured Workflow for Mapping Human Sin3 Histone Deacetylase Complex Interactions Using Halo-MudPIT Affinity-Purification Mass Spectrometry. Molecular and Cellular Proteomics, 2018, 17, 1432-1447.	2.5	27
1141	Pan-cancer analysis of somatic mutations and transcriptomes reveals common functional gene clusters shared by multiple cancer types. Scientific Reports, 2018, 8, 6041.	1.6	46
1142	Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome. Carcinogenesis, 2018, 39, 752-757.	1.3	18
1143	Targeting Wnt/Î²-Catenin Signaling for Cancer Immunotherapy. Trends in Pharmacological Sciences, 2018, 39, 648-658.	4.0	159
1144	The DNMT3A R882H mutant displays altered flanking sequence preferences. Nucleic Acids Research, 2018, 46, 3130-3139.	6.5	44
1145	Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. Journal of Pathology, 2018, 245, 283-296.	2.1	71
1146	Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell, 2018, 173, 371-385.e18.	13.5	1,670
1147	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell, 2018, 173, 305-320.e10.	13.5	272
1148	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Reports, 2018, 23, 227-238.e3.	2.9	407

#	Article	IF	Citations
1149	Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Nonâ€“Small Cell Lung Carcinoma (NSCLC). Clinical Cancer Research, 2018, 24, 3087-3096.	3.2	116
1150	Wingless Signaling: A Genetic Journey from Morphogenesis to Metastasis. Genetics, 2018, 208, 1311-1336.	1.2	47
1151	Association between TAp73, p53 and VASH1 expression in lung adenocarcinoma. Oncology Letters, 2018, 15, 5175-5180.	0.8	1
1152	Adenosine induces intrinsic apoptosis via the PI3K/Akt/mTOR signaling pathway in human pharyngeal squamous carcinoma FaDu cells. Oncology Letters, 2018, 15, 6489-6496.	0.8	16
1153	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. Cell Reports, 2018, 23, 270-281.e3.	2.9	177
1154	Sequencing of Tumor DNA to Guide Cancer Risk Assessment and Therapy. JAMA - Journal of the American Medical Association, 2018, 319, 1497.	3.8	9
1155	CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia. International Journal of Hematology, 2018, 108, 47-57.	0.7	0
1156	Applied RNA Bioscience. , 2018, , .		1
1157	Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Science Translational Medicine, 2018, 10, .	5.8	187
1158	Generation of autochthonous mouse models of clear cell renal cell carcinoma: mouse models of renal cell carcinoma. Experimental and Molecular Medicine, 2018, 50, 1-10.	3.2	14
1159	Restoration of conformation of mutant p53. Annals of Oncology, 2018, 29, 1325-1328.	0.6	7
1160	The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines. Endocrine-Related Cancer, 2018, 25, 367-380.	1.6	58
1161	Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Nonâ€“Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing. Neoplasia, 2018, 20, 256-262.	2.3	44
1162	Expression of phosphorylated sphingosine kinase 1 is associated with diffuse type and lymphatic invasion in human gastric cancer. Surgery, 2018, 163, 1301-1306.	1.0	15
1163	Harnessing genomics to improve outcomes for women with cancer in India: key priorities for research. Lancet Oncology, The, 2018, 19, e102-e112.	5.1	14
1164	Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer. International Journal of Biochemistry and Cell Biology, 2018, 96, 157-164.	1.2	84
1165	Blocking mutation independent p53 aggregation by emodin modulates autophagic cell death pathway in lung cancer. International Journal of Biochemistry and Cell Biology, 2018, 96, 90-95.	1.2	32
1166	Base of tongue cancerâ€”is it tongue cancer located at the base of the tongue, or is it a type of lingual tonsil cancer? The perspective from a genomic analysis. International Journal of Oral and Maxillofacial Surgery, 2018, 47, 846-853.	0.7	2

#	Article	IF	Citations
1167	Utx loss causes myeloid transformation. Leukemia, 2018, 32, 1458-1465.	3.3	20
1168	Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival. Npj Genomic Medicine, 2018, 3, 1.	1.7	79
1169	Combined aptamer and transcriptome sequencing of single cells. Scientific Reports, 2018, 8, 2919.	1.6	23
1170	KMT2D regulates p63 target enhancers to coordinate epithelial homeostasis. Genes and Development, 2018, 32, 181-193.	2.7	77
1171	Non-coding RNAs, epigenetics, and cancer: tying it all together. Cancer and Metastasis Reviews, 2018, 37, 55-73.	2.7	87
1172	Pan-cancer analysis of expressed somatic nucleotide variants in long intergenic non-coding RNA. , 2018, , .		1
1173	Whole Genome Sequencing-Based Discovery of Structural Variants in Glioblastoma. Methods in Molecular Biology, 2018, 1741, 1-29.	0.4	11
1174	Genome Evolution Analysis of Recurrent Testicular Malignant Mesothelioma by Whole-Genome Sequencing. Cellular Physiology and Biochemistry, 2018, 45, 163-174.	1.1	14
1175	Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing. Nature Communications, 2018, 9, 216.	5.8	136
1176	A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma. Annals of Oncology, 2018, 29, 938-944.	0.6	76
1177	Application of single-cell sequencing in human cancer. Briefings in Functional Genomics, 2018, 17, 273-282.	1.3	34
1178	MRHCA: a nonparametric statistics based method for hub and coâ€expression module identification in large gene coâ€expression network. Quantitative Biology, 2018, 6, 40-55.	0.3	1
1179	Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers. Oncogene, 2018, 37, 1669-1684.	2.6	72
1180	Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on Clinical Outcomes in East-Asian Patients with EGFR-Mutated Lung Adenocarcinoma. Scientific Reports, 2018, 8, 1005.	1.6	22
1181	A whole-animal platform to advance a clinical kinase inhibitor into new disease space. Nature Chemical Biology, 2018, 14, 291-298.	3.9	56
1182	Quantitative Single Cell Analysis for Transcriptional Activity of p53 Hetero-tetramers between Wild-type Protein and Oligomerization Domain. Chemistry Letters, 2018, 47, 217-220.	0.7	0
1183	Network science in clinical trials: A patient-centered approach. Seminars in Cancer Biology, 2018, 52, 135-150.	4.3	9
1184	Cohesin mutations in myeloid malignancies made simple. Current Opinion in Hematology, 2018, 25, 61-66.	1.2	34

#	Article	IF	Citations
1185	From bad to worse: when lung cancer complicates idiopathic pulmonary fibrosis. Journal of Pathology, 2018, 244, 383-385.	2.1	9
1186	Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook. Journal of Drug Targeting, 2018, 26, 435-447.	2.1	26
1187	Interactome INSIDER: a structural interactome browser for genomic studies. Nature Methods, 2018, 15, 107-114.	9.0	133
1188	The long noncoding RNA LUCAT1 promotes tumorigenesis by controlling ubiquitination and stability of DNA methyltransferase 1 in esophageal squamous cell carcinoma. Cancer Letters, 2018, 417, 47-57.	3.2	112
1189	Genetics and Immunology: Tumor-Specific Genetic Alterations as a Target for Immune Modulating Therapies. , 2018, , 231-246.		0
1190	BCG and Anti-PDL-1 Ab in Bladder Cancers. , 2018, , 357-369.		0
1191	Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant p53 by Downregulating PTEN. Cancer Research, 2018, 78, 1511-1521.	0.4	27
1192	Characterizing genomic differences of human cancer stratified by the TP53 mutation status. Molecular Genetics and Genomics, 2018, 293, 737-746.	1.0	4
1193	iUUCD 2.0: an update with rich annotations for ubiquitin and ubiquitin-like conjugations. Nucleic Acids Research, 2018, 46, D447-D453.	6.5	57
1194	Frontline therapy of ovarian cancer: trials and tribulations. Current Opinion in Obstetrics and Gynecology, 2018, 30, 1-6.	0.9	7
1195	Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma. Neuro-Oncology, 2018, 20, 472-483.	0.6	42
1196	Alterations in cancer stem-cell marker CD44 expression predict oncologic outcome in soft-tissue sarcomas. Journal of Surgical Research, 2018, 223, 207-214.	0.8	20
1197	TP53 p.R72P genotype is a marker of poor prognosis in lung cancer. Cancer Biomarkers, 2018, 21, 747-754.	0.8	4
1198	Comprehensive Genomic Characterization of RNA-Binding Proteins across Human Cancers. Cell Reports, 2018, 22, 286-298.	2.9	166
1200	Surface enhanced Raman spectroscopy based immunosensor for ultrasensitive and selective detection of wild type p53 and mutant p53R175H. Analytica Chimica Acta, 2018, 1029, 86-96.	2.6	29
1201	Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer. BMC Cancer, 2018, 18, 136.	1.1	13
1202	Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Genome Medicine, 2018, 10, 25.	3.6	366
1203	Targeted therapy according to next generation sequencing-based panel sequencing. Fukushima Journal of Medical Sciences, 2018, 64, 9-14.	0.1	17

#	Article	IF	Citations
1205	The current evidence for a biomarker-based approach in cancer of unknown primary. Cancer Treatment Reviews, 2018, 67, 21-28.	3.4	30
1206	Survey and evaluation of mutations in the human KLF1 transcription unit. Scientific Reports, 2018, 8, 6587.	1.6	5
1207	Mapping three guanine oxidation products along DNA following exposure to three types of reactive oxygen species. Free Radical Biology and Medicine, 2018, 121, 180-189.	1.3	20
1208	Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 959-968.	1.4	13
1209	The emerging clinical relevance of genomics in cancer medicine. Nature Reviews Clinical Oncology, 2018, 15, 353-365.	12.5	351
1210	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Systems, 2018, 6, 271-281.e7.	2.9	605
1211	Biallelic TP53 gain of function mutations in rapidly progressing solid tumors. Cancer Genetics, 2018, 222-223, 20-24.	0.2	6
1212	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 2018, 33, 721-735.e8.	7.7	396
1213	Profiling of proteinâ€“protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors. Nature Biomedical Engineering, 2018, 2, 239-253.	11.6	18
1214	Systematic characterization of panâ€cancer mutation clusters. Molecular Systems Biology, 2018, 14, e7974.	3.2	39
1215	Double agents: genes with both oncogenic and tumor-suppressor functions. Oncogenesis, 2018, 7, 25.	2.1	88
1216	Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective. Leukemia, 2018, 32, 2049-2054.	3.3	4
1217	Exploring the interactions of EGFR with phosphorylated Mig6 by molecular dynamics simulations and MM-PBSA calculations. Journal of Theoretical Biology, 2018, 447, 118-125.	0.8	11
1218	Mutant p53 in breast cancer: potential as a therapeutic target and biomarker. Breast Cancer Research and Treatment, 2018, 170, 213-219.	1.1	144
1219	Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. European Journal of Cancer, 2018, 94, 179-186.	1.3	82
1220	On the low reproducibility of cancer studies. National Science Review, 2018, 5, 619-624.	4.6	38
1221	Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell, 2018, 33, 450-462.e10.	7.7	213
1222	Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation. Cell Research, 2018, 28, 476-490.	5.7	43

#	Article	IF	Citations
1223	NRF2 addiction in cancer cells. Cancer Science, 2018, 109, 900-911.	1.7	197
1224	The Discovery of Mutated Driver Pathways in Cancer: Models and Algorithms. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2018, 15, 988-998.	1.9	53
1225	Intranuclear and higherâ€order chromatin organization of the major histone gene cluster in breast cancer. Journal of Cellular Physiology, 2018, 233, 1278-1290.	2.0	40
1226	Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitisâ€like Tâ€cell lymphoma. British Journal of Haematology, 2018, 181, 406-410.	1.2	22
1227	Tumor infiltrating lymphocytes in early breast cancer. Breast, 2018, 37, 207-214.	0.9	108
1228	TP53in adult acute lymphoblastic leukemia. Leukemia and Lymphoma, 2018, 59, 778-789.	0.6	11
1229	Clinical implications of germline mutations in breast cancer: TP53. Breast Cancer Research and Treatment, 2018, 167, 417-423.	1.1	112
1230	Computational drug repositioning for rare diseases in the era of precision medicine. Drug Discovery Today, 2018, 23, 382-394.	3.2	76
1231	Small molecule promotes Î²-catenin citrullination and inhibits Wnt signaling in cancer. Nature Chemical Biology, 2018, 14, 94-101.	3.9	105
1232	Regulation and Dysregulation of Chromosome Structure in Cancer. Annual Review of Cancer Biology, 2018, 2, 21-40.	2.3	26
1233	Mutational landscape of RNA-binding proteins in human cancers. RNA Biology, 2018, 15, 115-129.	1.5	87
1234	State-of-the-Art CMOS In Vitro Diagnostic Devices. , 2018, , 11-39.		1
1235	p53 shades of Hippo. Cell Death and Differentiation, 2018, 25, 81-92.	5.0	70
1236	The mixed lineage leukemia 4 (MLL4) methyltransferase complex is involved in transforming growth factor beta (TGF-Î²)-activated gene transcription. Transcription, 2018, 9, 67-74.	1.7	6
1237	A Practical Approach to Tumor Heterogeneity in Clinical Research and Diagnostics. Pathobiology, 2018, 85, 7-17.	1.9	13
1238	Single-cell sequencing to quantify genomic integrity in cancer. International Journal of Biochemistry and Cell Biology, 2018, 94, 146-150.	1.2	15
1239	Subclonal Evolution of Cancer-Related Gene Mutations in p53 Immunopositive Patches in Human Skin. Journal of Investigative Dermatology, 2018, 138, 189-198.	0.3	28
1240	Cancerâ€testis gene <scp>PIWIL</scp>1 promotes cell proliferation, migration, and invasion in lung adenocarcinoma. Cancer Medicine, 2018, 7, 157-166.	1.3	45

#	Article	IF	Citations
1241	Computational approaches for inferring tumor evolution from single-cell genomic data. Current Opinion in Systems Biology, 2018, 7, 16-25.	1.3	36
1242	Targeting mutant p53 for efficient cancer therapy. Nature Reviews Cancer, 2018, 18, 89-102.	12.8	655
1243	Whole exome sequencing reveals intertumor heterogeneity and distinct genetic origins of sporadic synchronous colorectal cancer. International Journal of Cancer, 2018, 142, 927-939.	2.3	21
1244	Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Research, 2018, 28, 172-186.	5.7	62
1245	A P53-Deficiency Gene Signature Predicts Recurrence Risk of Patients with Early-Stage Lung Adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 86-95.	1.1	42
1246	Roles and clinical implications of microRNAs in acute lymphoblastic leukemia. Journal of Cellular Physiology, 2018, 233, 5642-5654.	2.0	35
1247	Enhancing Next-Generation Sequencing-Guided Cancer Care Through Cognitive Computing. Oncologist, 2018, 23, 179-185.	1.9	78
1248	Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology. Annual Review of Medicine, 2018, 69, 319-331.	5.0	61
1249	Synthesis and antiproliferative and apoptosis-inducing activity of novel 3-substituted-3-hydroxy-2-oxindole compounds. In Vitro Cellular and Developmental Biology - Animal, 2018, 54, 61-70.	0.7	4
1250	Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. British Journal of Cancer, 2018, 118, 312-324.	2.9	184
1251	Insights from structures of cancer-relevant pre-mRNA splicing factors. Current Opinion in Genetics and Development, 2018, 48, 57-66.	1.5	16
1252	Intratumor heterogeneity ofHMCN1mutant alleles associated with poor prognosis in patients with breast cancer. Oncotarget, 2018, 9, 33337-33347.	0.8	18
1253	Immunotherapy in Older Adults With Advanced Cancers: Implications for Clinical Decision-Making and Future Research. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 400-414.	1.8	63
1254	Complexity of Delivering Precision Medicine: Opportunities and Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 998-1007.	1.8	22
1255	Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer. Journal of Clinical Oncology, 2018, 36, 1339-1342.	0.8	11
1256	Tumor Mutation Burden as a Biomarker in Resected Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2995-3006.	0.8	223
1257	Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2018, 36, 543-553.	0.8	162
1258	Transcriptional deregulation underlying the pathogenesis of small cell lung cancer. Translational Lung Cancer Research, 2018, 7, 4-20.	1.3	26

#	Article	IF	Citations
1259	Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. JCI Insight, 2018, 3, .	2.3	168
1260	Driver Versus Passenger Mutations in Tumors. , 2018, , 551-551.		2
1261	The landscape of somatic mutation in sporadic Chinese colorectal cancer. Oncotarget, 2018, 9, 27412-27422.	0.8	26
1262	Correcting genomic deletion calls with complex boundaries from next generation sequencing data. , 2018, , .		0
1263	Estimating heterogeneous treatment effect by balancing heterogeneity and fitness. BMC Bioinformatics, 2018, 19, 518.	1.2	3
1264	Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations. Disease Markers, 2018, 2018, 1-7.	0.6	13
1265	A New Insight into the Development of Novel Anti-Cancer Drugs that Improve the Expression of Mitochondrial Function-Associated Genes. , 2018, , .		0
1266	Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer. Nature Communications, 2018, 9, 2447.	5.8	100
1267	A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget, 2018, 9, 15001-15014.	0.8	33
1268	Precision Trial Drawer, a Computational Tool to Assist Planning of Genomics-Driven Trials in Oncology. JCO Precision Oncology, 2018, 2, 1-16.	1.5	2
1269	Bioinformatics analysis of aberrantly methylated-differentially expressed genes and pathways in hepatocellular carcinoma. World Journal of Gastroenterology, 2018, 24, 2605-2616.	1.4	56
1270	Molecular targets of curcumin in breast cancer (Review). Molecular Medicine Reports, 2019, 19, 23-29.	1.1	52
1271	TET2 coactivates gene expression through demethylation of enhancers. Science Advances, 2018, 4, eaau6986.	4.7	86
1272	Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. BMC Cancer, 2018, 18, 1082.	1.1	42
1273	Metachronous triple primary neoplasms with primary prostate cancer, lung cancer, and colon cancer. Medicine (United States), 2018, 97, e11332.	0.4	5
1274	IKKÎ² activates p53 to promote cancer cell adaptation to glutamine deprivation. Oncogenesis, 2018, 7, 93.	2.1	24
1275	The 150 most important questions in cancer research and clinical oncology series: questions 94â€“101. Cancer Communications, 2018, 38, 1-9.	3.7	9
1276	Aberrant RNA Splicing in Cancer and Drug Resistance. Cancers, 2018, 10, 458.	1.7	145

#	Article	IF	Citations
1277	Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway. Cancer Biology and Medicine, 2018, 15, 314.	1.4	6
1278	The Impact of miRNA in Colorectal Cancer Progression and Its Liver Metastases. International Journal of Molecular Sciences, 2018, 19, 3711.	1.8	103
1279	Targeted Synthesis of Complex Spiro[3Hâ€indoleâ€3,2â€²â€pyrrolidin]â€2(1H)â€ones by Intramolecular Cyclization of Azomethine Ylides: Highly Potent MDM2â€“p53 Inhibitors. ChemMedChem, 2019, 14, 88-93.	1.6	16
1280	Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma. Future Science OA, 2018, 4, FSO341.	0.9	8
1281	Solid Tumor Genomics. , 2018, , 191-200.		0
1282	Knockout of MTF1 Inhibits the Epithelial to Mesenchymal Transition in Ovarian Cancer Cells. Journal of Cancer, 2018, 9, 4578-4585.	1.2	45
1283	Genetic and Epigenetic Deregulation of Enhancers in Cancer. , 2018, , .		0
1284	Distinct Expression and Clinical Significance of Zinc Finger AN-1-Type Containing 4 in Oral Squamous Cell Carcinomas. Journal of Clinical Medicine, 2018, 7, 534.	1.0	2
1285	Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy. Cancers, 2018, 10, 483.	1.7	120
1287	miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC. Nature Communications, 2018, 9, 5110.	5.8	38
1288	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. Oncotarget, 2018, 9, 20617-20630.	0.8	36
1289	Clonality and heterogeneity of metachronous colorectal cancer. Molecular Carcinogenesis, 2018, 58, 447-457.	1.3	3
1290	THE HDAC INHIBITOR SODIUM PHENYLBUTYRATE ENHANCES THE CYTOTOXICITY INDUCED BY 5-FLUOROURACIL, OXALIPLATIN, AND IRINOTECAN IN COLORECTAL CANCER CELL LINES. International Journal of Pharmacy and Pharmaceutical Sciences, 2018, 10, 155.	0.3	8
1291	CTCF Expression is Essential for Somatic Cell Viability and Protection Against Cancer. International Journal of Molecular Sciences, 2018, 19, 3832.	1.8	17
1292	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell, 2018, 34, 893-905.e8.	7.7	307
1293	PI3K pathway in prostate cancer: All resistant roads lead to PI3K. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 198-206.	3.3	27
1294	Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell, 2018, 34, 549-560.e9.	7.7	168
1295	Science in Focus: Genomic Instability and its Implications for Clinical Cancer Care. Clinical Oncology, 2018, 30, 751-755.	0.6	8

#	Article	IF	Citations
1296	Warburg Effect Metabolism Drives Neoplasia in a Drosophila Genetic Model of Epithelial Cancer. Current Biology, 2018, 28, 3220-3228.e6.	1.8	33
1297	Indel sensitive and comprehensive variant/mutation detection from RNA sequencing data for precision medicine. BMC Medical Genomics, 2018, 11, 67.	0.7	5
1298	Dynasore-induced potent ubiquitylation of the exon 19 deletion mutant of epidermal growth factor receptor suppresses cell growth and migration in non-small cell lung cancer. International Journal of Biochemistry and Cell Biology, 2018, 105, 1-12.	1.2	8
1299	Proteogenomic characterization and comprehensive integrative genomic analysis of human colorectal cancer liver metastasis. Molecular Cancer, 2018, 17, 139.	7.9	62
1300	Molecular Drivers in Chondrosarcoma. , 2018, , 31-41.		0
1301	Updates on Molecular Classification of Triple Negative Breast Cancer. Current Breast Cancer Reports, 2018, 10, 289-295.	0.5	1
1302	MiPanda: A Resource for Analyzing and Visualizing Next-Generation Sequencing Transcriptomics Data. Neoplasia, 2018, 20, 1144-1149.	2.3	20
1303	Literature-based automated discovery of tumor suppressor p53 phosphorylation and inhibition by NEK2. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10666-10671.	3.3	33
1304	Onco-Multi-OMICS Approach: A New Frontier in Cancer Research. BioMed Research International, 2018, 2018, 1-14.	0.9	218
1305	Conditional generative adversarial network for gene expression inference. Bioinformatics, 2018, 34, i603-i611.	1.8	48
1306	Restoring guardianship of the genome: Anticancer drug strategies to reverse oncogenic mutant p53 misfolding. Cancer Treatment Reviews, 2018, 71, 19-31.	3.4	7
1307	RNA editing derived epitopes function as cancer antigens to elicit immune responses. Nature Communications, 2018, 9, 3919.	5.8	120
1308	PHLI-seq: constructing and visualizing cancer genomic maps in 3D by phenotype-based high-throughput laser-aided isolation and sequencing. Genome Biology, 2018, 19, 158.	3.8	18
1309	Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysis. Cancer Management and Research, 2018, Volume 10, 3945-3954.	0.9	15
1310	BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance. ESMO Open, 2018, 3, e000387.	2.0	21
1311	KDM5A Regulates a Translational Program that Controls p53 Protein Expression. IScience, 2018, 9, 84-100.	1.9	25
1312	SOX17 regulates uterine epithelialâ€“stromal cross-talk acting via a distal enhancer upstream of Ihh. Nature Communications, 2018, 9, 4421.	5.8	69
1313	Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a â€œdominant-positiveâ€•mechanism. Oncotarget, 2018, 9, 32063-32080.	0.8	12

#	Article	IF	Citations
1314	Principles of Molecular Biology. , 2018, , 1-16.		0
1315	Functional characterization of the p53 â€œmutomeâ€• Molecular and Cellular Oncology, 2018, 5, e1511207.	0.3	4
1316	Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?. Expert Review of Molecular Diagnostics, 2018, 18, 947-961.	1.5	12
1317	Hierarchical HotNet: identifying hierarchies of altered subnetworks. Bioinformatics, 2018, 34, i972-i980.	1.8	102
1318	Network integration of multi-tumour omics data suggests novel targeting strategies. Nature Communications, 2018, 9, 4514.	5.8	33
1319	Predominance of triple wild-type and IGF2R mutations in mucosal melanomas. BMC Cancer, 2018, 18, 1054.	1.1	15
1320	Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas. Genome Medicine, 2018, 10, 69.	3.6	10
1321	The Role of Hepatocyte Growth Factor (HGF) in Insulin Resistance and Diabetes. Frontiers in Endocrinology, 2018, 9, 503.	1.5	70
1322	Classification and mutation prediction from nonâ€“small cell lung cancer histopathology images using deep learning. Nature Medicine, 2018, 24, 1559-1567.	15.2	1,768
1323	p53 and metabolism: from mechanism to therapeutics. Oncotarget, 2018, 9, 23780-23823.	0.8	103
1324	Cancer-Associated PIK3CA Mutations in Overgrowth Disorders. Trends in Molecular Medicine, 2018, 24, 856-870.	3.5	181
1325	Conservation of epigenetic regulation by the MLL3/4 tumour suppressor in planarian pluripotent stem cells. Nature Communications, 2018, 9, 3633.	5.8	29
1326	Selecting immuno-oncologyâ€“based drug combinations â€“ what should we be considering?. Expert Review of Clinical Pharmacology, 2018, 11, 971-985.	1.3	5
1327	Graph CNN for Survival Analysis on Whole Slide Pathological Images. Lecture Notes in Computer Science, 2018, , 174-182.	1.0	81
1328	An Introduction to the Mathematical Modeling in the Study of Cancer Systems Biology. Cancer Informatics, 2018, 17, 117693511879975.	0.9	6
1329	Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine. Genes and Diseases, 2018, 5, 204-219.	1.5	66
1330	Advances in risk stratification of bladder cancer to guide personalized medicine. F1000Research, 2018, 7, 1137.	0.8	34
1331	Immunological-based approaches for cancer therapy. Clinics, 2018, 73, e429s.	0.6	7

#	Article	IF	Citations
1332	In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. Nature Communications, 2018, 9, 3501.	5.8	45
1333	Long noncoding RNA NEAT1, regulated by LIN28B, promotes cell proliferation and migration through sponging miR-506 in high-grade serous ovarian cancer. Cell Death and Disease, 2018, 9, 861.	2.7	94
1334	Time-Series Analysis of Tumorigenesis in a Murine Skin Carcinogenesis Model. Scientific Reports, 2018, 8, 12994.	1.6	6
1335	Genomic Copy Number Alterations in Serous Ovarian Cancer. , 2018, , .		0
1336	PI3K/Akt/mTOR Signaling Pathway and the Biphasic Effect of Arsenic in Carcinogenesis. Molecular Pharmacology, 2018, 94, 784-792.	1.0	62
1337	How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. ESMO Open, 2018, 3, e000357.	2.0	112
1338	Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer. Annals of Surgical Oncology, 2018, 25, 2323-2331.	0.7	107
1339	Multiplex assessment of protein variant abundance by massively parallel sequencing. Nature Genetics, 2018, 50, 874-882.	9.4	323
1340	Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy. Nature Medicine, 2018, 24, 758-769.	15.2	125
1341	Centrosome Linkerâ€“induced Tetraploid Segregation Errors Link Rhabdoid Phenotypes and Lethal Colorectal Cancers. Molecular Cancer Research, 2018, 16, 1385-1395.	1.5	13
1342	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptorâ€“Positive Advanced Breast Cancer. Clinical Cancer Research, 2018, 24, 4380-4387.	3.2	49
1343	Multiâ€layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/Î²â€catenin signaling activation (Review). International Journal of Molecular Medicine, 2018, 42, 713-725.	1.8	125
1344	3D genome and its disorganization in diseases. Cell Biology and Toxicology, 2018, 34, 351-365.	2.4	41
1345	The functions and unique features of long intergenic non-coding RNA. Nature Reviews Molecular Cell Biology, 2018, 19, 143-157.	16.1	968
1347	Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS. Cell Reports, 2018, 23, 2819-2831.e5.	2.9	36
1348	TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma. EBioMedicine, 2018, 32, 119-124.	2.7	61
1350	Chemical and CRISPR/Cas9 Tools for Functional Characterization of RNA Helicases. , 2018, , 221-245.		0
1351	KMT2C mediates the estrogen dependence of breast cancer through regulation of ERÎ± enhancer function. Oncogene, 2018, 37, 4692-4710.	2.6	102

#	Article	IF	Citations
1352	Pre-clinical Profile and Expectations for Pharmacological ATM Inhibition. Cancer Drug Discovery and Development, 2018, , 155-183.	0.2	0
1353	Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes and Diseases, 2018, 5, 77-106.	1.5	714
1354	p53 is required for brain growth but is dispensable for resistance to nutrient restriction during Drosophila larval development. PLoS ONE, 2018, 13, e0194344.	1.1	6
1355	Is Î²-Catenin a Druggable Target for Cancer Therapy?. Trends in Biochemical Sciences, 2018, 43, 623-634.	3.7	101
1356	Mechanisms and impact of altered tumour mechanics. Nature Cell Biology, 2018, 20, 766-774.	4.6	201
1357	Complex rearrangements and oncogene amplifications revealed by long-read DNA and RNA sequencing of a breast cancer cell line. Genome Research, 2018, 28, 1126-1135.	2.4	142
1358	Quantifying the similarity of topological domains across normal and cancer human cell types. Bioinformatics, 2018, 34, i475-i483.	1.8	32
1359	p190 RhoGAP promotes contact inhibition in epithelial cells by repressing YAP activity. Journal of Cell Biology, 2018, 217, 3183-3201.	2.3	21
1360	More than fishing for a cure: The promises and pitfalls of high throughput cancer cell line screens. , 2018, 191, 178-189.		26
1361	Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer. Advances in Clinical Chemistry, 2018, 83, 53-72.	1.8	22
1362	The Role of Chromosome Deletions in Human Cancers. Advances in Experimental Medicine and Biology, 2018, 1044, 135-148.	0.8	10
1363	Synthesizing a Genetic Sensor Based on CRISPR-Cas9 for Specifically Killing p53-Deficient Cancer Cells. ACS Synthetic Biology, 2018, 7, 1798-1807.	1.9	24
1364	Mutant p53 regulates enhancer-associated H3K4 monomethylation through interactions with the methyltransferase MLL4. Journal of Biological Chemistry, 2018, 293, 13234-13246.	1.6	22
1365	Germ line predisposition to myeloid malignancies appearing in adulthood. Expert Review of Hematology, 2018, 11, 625-636.	1.0	5
1367	Tongue carcinoma in young adults: a review of the literature. Acta Otorhinolaryngologica Italica, 2018, 38, 175-180.	0.7	50
1368	Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies. Cell Reports, 2018, 24, 1363-1376.	2.9	288
1369	Explaining cancer type specific mutations with transcriptomic and epigenomic features in normal tissues. Scientific Reports, 2018, 8, 11456.	1.6	11
1370	Complexes formed by mutant p53 and their roles in breast cancer. Breast Cancer: Targets and Therapy, 2018, Volume 10, 101-112.	1.0	14

#	Article	IF	Citations
1371	Immune ligands for cytotoxic T Lymphocytes CTLS in cancer stem cells CSCS. Frontiers in Bioscience - Landmark, 2018, 23, 563-583.	3.0	6
1372	Genomic instability in mutant p53 cancer cells upon entotic engulfment. Nature Communications, 2018, 9, 3070.	5.8	64
1373	MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design. BMC Genomics, 2018, 19, 582.	1.2	42
1374	Genetic characterisation of molecular targets in carcinoma of unknown primary. Journal of Translational Medicine, 2018, 16, 185.	1.8	23
1375	Using Regularization to Infer Cell Line Specificity in Logical Network Models of Signaling Pathways. Frontiers in Physiology, 2018, 9, 550.	1.3	3
1376	Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features. Theranostics, 2018, 8, 1740-1751.	4.6	80
1377	STAT3/p53 pathway activation disrupts IFN-Î²â€“induced dormancy in tumor-repopulating cells. Journal of Clinical Investigation, 2018, 128, 1057-1073.	3.9	86
1378	Dissecting the expression landscape of mitochondrial genes in lung squamous cell carcinoma and lung adenocarcinoma. Oncology Letters, 2018, 16, 3992-4000.	0.8	6
1379	Cancer-associated mutations of histones H2B, H3.1 and H2A.Z.1 affect the structure and stability of the nucleosome. Nucleic Acids Research, 2018, 46, 10007-10018.	6.5	58
1380	Molecular Regulation of Carcinogenesis: Friend and Foe. Toxicological Sciences, 2018, 165, 277-283.	1.4	34
1381	Integrative omics analyses broaden treatment targets in human cancer. Genome Medicine, 2018, 10, 60.	3.6	17
1382	Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma. Theranostics, 2018, 8, 1850-1868.	4.6	65
1383	Nonviral Delivery Systems for Cancer Gene Therapy: Strategies and Challenges. Current Gene Therapy, 2018, 18, 3-20.	0.9	51
1384	YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting. Cancers, 2018, 10, 137.	1.7	89
1385	The exon 19-deleted EGFR undergoes ubiquitylation-mediated endocytic degradation via dynamin activity-dependent and -independent mechanisms. Cell Communication and Signaling, 2018, 16, 40.	2.7	17
1386	Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy. Clinical Pharmacology: Advances and Applications, 2018, Volume 10, 23-29.	0.8	3
1387	Role of Thiol Reactivity for Targeting Mutant p53. Cell Chemical Biology, 2018, 25, 1219-1230.e3.	2.5	20
1388	SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. Cancer Discovery, 2018, 8, 1237-1249.	7.7	216

#	Article	IF	Citations
1389	The impact of pharmacokinetic gene profiles across human cancers. BMC Cancer, 2018, 18, 577.	1.1	3
1390	Exploring the OncoGenomic Landscape of cancer. Genome Medicine, 2018, 10, 61.	3.6	7
1392	Comprehensive Characterization of the RNA Editomes in Cancer Development and Progression. Frontiers in Genetics, 2017, 8, 230.	1.1	4
1393	Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma. Frontiers in Genetics, 2018, 9, 2.	1.1	32
1394	Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors. Frontiers in Oncology, 2017, 7, 323.	1.3	22
1395	Zinc Metallochaperones as Mutant p53 Reactivators: A New Paradigm in Cancer Therapeutics. Cancers, 2018, 10, 166.	1.7	25
1396	Role of p53 in the Regulation of the Inflammatory Tumor Microenvironment and Tumor Suppression. Cancers, 2018, 10, 219.	1.7	83
1397	A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation. Molecular Cell, 2018, 71, 178-190.e8.	4.5	177
1398	Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer. International Journal of Molecular Sciences, 2018, 19, 240.	1.8	29
1399	The Prognostic Significance of Histone Demethylase UTX in Esophageal Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2018, 19, 297.	1.8	14
1400	Carotenoid Lutein Selectively Inhibits Breast Cancer Cell Growth and Potentiates the Effect of Chemotherapeutic Agents through ROS-Mediated Mechanisms. Molecules, 2018, 23, 905.	1.7	104
1401	PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data. Genome Medicine, 2018, 10, 41.	3.6	63
1402	Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer. Clinical Epigenetics, 2018, 10, 88.	1.8	49
1403	Radio-sensitizing effects of VE-821 and beyond: Distinct phosphoproteomic and metabolomic changes after ATR inhibition in irradiated MOLT-4 cells. PLoS ONE, 2018, 13, e0199349.	1.1	8
1404	Pulmonary Malignancies (1): Lung Cancerâ€"What Are the Roles of Genetic Factors in Lung Cancer Pathogenesis?. Respiratory Disease Series, 2018, , 193-206.	0.1	0
1405	Negative selection in tumor genome evolution acts on essential cellular functions and the immunopeptidome. Genome Biology, 2018, 19, 67.	3.8	81
1406	Deep sequencing of human papillomavirus positive loco-regionally advanced oropharyngeal squamous cell carcinomas reveals novel mutational signature. BMC Cancer, 2018, 18, 640.	1.1	14
1407	A Pan-Cancer Compendium of Genes Deregulated by Somatic Genomic Rearrangement across More Than 1,400 Cases. Cell Reports, 2018, 24, 515-527.	2.9	70

#	Article	IF	Citations
1408	Targeting epigenetics using synthetic lethality in precision medicine. Cellular and Molecular Life Sciences, 2018, 75, 3381-3392.	2.4	8
1409	Genome-wide identification of transcription factors that are critical to non-small cell lung cancer. Cancer Letters, 2018, 434, 132-143.	3.2	54
1410	Ten hub genes associated with progression and prognosis of pancreatic carcinoma identified by co-expression analysis. International Journal of Biological Sciences, 2018, 14, 124-136.	2.6	135
1411	SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients. BMC Cancer, 2018, 18, 479.	1.1	34
1412	Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma. Clinical Epigenetics, 2018, 10, 19.	1.8	22
1413	Chromatin 3D â€“ will it make understanding of cancer transformation finally possible?. Bio-Algorithms and Med-Systems, 2018, 14, .	1.0	0
1414	<scp>C</scp>opy number variant analysis using genomeâ€wide mateâ€pair sequencing. Genes Chromosomes and Cancer, 2018, 57, 459-470.	1.5	44
1415	Pan-cancer transcriptional signatures predictive of oncogenic mutations reveal that Fbw7 regulates cancer cell oxidative metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 5462-5467.	3.3	31
1416	How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance. Drug Resistance Updates, 2018, 38, 27-43.	6.5	91
1417	VAReporter: variant reporter for cancer research of massive parallel sequencing. BMC Genomics, 2018, 19, 86.	1.2	2
1418	The UDP-glucose ceramide glycosyltransferase (UGCG) and the link to multidrug resistance protein 1 (MDR1). BMC Cancer, 2018, 18, 153.	1.1	42
1419	New therapeutic strategies to treat human cancers expressing mutant p53 proteins. Journal of Experimental and Clinical Cancer Research, 2018, 37, 30.	3.5	160
1420	ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nature Medicine, 2018, 24, 556-562.	15.2	372
1421	Polîµ Instability Drives Replication Stress, Abnormal Development, and Tumorigenesis. Molecular Cell, 2018, 70, 707-721.e7.	4.5	69
1422	Molecular Characterization of Colorectal Signet-Ring Cell Carcinoma Using Whole-Exome and RNA Sequencing. Translational Oncology, 2018, 11, 836-844.	1.7	14
1423	Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9. Laboratory Investigation, 2018, 98, 968-976.	1.7	33
1424	PML Recruits TET2 to Regulate DNA Modification and Cell Proliferation in Response to Chemotherapeutic Agent. Cancer Research, 2018, 78, 2475-2489.	0.4	23
1425	Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial. Clinical and Translational Oncology, 2018, 20, 1474-1483.	1.2	20

#	Article	IF	Citations
1426	Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. OncoImmunology, 2018, 7, e1490854.	2.1	200
1427	Glycogen synthase kinaseâ€3 and alternative splicing. Wiley Interdisciplinary Reviews RNA, 2018, 9, e1501.	3.2	20
1428	Association of mRNA expression of TP53 and the TP53 codon 72 Arg/Pro gene polymorphism with colorectal cancer risk in Asian population: a bioinformatics analysis and meta-analysis. Cancer Management and Research, 2018, Volume 10, 1341-1349.	0.9	8
1429	De Novo Mutations Activating Germline TP53 in an Inherited Bone-Marrow-Failure Syndrome. American Journal of Human Genetics, 2018, 103, 440-447.	2.6	33
1430	Mutational Intratumor Heterogeneity is a Complex and Early Event in the Development of Adult T-cell Leukemia/Lymphoma. Neoplasia, 2018, 20, 883-893.	2.3	12
1431	Three distinct genomic subtypes of head and neck squamous cell carcinoma associated with clinical outcomes. Oral Oncology, 2018, 85, 44-51.	0.8	11
1432	STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis. Genes and Development, 2018, 32, 1175-1187.	2.7	55
1433	Elevated expression of p53 in early colon polyps in a pig model of human familial adenomatous polyposis. Journal of Applied Genetics, 2018, 59, 485-491.	1.0	7
1434	Diagnostic Targeted Sequencing Panel for Hepatocellular Carcinoma Genomic Screening. Journal of Molecular Diagnostics, 2018, 20, 836-848.	1.2	15
1435	Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246. Scientific Reports, 2018, 8, 12671.	1.6	53
1436	Incidence of adrenal gland tumor as a second primary malignancy: SEER-based study. Endocrine Connections, 2018, 7, 1040-1048.	0.8	6
1437	Toxicity mechanism-based prodrugs: glutathione-dependent bioactivation as a strategy for anticancer prodrug design. Expert Opinion on Drug Discovery, 2018, 13, 815-824.	2.5	12
1438	FAT1 somatic mutations in head and neck carcinoma are associated with tumor progression and survival. Carcinogenesis, 2018, 39, 1320-1330.	1.3	54
1439	KMT2C Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition. Clinical Cancer Research, 2018, 24, 6556-6569.	3.2	70
1440	Genomic landscape and mutational impacts of recurrently mutated genes in cancers. Molecular Genetics & Genomic Medicine, 2018, 6, 910-923.	0.6	15
1441	Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late. International Journal of Molecular Sciences, 2018, 19, 2380.	1.8	39
1442	Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature, 2018, 560, 499-503.	13.7	477
1443	The clinical applications of The Cancer Genome Atlas project for bladder cancer. Expert Review of Anticancer Therapy, 2018, 18, 973-980.	1.1	12

#	Article	IF	Citations
1444	Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC). Cancers of the Head & Neck, 2018, 3, 3.	6.2	58
1445	Comparison of Burnet's clonal selection theory with tumor cell-clone development. Theranostics, 2018, 8, 3392-3399.	4.6	9
1446	Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer. JAMA Oncology, 2018, 4, 1691.	3.4	190
1447	Gene editing in the context of an increasingly complex genome. BMC Genomics, 2018, 19, 595.	1.2	8
1450	Cancer-mutation network and the number and specificity of driver mutations. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6010-E6019.	3.3	91
1451	Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison. Expert Opinion on Therapeutic Targets, 2018, 22, 639-653.	1.5	14
1452	Molecular Characterization and Putative Pathogenic Pathways of Tuberous Sclerosis Complexâ€“Associated Renal Cell Carcinoma. Translational Oncology, 2018, 11, 962-970.	1.7	8
1453	Genetic Variations of Long Noncoding RNAs in Cancer. , 2018, , 289-308.		0
1454	The causal relationship between epigenetic abnormality and cancer development: <i>in vivo</i> reprogramming and its future application. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2018, 94, 235-247.	1.6	6
1455	Unraveling the role of low-frequency mutated genes in breast cancer. Bioinformatics, 2019, 35, 36-46.	1.8	13
1456	Translational Control in Cancer. Cold Spring Harbor Perspectives in Biology, 2019, 11, a032896.	2.3	191
1457	p53 tumor suppressor and iron homeostasis. FEBS Journal, 2019, 286, 620-629.	2.2	39
1458	Composite Coefficient of Determination and Its Application in Ultrahigh Dimensional Variable Screening. Journal of the American Statistical Association, 2019, 114, 1740-1751.	1.8	9
1459	Identification of Local Clusters of Mutation Hotspots in Cancer-Related Genes and Their Biological Relevance. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2019, 16, 1656-1662.	1.9	11
1460	Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers. Breast Cancer Research, 2019, 21, 87.	2.2	26
1461	Characterization of a new glioblastoma cell line, GB-val4, with unusual TP53 mutation. Human Cell, 2019, 32, 557-567.	1.2	0
1462	p53 Activation by Cr(VI): A Transcriptionally Limited Response Induced by ATR Kinase in S-Phase. Toxicological Sciences, 2019, 172, 11-22.	1.4	6
1463	Identification of Coding and Long Noncoding RNAs Differentially Expressed in Tumors and Preferentially Expressed in Healthy Tissues. Cancer Research, 2019, 79, 5167-5180.	0.4	38

#	Article	IF	Citations
1464	Ras Downstream Effector GGCT Alleviates Oncogenic Stress. IScience, 2019, 19, 256-266.	1.9	12
1465	Mission Possible: Advances in MYC Therapeutic Targeting in Cancer. BioDrugs, 2019, 33, 539-553.	2.2	113
1466	CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nature Communications, 2019, 10, 3637.	5.8	170
1467	PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells. Trends in Cell Biology, 2019, 29, 820-834.	3.6	297
1468	Artificial Selection for Reduced Fitness in Panmictic Populations of Drosophila melanogaster. Russian Journal of Genetics, 2019, 55, 411-417.	0.2	0
1469	SCF(FBXW7)â€mediated degradation of p53 promotes cell recovery after UVâ€induced DNA damage. FASEB Journal, 2019, 33, 11420-11430.	0.2	19
1470	Analysis of the FLVR motif of SHIP1 and its importance for the protein stability of SH2 containing signaling proteins. Cellular Signalling, 2019, 63, 109380.	1.7	4
1471	IL-17F expression correlates with clinicopathologic factors and biological markers in non-small cell lung cancer. Pathology Research and Practice, 2019, 215, 152562.	1.0	5
1472	Integrated bioinformatics analysis to identify 15 hub genes in breast cancer. Oncology Letters, 2019, 18, 1023-1034.	0.8	16
1473	Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response. BMC Cancer, 2019, 19, 824.	1.1	34
1474	Mutant p53â€”a potential player in shaping the tumorâ€“stroma crosstalk. Journal of Molecular Cell Biology, 2019, 11, 600-604.	1.5	21
1475	Intratumour heterogeneity of p53 expression; causes and consequences. Journal of Pathology, 2019, 249, 274-285.	2.1	31
1476	Intergrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma. EBioMedicine, 2019, 46, 105-118.	2.7	30
1477	Multiple Molecular Targets Associated with Genomic Instability in Lung Cancer. International Journal of Genomics, 2019, 2019, 1-8.	0.8	16
1478	Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin. PLoS ONE, 2019, 14, e0219547.	1.1	38
1479	Integrative genomic analysis identifies associations of molecular alterations to APOBEC and BRCA1/2 mutational signatures in breast cancer. Molecular Genetics & Genomic Medicine, 2019, 7, e810.	0.6	7
1480	mTOR Signaling Upregulates CDC6 via Suppressing miR-3178 and Promotes the Loading of DNA Replication Helicase. Scientific Reports, 2019, 9, 9805.	1.6	8
1481	Systematic discovery of the functional impact of somatic genome alterations in individual tumors through tumor-specific causal inference. PLoS Computational Biology, 2019, 15, e1007088.	1.5	31

#	Article	IF	Citations
1482	p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition. Journal of Experimental and Clinical Cancer Research, 2019, 38, 307.	3.5	22
1483	Optimization of Population Frequency Cutoffs for Filtering Common Germline Polymorphisms from Tumor-Only Next-Generation Sequencing Data. Journal of Molecular Diagnostics, 2019, 21, 903-912.	1.2	13
1484	Î²-Catenin/TCF4 Complex-Mediated Induction of the NRF3 (NFE2L3) Gene in Cancer Cells. International Journal of Molecular Sciences, 2019, 20, 3344.	1.8	25
1485	Hepatocellular Carcinoma Xenografts Established From Needle Biopsies Preserve the Characteristics of the Originating Tumors. Hepatology Communications, 2019, 3, 971-986.	2.0	24
1486	Targeted sequencing of cancerâ€related genes in nasopharyngeal carcinoma identifies mutations in the TGFâ€Î² pathway. Cancer Medicine, 2019, 8, 5116-5127.	1.3	13
1487	Quantifying gene selection in cancer through protein functional alteration bias. Nucleic Acids Research, 2019, 47, 6642-6655.	6.5	21
1488	Rare, functional, somatic variants in gene families linked to cancer genes: GPCR signaling as a paradigm. Oncogene, 2019, 38, 6491-6506.	2.6	20
1489	Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications. International Journal of Medical Sciences, 2019, 16, 981-989.	1.1	104
1490	The immune responseâ€related mutational signatures and driver genes in nonâ€smallâ€cell lung cancer. Cancer Science, 2019, 110, 2348-2356.	1.7	86
1491	Comprehensive elaboration of database resources utilized in next-generation sequencing-based tumor somatic mutation detection. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1872, 122-137.	3.3	5
1492	Therapeutic Implication of Genomic Landscape of Adult Metastatic Sarcoma. JCO Precision Oncology, 2019, 3, 1-25.	1.5	12
1493	Inflammatory signaling in genomically instable cancers. Cell Cycle, 2019, 18, 1830-1848.	1.3	21
1494	Label propagation defines signaling networks associated with recurrently mutated cancer genes. Scientific Reports, 2019, 9, 9401.	1.6	1
1495	Combined Fascin-1 and MAP17 Expression in Breast Cancer Identifies Patients with High Risk for Disease Recurrence. Molecular Diagnosis and Therapy, 2019, 23, 635-644.	1.6	10
1496	Gene relevance based on multiple evidences in complex networks. Bioinformatics, 2020, 36, 865-871.	1.8	6
1497	PhISCS: a combinatorial approach for subperfect tumor phylogeny reconstruction via integrative use of single-cell and bulk sequencing data. Genome Research, 2019, 29, 1860-1877.	2.4	73
1498	SiCloneFit: Bayesian inference of population structure, genotype, and phylogeny of tumor clones from single-cell genome sequencing data. Genome Research, 2019, 29, 1847-1859.	2.4	97
1499	Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors. ESMO Open, 2019, 4, e000531.	2.0	60

#	Article	IF	Citations
1500	CUTseq is a versatile method for preparing multiplexed DNA sequencing libraries from low-input samples. Nature Communications, 2019, 10, 4732.	5.8	12
1501	PD-1-Associated Gene Expression Signature of Neoadjuvant Trastuzumab-Treated Tumors Correlates with Patient Survival in HER2-Positive Breast Cancer. Cancers, 2019, 11, 1566.	1.7	7
1502	DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patientsâ€™ survival, immune cell infiltrates, mutational load, and interferon Î³ signature. EBioMedicine, 2019, 48, 341-352.	2.7	22
1503	Plasticity and Clonality of Cancer Cell States. Trends in Cancer, 2019, 5, 655-656.	3.8	15
1504	Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy. Journal of Translational Medicine, 2019, 17, 339.	1.8	8
1505	MicroRNA and mRNA Interaction Network Regulates the Malignant Transformation of Human Bronchial Epithelial Cells Induced by Cigarette Smoke. Frontiers in Oncology, 2019, 9, 1029.	1.3	27
1506	Unraveling the role of peroxisome proliferator-activated receptor-Î²/Î´ (PPARÎ²/Î´) expression in colon carcinogenesis. Npj Precision Oncology, 2019, 3, 26.	2.3	8
1507	Study on evaluation of emergency plan for production accident. IOP Conference Series: Earth and Environmental Science, 2019, 304, 042074.	0.2	0
1508	MYC predetermines the sensitivity of gastrointestinal cancer to antifolate drugs through regulating TYMS transcription. EBioMedicine, 2019, 48, 289-300.	2.7	20
1509	Five Core Genes Related to the Progression and Prognosis of Hepatocellular Carcinoma Identified by Analysis of a Coexpression Network. DNA and Cell Biology, 2019, 38, 1564-1576.	0.9	37
1510	Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer. Archives of Pharmacal Research, 2019, 42, 947-961.	2.7	24
1511	PRODIGY: personalized prioritization of driver genes. Bioinformatics, 2020, 36, 1831-1839.	1.8	32
1512	RITA requires eIF2Î±-dependent modulation of mRNA translation for its anti-cancer activity. Cell Death and Disease, 2019, 10, 845.	2.7	7
1513	Rapid generation and selection of Cas9-engineering TRP53 R172P mice that do not have off-target effects. BMC Biotechnology, 2019, 19, 74.	1.7	0
1514	Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Molecular Cancer, 2019, 18, 157.	7.9	1,121
1515	DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. Theranostics, 2019, 9, 7251-7267.	4.6	99
1517	Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells. Nature Communications, 2019, 10, 5011.	5.8	43
1518	GATA3 recruits UTX for gene transcriptional activation to suppress metastasis of breast cancer. Cell Death and Disease, 2019, 10, 832.	2.7	30

#	Article	IF	Citations
1519	Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3KÎ± inhibitors. Science, 2019, 366, 714-723.	6.0	185
1520	Mapping genetic interactions in cancer: a road to rational combination therapies. Genome Medicine, 2019, 11, 62.	3.6	16
1521	Mathematical Modeling of p53 Pathways. International Journal of Molecular Sciences, 2019, 20, 5179.	1.8	12
1522	Cancer Sample Biobanking at the Next Level: Combining Tissue With Living Cell Repositories to Promote Precision Medicine. Frontiers in Cell and Developmental Biology, 2019, 7, 246.	1.8	24
1523	BRK phosphorylates SMAD4 for proteasomal degradation and inhibits tumor suppressor FRK to control SNAIL, SLUG, and metastatic potential. Science Advances, 2019, 5, eaaw3113.	4.7	16
1524	Tollâ€like receptors: The role in bladder cancer development, progression and immunotherapy. Scandinavian Journal of Immunology, 2019, 90, e12818.	1.3	46
1525	Genome-wide somatic mutation analysis via Hawk-Seqâ„¢ reveals mutation profiles associated with chemical mutagens. Archives of Toxicology, 2019, 93, 2689-2701.	1.9	24
1526	p53 nuclear accumulation as an early indicator of lethal prostate cancer. British Journal of Cancer, 2019, 121, 578-583.	2.9	10
1527	Molecular Subtyping and Prognostic Assessment Based on Tumor Mutation Burden in Patients with Lung Adenocarcinomas. International Journal of Molecular Sciences, 2019, 20, 4251.	1.8	29
1528	A Pan-cancer Transcriptome Analysis Reveals Pervasive Regulation through Alternative Promoters. Cell, 2019, 178, 1465-1477.e17.	13.5	144
1529	Identifying Hepatocellular Carcinoma Driver Genes by Integrative Pathway Crosstalk and Protein Interaction Network. DNA and Cell Biology, 2019, 38, 1112-1124.	0.9	8
1530	Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1. Molecular Cell, 2019, 76, 82-95.e7.	4.5	84
1531	SigProfilerMatrixGenerator: a tool for visualizing and exploring patterns of small mutational events. BMC Genomics, 2019, 20, 685.	1.2	162
1532	Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. Biomedicines, 2019, 7, 69.	1.4	136
1533	Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research. Cancers, 2019, 11, 1321.	1.7	34
1534	Li-Fraumeni syndrome: not a straightforward diagnosis anymoreâ€"the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. Breast Cancer Research, 2019, 21, 107.	2.2	51
1535	Comprehensive Characterization of Somatic Mutations Impacting lncRNA Expression for Pan-Cancer. Molecular Therapy - Nucleic Acids, 2019, 18, 66-79.	2.3	27
1536	The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas. Cancers, 2019, 11, 1347.	1.7	31

#	Article	IF	Citations
1537	Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response. Cell Death and Disease, 2019, 10, 666.	2.7	19
1538	Fatty acid transport protein 4 is required for incorporation of saturated ultralong-chain fatty acids into epidermal ceramides and monoacylglycerols. Scientific Reports, 2019, 9, 13254.	1.6	17
1539	STAT3 and STAT5 Activation in Solid Cancers. Cancers, 2019, 11, 1428.	1.7	71
1540	Cetuximab and Radiation Therapy in Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 678-679.	0.4	2
1541	Pathway analysis of genomic pathology tests for prognostic cancer subtyping. Journal of Biomedical Informatics, 2019, 98, 103286.	2.5	3
1542	RNA Transcription and Splicing Errors as a Source of Cancer Frameshift Neoantigens for Vaccines. Scientific Reports, 2019, 9, 14184.	1.6	32
1543	Association of BCG Vaccination in Childhood With Subsequent Cancer Diagnoses. JAMA Network Open, 2019, 2, e1912014.	2.8	67
1544	NoMAS: A Computational Approach to Find Mutated Subnetworks Associated With Survival in Genome-Wide Cancer Studies. Frontiers in Genetics, 2019, 10, 265.	1.1	8
1546	A prognostic index based on an eleven gene signature to predict systemic recurrences in colorectal cancer. Experimental and Molecular Medicine, 2019, 51, 1-12.	3.2	21
1547	â€œNRF2 addictionâ€•in lung cancer cells and its impact on cancer therapy. Cancer Letters, 2019, 467, 40-49.	3.2	55
1548	Oncogenic Mutations Rewire Signaling Pathways by Switching Protein Recruitment to Phosphotyrosine Sites. Cell, 2019, 179, 543-560.e26.	13.5	65
1549	Even Cancer Cells Watch Their Cholesterol!. Molecular Cell, 2019, 76, 220-231.	4.5	118
1550	Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes. Biometrical Journal, 2019, 61, 1219-1231.	0.6	15
1551	Biological Interpretation of Complex Genomic Data. Methods in Molecular Biology, 2019, 1908, 61-71.	0.4	1
1552	Tissue-Specific Chk1 Activation Determines Apoptosis by Regulating the Balance of p53 and p21. IScience, 2019, 12, 27-40.	1.9	8
1553	Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. Nature Protocols, 2019, 14, 482-517.	5.5	1,172
1554	A Cell Lineâ€“based Immunohistochemical p53 Expression Pattern Control Panel. International Journal of Gynecological Pathology, 2019, 38, 449-458.	0.9	1
1555	Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier. Breast Cancer Research, 2019, 21, 14.	2.2	5

#	Article	IF	Citations
1556	Fam83F induces p53 stabilisation and promotes its activity. Cell Death and Differentiation, 2019, 26, 2125-2138.	5.0	16
1557	Whole genome sequencing of breast cancer. Apmis, 2019, 127, 303-315.	0.9	23
1558	Molecular Insights into the Classification of Luminal Breast Cancers: The Genomic Heterogeneity of Progesterone-Negative Tumors. International Journal of Molecular Sciences, 2019, 20, 510.	1.8	25
1559	Experimental Evolution of Extreme Resistance to Ionizing Radiation in Escherichia coli after 50 Cycles of Selection. Journal of Bacteriology, 2019, 201, .	1.0	30
1560	Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open, 2019, 4, e000442.	2.0	257
1561	Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance. Molecular Cell, 2019, 73, 1162-1173.e5.	4.5	81
1562	The lysineâ€specific methyltransferase <scp>KMT</scp> 2C/ <scp>MLL</scp> 3 regulates <scp>DNA</scp> repair components in cancer. EMBO Reports, 2019, 20, .	2.0	93
1563	Pathway Instability Is an Effective New Mutation-Based Type of Cancer Biomarkers. Frontiers in Oncology, 2018, 8, 658.	1.3	21
1564	Isoprenylcysteine carboxy methyltransferase (ICMT) is associated with tumor aggressiveness and its expression is controlled by the p53 tumor suppressor. Journal of Biological Chemistry, 2019, 294, 5060-5073.	1.6	15
1565	Clinical factors associated with circulating tumor <scp>DNA</scp> (ct<scp>DNA</scp>) in primary breast cancer. Molecular Oncology, 2019, 13, 1033-1046.	2.1	30
1566	Whole-Exome Sequencing Reveals Frequent Mutations in Chromatin Remodeling Genes in Mammary and Extramammary Pagetâ€™s Diseases. Journal of Investigative Dermatology, 2019, 139, 789-795.	0.3	35
1567	Oncogenic KRAS hotspot mutations are rare in IDHâ€mutant gliomas. Brain Pathology, 2019, 29, 321-324.	2.1	4
1568	Plasma Epsteinâ€“Barr virus DNA as an archetypal circulating tumour DNA marker. Journal of Pathology, 2019, 247, 641-649.	2.1	53
1569	Control of p53-dependent transcription and enhancer activity by the p53 family member p63. Journal of Biological Chemistry, 2019, 294, 10720-10736.	1.6	27
1570	Liquid biopsy for lung cancer immunotherapy (Review). Oncology Letters, 2019, 17, 4751-4760.	0.8	14
1571	Dangerous liaisons: interplay between SWI/SNF, NuRD, and Polycomb in chromatin regulation and cancer. Genes and Development, 2019, 33, 936-959.	2.7	127
1572	Functions of Nuclear Polyphosphoinositides. Handbook of Experimental Pharmacology, 2019, 259, 163-181.	0.9	1
1573	Precision Medicine in Cancer Therapy. Cancer Treatment and Research, 2019, , .	0.2	4

#	Article	IF	Citations
1574	CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers. Cell Systems, 2019, 9, 9-23.e8.	2.9	83
1575	Genomics-Enabled Precision Medicine for Cancer. Cancer Treatment and Research, 2019, 178, 137-169.	0.2	9
1576	Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation. Clinical Cancer Research, 2019, 25, 6392-6405.	3.2	37
1577	An EGFR-Induced Drosophila Lung Tumor Model Identifies Alternative Combination Treatments. Molecular Cancer Therapeutics, 2019, 18, 1659-1668.	1.9	14
1578	PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer. Frontiers in Oncology, 2019, 9, 462.	1.3	41
1579	The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. Experimental and Molecular Medicine, 2019, 51, 1-17.	3.2	118
1580	Residual Structures and Transient Long-Range Interactions of p53 Transactivation Domain: Assessment of Explicit Solvent Protein Force Fields. Journal of Chemical Theory and Computation, 2019, 15, 4708-4720.	2.3	32
1581	Restoration of p53 Function in Ovarian Cancer Mediated by Gold Nanoparticle-Based EGFR Targeted Gene Delivery System. ACS Biomaterials Science and Engineering, 2019, 5, 3631-3644.	2.6	25
1582	Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing. Molecular Cancer Therapeutics, 2019, 18, 1460-1471.	1.9	24
1583	YY1-Induced Upregulation of Long Noncoding RNA ARAP1-AS1 Promotes Cell Migration and Invasion in Colorectal Cancer Through the Wnt/Î²-Catenin Signaling Pathway. Cancer Biotherapy and Radiopharmaceuticals, 2019, 34, 519-528.	0.7	36
1584	Quantitative next-generation sequencing-based analysis indicates progressive accumulation of microsatellite instability between atypical hyperplasia/endometrial intraepithelial neoplasia and paired endometrioid endometrial carcinoma. Modern Pathology, 2019, 32, 1508-1520.	2.9	15
1585	Immunosuppressive Tumor Microenvironment Status and Histological Grading of Endometrial Carcinoma. Cancer Microenvironment, 2019, 12, 169-179.	3.1	21
1586	Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis. Laboratory Investigation, 2019, 99, 1454-1469.	1.7	18
1587	Efficient algorithms to discover alterations with complementary functional association in cancer. PLoS Computational Biology, 2019, 15, e1006802.	1.5	9
1588	Construing the Biochemical and Molecular Mechanism Underlying the In Vivo and In Vitro Chemotherapeutic Efficacy of Ruthenium-Baicalein Complex in Colon Cancer. International Journal of Biological Sciences, 2019, 15, 1052-1071.	2.6	21
1589	Unraveling the ECM-Immune Cell Crosstalk in Skin Diseases. Frontiers in Cell and Developmental Biology, 2019, 7, 68.	1.8	83
1590	Events of alternative splicing in head and neck cancer via RNA sequencing â€“ an update. BMC Genomics, 2019, 20, 442.	1.2	4
1592	Graphlet Laplacians for topology-function and topology-disease relationships. Bioinformatics, 2019, 35, 5226-5234.	1.8	8

#	Article	IF	Citations
1593	Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential. Cancer Medicine, 2019, 8, 4338-4347.	1.3	44
1594	Breast cancer mutation in GATA3 zinc finger 1 induces conformational changes leading to the closer binding of ZnFn2 with a wrapping architecture. Journal of Biomolecular Structure and Dynamics, 2019, 38, 1-15.	2.0	5
1595	Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53-Deficient Cancers. Molecular Cancer Research, 2019, 17, 1652-1664.	1.5	10
1596	Mutant p53 and Cellular Stress Pathways: A Criminal Alliance That Promotes Cancer Progression. Cancers, 2019, 11, 614.	1.7	51
1597	Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. JAMA Oncology, 2019, 5, 1118.	3.4	152
1598	Gene coexpression network analysis of multiple cancers discovers the varying stem cell features between gastric and breast cancer. Meta Gene, 2019, 21, 100576.	0.3	2
1599	A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1. Cancer Discovery, 2019, 9, 962-979.	7.7	58
1600	p190RhoGAPs, the ARHGAP35- and ARHGAP5-Encoded Proteins, in Health and Disease. Cells, 2019, 8, 351.	1.8	31
1601	Synchronous recurrence of concurrent colon adenocarcinoma and dedifferentiated liposarcoma. BMJ Case Reports, 2019, 12, e228868.	0.2	4
1602	CRISPR-Cas9: A multifaceted therapeutic strategy for cancer treatment. Seminars in Cell and Developmental Biology, 2019, 96, 4-12.	2.3	15
1603	Measuring Clonal Evolution in Cancer with Genomics. Annual Review of Genomics and Human Genetics, 2019, 20, 309-329.	2.5	52
1604	mTOR Signaling Pathway in Cancer Targets Photodynamic Therapy In Vitro. Cells, 2019, 8, 431.	1.8	19
1605	Systems Biology in Biomarker Development for Cancer Signaling Therapy. , 2019, , 27-51.		1
1606	The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma. OncoImmunology, 2019, 8, 1608132.	2.1	37
1607	Recent advances in triple negative breast cancer: the immunotherapy era. BMC Medicine, 2019, 17, 90.	2.3	267
1608	CRISPR/Cas9 as a tool to dissect cancer mutations. Methods, 2019, 164-165, 36-48.	1.9	5
1609	Functional characterization of novel germline TP53 variants in Swedish families. Clinical Genetics, 2019, 96, 216-225.	1.0	7
1610	Three novel genetic variants in NRF2 signaling pathway genes are associated with pancreatic cancer risk. Cancer Science, 2019, 110, 2022-2032.	1.7	14

#	Article	IF	Citations
1611	KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes. Biomedicine and Pharmacotherapy, 2019, 115, 108924.	2.5	24
1612	Mouse Models for Exploring the Biological Consequences and Clinical Significance of PIK3CA Mutations. Biomolecules, 2019, 9, 158.	1.8	13
1613	Genotyping of Circulating Tumor DNA Reveals the Clinically Actionable Mutation Landscape of Advanced Colorectal Cancer. Molecular Cancer Therapeutics, 2019, 18, 1158-1167.	1.9	14
1614	Unsupervised Domain Adaptation for Classification of Histopathology Whole-Slide Images. Frontiers in Bioengineering and Biotechnology, 2019, 7, 102.	2.0	50
1615	Germline Missense Variants in BRCA1: New Trends and Challenges for Clinical Annotation. Cancers, 2019, 11, 522.	1.7	16
1616	Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nature Medicine, 2019, 25, 744-750.	15.2	443
1617	Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nature Medicine, 2019, 25, 751-758.	15.2	362
1618	Prognostic role of ARID1A negative expression in gastric cancer. Scientific Reports, 2019, 9, 6769.	1.6	34
1619	Basket Trials for Intractable Cancer. Frontiers in Oncology, 2019, 9, 229.	1.3	22
1620	Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer. Journal of Immunology, 2019, 202, 3458-3467.	0.4	36
1621	Long Non-Coding RNA and Breast Cancer. Technology in Cancer Research and Treatment, 2019, 18, 153303381984388.	0.8	67
1622	Cell Cycle. , 2019, , .		7
1623	High-throughput Exploration of the Network Dependent on AKT1 in Mouse Ovarian Granulosa Cells. Molecular and Cellular Proteomics, 2019, 18, 1307-1319.	2.5	10
1624	Evolution of biosequence search algorithms: a brief survey. Bioinformatics, 2019, 35, 3547-3552.	1.8	27
1625	Differentially mutated subnetworks discovery. Algorithms for Molecular Biology, 2019, 14, 10.	0.3	7
1626	Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors. PLoS ONE, 2019, 14, e0209134.	1.1	16
1627	Genome-wide nucleotide patterns and potential mechanisms of genome divergence following domestication in maize and soybean. Genome Biology, 2019, 20, 74.	3.8	13
1628	The expanding landscape of â€˜oncohistoneâ€™ mutations in human cancers. Nature, 2019, 567, 473-478.	13.7	271

#	Article	IF	Citations
1629	A patent update on PDK1 inhibitors (2015-present). Expert Opinion on Therapeutic Patents, 2019, 29, 271-282.	2.4	18
1630	Dynamic host immune response in virus-associated cancers. Communications Biology, 2019, 2, 109.	2.0	34
1631	IFN/STAT signaling controls tumorigenesis and the drug response in colorectal cancer. Cancer Science, 2019, 110, 1293-1305.	1.7	13
1632	A Systematic Pan-Cancer Analysis of Genetic Heterogeneity Reveals Associations with Epigenetic Modifiers. Cancers, 2019, 11, 391.	1.7	12
1633	Genomic Heterogeneity and Branched Evolution of Early Stage Primary Acral Melanoma Shown by Multiregional Microdissection Sequencing. Journal of Investigative Dermatology, 2019, 139, 1526-1534.	0.3	7
1634	Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine, 2019, 42, 363-374.	2.7	257
1635	Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers. Cancer Science, 2019, 110, 1389-1400.	1.7	29
1636	p53 overexpression is a prognosticator of poor outcome in esophageal cancer. Oncology Letters, 2019, 17, 3826-3834.	0.8	19
1637	The neoepitope landscape of breast cancer: implications for immunotherapy. BMC Cancer, 2019, 19, 200.	1.1	68
1638	Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma. Current Oncology Reports, 2019, 21, 34.	1.8	37
1639	isma: an R package for the integrative analysis of mutations detected by multiple pipelines. BMC Bioinformatics, 2019, 20, 107.	1.2	5
1640	Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. European Urology, 2019, 76, 73-81.	0.9	117
1641	Tumorigenesis as the Paradigm of Quasi-neutral Molecular Evolution. Molecular Biology and Evolution, 2019, 36, 1430-1441.	3.5	17
1642	Early activating somatic PIK3CA mutations promote ectopic muscle development and upper limb overgrowth. Clinical Genetics, 2019, 96, 118-125.	1.0	14
1643	TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer. Human Pathology, 2019, 87, 95-102.	1.1	34
1644	Ancestral characterization of 1018 cancer cell lines highlights disparities and reveals gene expression and mutational differences. Cancer, 2019, 125, 2076-2088.	2.0	16
1645	A graph-based algorithm for estimating clonal haplotypes of tumor sample from sequencing data. BMC Medical Genomics, 2019, 12, 27.	0.7	4
1648	Ribosomal protein RPL22/eL22 regulates the cell cycle by acting as an inhibitor of the CDK4-cyclin D complex. Cell Cycle, 2019, 18, 759-770.	1.3	14

#	Article	IF	Citations
1649	Identification of aberrantly methylated differentially expressed genes in prostate carcinoma using integrated bioinformatics. Cancer Cell International, 2019, 19, 51.	1.8	16
1650	Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs). Clinical Sarcoma Research, 2019, 9, 3.	2.3	26
1651	A secure SNP panel scheme using homomorphically encrypted K-mers without SNP calling on the user side. BMC Genomics, 2019, 20, 188.	1.2	1
1652	The anticancer effects of cinobufagin on hepatocellular carcinoma Huhâ€˜7ï¿½cells are associated with activation of the p73 signaling pathway. Molecular Medicine Reports, 2019, 19, 4119-4128.	1.1	9
1653	Metabolic regulation of cell growth and proliferation. Nature Reviews Molecular Cell Biology, 2019, 20, 436-450.	16.1	577
1654	Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers. Scientific Reports, 2019, 9, 5244.	1.6	19
1655	Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers. PLoS Computational Biology, 2019, 15, e1006658.	1.5	83
1656	The role of ASXL1 in hematopoiesis and myeloid malignancies. Cellular and Molecular Life Sciences, 2019, 76, 2511-2523.	2.4	82
1657	Functional analysis of BARD1 missense variants in homology-directed repair and damage sensitivity. PLoS Genetics, 2019, 15, e1008049.	1.5	23
1658	Chasing the FOXO3: Insights into Its New Mitochondrial Lair in Colorectal Cancer Landscape. Cancers, 2019, 11, 414.	1.7	19
1659	TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers. Modern Pathology, 2019, 32, 1168-1179.	2.9	27
1660	The prognostic signature of the somatic mutations in Ewing sarcoma: from a network view. Japanese Journal of Clinical Oncology, 2019, 49, 604-613.	0.6	2
1661	Investigation of somatic single nucleotide variations in human endogenous retrovirus elements and their potential association with cancer. PLoS ONE, 2019, 14, e0213770.	1.1	12
1662	Prevalence and role of HER2 mutations in cancer. , 2019, 199, 188-196.		44
1663	Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early Onco/Suppressor Gene Expression with Tissue-Specificity in Mice. BioMed Research International, 2019, 2019, 1-12.	0.9	5
1664	Clinical and Genomic Considerations for Variant Histology in Bladder Cancer. Current Oncology Reports, 2019, 21, 23.	1.8	16
1665	Molecular Cancer Biology. , 2019, , 89-104.		0
1666	The circ<scp>RNA</scp>â€“micro<scp>RNA</scp> code: emerging implications for cancer diagnosis and treatment. Molecular Oncology, 2019, 13, 669-680.	2.1	300

#	Article	IF	Citations
1667	Drug Design of â€œUndruggableâ€•Targets. Chinese Journal of Chemistry, 2019, 37, 501-512.	2.6	8
1668	Evaluation of site-specific homologous recombination activity of BRCA1 by direct quantitation of gene editing efficiency. Scientific Reports, 2019, 9, 1644.	1.6	15
1669	Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica, 2019, 104, 1440-1450.	1.7	67
1670	RPS7 promotes cell migration through targeting epithelial-mesenchymal transition in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 297.e1-297.e7.	0.8	9
1671	UTX Mutations in Human Cancer. Cancer Cell, 2019, 35, 168-176.	7.7	113
1672	Immune Cell Types and Secreted Factors Contributing to Inflammation-to-Cancer Transition and Immune Therapy Response. Cell Reports, 2019, 26, 1965-1977.e4.	2.9	28
1673	Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing. Molecular Cell, 2019, 73, 1292-1305.e8.	4.5	218
1674	Analysis across multiple tumor types provides no evidence that mutant p53 exerts dominant negative activity. Npj Precision Oncology, 2019, 3, 1.	2.3	73
1675	Directional Association Measurement in Contingency Tables: Genomic Case. Journal of Computational Biology, 2019, 26, 235-240.	0.8	2
1676	Computational Intelligence Methods for Bioinformatics and Biostatistics. Lecture Notes in Computer Science, 2019, , .	1.0	0
1677	The multiple mechanisms that regulate p53 activity and cell fate. Nature Reviews Molecular Cell Biology, 2019, 20, 199-210.	16.1	711
1678	Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases. Expert Opinion on Investigational Drugs, 2019, 28, 337-349.	1.9	13
1679	Wnt/Beta-Catenin Signaling Regulation and a Role for Biomolecular Condensates. Developmental Cell, 2019, 48, 429-444.	3.1	143
1680	Nanotechnology in the diagnosis and treatment of lung cancer. , 2019, 198, 189-205.		106
1681	Giant Congenital Melanocytic Nevus Treated With Trametinib. Pediatrics, 2019, 143, .	1.0	38
1682	Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer. Nature Communications, 2019, 10, 716.	5.8	36
1683	NRF2 Activation in Cancer: From DNA to Protein. Cancer Research, 2019, 79, 889-898.	0.4	140
1685	p53 as a hub in cellular redox regulation and therapeutic target in cancer. Journal of Molecular Cell Biology, 2019, 11, 330-341.	1.5	71

#	Article	IF	Citations
1686	Beware of thy neighbor: Senescent cancer cells feast on adjacent cells to persist. Journal of Cell Biology, 2019, 218, 3535-3536.	2.3	1
1687	Characterizing Mutually Exclusive Driver Mutations in Pan-Cancer. , 2019, , .		0
1688	Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer. ESMO Open, 2019, 4, e000523.	2.0	11
1689	Germline POLE mutation in a child with hypermutated medulloblastoma and features of constitutional mismatch repair deficiency. Journal of Physical Education and Sports Management, 2019, 5, a004499.	0.5	19
1690	Identifying driver genes involving gene dysregulated expression, tissue-specific expression and gene-gene network. BMC Medical Genomics, 2019, 12, 168.	0.7	11
1691	Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy. Oncologist, 2019, 24, 791-797.	1.9	36
1692	Exploiting the Circadian Clock for Improved Cancer Therapy: Perspective From a Cell Biologist. Frontiers in Genetics, 2019, 10, 1210.	1.1	17
1693	A mechanism for the tissue specificity in BAP1 cancer syndrome. Translational Cancer Research, 2019, 8, S621-S624.	0.4	1
1694	Genomic Analysis of Metastatic Solid Tumors in Veterans: Findings From the VHA National Precision Oncology Program. JCO Precision Oncology, 2019, 3, 1-13.	1.5	7
1695	The Many Faces of Gene Regulation in Cancer: A Computational Oncogenomics Outlook. Genes, 2019, 10, 865.	1.0	34
1697	Binding partners of NRF2: Functions and regulatory mechanisms. Archives of Biochemistry and Biophysics, 2019, 678, 108184.	1.4	37
1698	CPEM: Accurate cancer type classification based on somatic alterations using an ensemble of aÂrandom forest and a deep neural network. Scientific Reports, 2019, 9, 16927.	1.6	21
1699	Future Approaches to Precision Oncologyâ€“Based Clinical Trials. Cancer Journal (Sudbury, Mass), 2019, 25, 300-304.	1.0	8
1700	Identification of Common and Subtype-Specific Mutated Sub-Pathways for a Cancer. Frontiers in Genetics, 2019, 10, 1228.	1.1	6
1701	Implications of non-uniqueness in phylogenetic deconvolution of bulk DNA samples of tumors. Algorithms for Molecular Biology, 2019, 14, 19.	0.3	13
1702	Does early diagnosis and treatment of myelodysplastic syndromes make a difference?. Best Practice and Research in Clinical Haematology, 2019, 32, 101099.	0.7	3
1703	Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen. Nature Communications, 2019, 10, 5382.	5.8	32
1704	GPCRs show widespread differential mRNA expression and frequent mutation and copy number variation in solid tumors. PLoS Biology, 2019, 17, e3000434.	2.6	55

#	Article	IF	Citations
1705	Emerging serine-threonine kinase inhibitors for treating ovarian cancer. Expert Opinion on Emerging Drugs, 2019, 24, 239-253.	1.0	6
1706	SMAD4 Somatic Mutations in Head and Neck Carcinoma Are Associated With Tumor Progression. Frontiers in Oncology, 2019, 9, 1379.	1.3	28
1708	Denoising of Aligned Genomic Data. Scientific Reports, 2019, 9, 15067.	1.6	7
1709	Mutational Patterns in Pancreatic Juice of Intraductal Papillary Mucinous Neoplasms and Concomitant Pancreatic Cancer. Pancreas, 2019, 48, 1032-1040.	0.5	13
1710	The use of DNA repair genes as prognostic indicators of gastric cancer. Journal of Cancer, 2019, 10, 4866-4875.	1.2	12
1711	The role of noncoding mutations in blood cancers. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	9
1712	Associating lncRNAs with small molecules via bilevel optimization reveals cancer-related lncRNAs. PLoS Computational Biology, 2019, 15, e1007540.	1.5	7
1713	Recent progress in mapping the emerging landscape of the small-cell lung cancer genome. Experimental and Molecular Medicine, 2019, 51, 1-13.	3.2	62
1714	The Emerging Landscape of p53 Isoforms in Physiology, Cancer and Degenerative Diseases. International Journal of Molecular Sciences, 2019, 20, 6257.	1.8	52
1715	Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. Nature Communications, 2019, 10, 5546.	5.8	98
1716	Comprehensive Molecular Characterization of Adamantinoma and OFD-like Adamantinoma Bone Tumors. American Journal of Surgical Pathology, 2019, 43, 965-974.	2.1	20
1717	CD20-negative primary middle ear diffuse large B-cell lymphoma coexpressing MYC and BCL-2 secondary to acute lymphoblastic leukemia. Medicine (United States), 2019, 98, e15204.	0.4	2
1718	Multiple Targets of the Canonical WNT/Î²-Catenin Signaling in Cancers. Frontiers in Oncology, 2019, 9, 1248.	1.3	135
1719	An analysis of mutational signatures of synonymous mutations across 15 cancer types. BMC Medical Genetics, 2019, 20, 190.	2.1	15
1720	Identifying Mutually Exclusive Gene Sets with Prognostic Value and Novel Potential Driver Genes in Patients with Glioblastoma. BioMed Research International, 2019, 2019, 1-7.	0.9	5
1721	A cis -element within the ARF locus mediates repression of p16 ^{INK4A} expression via long-range chromatin interactions. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26644-26652.	3.3	16
1722	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nature Medicine, 2019, 25, 1928-1937.	15.2	485
1723	p53 Isoforms in Cellular Senescence- and Ageing-Associated Biological and Physiological Functions. International Journal of Molecular Sciences, 2019, 20, 6023.	1.8	32

#	Article	IF	Citations
1724	Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma. Clinical Cancer Research, 2019, 25, 674-686.	3.2	44
1725	Mutational Landscape of Ovarian Adult Granulosa Cell Tumors from Whole Exome and Targeted TERT Promoter Sequencing. Molecular Cancer Research, 2019, 17, 177-185.	1.5	36
1726	The roles and mechanisms of G3BP1 in tumour promotion. Journal of Drug Targeting, 2019, 27, 300-305.	2.1	49
1727	Mutant p53^{R248Q} downregulates oxidative phosphorylation and upregulates glycolysis under normoxia and hypoxia in human cervix cancer cells. Journal of Cellular Physiology, 2019, 234, 5524-5536.	2.0	24
1728	An N-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells. Biochemical Pharmacology, 2019, 160, 134-145.	2.0	74
1729	Causal Reasoning on Boolean Control Networks Based on Abduction: Theory and Application to Cancer Drug Discovery. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2019, 16, 1574-1585.	1.9	34
1730	Starvation and Pseudo-Starvation as Drivers of Cancer Metastasis through Translation Reprogramming. Cell Metabolism, 2019, 29, 254-267.	7.2	88
1731	DCAF1 (VprBP): emerging physiological roles for a unique dual-service E3 ubiquitin ligase substrate receptor. Journal of Molecular Cell Biology, 2019, 11, 725-735.	1.5	26
1732	Fluorescent Biosensor for Detection of the R248Q Aggregationâ€Prone Mutant of p53. ChemBioChem, 2019, 20, 605-613.	1.3	9
1733	Cell death pathologies: targeting death pathways and the immune system for cancer therapy. Genes and Immunity, 2019, 20, 539-554.	2.2	39
1734	esiCancer: Evolutionary In Silico Cancer Simulator. Cancer Research, 2019, 79, 1010-1013.	0.4	5
1735	Defective repair capacity of variant proteins of the DNA glycosylase NTHL1 for 5-hydroxyuracil, an oxidation product of cytosine. Free Radical Biology and Medicine, 2019, 131, 264-273.	1.3	11
1736	Cellâ€based highâ€throughput screen for small molecule inhibitors of Bax translocation. Journal of Cellular and Molecular Medicine, 2019, 23, 1784-1797.	1.6	3
1737	Chromatin regulatory mechanisms and therapeutic opportunities in cancer. Nature Cell Biology, 2019, 21, 152-161.	4.6	140
1738	Deciphering molecular properties of hypermutated gastrointestinal cancer. Journal of Cellular and Molecular Medicine, 2019, 23, 370-379.	1.6	10
1739	MicroRNA-17 promotes osteosarcoma cells proliferation and migration and inhibits apoptosis by regulating SASH1 expression. Pathology Research and Practice, 2019, 215, 115-120.	1.0	16
1740	Modeling human RNA spliceosome mutations in the mouse: not all mice were created equal. Experimental Hematology, 2019, 70, 10-23.	0.2	13
1741	The UCSC Genome Browser database: 2019 update. Nucleic Acids Research, 2019, 47, D853-D858.	6.5	699

#	Article	IF	Citations
1742	A systematic review of the use of the alkaline comet assay for genotoxicity studies in human colon-derived cells. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2019, 845, 402976.	0.9	10
1743	Altered cancer metabolism in mechanisms of immunotherapy resistance. , 2019, 195, 162-171.		97
1744	Overexpression of novel lncRNA NLIPMT inhibits metastasis by reducing phosphorylated glycogen synthase kinase 3Î² in breast cancer. Journal of Cellular Physiology, 2019, 234, 10698-10708.	2.0	21
1745	Recent advances in breast cancer research impacting clinical diagnostic practice. Journal of Pathology, 2019, 247, 552-562.	2.1	24
1746	Characterization of circulating tumor cells in breast cancer patients by spiral microfluidics. Cell Biology and Toxicology, 2019, 35, 59-66.	2.4	25
1747	Units and Targets of Natural Selection. , 2019, , 339-386.		0
1748	Establishing a human adrenocortical carcinoma (ACC)-specific gene mutation signature. Cancer Genetics, 2019, 230, 1-12.	0.2	19
1749	The linear quadratic model: usage, interpretation and challenges. Physics in Medicine and Biology, 2019, 64, 01TR01.	1.6	224
1750	Crosstalk between Estrogen Signaling and Breast Cancer Metabolism. Trends in Endocrinology and Metabolism, 2019, 30, 25-38.	3.1	93
1751	Elevated preâ€existing lymphocytic infiltrates in tumour stroma predict poor prognosis in resectable urothelial carcinoma of the bladder. Histopathology, 2019, 75, 354-364.	1.6	4
1752	Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma. Oncogene, 2019, 38, 2994-3002.	2.6	13
1753	Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets. Journal of Ovarian Research, 2019, 12, 1.	1.3	69
1754	Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies. Pediatric Blood and Cancer, 2019, 66, e27595.	0.8	42
1755	Ultraviolet lightâ€related DNA damage mutation signature distinguishes cutaneous from mucosal or other origin for head and neck squamous cell carcinoma of unknown primary site. Head and Neck, 2019, 41, E82-E85.	0.9	17
1756	A whitening approach to probabilistic canonical correlation analysis for omics data integration. BMC Bioinformatics, 2019, 20, 15.	1.2	38
1757	Intravesical BCG: where do we stand? Past, present and future. Journal of Clinical Urology, 2019, 12, 425-435.	0.1	1
1758	Akt and SGK protein kinases are required for efficient feeding by macropinocytosis. Journal of Cell Science, 2019, 132, .	1.2	26
1759	Epigenetic Biomarkers in Cell-Free DNA and Applications in Liquid Biopsy. Genes, 2019, 10, 32.	1.0	96

#	Article	IF	Citations
1760	A cancer-testis non-coding RNA LIN28B-AS1 activates driver gene LIN28B by interacting with IGF2BP1 in lung adenocarcinoma. Oncogene, 2019, 38, 1611-1624.	2.6	61
1761	Tumor Antigens. , 2019, , 61-74.		4
1762	Molecular Genetics of Endometrial Carcinoma. Annual Review of Pathology: Mechanisms of Disease, 2019, 14, 339-367.	9.6	163
1763	Predictors of disease aggressiveness influence outcome from immunotherapy treatment in renal clear cell carcinoma. OncoImmunology, 2019, 8, e1500106.	2.1	18
1764	Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms. International Journal of Hematology, 2019, 110, 179-186.	0.7	17
1765	Mutant p53 as a guardian of the cancer cell. Cell Death and Differentiation, 2019, 26, 199-212.	5.0	523
1766	Activating Mutations in Pik3ca Contribute to Anal Carcinogenesis in the Presence or Absence of HPV-16 Oncogenes. Clinical Cancer Research, 2019, 25, 1889-1900.	3.2	24
1767	Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors. International Journal of Clinical Oncology, 2019, 24, 115-122.	1.0	35
1768	Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. Clinical Cancer Research, 2019, 25, 2537-2548.	3.2	101
1769	Plasma DNA for early cancer detection â€“ opportunities and challenges. Expert Review of Molecular Diagnostics, 2019, 19, 5-7.	1.5	5
1770	HSP90: Enabler of Cancer Adaptation. Annual Review of Cancer Biology, 2019, 3, 275-297.	2.3	59
1771	Mutant p53 in colon cancer. Journal of Molecular Cell Biology, 2019, 11, 267-276.	1.5	170
1772	Quinaldic acid induces changes in the expression of p53 tumor suppressor both on protein and gene level in colon cancer LS180 cells. Pharmacological Reports, 2019, 71, 189-193.	1.5	4
1773	Understanding Specialized Ribosomal Protein Functions and Associated Ribosomopathies by Navigating Across Sequence, Literature, and Phenotype Information Resources. , 2019, , 35-51.		6
1774	Framework for microRNA variant annotation and prioritization using human population and disease datasets. Human Mutation, 2019, 40, 73-89.	1.1	18
1775	Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone. Journal of Pathology, 2019, 247, 166-176.	2.1	28
1776	Epigenetically Silenced Candidate Tumor Suppressor Genes in Prostate Cancer: Identified by Modeling Methylation Stratification and Applied to Progression Prediction. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 198-207.	1.1	5
1777	Precision medicine needs pioneering clinical bioinformaticians. Briefings in Bioinformatics, 2019, 20, 752-766.	3.2	40

#	Article	IF	Citations
1778	Identifying mutual exclusivity across cancer genomes: computational approaches to discover genetic interaction and reveal tumor vulnerability. Briefings in Bioinformatics, 2019, 20, 254-266.	3.2	46
1779	CircView: a visualization and exploration tool for circular RNAs. Briefings in Bioinformatics, 2019, 20, 745-751.	3.2	42
1780	Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications. Seminars in Cancer Biology, 2019, 54, 14-28.	4.3	51
1781	Systematic Inspection of the Clinical Relevance of TP53 Missense Mutations in Gastric Cancer. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2019, 16, 1693-1701.	1.9	12
1782	The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer. Carcinogenesis, 2020, 41, 67-77.	1.3	12
1783	Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia. Haematologica, 2020, 105, 170-181.	1.7	37
1784	Trimester-specific plasma exosome microRNA expression profiles in preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2020, 33, 3116-3124.	0.7	32
1785	Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. International Journal of Cancer, 2020, 146, 1359-1368.	2.3	55
1786	Comparison and integration of computational methods for deleterious synonymous mutation prediction. Briefings in Bioinformatics, 2020, 21, 970-981.	3.2	56
1787	Drug Selection via Joint Push and Learning to Rank. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2020, 17, 110-123.	1.9	9
1788	PI3K Catalytic Subunits Î± and Î² Modulate Cell Death and IL-6 Secretion Induced by Talc Particles in Human Lung Carcinoma Cells. American Journal of Respiratory Cell and Molecular Biology, 2020, 62, 331-341.	1.4	2
1789	COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells. Breast Cancer Research and Treatment, 2020, 179, 47-56.	1.1	51
1790	Circulating cell-free tumor DNA analysis in pediatric cancers. Molecular Aspects of Medicine, 2020, 72, 100819.	2.7	24
1791	Genetic alterations in cell cycle regulation-associated genes may promote primary progression of gastrointestinal stromal tumors. Laboratory Investigation, 2020, 100, 426-437.	1.7	6
1792	Adapt and conquer: Metabolic flexibility in cancer growth, invasion and evasion. Molecular Metabolism, 2020, 33, 83-101.	3.0	93
1793	Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk. Environmental and Molecular Mutagenesis, 2020, 61, 152-175.	0.9	13
1794	Targeting DNA repair in cancer: current state and novel approaches. Cellular and Molecular Life Sciences, 2020, 77, 677-703.	2.4	65
1795	Pathology, Biomarkers, and Molecular Diagnostics. , 2020, , 225-253.e8.		4

#	Article	IF	Citations
1796	Carcinoma of the Bladder. , 2020, , 1382-1400.e4.		2
1797	New insights on human essential genes based on integrated analysis and the construction of the HEGIAP web-based platform. Briefings in Bioinformatics, 2020, 21, 1397-1410.	3.2	51
1798	Statistical genomics in rare cancer. Seminars in Cancer Biology, 2020, 61, 1-10.	4.3	15
1799	SOX4: The unappreciated oncogene. Seminars in Cancer Biology, 2020, 67, 57-64.	4.3	114
1800	Modulatory effect of photobiomodulation on stem cell epigenetic memory: a highlight on differentiation capacity. Lasers in Medical Science, 2020, 35, 299-306.	1.0	28
1801	Metastasis Associated Lung Adenocarcinoma Transcript 1: An update on expression pattern and functions in carcinogenesis. Experimental and Molecular Pathology, 2020, 112, 104330.	0.9	10
1802	Nucleic Acid Detection and Structural Investigations. Methods in Molecular Biology, 2020, , .	0.4	1
1803	Multiâ€omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma. Journal of Cellular Physiology, 2020, 235, 3849-3863.	2.0	32
1804	Translational genomics of ovarian clear cell carcinoma. Seminars in Cancer Biology, 2020, 61, 121-131.	4.3	25
1805	Whole-Exome Sequencing of Matched Primary and Metastatic Papillary Thyroid Cancer. Thyroid, 2020, 30, 42-56.	2.4	31
1806	The PI3Kâ€“AKT network at the interface of oncogenic signalling and cancer metabolism. Nature Reviews Cancer, 2020, 20, 74-88.	12.8	1,087
1807	ATM activity in T cells is critical for immune surveillance of lymphoma in vivo. Leukemia, 2020, 34, 771-786.	3.3	13
1808	Genomeâ€wide association study of INDELs identified four novel susceptibility loci associated with lung cancer risk. International Journal of Cancer, 2020, 146, 2855-2864.	2.3	7
1809	Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PDâ€L1 expression in cancer patients. International Journal of Cancer, 2020, 146, 3087-3097.	2.3	20
1810	PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis. Cancers, 2020, 12, 93.	1.7	57
1811	The p53 family reaches the final frontier: the variegated regulation of the dark matter of the genome by the p53 family in cancer. RNA Biology, 2020, 17, 1636-1647.	1.5	5
1812	Diffuse capillary malformation with overgrowth contains somatic PIK3CA variants. Clinical Genetics, 2020, 97, 736-740.	1.0	22
1813	Molecular crosstalk between cancer and neurodegenerative diseases. Cellular and Molecular Life Sciences, 2020, 77, 2659-2680.	2.4	63

#	Article	IF	Citations
1814	Histone H2A-peptide-hybrided upconversion mesoporous silica nanoparticles for bortezomib/p53 delivery and apoptosis induction. Colloids and Surfaces B: Biointerfaces, 2020, 186, 110674.	2.5	17
1815	Clinical application of genomic high-throughput data: Infrastructural, ethical, legal and psychosocial aspects. European Neuropsychopharmacology, 2020, 31, 1-15.	0.3	4
1816	Molecular switches in signaling networks as a mechanism of action for oncogenic mutations in proximity of tyrosine residues. Molecular and Cellular Oncology, 2020, 7, 1692643.	0.3	0
1817	The phenotypic spectrum of Kabuki syndrome in patients of Chinese descent: A case series. American Journal of Medical Genetics, Part A, 2020, 182, 640-651.	0.7	8
1818	High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities. Targeted Oncology, 2020, 15, 127-138.	1.7	23
1819	Genetic alterations related to endoscopic treatment of colorectal tumors. JGH Open, 2020, 4, 75-82.	0.7	1
1820	Protecting the Aging Genome. Trends in Cell Biology, 2020, 30, 117-132.	3.6	84
1821	Cracking the context-specific PI3K signaling code. Science Signaling, 2020, 13, .	1.6	49
1822	Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy. Clinical Cancer Research, 2020, 26, 2908-2920.	3.2	30
1823	Targeting fusions for improved outcomes in oncology treatment. Cancer, 2020, 126, 1315-1321.	2.0	14
1824	The Genomic and Molecular Pathology of Prostate Cancer: Clinical Implications for Diagnosis, Prognosis, and Therapy. Advances in Anatomic Pathology, 2020, 27, 11-19.	2.4	12
1825	Driver Gene Mutations and Epigenetics in Colorectal Cancer. Annals of Surgery, 2020, 271, 75-85.	2.1	70
1826	Mutations Beget More Mutationsâ€"Rapid Evolution of Mutation Rate in Response to the Risk of Runaway Accumulation. Molecular Biology and Evolution, 2020, 37, 1007-1019.	3.5	10
1827	Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer. Radiotherapy and Oncology, 2020, 142, 202-209.	0.3	47
1828	Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Science Translational Medicine, 2020, 12, .	5.8	260
1829	PYHIN Proteins and HPV: Role in the Pathogenesis of Head and Neck Squamous Cell Carcinoma. Microorganisms, 2020, 8, 14.	1.6	15
1830	Mutant p53 on the Path to Metastasis. Trends in Cancer, 2020, 6, 62-73.	3.8	85
1831	Heightened protein-translation activities in mammalian cells and the disease/treatment implications. National Science Review, 2020, 7, 1851-1855.	4.6	7

#	Article	IF	Citations
1832	Simulation of multiple microenvironments shows a pivot role of RPTPs on the control of Epithelial-to-Mesenchymal Transition. BioSystems, 2020, 198, 104268.	0.9	3
1833	The role of alternative splicing in cancer: From oncogenesis to drug resistance. Drug Resistance Updates, 2020, 53, 100728.	6.5	118
1834	Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand. Cancer Gene Therapy, 2021, 28, 590-601.	2.2	18
1835	Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation. Nature Communications, 2020, 11, 5156.	5.8	12
1836	Mutant p53 in Cancer Progression and Targeted Therapies. Frontiers in Oncology, 2020, 10, 595187.	1.3	116
1837	Paradoxical Role of AT-rich Interactive Domain 1A in Restraining Pancreatic Carcinogenesis. Cancers, 2020, 12, 2695.	1.7	12
1838	Dual inhibition of Src and PLK1 regulate stemness and induce apoptosis through Notch1-SOX2 signaling in EGFRvIII positive glioma stem cells (GSCs). Experimental Cell Research, 2020, 396, 112261.	1.2	9
1839	Acquired genetic changes in human pluripotent stem cells: origins and consequences. Nature Reviews Molecular Cell Biology, 2020, 21, 715-728.	16.1	59
1840	The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy-Drug Repurposing. Cancers, 2020, 12, 2717.	1.7	8
1841	Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification. Drug Resistance Updates, 2020, 53, 100720.	6.5	107
1842	HybridSucc: A Hybrid-learning Architecture for General and Species-specific Succinylation Site Prediction. Genomics, Proteomics and Bioinformatics, 2020, 18, 194-207.	3.0	28
1843	Transcriptomic characterization and innovative molecular classification of clear cell renal cell carcinoma in the Chinese population. Cancer Cell International, 2020, 20, 461.	1.8	10
1844	Bioinformatics-Based Identification of a circRNA-miRNA-mRNA Axis in Esophageal Squamous Cell Carcinomas. Journal of Oncology, 2020, 2020, 1-9.	0.6	7
1845	Screening for Early Gastric Cancer Using a Noninvasive Urine Metabolomics Approach. Cancers, 2020, 12, 2904.	1.7	24
1846	Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives. Biomarkers in Medicine, 2020, 14, 1383-1392.	0.6	16
1847	Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma. Cell Reports, 2020, 33, 108293.	2.9	39
1848	Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. Npj Breast Cancer, 2020, 6, 54.	2.3	181
1849	Single molecule studies reveal that p53 tetramers dynamically bind response elements containing one or two half sites. Scientific Reports, 2020, 10, 16176.	1.6	6

#	Article	IF	Citations
1850	Acquired Cystic Kidney Diseaseâ€“associated Renal Cell Carcinoma (ACKD-RCC) Harbor Recurrent Mutations in KMT2C and TSC2 Genes. American Journal of Surgical Pathology, 2020, 44, 1479-1486.	2.1	20
1851	Therapeutic applications oftrans-splicing. British Medical Bulletin, 2020, 136, 4-20.	2.7	16
1852	Effects of different mobile phone UMTS signals on DNA, apoptosis and oxidative stress in human lymphocytes. Environmental Pollution, 2020, 267, 115632.	3.7	15
1853	SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia. Oncogene, 2020, 39, 7239-7252.	2.6	17
1854	Establishment and validation of an immune-associated signature in lung adenocarcinoma. International Immunopharmacology, 2020, 88, 106867.	1.7	10
1856	Reshaping the tumor microenvironment: extracellular vesicles as messengers of cancer cells. Carcinogenesis, 2020, 41, 1461-1470.	1.3	17
1857	DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets. Cancers, 2020, 12, 2874.	1.7	3
1858	Cancer biology functional genomics: From small RNAs to big dreams. Molecular Carcinogenesis, 2020, 59, 1343-1361.	1.3	6
1859	Dysregulated Phosphorylation of p53, Autophagy and Stemness Attributes the Mutant p53 Harboring Colon Cancer Cells Impaired Sensitivity to Oxaliplatin. Frontiers in Oncology, 2020, 10, 1744.	1.3	14
1860	PertInInt: An Integrative, Analytical Approach to Rapidly Uncover Cancer Driver Genes with Perturbed Interactions and Functionalities. Cell Systems, 2020, 11, 63-74.e7.	2.9	8
1861	Targeting DNA and mutant p53 by a naphthalimide derivative, NA20, exhibits selective inhibition in gastric tumorigenesis by blocking mutant p53-EGFR signaling pathway. European Journal of Pharmacology, 2020, 887, 173584.	1.7	4
1862	Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell cancer. British Journal of Cancer, 2020, 123, 1302-1314.	2.9	39
1863	Inactivating p53 is essential for nerve growth factor receptor to promote melanoma-initiating cell-stemmed tumorigenesis. Cell Death and Disease, 2020, 11, 550.	2.7	15
1864	Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival. Nature Communications, 2020, 11, 3644.	5.8	55
1865	Mutant p53 Drives Cancer Metastasis via RCP-Mediated Hsp90Î± Secretion. Cell Reports, 2020, 32, 107879.	2.9	38
1866	Neural reprogramming via microRNAs: the new kid on the p53-deficient block. Molecular and Cellular Oncology, 2020, 7, 1756723.	0.3	0
1867	Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factorâ€tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma. Pathology International, 2020, 70, 712-723.	0.6	5
1868	Prediction of cancer driver genes through network-based moment propagation of mutation scores. Bioinformatics, 2020, 36, i508-i515.	1.8	19

#	Article	IF	Citations
1869	Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy. Frontiers in Oncology, 2020, 10, 1460.	1.3	30
1870	SOX2 and p53 Expression Control Converges in PI3K/AKT Signaling with Versatile Implications for Stemness and Cancer. International Journal of Molecular Sciences, 2020, 21, 4902.	1.8	22
1871	Basket trials: From tumour gnostic to tumour agnostic drug development. Cancer Treatment Reviews, 2020, 90, 102082.	3.4	15
1872	Drug Repositioning for Noonan and LEOPARD Syndromes by Integrating Transcriptomics With a Structure-Based Approach. Frontiers in Pharmacology, 2020, 11, 927.	1.6	9
1873	Hydroa vacciniforme-like lymphoproliferative disorder: A study of clinicopathology and whole-exome sequencing in Chinese patients. Journal of Dermatological Science, 2020, 99, 128-134.	1.0	9
1874	The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions. Pharmaceuticals, 2020, 13, 389.	1.7	36
1875	TruNeo: an integrated pipeline improves personalized true tumor neoantigen identification. BMC Bioinformatics, 2020, 21, 532.	1.2	15
1876	Enhancer remodeling promotes tumor-initiating activity in NRF2-activated non-small cell lung cancers. Nature Communications, 2020, 11, 5911.	5.8	60
1877	Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44. Nature Cancer, 2020, 1, 1167-1175.	5.7	22
1878	Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics Analysis. Frontiers in Oncology, 2020, 10, 570654.	1.3	16
1879	Triangular Relationship between p53, Autophagy, and Chemotherapy Resistance. International Journal of Molecular Sciences, 2020, 21, 8991.	1.8	40
1880	Alternative Splicing: Expanding the Landscape of Cancer Biomarkers and Therapeutics. International Journal of Molecular Sciences, 2020, 21, 9032.	1.8	28
1881	Bioinformatics Analysis and Validation Identify CDK1 and MAD2L1 as Prognostic Markers of Rhabdomyosarcoma . Cancer Management and Research, 2020, Volume 12, 12123-12136.	0.9	10
1882	Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance. Cancers, 2020, 12, 3553.	1.7	22
1883	Clinical Perspectives of ERCC1 in Bladder Cancer. International Journal of Molecular Sciences, 2020, 21, 8829.	1.8	6
1884	Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden. Computational and Mathematical Methods in Medicine, 2020, 2020, 1-14.	0.7	4
1885	Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing. Nature Communications, 2020, 11, 5679.	5.8	41
1886	A small UTX stabilization domain of Trr is conserved within mammalian MLL3-4/COMPASS and is sufficient to rescue loss of viability in null animals. Genes and Development, 2020, 34, 1493-1502.	2.7	14

#	Article	IF	Citations
1887	Sodium cantharidinate, a novel anti-pancreatic cancer agent that activates functional p53. Science China Life Sciences, 2020, 64, 1295-1310.	2.3	12
1888	Atherosclerosis and carcinoma: Two facets of dysfunctional cholesterol homeostasis. Journal of Biochemical and Molecular Toxicology, 2020, 34, e22595.	1.4	3
1889	BAP1 regulates AMPK-mTOR signalling pathway through deubiquitinating and stabilizing tumour-suppressor LKB1. Biochemical and Biophysical Research Communications, 2020, 529, 1025-1032.	1.0	4
1890	The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer. Frontiers in Oncology, 2020, 10, 1256.	1.3	33
1891	Identification of 9-Core Immune-Related Genes in Bladder Urothelial Carcinoma Prognosis. Frontiers in Oncology, 2020, 10, 1142.	1.3	18
1892	Model-based optimization of combination protocols for irradiation-insensitive cancers. Scientific Reports, 2020, 10, 12652.	1.6	2
1893	Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer. Frontiers in Oncology, 2020, 10, 1103.	1.3	17
1894	Targeting p53 for the treatment of cancer. Seminars in Cancer Biology, 2022, 79, 58-67.	4.3	177
1895	Hotspot mutant p53-R273H inhibits KLF6 expression to promote cell migration and tumor metastasis. Cell Death and Disease, 2020, 11, 595.	2.7	15
1896	Genome-Wide Screen for Context-Dependent Tumor Suppressors Identified Using in Vivo Models for Neoplasia in Drosophila. G3: Genes, Genomes, Genetics, 2020, 10, 2999-3008.	0.8	3
1897	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	15.2	372
1898	A pan-cancer analysis reveals nonstop extension mutations causing SMAD4 tumour suppressor degradation. Nature Cell Biology, 2020, 22, 999-1010.	4.6	12
1899	The diagnostic challenges of patients with carcinoma of unknown primary. Expert Review of Anticancer Therapy, 2020, 20, 775-783.	1.1	12
1900	Predicting Lymph Node Metastasis Using Histopathological Images Based on Multiple Instance Learning With Deep Graph Convolution. , 2020, , .		87
1901	Single-cell epigenomics in cancer: charting a course to clinical impact. Epigenomics, 2020, 12, 1139-1151.	1.0	9
1902	Lysine Demethylase KDM6A in Differentiation, Development, and Cancer. Molecular and Cellular Biology, 2020, 40, .	1.1	84
1903	A molecular dynamics and docking study to screen anti-cancer compounds targeting mutated p53. Journal of Biomolecular Structure and Dynamics, 2020, , 1-10.	2.0	8
1904	Sample-specific perturbation of gene interactions identifies breast cancer subtypes. Briefings in Bioinformatics, 2021, 22, .	3.2	20

#	Article	IF	Citations
1905	Recycling the Purpose of Old Drugs to Treat Ovarian Cancer. International Journal of Molecular Sciences, 2020, 21, 7768.	1.8	18
1906	Higher cytolytic score correlates with an immunosuppressive tumor microenvironment and reduced survival in glioblastoma. Scientific Reports, 2020, 10, 17580.	1.6	19
1907	A Quest for New Cancer Diagnosis, Prognosis and Prediction Biomarkers and Their Use in Biosensors Development. Technology in Cancer Research and Treatment, 2020, 19, 153303382095703.	0.8	8
1908	Gene Expression Along with Genomic Copy Number Variation and Mutational Analysis Were Used to Develop a 9-Gene Signature for Estimating Prognosis of COAD . OncoTargets and Therapy, 2020, Volume 13, 10393-10408.	1.0	4
1909	Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments. Cells, 2020, 9, 2352.	1.8	31
1910	Single-cell analysis of copy-number alterations in serous ovarian cancer reveals substantial heterogeneity in both low- and high-grade tumors. Cell Cycle, 2020, 19, 3154-3166.	1.3	13
1911	Integration of Online Omics-Data Resources for Cancer Research. Frontiers in Genetics, 2020, 11, 578345.	1.1	50
1912	Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges. BioDrugs, 2020, 34, 611-623.	2.2	38
1913	Identifying bifurcated paths with differential function impact in glioblastomas evolution. International Journal of Cancer, 2020, 147, 3139-3151.	2.3	0
1914	Fully-Connected Neural Networks with Reduced Parameterization for Predicting Histological Types of Lung Cancer from Somatic Mutations. Biomolecules, 2020, 10, 1249.	1.8	19
1915	CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade. Cancer Discovery, 2020, 10, 1912-1933.	7.7	71
1916	Mutational Landscape of Esophageal Squamous Cell Carcinoma in an Indian Cohort. Frontiers in Oncology, 2020, 10, 1457.	1.3	21
1917	RECQL4, Negatively Regulated by miR-10a-5p, Facilitates Cell Proliferation and Invasion via MAFB in Ovarian Cancer. Frontiers in Oncology, 2020, 10, 524128.	1.3	18
1918	Biomarker testing for advanced lung cancer by next-generation sequencing; a valid method to achieve a comprehensive glimpse at mutational landscape. Applied Cancer Research, 2020, 40, .	1.0	8
1919	Roles of NRF3 in the Hallmarks of Cancer: Proteasomal Inactivation of Tumor Suppressors. Cancers, 2020, 12, 2681.	1.7	23
1920	Characterization of BRCA1-deficient premalignant tissues and cancers identifies Plekha5 as a tumor metastasis suppressor. Nature Communications, 2020, 11, 4875.	5.8	24
1921	Quantification of cancer driver mutations in human breast and lung <scp>DNA</scp> using targeted, errorâ€corrected <scp>CarcSeq</scp>. Environmental and Molecular Mutagenesis, 2020, 61, 872-889.	0.9	6
1922	Single-cell Sequencing and Methylation. Advances in Experimental Medicine and Biology, 2020, , .	0.8	4

#	Article	IF	Citations
1923	Single Cell Sequencing: A New Dimension in Cancer Diagnosis and Treatment. Advances in Experimental Medicine and Biology, 2020, 1255, 109-121.	0.8	3
1924	Illuminating the noncoding genome in cancer. Nature Cancer, 2020, 1, 864-872.	5.7	37
1925	Turmeric and Its Major Compound Curcumin on Health: Bioactive Effects and Safety Profiles for Food, Pharmaceutical, Biotechnological and Medicinal Applications. Frontiers in Pharmacology, 2020, 11, 01021.	1.6	345
1926	Î²-catenin represses miR455-3p to stimulate m6A modification of HSF1 mRNA and promote its translation in colorectal cancer. Molecular Cancer, 2020, 19, 129.	7.9	66
1927	Gut Î³Î´ T cells as guardians, disruptors, and instigators of cancer. Immunological Reviews, 2020, 298, 198-217.	2.8	28
1928	Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications. Frontiers in Molecular Biosciences, 2020, 7, 172.	1.6	25
1929	Molecular profile of a pleomorphic adenoma of the hard palate. Medicine (United States), 2020, 99, e21207.	0.4	1
1930	Identification of an Immune Signature Predicting Prognosis Risk and Lymphocyte Infiltration in Colon Cancer. Frontiers in Immunology, 2020, 11, 1678.	2.2	58
1931	Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences. Cancer Treatment Reviews, 2020, 90, 102090.	3.4	19
1932	Pterostilbene as a Phytochemical Compound Induces Signaling Pathways Involved in the Apoptosis and Death of Mutant P53-Breast Cancer Cell Lines. Nutrition and Cancer, 2021, 73, 1976-1984.	0.9	10
1933	Concordance of Genomic Alterations between Circulating Tumor DNA and Matched Tumor Tissue in Chinese Patients with Breast Cancer. Journal of Oncology, 2020, 2020, 1-8.	0.6	9
1934	Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. Genome Medicine, 2020, 12, 78.	3.6	10
1935	SET Domain Containing 2 Deficiency in Myelodysplastic Syndrome. Frontiers in Genetics, 2020, 11, 794.	1.1	0
1936	Methylomic Landscapes of Ovarian Cancer Precursor Lesions. Clinical Cancer Research, 2020, 26, 6310-6320.	3.2	15
1937	Dietary Flavonoids in p53â€"Mediated Immune Dysfunctions Linking to Cancer Prevention. Biomedicines, 2020, 8, 286.	1.4	18
1938	Clinical implication of oncogenic somatic mutations in early-stage cervical cancer with radical hysterectomy. Scientific Reports, 2020, 10, 18734.	1.6	8
1939	Class-Incremental Learning With Deep Generative Feature Replay for DNA Methylation-Based Cancer Classification. IEEE Access, 2020, 8, 210800-210815.	2.6	8
1940	Neural Networks Recapitulation by Cancer Cells Promotes Disease Progression: A Novel Role of p73 Isoforms in Cancer-Neuronal Crosstalk. Cancers, 2020, 12, 3789.	1.7	17

#	Article	IF	Citations
1941	Set-Wise Differential Interaction between Copy Number Alterations and Gene Expressions of Lower-Grade Glioma Reveals Prognosis-Associated Pathways. Entropy, 2020, 22, 1434.	1.1	4
1942	Role of immunotherapy in Ewing sarcoma. , 2020, 8, e000653.		42
1943	Aberrant Activity of Histoneâ€“Lysine N-Methyltransferase 2 (KMT2) Complexes in Oncogenesis. International Journal of Molecular Sciences, 2020, 21, 9340.	1.8	20
1944	KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors. Biomarker Research, 2020, 8, 71.	2.8	14
1945	Identification of Somatic Mutations in Papanicolaou Smear DNA and Plasma Circulating Cell-Free DNA for Detection of Endometrial and Epithelial Ovarian Cancers: A Pilot Study. Frontiers in Oncology, 2020, 10, 582546.	1.3	4
1946	Barrett's Esophagus and Esophageal Adenocarcinoma Biomarkers. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2486-2494.	1.1	13
1947	Female Malignancies and Immunotherapy: Whatâ€™s New?. Cancers, 2020, 12, 2909.	1.7	1
1948	Cutting the Brakes on Rasâ€”Cytoplasmic GAPs as Targets of Inactivation in Cancer. Cancers, 2020, 12, 3066.	1.7	6
1949	The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery. Life, 2020, 10, 231.	1.1	3
1950	Mutant p53 oncogenicity: dominant-negative or gain-of-function?. Carcinogenesis, 2020, 41, 1635-1647.	1.3	25
1951	The changing chromatome as a driver of disease: A panoramic view from different methodologies. BioEssays, 2020, 42, 2000203.	1.2	4
1952	Reprogrammed <scp>mRNA</scp> translation drives resistance to therapeutic targeting of ribosome biogenesis. EMBO Journal, 2020, 39, e105111.	3.5	17
1953	Revealing Prognosis-Related Pathways at the Individual Level by a Comprehensive Analysis of Different Cancer Transcription Data. Genes, 2020, 11, 1281.	1.0	5
1954	Cell proliferation inhibitors and apoptosis promoters. European Journal of Cancer, Supplement, 2020, 15, 73-76.	2.2	6
1955	Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discovery, 2020, 10, 1808-1825.	7.7	388
1956	Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program. Molecular Cell, 2020, 80, 452-469.e9.	4.5	44
1957	Population mutation properties of tumor evolution. Medical Oncology, 2020, 37, 94.	1.2	1
1958	PD-1 topographically defines distinct T cell subpopulations in urothelial cell carcinoma of the bladder and predicts patient survival. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 685.e1-685.e10.	0.8	7

#	Article	IF	Citations
1959	CDK7 inhibitors as anticancer drugs. Cancer and Metastasis Reviews, 2020, 39, 805-823.	2.7	101
1960	The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment. Technology in Cancer Research and Treatment, 2020, 19, 153303382092096.	0.8	14
1961	Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing. PLoS ONE, 2020, 15, e0232754.	1.1	19
1962	Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties. Nature Communications, 2020, 11, 2333.	5.8	33
1963	Restoration of KMT2C/MLL3 in human colorectal cancer cells reinforces genome-wide H3K4me1 profiles and influences cell growth and gene expression. Clinical Epigenetics, 2020, 12, 74.	1.8	22
1964	Trametes robiniophila Murr in the treatment of breast cancer. Biomedicine and Pharmacotherapy, 2020, 128, 110254.	2.5	12
1965	Supramolecular Polysaccharide Nanotheranostics that Inhibit Cancer Cells Growth and Monitor Targeted Therapy Response. Nanotheranostics, 2020, 4, 156-172.	2.7	7
1966	Integrated multiâ€omics data analyses for exploring the coâ€occurring and mutually exclusive gene alteration events in colorectal cancer. Human Mutation, 2020, 41, 1588-1599.	1.1	13
1967	A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia. Blood Reviews, 2020, 42, 100712.	2.8	16
1968	Epi-drugs as triple-negative breast cancer treatment. Epigenomics, 2020, 12, 725-742.	1.0	9
1969	Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis. Nature Reviews Cancer, 2020, 20, 365-382.	12.8	87
1970	Use of Single-Cell -Omic Technologies to Study the Gastrointestinal Tract and Diseases, From Single Cell Identities to Patient Features. Gastroenterology, 2020, 159, 453-466.e1.	0.6	17
1971	NRF3-POMP-20S Proteasome Assembly Axis Promotes Cancer Development via Ubiquitin-Independent Proteolysis of p53 and Retinoblastoma Protein. Molecular and Cellular Biology, 2020, 40, .	1.1	33
1972	Resolving DNA Damage: Epigenetic Regulation of DNA Repair. Molecules, 2020, 25, 2496.	1.7	39
1973	The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. , 2020, 213, 107579.		62
1974	Design, synthesis and evaluation of novel levoglucosenone derivatives as promising anticancer agents. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127247.	1.0	16
1975	p190A inactivating mutations cause aberrant RhoA activation and promote malignant transformation via the Hippo-YAP pathway in endometrial cancer. Signal Transduction and Targeted Therapy, 2020, 5, 81.	7.1	14
1976	The clonal evolution of metastatic colorectal cancer. Science Advances, 2020, 6, eaay9691.	4.7	41

#	Article	IF	Citations
1977	Convergent adaptive evolutionâ€"how common, or how rare?. National Science Review, 2020, 7, 945-946.	4.6	4
1978	The genomic profile of parathyroid carcinoma based on wholeâ€genome sequencing. International Journal of Cancer, 2020, 147, 2446-2457.	2.3	27
1979	Cellular Plasticity and Tumor Microenvironment in Gliomas: The Struggle to Hit a Moving Target. Cancers, 2020, 12, 1622.	1.7	29
1980	Cell polarity and oncogenesis: common mutations contribute to altered cellular polarity and promote malignancy. Nucleus (India), 2020, 63, 91-106.	0.9	3
1981	The Role of RNA Splicing Factors in Cancer: Regulation of Viral and Human Gene Expression in Human Papillomavirus-Related Cervical Cancer. Frontiers in Cell and Developmental Biology, 2020, 8, 474.	1.8	43
1982	A Driver Never Works Aloneâ€"Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer. Cancers, 2020, 12, 1532.	1.7	12
1983	Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics. Cancers, 2020, 12, 1579.	1.7	73
1984	Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells. Cell Death Discovery, 2020, 6, 42.	2.0	55
1985	DNA Methylation-based Diagnostic and Prognostic Biomarkers for Glioblastoma. Cell Transplantation, 2020, 29, 096368972093324.	1.2	11
1986	A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer. Oncologist, 2020, 25, 1013-e1824.	1.9	40
1987	Identification of methylated-differentially expressed genes and pathways in esophageal squamous cell carcinoma. Pathology Research and Practice, 2020, 216, 153050.	1.0	3
1988	Considering the Experimental Use of Temozolomide in Glioblastoma Research. Biomedicines, 2020, 8, 151.	1.4	25
1989	Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma. BMC Cancer, 2020, 20, 571.	1.1	7
1990	Convergent adaptation of the genomes of woody plants at the landâ€"sea interface. National Science Review, 2020, 7, 978-993.	4.6	44
1991	Regulation of Cancer Immune Checkpoints. Advances in Experimental Medicine and Biology, 2020, , .	0.8	7
1992	Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma. Cancer, 2020, 126, 2775-2783.	2.0	22
1993	Cetuximab and Radiation Therapy Versus Cisplatin and Radiation Therapy for Locally Advanced Head and Neck Cancer: Long-Term Survival and Toxicity Outcomes of a Randomized Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2020, 107, 469-477.	0.4	17
1994	Edgetic perturbation signatures represent known and novel cancer biomarkers. Scientific Reports, 2020, 10, 4350.	1.6	5

#	Article	IF	Citations
1995	Deciphering UVâ€induced DNA Damage Responses to Prevent and Treat Skin Cancer. Photochemistry and Photobiology, 2020, 96, 478-499.	1.3	47
1996	Regulation of cancer cell signaling pathways as key events for therapeutic relevance of edible and medicinal mushrooms. Seminars in Cancer Biology, 2022, 80, 145-156.	4.3	11
1997	MRI-based radiogenomics analysis for predicting genetic alterations in oncogenic signalling pathways in invasive breast carcinoma. Clinical Radiology, 2020, 75, 561.e1-561.e11.	0.5	11
1998	The Impact of Mutant p53 in the Non-Coding RNA World. Biomolecules, 2020, 10, 472.	1.8	18
1999	Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer. Cancers, 2020, 12, 719.	1.7	15
2000	OncoOmics approaches to reveal essential genes in breast cancer: a panoramic view from pathogenesis to precision medicine. Scientific Reports, 2020, 10, 5285.	1.6	36
2001	A longitudinal study of prediagnostic metabolic biomarkers and the risk of molecular subtypes of colorectal cancer. Scientific Reports, 2020, 10, 5336.	1.6	7
2002	QuaDMutNetEx: a method for detecting cancer driver genes with low mutation frequency. BMC Bioinformatics, 2020, 21, 122.	1.2	8
2003	Tumor mutational burden is associated with poor outcomes in diffuse glioma. BMC Cancer, 2020, 20, 213.	1.1	46
2004	A Pan-Cancer and Polygenic Bayesian Hierarchical Model for the Effect of Somatic Mutations on Survival. Cancer Informatics, 2020, 19, 117693512090739.	0.9	2
2005	CHG: A Systematically Integrated Database of Cancer Hallmark Genes. Frontiers in Genetics, 2020, 11, 29.	1.1	36
2006	Neoantigens in Hematologic Malignancies. Frontiers in Immunology, 2020, 11, 121.	2.2	26
2007	A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2. Cancers, 2020, 12, 533.	1.7	7
2008	Clinicopathological significance of EGFR pathway gene mutations and CRTC1/3â€“MAML2 fusions in salivary gland mucoepidermoid carcinoma. Histopathology, 2020, 76, 1013-1022.	1.6	11
2009	Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16). Translational Cancer Research, 2020, 9, 3222-3230.	0.4	3
2010	Anillin facilitates cell proliferation and induces tumor growth of hepatocellular carcinoma via miR-138/SOX4 axis regulation. Translational Oncology, 2020, 13, 100815.	1.7	13
2011	Comprehensive nucleosome interactome screen establishes fundamental principles of nucleosome binding. Nucleic Acids Research, 2020, 48, 9415-9432.	6.5	67
2012	Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer. OncoImmunology, 2020, 9, 1788252.	2.1	20

#	Article	IF	Citations
2013	Microenvironmental Activation of Nrf2 Restricts the Progression of Nrf2-Activated Malignant Tumors. Cancer Research, 2020, 80, 3331-3344.	0.4	36
2014	A comparison of epigenetic mitotic-like clocks for cancer risk prediction. Genome Medicine, 2020, 12, 56.	3.6	56
2015	p190A RhoGAP induces CDH1 expression and cooperates with E-cadherin to activate LATS kinases and suppress tumor cell growth. Oncogene, 2020, 39, 5570-5587.	2.6	11
2016	Stem Cells and Aging. , 2020, , 213-234.		1
2017	SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways. Cancer Cell, 2020, 38, 350-365.e7.	7.7	113
2018	Correlation between fluorodeoxyglucose hotspots on preradiotherapy PET/CT and areas of cancer local relapse: Systematic review of literature. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 444-452.	0.6	3
2019	Genomic profiling of colorectal cancer with isolated lung metastasis. Cancer Cell International, 2020, 20, 281.	1.8	7
2020	Identification of the Mutational Landscape of Gynecological Malignancies. Journal of Cancer, 2020, 11, 4870-4883.	1.2	11
2021	Patterns of stemnessâ€associated markers in the development of castrationâ€resistant prostate cancer. Prostate, 2020, 80, 1108-1117.	1.2	17
2022	PARP and PARG inhibitors in cancer treatment. Genes and Development, 2020, 34, 360-394.	2.7	360
2023	Precision Medicine in Oncology: In Vitro Drug Sensitivity and Resistance Test (DSRT) for Selection of Personalized Anticancer Therapy. Advanced Therapeutics, 2020, 3, 1900100.	1.6	25
2025	The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nature Medicine, 2020, 26, 181-187.	15.2	158
2026	Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. PLoS ONE, 2020, 15, e0224775.	1.1	15
2027	Renal Cell Carcinoma: genomic landscape and clinical implications. Expert Review of Precision Medicine and Drug Development, 2020, 5, 95-100.	0.4	1
2028	BATCAVE: calling somatic mutations with a tumor- and site-specific prior. NAR Genomics and Bioinformatics, 2020, 2, lqaa004.	1.5	1
2029	Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemia. Therapeutic Advances in Hematology, 2020, 11, 204062071989981.	1.1	29
2030	p53â€™s Extended Reach: The Mutant p53 Secretome. Biomolecules, 2020, 10, 307.	1.8	35
2031	Phenotypic expansion of KMT2Dâ€related disorder: Beyond Kabuki syndrome. American Journal of Medical Genetics, Part A, 2020, 182, 1053-1065.	0.7	23

#	Article	IF	Citations
2032	Comprehensive Detection of Single Amino Acid Variants and Evaluation of Their Deleterious Potential in a PANC-1 Cell Line. Journal of Proteome Research, 2020, 19, 1635-1646.	1.8	11
2033	Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells. Biomolecules, 2020, 10, 361.	1.8	79
2034	Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology. International Journal of Molecular Sciences, 2020, 21, 1580.	1.8	17
2035	Multi-omics analysis at epigenomics and transcriptomics levels reveals prognostic subtypes of lung squamous cell carcinoma. Biomedicine and Pharmacotherapy, 2020, 125, 109859.	2.5	9
2036	CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer. Clinical Cancer Research, 2020, 26, 2595-2602.	3.2	16
2037	Alternative Mechanisms of p53 Action During the Unfolded Protein Response. Cancers, 2020, 12, 401.	1.7	14
2038	Cell Cycle Deficits in Neurodegenerative Disorders: Uncovering Molecular Mechanisms to Drive Innovative Therapeutic Development. , 2020, 11, 946.		51
2039	Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer. Annals of Oncology, 2020, 31, 395-403.	0.6	75
2040	Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes. Communications Biology, 2020, 3, 6.	2.0	9
2041	Impacts of NRF2 activation in nonâ€“smallâ€cell lung cancer cell lines on extracellular metabolites. Cancer Science, 2020, 111, 667-678.	1.7	29
2042	Applications of Next Generation Sequencing to the Analysis of Familial Breast/Ovarian Cancer. High-Throughput, 2020, 9, 1.	4.4	22
2043	Dissecting Molecular Features of Gliomas: Genetic Loci and Validated Biomarkers. International Journal of Molecular Sciences, 2020, 21, 685.	1.8	18
2044	â€œMetastatic Cancer of Unknown Primaryâ€•or â€œPrimary Metastatic Cancerâ€?. Frontiers in Oncology, 2019, 9, 1546.	1.3	35
2045	Singleâ€molecule detection of cancer mutations using a novel PCRâ€LDRâ€qPCR assay. Human Mutation, 2020, 41, 1051-1068.	1.1	8
2046	Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer. Hormones and Cancer, 2020, 11, 63-75.	4.9	13
2047	Epigenetic plasticity of enhancers in cancer. Transcription, 2020, 11, 26-36.	1.7	23
2048	Utility of the immunohistochemical analysis of DNA mismatch-repair proteins in endometrial hyperplasia. Acta Histochemica, 2020, 122, 151505.	0.9	1
2049	Anti-tumor immune response varies among individuals: A gene expression profiling of mouse melanoma. International Immunopharmacology, 2020, 80, 106211.	1.7	1

#	Article	IF	Citations
2050	Smoke signals in the DNA of normal lung cells. Nature, 2020, 578, 224-226.	13.7	6
2051	Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma. Cells, 2020, 9, 287.	1.8	37
2052	Molecular profiling of gynecologic cancers for treatment and management of disease â€“ demonstrating clinical significance using the AMP/ASCO/CAP guidelines for interpretation and reporting of somatic variants. Cancer Genetics, 2020, 242, 25-34.	0.2	2
2053	Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy. Cancer Letters, 2020, 474, 158-167.	3.2	54
2054	DNA methylation markers in the diagnosis and prognosis of common leukemias. Signal Transduction and Targeted Therapy, 2020, 5, 3.	7.1	27
2055	Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells. Journal of Virology, 2020, 94, .	1.5	25
2056	A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nature Communications, 2020, 11, 728.	5.8	140
2057	Epigenetic Control of a Local Chromatin Landscape. International Journal of Molecular Sciences, 2020, 21, 943.	1.8	15
2058	Progress in refining the clinical management of cancer of unknown primary in the molecular era. Nature Reviews Clinical Oncology, 2020, 17, 541-554.	12.5	62
2059	Comparison of Annotation Services for Next-Generation Sequencing in a Large-Scale Precision Oncology Program. JCO Precision Oncology, 2020, 4, 212-221.	1.5	19
2060	Intratumor Heterogeneity in Early Lung Adenocarcinoma. Frontiers in Oncology, 2020, 10, 349.	1.3	41
2061	KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer. Cancer Cell, 2020, 37, 599-617.e7.	7.7	137
2062	Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. Cancer Cell, 2020, 37, 471-484.	7.7	485
2063	Genome-wide Screens Implicate Loss of Cullin Ring Ligase 3 in Persistent Proliferation and Genome Instability in TP53-Deficient Cells. Cell Reports, 2020, 31, 107465.	2.9	24
2064	Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. Nature Cancer, 2020, 1, 452-468.	5.7	103
2065	Phytochemicals modulate cancer aggressiveness: A review depicting the anticancer efficacy of dietary polyphenols and their combinations. Journal of Cellular Physiology, 2020, 235, 7696-7708.	2.0	32
2066	Contribution of Macrophages and T Cells in Skeletal Metastasis. Cancers, 2020, 12, 1014.	1.7	19
2067	The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. International Journal of Molecular Sciences, 2020, 21, 2907.	1.8	158

#	Article	IF	Citations
2068	Tumor-Agnostic Treatment for Cancer: When How is Better than Where. Clinical Drug Investigation, 2020, 40, 519-527.	1.1	32
2069	Pan-cancer analysis and applications. , 2020, , 307-316.		0
2070	Integrative Modeling of a Sin3/HDAC Complex Sub-structure. Cell Reports, 2020, 31, 107516.	2.9	29
2071	Overcoming Wntâ€“Î²-catenin dependent anticancer therapy resistance in leukaemia stem cells. Nature Cell Biology, 2020, 22, 689-700.	4.6	89
2072	Roles and mechanisms of alternative splicing in cancer â€” implications for care. Nature Reviews Clinical Oncology, 2020, 17, 457-474.	12.5	400
2073	Cell cycleâ€“dependent localization of the proteasome to chromatin. Scientific Reports, 2020, 10, 5801.	1.6	25
2074	Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic development. Expert Review of Anticancer Therapy, 2020, 20, 355-363.	1.1	13
2075	The role of Sp1 in the detection and elimination of cells with persistent DNA strand breaks. NAR Cancer, 2020, 2, zcaa004.	1.6	2
2076	Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort. , 2020, 8, e000613.		15
2077	Metabolic Reprogramming in Cancer Is Induced to Increase Proton Production. Cancer Research, 2020, 80, 1143-1155.	0.4	43
2078	Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. Genome Medicine, 2020, 12, 32.	3.6	32
2079	The Changing Landscape of Treatment in Acute Myeloid Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 343-354.	1.8	9
2080	Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers. Journal of Cancer, 2020, 11, 3349-3356.	1.2	57
2081	Genetics and Genomics of Breast Cancer: update and translational perspectives. Seminars in Cancer Biology, 2021, 72, 27-35.	4.3	14
2082	Testing tumors from different anatomic sites for clonal relatedness using somatic mutation data. Biometrics, 2021, 77, 283-292.	0.8	2
2083	Evolutionary Action Score of TP53 Enhances the Prognostic Prediction for Stage I Lung Adenocarcinoma. Seminars in Thoracic and Cardiovascular Surgery, 2021, 33, 221-229.	0.4	2
2084	Comprehensive analysis reveals distinct mutational signature and its mechanistic insights of alcohol consumption in human cancers. Briefings in Bioinformatics, 2021, 22, .	3.2	14
2085	Squamous Cell Carcinoma of the Upper Aerodigestive System. , 2021, , 63-125.		0

#	Article	IF	Citations
2086	Transcription factors in epithelial ovarian cancer: histotype-specific drivers and novel therapeutic targets. , 2021, 220, 107722.		16
2087	Systemic and rapid restructuring of the genome: a new perspective on punctuated equilibrium. Current Genetics, 2021, 67, 57-63.	0.8	15
2088	Downregulation of ARID1A in gastric cancer cells: a putative protective molecular mechanism against the Harakiri-mediated apoptosis pathway. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 401-411.	1.4	3
2089	Identifying the hub gene and immune infiltration of osteoarthritis by bioinformatical methods. Clinical Rheumatology, 2021, 40, 1027-1037.	1.0	19
2090	Expression-based prediction of human essential genes and candidate lncRNAs in cancer cells. Bioinformatics, 2021, 37, 396-403.	1.8	13
2091	Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system. Journal of Cancer Research and Clinical Oncology, 2021, 147, 263-273.	1.2	5
2092	The roles of <scp>PAD2</scp>â€•and <scp>PAD4</scp>â€•mediated protein citrullination catalysis in cancers. International Journal of Cancer, 2021, 148, 267-276.	2.3	28
2093	Challenges and Opportunities in Cancer Drug Resistance. Chemical Reviews, 2021, 121, 3297-3351.	23.0	203
2094	Context is key: Understanding the regulation, functional control, and activities of the p53 tumour suppressor. Cell Biochemistry and Function, 2021, 39, 235-247.	1.4	16
2095	Identification of lncRNA Signature Associated With Pan-Cancer Prognosis. IEEE Journal of Biomedical and Health Informatics, 2021, 25, 2317-2328.	3.9	10
2096	Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers. Oncologist, 2021, 26, e153-e163.	1.9	14
2097	CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia. Nature Biomedical Engineering, 2021, 5, 399-413.	11.6	46
2098	The current landscape of molecular profiling in the treatment of epithelial ovarian cancer. Gynecologic Oncology, 2021, 160, 333-345.	0.6	40
2099	Inorganic Nanomaterialâ€Mediated Gene Therapy in Combination with Other Antitumor Treatment Modalities. Advanced Functional Materials, 2021, 31, 2007096.	7.8	32
2100	Dysregulation of lysophospholipid signaling by p53 in malignant cells and the tumor microenvironment. Cellular Signalling, 2021, 78, 109850.	1.7	6
2101	Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Current Treatment Options in Oncology, 2021, 22, 7.	1.3	6
2102	Encorafenib enhances TRAIL-induced apoptosis of colorectal cancer cells dependent on p53/PUMA signaling. Cytotechnology, 2021, 73, 63-70.	0.7	3
2103	MEScan: a powerful statistical framework for genome-scale mutual exclusivity analysis of cancer mutations. Bioinformatics, 2021, 37, 1189-1197.	1.8	7

#	Article	IF	Citations
2104	Development and clinical validation of a novel 9-gene prognostic model based on multi-omics in pancreatic adenocarcinoma. Pharmacological Research, 2021, 164, 105370.	3.1	33
2105	HPV-inactive cell populations arise from HPV16-transformed human keratinocytes after p53 knockout. Virology, 2021, 554, 9-16.	1.1	8
2106	Mutant p53 as a Regulator and Target of Autophagy. Frontiers in Oncology, 2020, 10, 607149.	1.3	32
2107	Blueprint for cancer research: Critical gaps and opportunities. Ca-A Cancer Journal for Clinicians, 2021, 71, 107-139.	157.7	47
2108	Machine learning in plant science and plant breeding. IScience, 2021, 24, 101890.	1.9	127
2109	Filling the gap between risk assessment and molecular determinants of tumor onset. Carcinogenesis, 2021, 42, 507-516.	1.3	3
2110	Cancer cell-targeted cisplatin prodrug delivery in vivo via metabolic labeling and bioorthogonal click reaction. Biomaterials Science, 2021, 9, 1301-1312.	2.6	11
2111	A novel human anti-TIGIT monoclonal antibody with excellent function in eliciting NK cell-mediated antitumor immunity. Biochemical and Biophysical Research Communications, 2021, 534, 134-140.	1.0	12
2112	Sorting nexins: A novel promising therapy target for cancerous/neoplastic diseases. Journal of Cellular Physiology, 2021, 236, 3317-3335.	2.0	6
2113	Landscape of clinically actionable mutations in breast cancer â€˜A cohort studyâ€™. Translational Oncology, 2021, 14, 100877.	1.7	4
2114	Histone lysine demethylases and their functions in cancer. International Journal of Cancer, 2021, 148, 2375-2388.	2.3	46
2115	SET1/MLL family of proteins: functions beyond histone methylation. Epigenetics, 2021, 16, 469-487.	1.3	27
2116	Integrating proteomics into precision oncology. International Journal of Cancer, 2021, 148, 1438-1451.	2.3	15
2117	Fine needle aspiration of an intranodal follicular dendritic cell sarcoma: A case report with molecular analysis and review of the literature. Diagnostic Cytopathology, 2021, 49, E65-E70.	0.5	4
2118	Interplay between HMGA and TP53 in cell cycle control along tumor progression. Cellular and Molecular Life Sciences, 2021, 78, 817-831.	2.4	10
2119	Cell surface GRP78 signaling: An emerging role as a transcriptional modulator in cancer. Journal of Cellular Physiology, 2021, 236, 2352-2363.	2.0	27
2120	The role of p53/p21/p16 in DNA damage signaling and DNA repair. , 2021, , 257-274.		2
2121	Oncoprotein HBXIP promotes tumorigenesis through MAPK/ERK pathway activation in non-small cell lung cancer. Cancer Biology and Medicine, 2021, 18, 105-119.	1.4	4

#	Article	IF	Citations
2122	Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC. BMC Cancer, 2021, 21, 34.	1.1	3
2123	Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib. International Journal of Molecular Sciences, 2021, 22, 592.	1.8	4
2124	Tumor Profiling at the Service of Cancer Therapy. Frontiers in Oncology, 2020, 10, 595613.	1.3	9
2125	Tiny Drosophila makes giant strides in cancer research. Cancer Science, 2021, 112, 505-514.	1.7	12
2126	Hybrid Aggregation Network for Survival Analysis from Whole Slide Histopathological Images. Lecture Notes in Computer Science, 2021, , 731-740.	1.0	6
2127	TERRA Gene Expression in Gastric Cancer: Role of hTERT. Journal of Gastrointestinal Cancer, 2021, 52, 431-447.	0.6	6
2128	Integration of Patch Features Through Self-supervised Learning and Transformer for Survival Analysis on Whole Slide Images. Lecture Notes in Computer Science, 2021, , 561-570.	1.0	20
2130	MYCN Function in Neuroblastoma Development. Frontiers in Oncology, 2020, 10, 624079.	1.3	68
2131	TheÂDNA methylation landscape of PD-1 (PDCD1) and adjacent lncRNA AC131097.3 in head and neck squamous cell carcinoma. Epigenomics, 2021, 13, 113-127.	1.0	9
2132	Distinct kinetic mechanisms of H3K4 methylation catalyzed by MLL3 and MLL4 core complexes. Journal of Biological Chemistry, 2021, 296, 100635.	1.6	6
2133	PathMEx: Pathway-Based Mutual Exclusivity for Discovering Rare Cancer Driver Mutations. Lecture Notes in Computer Science, 2021, , 564-577.	1.0	0
2134	The management of patients with cancer of unknown primary in middle-income countries: an ESO-AROME survey. Future Oncology, 2021, 17, 151-157.	1.1	2
2135	Clinical and genetic evidence and population evidence. , 2021, , 59-87.		0
2136	Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies. Cells, 2021, 10, 108.	1.8	16
2137	m⁶A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer. Theranostics, 2021, 11, 2201-2217.	4.6	148
2138	Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy. Advances in Cancer Research, 2021, 151, 231-304.	1.9	8
2139	Pan-cancer analysis of non-coding recurrent mutations and their possible involvement in cancer pathogenesis. NAR Cancer, 2021, 3, zcab008.	1.6	8
2141	Cholesterol: A Prelate in Cell Nucleus and its Serendipity. Current Molecular Medicine, 2021, 20, 692-707.	0.6	5

#	Article	IF	Citations
2142	Mitotic syndicates Aurora Kinase B (AURKB) and mitotic arrest deficient 2 like 2 (MAD2L2) in cohorts of DNA damage response (DDR) and tumorigenesis. Mutation Research - Reviews in Mutation Research, 2021, 787, 108376.	2.4	22
2143	Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy. Cancer Journal (Sudbury, Mass), 2021, 27, 41-49.	1.0	26
2144	Learning Visual Features by Colorization for Slide-Consistent Survival Prediction from Whole Slide Images. Lecture Notes in Computer Science, 2021, , 592-601.	1.0	9
2145	Building a precision oncology workforce by multidisciplinary and case-based learning. BMC Medical Education, 2021, 21, 75.	1.0	7
2146	p66ShcA potentiates the cytotoxic response of triple negative breast cancers to PARP inhibitors. JCI Insight, 2021, 6, .	2.3	0
2147	Low KRT15 expression is associated with poor prognosis in patients with breast invasive carcinoma. Experimental and Therapeutic Medicine, 2021, 21, 305.	0.8	18
2148	Advances in Tumor Sampling and Sequencing in Breast Cancer and their Application in Precision Diagnostics and Therapeutics. Advances in Experimental Medicine and Biology, 2021, 1187, 215-244.	0.8	0
2149	HPV Meets APOBEC: New Players in Head and Neck Cancer. International Journal of Molecular Sciences, 2021, 22, 1402.	1.8	25
2150	Emerging roles of DYRK2 in cancer. Journal of Biological Chemistry, 2021, 296, 100233.	1.6	34
2151	Targeting the mutant PIK3CA gene by DNAâ€alkylating pyrroleâ€imidazole polyamide in cervical cancer. Cancer Science, 2021, 112, 1141-1149.	1.7	12
2152	Small molecules targeting misfolded mutants of p53 as a rescue strategy to improve glioblastoma chemotherapy. , 2021, , 749-771.		0
2153	Integrating CD4 ⁺ T cell help for therapeutic cancer vaccination in a preclinical head and neck cancer model. OncoImmunology, 2021, 10, 1958589.	2.1	9
2154	CDC25B induces cellular senescence and correlates with tumor suppression in a p53-dependent manner. Journal of Biological Chemistry, 2021, 296, 100564.	1.6	9
2155	Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. Theranostics, 2021, 11, 3089-3108.	4.6	207
2156	Construction of coâ€expression modules related to survival by WGCNA and identification of potential prognostic biomarkers in glioblastoma. Journal of Cellular and Molecular Medicine, 2021, 25, 1633-1644.	1.6	29
2157	Revisiting immunogenic cell death to improve treatment response in cancer. , 2021, , 65-90.		4
2158	Single Cell Genomics for Tumor Heterogeneity. Advances in Experimental Medicine and Biology, 2021, 1187, 205-214.	0.8	0
2159	Artificial Intelligence in Skin Cancer: Diagnosis and Therapy. , 2021, , 143-171.		4

#	Article	IF	Citations
2160	Recurrent ZNF83-E293V Mutation Promotes Bladder Cancer Progression through the NF-Î²B Pathway via Transcriptional Dysregulation of S100A8. Molecular Therapy, 2021, 29, 275-290.	3.7	8
2161	Cytologic and Molecular Diagnostics for Vitreoretinal Lymphoma: Current Approaches and Emerging Single-Cell Analyses. Frontiers in Molecular Biosciences, 2020, 7, 611017.	1.6	6
2162	Progress towards a clinically-successful ATR inhibitor for cancer therapy. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100017.	1.7	64
2163	The biology of the tumor microenvironment in DLBCL: Targeting the â€œdonâ€™t eat meâ€•signal. Journal of Clinical and Experimental Hematopathology: JCEH, 2021, 61, 210-215.	0.3	5
2164	Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients. Nature Communications, 2021, 12, 11.	5.8	121
2165	Identification of Core Genes Related to Progression and Prognosis of Hepatocellular Carcinoma and Small-Molecule Drug Predication. Frontiers in Genetics, 2021, 12, 608017.	1.1	5
2166	BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series. Cancer Chemotherapy and Pharmacology, 2021, 87, 437-441.	1.1	5
2167	A mesoscopic simulator to uncover heterogeneity and evolutionary dynamics in tumors. PLoS Computational Biology, 2021, 17, e1008266.	1.5	10
2168	Functional impact of cancer-associated cohesin variants on gene expression and cellular identity. Genetics, 2021, 217, .	1.2	8
2169	Pathogenetic Features and Current Management of Glioblastoma. Cancers, 2021, 13, 856.	1.7	29
2170	Comprehensive analysis of tumour mutational burden and its clinical significance in prostate cancer. BMC Urology, 2021, 21, 29.	0.6	15
2171	The Role of mTOR Signaling as a Therapeutic Target in Cancer. International Journal of Molecular Sciences, 2021, 22, 1743.	1.8	128
2172	Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?. Seminars in Cancer Biology, 2021, 77, 67-82.	4.3	12
2173	MNS1 promotes hepatocarcinogenesis and metastasis via activating PI3K/AKT by translocating Î²â€catenin and predicts poor prognosis. Liver International, 2021, 41, 1409-1420.	1.9	4
2175	A newly identified small molecular compound acts as a protein kinase inhibitor to suppress metastasis of colorectal cancer. Bioorganic Chemistry, 2021, 107, 104625.	2.0	5
2176	Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer. Journal of Personalized Medicine, 2021, 11, 149.	1.1	16
2177	Low-coverage whole-genome sequencing of extracellular vesicle-associated DNA in patients with metastatic cancer. Scientific Reports, 2021, 11, 4016.	1.6	6
2178	Biological Role of AKT and Regulation of AKT Signaling Pathway by Thymoquinone: Perspectives in Cancer Therapeutics. Mini-Reviews in Medicinal Chemistry, 2021, 21, 288-301.	1.1	12

#	Article	IF	Citations
2179	Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome. Orphanet Journal of Rare Diseases, 2021, 16, 109.	1.2	43
2180	Visualization and Analysis in the Field of Pan-Cancer Studies and Its Application in Breast Cancer Treatment. Frontiers in Medicine, 2021, 8, 635035.	1.2	8
2182	A rare multiple primary sarcomatoid carcinoma (SCA) of small intestine harboring driver gene mutations: a case report and a literature review. Translational Cancer Research, 2021, 10, 1150-1161.	0.4	2
2183	A New Era of Protein-Based Assays for Cancer Early Detection. Journal of Thoracic Oncology, 2021, 16, 191-193.	0.5	1
2184	Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site. Cancer Cell, 2021, 39, 225-239.e8.	7.7	125
2185	Identification of a Metastasis-Associated Gene Signature of Clear Cell Renal Cell Carcinoma. Frontiers in Genetics, 2020, 11, 603455.	1.1	16
2186	Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects. Frontiers in Oncology, 2020, 10, 600573.	1.3	100
2187	Therapeutic targeting of the oncogenic Wnt signaling pathway for treating colorectal cancer and other colonic disorders. Advanced Drug Delivery Reviews, 2021, 169, 118-136.	6.6	58
2188	Clinical-grade whole-genome sequencing and 3â€² transcriptome analysis of colorectal cancer patients. Genome Medicine, 2021, 13, 33.	3.6	5
2189	Identification of immune-associated lncRNAs as a prognostic marker for lung adenocarcinoma. Translational Cancer Research, 2021, 10, 998-1012.	0.4	15
2190	The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies. IUBMB Life, 2021, 73, 618-642.	1.5	19
2191	TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?. Frontiers in Oncology, 2020, 10, 610820.	1.3	38
2192	PCNA-associated factor (KIAA0101/PCLAF) overexpression and gene copy number alterations in hepatocellular carcinoma tissues. BMC Cancer, 2021, 21, 295.	1.1	7
2193	Multiâ€modal metaâ€analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor. Molecular Systems Biology, 2021, 17, e9526.	3.2	8
2194	Identification of the Prognostic Significance of Somatic Mutation-Derived LncRNA Signatures of Genomic Instability in Lung Adenocarcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 657667.	1.8	31
2195	Computational Image Analysis Identifies Histopathological Image Features Associated With Somatic Mutations and Patient Survival in Gastric Adenocarcinoma. Frontiers in Oncology, 2021, 11, 623382.	1.3	4
2196	The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions. Cancers, 2021, 13, 1478.	1.7	65
2197	Breast Cancer Patient Prognosis Is Determined by the Interplay between TP53 Mutation and Alternative Transcript Expression: Insights from TP53 Long Amplicon Digital PCR Assays. Cancers, 2021, 13, 1531.	1.7	5

#	Article	IF	Citations
2198	First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Research, 2021, 23, 29.	2.2	31
2199	RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma. Frontiers in Oncology, 2021, 11, 642159.	1.3	30
2200	The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma. Journal of Nanobiotechnology, 2021, 19, 74.	4.2	13
2201	High expression of SPP1 in patients with chronic obstructive pulmonary disease (COPD) is correlated with increased risk of lung cancer. FEBS Open Bio, 2021, 11, 1237-1249.	1.0	17
2202	Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors. Frontiers in Immunology, 2021, 12, 619209.	2.2	13
2203	If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 3025.	1.8	5
2205	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. Frontiers in Oncology, 2021, 11, 622648.	1.3	11
2207	Computing the Hazard Ratios Associated With Explanatory Variables Using Machine Learning Models of Survival Data. JCO Clinical Cancer Informatics, 2021, 5, 364-378.	1.0	14
2208	Cancer genome datamining and functional genetic analysis implicate mechanisms of ATM/ATR dysfunction underpinning carcinogenesis. Communications Biology, 2021, 4, 363.	2.0	5
2209	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptorâ€“Positive Advanced Breast Cancer (EVERMET). Clinical Cancer Research, 2021, 27, 3443-3455.	3.2	4
2210	Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma. Human Vaccines and Immunotherapeutics, 2021, 17, 1882-1896.	1.4	10
2211	Aberrant Claudin-6â€“Adhesion Signaling Promotes Endometrial Cancer Progression via Estrogen Receptor Î±. Molecular Cancer Research, 2021, 19, 1208-1220.	1.5	19
2212	Cis-regulatory mutations with driver hallmarks in major cancers. IScience, 2021, 24, 102144.	1.9	10
2213	Aberrant phase separation and cancer. FEBS Journal, 2022, 289, 17-39.	2.2	42
2214	The Emerging Clinical Role of Spermine in Prostate Cancer. International Journal of Molecular Sciences, 2021, 22, 4382.	1.8	15
2215	A New Insight for the Identification of Oncogenic Variants in Breast and Prostate Cancers in Diverse Human Populations, With a Focus on Latinos. Frontiers in Pharmacology, 2021, 12, 630658.	1.6	3
2216	Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecologic Oncology, 2021, 161, 113-121.	0.6	42
2217	The Role of p53 Signaling in Colorectal Cancer. Cancers, 2021, 13, 2125.	1.7	106

#	Article	IF	Citations
2218	Genomic analysis of pancreatic cancer reveals 3 molecular subtypes with different clinical outcomes. Medicine (United States), 2021, 100, e24969.	0.4	0
2219	p53 and Tumor Suppression: It Takes a Network. Trends in Cell Biology, 2021, 31, 298-310.	3.6	156
2220	Exosome-based liquid biopsies in cancer: opportunities and challenges. Annals of Oncology, 2021, 32, 466-477.	0.6	405
2221	CanDriS: posterior profiling of cancer-driving sites based on two-component evolutionary model. Briefings in Bioinformatics, 2021, 22, .	3.2	5
2222	Mutant p53 in cell-cell interactions. Genes and Development, 2021, 35, 433-448.	2.7	26
2224	Iron at the Interface of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 4097.	1.8	27
2225	Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma. Cell Death and Disease, 2021, 12, 419.	2.7	21
2226	Prediction of diseaseâ€associated functional variants in noncoding regions through a comprehensive analysis by integrating datasets and features. Human Mutation, 2021, 42, 667-684.	1.1	0
2227	Whole-exome sequencing identifies somatic mutations associated with lung cancer metastasis to the brain. Annals of Translational Medicine, 2021, 9, 694-694.	0.7	8
2228	Patterns of immune infiltration in gastric cancer and their clinical significance. Japanese Journal of Clinical Oncology, 2021, 51, 1067-1079.	0.6	3
2229	Treatment of primary and metastatic breast and pancreatic tumors upon intravenous delivery of a <scp>PRDM14</scp>â€specific chimeric <scp>siRNA</scp>/nanocarrier complex. International Journal of Cancer, 2021, 149, 646-656.	2.3	10
2230	Epigenetics in a Spectrum of Myeloid Diseases and Its Exploitation for Therapy. Cancers, 2021, 13, 1746.	1.7	7
2231	Distinguishing Rectal Cancer from Colon Cancer Based on the Support Vector Machine Method and RNA-sequencing Data. Current Medical Science, 2021, 41, 368-374.	0.7	8
2232	Ferroptosis: Biochemistry and Biology in Cancers. Frontiers in Oncology, 2021, 11, 579286.	1.3	39
2233	Eleven immune-gene pairs signature associated with TP53 predicting the overall survival of gastric cancer: a retrospective analysis of large sample and multicenter from public database. Journal of Translational Medicine, 2021, 19, 183.	1.8	10
2234	MAP17 Expression in Colorectal Cancer Is a Prognostic Factor for Disease Recurrence and Dismal Prognosis Already in Early Stage Disease. Oncology, 2021, 99, 471-482.	0.9	0
2235	The actin nucleation factors JMY and WHAMM enable a rapid Arp2/3 complex-mediated intrinsic pathway of apoptosis. PLoS Genetics, 2021, 17, e1009512.	1.5	13
2237	Possibility of inducing tumor cell senescence during therapy (Review). Oncology Letters, 2021, 22, 496.	0.8	8

#	Article	IF	Citations
2239	Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8. Biomaterials, 2021, 271, 120720.	5.7	14
2240	Risk of Colorectal Carcinoma May Predispose to the Genetic Variants of the GST, CYP450, and TP53 Genes Among Nonsmokers in the Saudi Community. International Journal of General Medicine, 2021, Volume 14, 1311-1323.	0.8	4
2241	Genomic Alteration Characterization in Colorectal Cancer Identifies a Prognostic and Metastasis Biomarker: FAM83A|IDO1. Frontiers in Oncology, 2021, 11, 632430.	1.3	32
2242	Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer. Cancers, 2021, 13, 2023.	1.7	8
2243	EIF5A2 controls ovarian tumor growth and metastasis by promoting epithelial to mesenchymal transition via the TGFÎ² pathway. Cell and Bioscience, 2021, 11, 70.	2.1	16
2244	Identifying Genomic Alterations in Small Cell Lung Cancer Using the Liquid Biopsy of Bronchial Washing Fluid. Frontiers in Oncology, 2021, 11, 647216.	1.3	4
2245	MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. Cancer Cell, 2021, 39, 529-547.e7.	7.7	17
2246	Exploring effects of DNA methylation and gene expression on pan-cancer drug response by mathematical models. Experimental Biology and Medicine, 2021, 246, 1626-1642.	1.1	1
2247	Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study. Molecular Oncology, 2022, 16, 206-218.	2.1	7
2248	Deep Large-Scale Multitask Learning Network for Gene Expression Inference. Journal of Computational Biology, 2021, 28, 485-500.	0.8	1
2249	Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer. Breast Cancer Research and Treatment, 2021, 188, 661-673.	1.1	6
2250	The Triple Health Threat of Diabetes, Obesity, and Cancerâ€"Epidemiology, Disparities, Mechanisms, and Interventions. Obesity, 2021, 29, 954-959.	1.5	21
2251	Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib. Clinical Cancer Research, 2021, 27, 4531-4538.	3.2	20
2252	Genomic characterization of small cell carcinomas of the uterine cervix. Molecular Oncology, 2022, 16, 833-845.	2.1	14
2253	Current Trends in Prevalence and Role of Long Noncoding RNA and Gene Fusion in Prostate Cancer: An Overview. Annals of the National Academy of Medical Sciences (India), 2021, 57, 93-101.	0.2	0
2254	Significance of KDM6A mutation in bladder cancer immune escape. BMC Cancer, 2021, 21, 635.	1.1	19
2255	Molecular evolution and the decline of purifying selection with age. Nature Communications, 2021, 12, 2657.	5.8	16
2256	Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets. International Journal of Cancer, 2021, 149, 1166-1180.	2.3	10

#	Article	IF	Citations
2257	Design, synthesis, and biological evaluation of nitroisoxazole-containing spiro[pyrrolidin-oxindole] derivatives as novel glutathione peroxidase 4/mouse double minute 2 dual inhibitors that inhibit breast adenocarcinoma cell proliferation. European Journal of Medicinal Chemistry, 2021, 217, 113359.	2.6	34
2258	Frontiers in Bladder Cancer Genomic Research. Frontiers in Oncology, 2021, 11, 670729.	1.3	11
2259	Common DNA methylation dynamics in endometriod adenocarcinoma and glioblastoma suggest universal epigenomic alterations in tumorigenesis. Communications Biology, 2021, 4, 607.	2.0	9
2261	Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer. Cancer Science, 2021, 112, 2081-2088.	1.7	21
2262	Improvement of Neoantigen Identification Through Convolution Neural Network. Frontiers in Immunology, 2021, 12, 682103.	2.2	4
2263	Rely on Each Other: DNA Binding Cooperativity Shapes p53 Functions in Tumor Suppression and Cancer Therapy. Cancers, 2021, 13, 2422.	1.7	6
2264	Are Molecular Alterations Linked to Genetic Instability Worth to Be Included as Biomarkers for Directing or Excluding Melanoma Patients to Immunotherapy?. Frontiers in Oncology, 2021, 11, 666624.	1.3	5
2265	Systematic interrogation of mutation groupings reveals divergent downstream expression programs within key cancer genes. BMC Bioinformatics, 2021, 22, 233.	1.2	1
2266	Multi-Omics Model Applied to Cancer Genetics. International Journal of Molecular Sciences, 2021, 22, 5751.	1.8	19
2267	TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 665265.	1.8	6
2268	Multi-Site Tumour Sampling Improves the Detection of Intra-Tumour Heterogeneity in Oral and Oropharyngeal Squamous Cell Carcinoma. Frontiers in Medicine, 2021, 8, 670305.	1.2	6
2269	The many facets of <scp>miR</scp>â€223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response. Wiley Interdisciplinary Reviews RNA, 2021, 12, e1659.	3.2	24
2270	CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 5782.	1.8	16
2271	Glutamatergic Mechanisms in Glioblastoma and Tumor-Associated Epilepsy. Cells, 2021, 10, 1226.	1.8	40
2272	Integrative genomic analysis of blood pressure and related phenotypes in rats. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	6
2273	Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer. Clinical Cancer Research, 2021, 27, 3734-3743.	3.2	17
2274	Analysis and Interpretation of the Impact of Missense Variants in Cancer. International Journal of Molecular Sciences, 2021, 22, 5416.	1.8	28
2275	Histological and mutational profile of diffuse gastric cancer: current knowledge and future challenges. Molecular Oncology, 2021, 15, 2841-2867.	2.1	27

#	Article	IF	Citations
2276	Epigenetic Regulation of Genomic Stability by Vitamin C. Frontiers in Genetics, 2021, 12, 675780.	1.1	45
2277	Empirical relationships between compressive and flexural strength of concrete containing recycled asphalt material for pavement applications using different specimen configurations. Materiales De Construccion, 2021, 71, e249.	0.2	2
2278	Strategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges. Frontiers in Molecular Biosciences, 2021, 8, 662331.	1.6	16
2279	Anti-proliferative and apoptotic effect of gemini curcumin in p53-wild type and p53-mutant colorectal cancer cell lines. International Journal of Pharmaceutics, 2021, 601, 120592.	2.6	14
2280	Arming â€œold guardsâ€•with â€œnew dual-targeting weaponsâ€• Cancer Cell, 2021, 39, 604-606.	7.7	3
2281	Detection of PIK3CA Gene Mutation in Head and Neck Squamous Cell Carcinoma Using Droplet Digital PCR and RT-qPCR. Biomolecules, 2021, 11, 818.	1.8	6
2282	The Immunology of Hormone Receptor Positive Breast Cancer. Frontiers in Immunology, 2021, 12, 674192.	2.2	68
2283	Targeting the Y-box Binding Protein-1 Axis to Overcome Radiochemotherapy Resistance in Solid Tumors. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1072-1087.	0.4	6
2284	Anticancer drug discovery from Iranian Chrysanthemum cultivars through system pharmacology exploration and experimental validation. Scientific Reports, 2021, 11, 11767.	1.6	5
2285	Genetic modifiers regulating DNA replication and double-strand break repair are associated with differences in mammary tumors in mouse models of Li-Fraumeni syndrome. Oncogene, 2021, 40, 5026-5037.	2.6	6
2286	Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors. Oncotarget, 2021, 12, 1296-1308.	0.8	19
2287	CTCF as a regulator of alternative splicing: new tricks for an old player. Nucleic Acids Research, 2021, 49, 7825-7838.	6.5	31
2288	Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. Cancers, 2021, 13, 2776.	1.7	9
2289	A Systems-Based Key Innovation-Driven Approach Infers Co-option of Jaw Developmental Programs During Cancer Progression. Frontiers in Cell and Developmental Biology, 2021, 9, 682619.	1.8	3
2290	A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures. Npj Precision Oncology, 2021, 5, 55.	2.3	16
2291	A Novel Immune-Related Prognostic Signature in Head and Neck Squamous Cell Carcinoma. Frontiers in Genetics, 2021, 12, 570336.	1.1	11
2292	An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment. Frontiers in Pharmacology, 2021, 12, 707930.	1.6	12
2293	Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer. Cancer Medicine, 2021, 10, 5375-5391.	1.3	6

#	Article	IF	Citations
2294	Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. Oncogene, 2021, 40, 4894-4905.	2.6	19
2295	The MLL3/4 H3K4 methyltransferase complex in establishing an active enhancer landscape. Biochemical Society Transactions, 2021, 49, 1041-1054.	1.6	29
2296	Anticancer innovative therapy congress: Highlights from the 10th anniversary edition. Cytokine and Growth Factor Reviews, 2021, 59, 1-8.	3.2	4
2297	Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy. Urology, 2021, 157, 93-101.	0.5	6
2298	Virus-inspired strategies for cancer therapy. Seminars in Cancer Biology, 2022, 86, 1143-1157.	4.3	15
2299	Cancer Cells Shuttle Extracellular Vesicles Containing Oncogenic Mutant p53 Proteins to the Tumor Microenvironment. Cancers, 2021, 13, 2985.	1.7	10
2300	Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. , 2021, 9, e002255.		61
2301	Cohesin Mutations in Cancer: Emerging Therapeutic Targets. International Journal of Molecular Sciences, 2021, 22, 6788.	1.8	22
2302	Case Report: Sequential Chemotherapy and Immunotherapy Produce Sustained Response in Osteosarcoma With High Tumor Mutational Burden. Frontiers in Endocrinology, 2021, 12, 625226.	1.5	5
2303	Recent scientific/intellectual movements in biomedicine. Social Science and Medicine, 2021, 278, 113950.	1.8	7
2304	Exosome component 1 cleaves single-stranded DNA and sensitizes human kidney renal clear cell carcinoma cells to poly(ADP-ribose) polymerase inhibitor. ELife, 2021, 10, .	2.8	9
2306	Comparison of 3-carbethoxy-4-phenyl-but-3-en-2-one and methylene quinuclidinone as a ligand to reactivate mutant p53: molecular docking study in three types of crystal structure mutant p53: 2BIM, 2JIY, and 2J21. Research Journal of Pharmacy and Technology, 2021, , 3358-3364.	0.2	1
2307	Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesisâ€"New insight and futuristic vision. International Journal of Biological Macromolecules, 2021, 180, 739-752.	3.6	39
2308	Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies. Pharmacological Research, 2021, 168, 105579.	3.1	39
2309	Porcine pancreatic ductal epithelial cells transformed with KRASG12D and SV40T are tumorigenic. Scientific Reports, 2021, 11, 13436.	1.6	5
2310	Determining subpopulation methylation profiles from bisulfite sequencing data of heterogeneous samples using DXM. Nucleic Acids Research, 2021, 49, e93-e93.	6.5	7
2311	Macrophages in Acute Myeloid Leukaemia: Significant Players in Therapy Resistance and Patient Outcomes. Frontiers in Cell and Developmental Biology, 2021, 9, 692800.	1.8	27
2312	T-17, a spirostanol saponin, inhibits p53-independent proliferation and p53-dependent migration of gastric cancer cells. Steroids, 2021, 170, 108828.	0.8	4

#	Article	IF	Citations
2313	Transcriptomic heterogeneity of driver gene mutations reveals novel mutual exclusivity and improves exploration of functional associations. Cancer Medicine, 2021, 10, 4977-4993.	1.3	1
2314	Yeast-based screening of cancer mutations in the DNA damage response protein Mre11 demonstrates importance of conserved capping domain residues. Molecular Biology Reports, 2021, 48, 4107-4119.	1.0	0
2316	Cross-talk between next generation sequencing methodologies to identify genomic signatures of esophageal cancer. Critical Reviews in Oncology/Hematology, 2021, 162, 103348.	2.0	1
2317	Innovative dual system approach for selective eradication of cancer cells using viral-based delivery of natural bacterial toxinâ€“antitoxin system. Oncogene, 2021, 40, 4967-4979.	2.6	6
2318	Shifting the paradigms for tumor suppression: lessons from the p53 field. Oncogene, 2021, 40, 4281-4290.	2.6	15
2320	Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?. Cancers, 2021, 13, 3415.	1.7	15
2322	Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair. Communications Biology, 2021, 4, 862.	2.0	5
2323	Novel insights of acute myeloid leukemia with CEBPA deregulation: Heterogeneity dissection and re-stratification. Critical Reviews in Oncology/Hematology, 2021, 163, 103379.	2.0	5
2324	Quantitative neurogenetics: applications in understanding disease. Biochemical Society Transactions, 2021, 49, 1621-1631.	1.6	7
2325	Mutated p53 in HGSCâ€”From a Common Mutation to a Target for Therapy. Cancers, 2021, 13, 3465.	1.7	12
2326	Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 3453.	1.7	6
2327	PI3KÎ±Î´ Inhibitor Combined With Radiation Enhances the Antitumor Immune Effect of Anti-PD1 in a Syngeneic Murine Triple-Negative Breast Cancer Model. International Journal of Radiation Oncology Biology Physics, 2021, 110, 845-858.	0.4	15
2328	Tumor Mutation Burden Prediction Model in Egyptian Breast Cancer patients based on Next Generation Sequencing. Asian Pacific Journal of Cancer Prevention, 2021, 22, 2053-2059.	0.5	5
2329	TIMâ€3 in normal and malignant hematopoiesis: Structure, function, and signaling pathways. Cancer Science, 2021, 112, 3419-3426.	1.7	18
2330	Rethinking pre-training on medical imaging. Journal of Visual Communication and Image Representation, 2021, 78, 103145.	1.7	33
2331	Systematic identification of novel cancer genes through analysis of deep shRNA perturbation screens. Nucleic Acids Research, 2021, 49, 8488-8504.	6.5	4
2332	Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP). Scientific Reports, 2021, 11, 15112.	1.6	2
2333	Role of NRF2 in Lung Cancer. Cells, 2021, 10, 1879.	1.8	35

#	Article	IF	Citations
2334	MicroRNAâ€‘449a inhibits cell proliferation and migration by regulating mutant p53 in MDAâ€‘MBâ€‘468 cells. Experimental and Therapeutic Medicine, 2021, 22, 1020.	0.8	2
2335	Shorter Leukocyte Telomere Length Is Associated with Worse Survival of Patients with Bladder Cancer and Renal Cell Carcinoma. Cancers, 2021, 13, 3774.	1.7	3
2336	Human Radiosensitivity and Radiosusceptibility: What Are the Differences?. International Journal of Molecular Sciences, 2021, 22, 7158.	1.8	31
2337	Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells. Cell Death and Disease, 2021, 12, 709.	2.7	11
2338	Chronic Psychological Stress Attenuates the Efficacy of anti-PD-L1 Immunotherapy for Bladder Cancer in Immunocompetent Mice. Cancer Investigation, 2021, 39, 571-581.	0.6	7
2339	Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma. , 2021, 9, e002882.		13
2340	Cancer-Associated Mutations Perturb the Disordered Ensemble and Interactions of the Intrinsically Disordered p53 Transactivation Domain. Journal of Molecular Biology, 2021, 433, 167048.	2.0	14
2341	Chemopreventive effects of pterostilbene through p53 and cell cycle in mouse lung of squamous cell carcinoma model. Scientific Reports, 2021, 11, 14862.	1.6	10
2342	Vaginal Squamous Cell Carcinoma Develops in Mice with Conditional Arid1a Loss and Gain of Oncogenic Kras Driven by Progesterone Receptor Cre. American Journal of Pathology, 2021, 191, 1281-1291.	1.9	3
2343	KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer. Breast Cancer Research and Treatment, 2021, 189, 347-361.	1.1	11
2344	Synthesis and biological evaluation of a novel anticancer agent CBISC that induces DNA damage response and diminishes levels of mutant-p53. Biochemical and Biophysical Research Communications, 2021, 562, 127-132.	1.0	1
2345	Exploration of the Activation Mechanism of the Epigenetic Regulator MLL3: A QM/MM Study. Biomolecules, 2021, 11, 1051.	1.8	3
2346	Ternary Copper (II) Complex Induced Apoptosis and Cell Cycle Arrest in Colorectal Cancer Cells. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 999-1011.	0.9	4
2347	Global mapping of cancers: The Cancer Genome Atlas and beyond. Molecular Oncology, 2021, 15, 2823-2840.	2.1	55
2348	Genomic and Clinical Significance of Multiple Primary Lung Cancers as Determined by Next-Generation Sequencing. Journal of Thoracic Oncology, 2021, 16, 1166-1175.	0.5	17
2349	Loss of KMT2C reprograms the epigenomic landscape in hPSCs resulting in NODAL overexpression and a failure of hemogenic endothelium specification. Epigenetics, 2022, 17, 220-238.	1.3	7
2350	Autoimmune Responses in Oncology: Causes and Significance. International Journal of Molecular Sciences, 2021, 22, 8030.	1.8	12
2351	Loss of MGA repression mediated by an atypical polycomb complex promotes tumor progression and invasiveness. ELife, 2021, 10, .	2.8	26

#	Article	IF	Citations
2352	Chemical rescue of mutant proteins in living Saccharomyces cerevisiae cells by naturally occurring small molecules. G3: Genes, Genomes, Genetics, 2021, 11, .	0.8	2
2353	A Diffusion-like Process Accommodates New Crypts During Clonal Expansion in Human Colonic Epithelium. Gastroenterology, 2021, 161, 548-559.e23.	0.6	6
2354	Unleashing the power of NK cells in anticancer immunotherapy. Journal of Molecular Medicine, 2022, 100, 337-349.	1.7	12
2355	Biochemical perspectives on targeting KMT2 methyltransferases in cancer. Trends in Pharmacological Sciences, 2021, 42, 688-699.	4.0	10
2356	PTEN downregulation induces apoptosis and cell cycle arrest in uterine cervical cancer cells. Experimental and Therapeutic Medicine, 2021, 22, 1100.	0.8	4
2357	Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies. Frontiers in Immunology, 2021, 12, 707734.	2.2	30
2358	A narrative review of tumor heterogeneity and challenges to tumor drug therapy. Annals of Translational Medicine, 2021, 9, 1351-1351.	0.7	27
2359	Investigating the Mechanism of Scutellariae barbata Herba in the Treatment of Colorectal Cancer by Network Pharmacology and Molecular Docking. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-18.	0.5	8
2360	The effect of the TP53 and RB1 mutations on the survival of hepatocellular carcinoma patients with different racial backgrounds. Journal of Gastrointestinal Oncology, 2021, 12, 1786-1796.	0.6	5
2361	SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions. Molecular Cancer, 2021, 20, 100.	7.9	36
2362	Genomic Analysis Reveals Heterogeneity Between Lesions in Synchronous Primary Right-Sided and Left-Sided Colon Cancer. Frontiers in Molecular Biosciences, 2021, 8, 689466.	1.6	5
2363	Pan-cancer analysis of pathway-based gene expression pattern at the individual level reveals biomarkers of clinical prognosis. Cell Reports Methods, 2021, 1, 100050.	1.4	10
2364	The Changes in the p53 Protein across the Animal Kingdom Point to Its Involvement in Longevity. International Journal of Molecular Sciences, 2021, 22, 8512.	1.8	9
2365	A Pan-Cancer Analysis of Transcriptome and Survival Reveals Prognostic Differentially Expressed LncRNAs and Predicts Novel Drugs for Glioblastoma Multiforme Therapy. Frontiers in Genetics, 2021, 12, 723725.	1.1	0
2366	Cellular feedback dynamics and multilevel regulation driven by the hippo pathway. Biochemical Society Transactions, 2021, 49, 1515-1527.	1.6	11
2367	Clinical significance of TP53 mutations in adult Tâ€cell leukemia/lymphoma. British Journal of Haematology, 2021, 195, 571-584.	1.2	14
2368	TP53 in Biology and Treatment of Osteosarcoma. Cancers, 2021, 13, 4284.	1.7	26
2369	Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes. Nature Communications, 2021, 12, 5184.	5.8	30

#	Article	IF	Citations
2370	miR-22 promotes stem cell traits via activating Wnt/Î²-catenin signaling in cutaneous squamous cell carcinoma. Oncogene, 2021, 40, 5799-5813.	2.6	21
2371	N6-Methyladenosine Writer Gene ZC3H13 Predicts Immune Phenotype and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma. Frontiers in Oncology, 2021, 11, 718644.	1.3	15
2373	Structure, Activity and Function of the MLL2 (KMT2B) Protein Lysine Methyltransferase. Life, 2021, 11, 823.	1.1	10
2374	VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigensâ€™ Prediction. Vaccines, 2021, 9, 880.	2.1	8
2375	Current status and future perspectives of immunotherapy against urothelial and kidney cancer. Japanese Journal of Clinical Oncology, 2021, 51, 1481-1492.	0.6	7
2376	Definitive evidence for Club cells as progenitors for mutant Kras/Trp53â€deficient lung cancer. International Journal of Cancer, 2021, 149, 1670-1682.	2.3	5
2377	Reduction of Derlin activity suppresses Notch-dependent tumours in the C. elegans germ line. PLoS Genetics, 2021, 17, e1009687.	1.5	2
2378	Therapeutic cancer vaccines: reasons to believe. Emerging Topics in Life Sciences, 2021, 5, 591-595.	1.1	0
2379	Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy. Frontiers in Oncology, 2021, 11, 727433.	1.3	57
2380	The Genomic Processes of Biological Invasions: From Invasive Species to Cancer Metastases and Back Again. Frontiers in Ecology and Evolution, 2021, 9, .	1.1	9
2381	The Interplay Between Prostate Cancer Genomics, Metabolism, and the Epigenome: Perspectives and Future Prospects. Frontiers in Oncology, 2021, 11, 704353.	1.3	8
2382	Bridging Tumorigenesis and Therapy Resistance With a Non-Darwinian and Non-Lamarckian Mechanism of Adaptive Evolution. Frontiers in Oncology, 2021, 11, 732081.	1.3	3
2383	Distance-based clustering challenges for unbiased benchmarking studies. Scientific Reports, 2021, 11, 18988.	1.6	9
2385	A Ferroptosis-Related Prognostic Signature Based on Antitumor Immunity and Tumor Protein p53 Mutation Exploration for Guiding Treatment in Patients With Head and Neck Squamous Cell Carcinoma. Frontiers in Genetics, 2021, 12, 732211.	1.1	13
2386	Genomic Characterization and Therapeutic Targeting of HPV Undetected Cervical Carcinomas. Cancers, 2021, 13, 4551.	1.7	13
2387	Oncogene-independent resistance in Philadelphia chromosome - positive (Ph+) acute lymphoblastic leukemia (ALL) is mediated by activation of AKT/mTOR pathway. Neoplasia, 2021, 23, 1016-1027.	2.3	2
2388	The Tumor Microenvironment-Dependent Transcription Factors AHR and HIF-1Î± Are Dispensable for Leukemogenesis in the EÂµ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia. Cancers, 2021, 13, 4518.	1.7	4
2389	Moving pan-cancer studies from basic research toward the clinic. Nature Cancer, 2021, 2, 879-890.	5.7	40

#	Article	IF	Citations
2390	Viral targeting of glioblastoma stem cells with patient-specific genetic and post-translational p53 deregulations. Cell Reports, 2021, 36, 109673.	2.9	6
2391	HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells. Cells, 2021, 10, 2371.	1.8	41
2392	The development and improvement of ribonucleic acid therapy strategies. Molecular Therapy - Nucleic Acids, 2021, 26, 997-1013.	2.3	11
2393	Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer. Gut, 2021, , gutjnl-2021-325405.	6.1	15
2394	Negative regulation of TGFÎ²-induced apoptosis by RAC1B enhances intestinal tumourigenesis. Cell Death and Disease, 2021, 12, 873.	2.7	6
2395	Root Bark ofMorus Alba L.Induced p53-Independent Apoptosis in Human Colorectal Cancer Cells by Suppression of STAT3 Activity. Nutrition and Cancer, 2022, 74, 1837-1848.	0.9	4
2396	Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)â€"Gene Rearrangements. Frontiers in Pharmacology, 2021, 12, 741413.	1.6	8
2397	Histone H1 Mutations in Lymphoma: A Link(er) between Chromatin Organization, Developmental Reprogramming, and Cancer. Cancer Research, 2021, 81, 6061-6070.	0.4	11
2398	Integrated Analysis of Copy Number Variation, Microsatellite Instability, and Tumor Mutation Burden Identifies an 11-Gene Signature Predicting Survival in Breast Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 721505.	1.8	5
2399	Informed Attentive Predictors: A Generalisable Architecture for Prior Knowledge-Based Assisted Diagnosis of Cancers. Sensors, 2021, 21, 6484.	2.1	1
2400	Harnessing the therapeutic potential of extracellular vesicles for cancer treatment. Seminars in Cancer Biology, 2021, 74, 92-104.	4.3	9
2401	Deep learning in cancer diagnosis, prognosis and treatment selection. Genome Medicine, 2021, 13, 152.	3.6	274
2402	A molecular taxonomy of tumors independent of tissue-of-origin. IScience, 2021, 24, 103084.	1.9	0
2403	Understanding the role of potential pathways and its components including hypoxia and immune system in case of oral cancer. Scientific Reports, 2021, 11, 19576.	1.6	16
2404	Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS. Pharmacological Research, 2021, 172, 105806.	3.1	17
2405	TP53 Co-Mutational Features and NGS-Calibrated Immunohistochemistry Threshold in Gastric Cancer. OncoTargets and Therapy, 2021, Volume 14, 4967-4978.	1.0	3
2406	Targeting translation: a promising strategy for anticancer metallodrugs. Coordination Chemistry Reviews, 2021, 446, 214129.	9.5	31
2407	Phytochemical based sestrin2 pharmacological modulators in the treatment of adenocarcinomas. Phytomedicine Plus, 2021, 1, 100133.	0.9	0

#	Article	IF	Citations
2408	Protein domain-based approaches for the identification and prioritization of therapeutically actionable cancer variants. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188614.	3.3	2
2409	Clinical significance of genetic alterations in endoscopically obtained pancreatic cancer specimens. Cancer Medicine, 2021, 10, 1264-1274.	1.3	11
2410	17-DMAG dually inhibits Hsp90 and histone lysine demethylases in alveolar rhabdomyosarcoma. IScience, 2021, 24, 101996.	1.9	7
2411	Overexpression of TICRR and PPIF confer poor prognosis in endometrial cancer identified by gene co-expression network analysis. Aging, 2021, 13, 4564-4589.	1.4	12
2412	Computational cancer genomics. , 2021, , 329-359.		0
2413	Modes of Regulated Cell Death in Cancer. Cancer Discovery, 2021, 11, 245-265.	7.7	186
2414	Germline Genetics in Cancer: The New Frontier. , 2021, , 379-385.		0
2415	The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary. International Journal of Cancer, 2021, 148, 2036-2047.	2.3	3
2416	A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with TP53 mutation. Translational Cancer Research, 2021, 10, 3963-3978.	0.4	4
2417	Deficiency of the X-inactivation escaping gene KDM5C in clear cell renal cell carcinoma promotes tumorigenicity by reprogramming glycogen metabolism and inhibiting ferroptosis. Theranostics, 2021, 11, 8674-8691.	4.6	39
2418	Somatic mutations in oral squamous cell carcinomas in 98 Japanese patients and their clinical implications. Cancer Treatment and Research Communications, 2021, 29, 100456.	0.7	3
2419	Personalized cancer vaccination in head and neck cancer. Cancer Science, 2021, 112, 978-988.	1.7	34
2420	Histone methylation modifiers in medical therapeutics. , 2021, , 693-720.		0
2421	Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 77-102.	2.3	498
2424	Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer. International Journal of Cancer, 2017, 141, 1215-1221.	2.3	24
2425	Molecular Pathway Analysis of Mutation Data for Biomarkers Discovery and Scoring of Target Cancer Drugs. Methods in Molecular Biology, 2020, 2063, 207-234.	0.4	8
2426	Investigating Conformational Dynamics and Allostery in the p53 DNA-Binding Domain Using Molecular Simulations. Methods in Molecular Biology, 2021, 2253, 221-244.	0.4	2
2427	Immunopathologic Assessment of PTEN Expression. Methods in Molecular Biology, 2016, 1388, 23-37.	0.4	8

#	Article	IF	Citations
2428	Molecular Basis of Lung Carcinogenesis. , 2017, , 447-496.		4
2429	On the Non-uniqueness of Solutions to the Perfect Phylogeny Mixture Problem. Lecture Notes in Computer Science, 2018, , 277-293.	1.0	9
2430	Adversarial Domain Adaptation forÂClassification of Prostate Histopathology Whole-Slide Images. Lecture Notes in Computer Science, 2018, 11071, 201-209.	1.0	69
2431	MicroRNAs in Drosophila Cancer Models. Advances in Experimental Medicine and Biology, 2019, 1167, 157-173.	0.8	8
2432	Mechanisms of Environmental and Occupational Carcinogenesis. , 2020, , 39-55.		1
2433	Epigenetic Regulation of Chromatin in Prostate Cancer. Advances in Experimental Medicine and Biology, 2019, 1210, 379-407.	0.8	10
2434	Rho-ROCK Signaling in Normal Physiology and as a Key Player in Shaping the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1223, 99-127.	0.8	17
2435	Deep Large-Scale Multi-task Learning Network for Gene Expression Inference. Lecture Notes in Computer Science, 2020, , 19-36.	1.0	4
2436	Notch Signaling and Human Papillomavirusâ€“Associated Oral Tumorigenesis. Advances in Experimental Medicine and Biology, 2021, 1287, 105-122.	0.8	5
2437	Ranking-Based Survival Prediction on Histopathological Whole-Slide Images. Lecture Notes in Computer Science, 2020, , 428-438.	1.0	24
2439	A Short History of Chromosome Rearrangements and Gene Fusions in Cancer. , 2015, , 3-11.		75
2440	Abduction Based Drug Target Discovery Using Boolean Control Network. Lecture Notes in Computer Science, 2017, , 57-73.	1.0	8
2441	Future Paradigm of Breast Cancer Resistance and Treatment. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 155-178.	0.1	2
2442	TNSim: A Tumor Sequencing Data Simulator for Incorporating Clonality Information. Lecture Notes in Computer Science, 2018, , 371-382.	1.0	2
2443	Contact Normalization or Escape from the Matrix. , 2015, , 297-342.		4
2444	Therapeutic Cancer Vaccines. Advances in Experimental Medicine and Biology, 2016, 909, 139-167.	0.8	12
2445	Cullin 3 and Its Role in Tumorigenesis. Advances in Experimental Medicine and Biology, 2020, 1217, 187-210.	0.8	16
2446	Genetic Alterations and Checkpoint Expression: Mechanisms and Models for Drug Discovery. Advances in Experimental Medicine and Biology, 2020, 1248, 227-250.	0.8	1

#	Article	IF	Citations
2447	Association analysis of KMT2D copy number variation as a positional candidate for growth traits. Gene, 2020, 753, 144799.	1.0	8
2448	Genetic alterations and their association with clinicopathologic characteristics in advanced breast carcinomas: focusing on clinically actionable genetic alterations. Human Pathology, 2020, 102, 94-103.	1.1	16
2449	Causes, effects, and clinical implications of perturbed patterns within the cancer epigenome. Seminars in Cancer Biology, 2022, 83, 15-35.	4.3	11
2451	Loss of p53 protein strikes a nerve to aid tumour growth. Nature, 2020, 578, 367-369.	13.7	4
2452	Chromatin dependencies in cancer and inflammation. Nature Reviews Molecular Cell Biology, 2018, 19, 245-261.	16.1	64
2453	H3K4 methylation at active genes mitigates transcription-replication conflicts during replication stress. Nature Communications, 2020, 11, 809.	5.8	41
2454	The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. Nature Genetics, 2019, 51, 506-516.	9.4	166
2455	Genomic landscape of lung adenocarcinoma in East Asians. Nature Genetics, 2020, 52, 177-186.	9.4	281
2456	Class IA PI3K regulatory subunits: p110-independent roles and structures. Biochemical Society Transactions, 2020, 48, 1397-1417.	1.6	34
2457	Multifaceted roles of long non-coding RNAs in triple-negative breast cancer: biology and clinical applications. Biochemical Society Transactions, 2020, 48, 2791-2810.	1.6	4
2458	iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17470-17479.	3.3	20
2459	SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. Journal of Experimental Medicine, 2021, 218, .	4.2	138
2460	AI-Driver: an ensemble method for identifying driver mutations in personal cancer genomes. NAR Genomics and Bioinformatics, 2020, 2, lqaa084.	1.5	19
2501	New addiction to the NRF2â€related factor NRF3 in cancer cells: Ubiquitinâ€independent proteolysis through the 20S proteasome. Cancer Science, 2020, 111, 6-14.	1.7	28
2502	Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab. Cancer Science, 2021, 112, 760-773.	1.7	49
2503	Recurrence analysis on prostate cancer patients with Gleason score 7 using integrated histopathology whole-slide images and genomic data through deep neural networks. Journal of Medical Imaging, 2018, 5, 1.	0.8	20
2504	Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study. , 2020, 8, e001532.		38
2505	An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discovery, 2016, 6, 700-702.	7.7	5

#	Article	IF	Citations
2506	CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade. JCI Insight, 2018, 3, .	2.3	40
2507	Secretome profiling identifies neuron-derived neurotrophic factor as a tumor-suppressive factor in lung cancer. JCI Insight, 2019, 4, .	2.3	15
2508	Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight, 2018, 3, .	2.3	107
2509	Human autologous iPSCâ€“derived dopaminergic progenitors restore motor function in Parkinsonâ€™s disease models. Journal of Clinical Investigation, 2020, 130, 904-920.	3.9	102
2510	Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. Journal of Clinical Investigation, 2020, 130, 2712-2726.	3.9	112
2511	Hijacking a key chromatin modulator creates epigenetic vulnerability for MYC-driven cancer. Journal of Clinical Investigation, 2018, 128, 3605-3618.	3.9	26
2512	Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia. Journal of Clinical Investigation, 2019, 129, 774-785.	3.9	128
2513	Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer. Journal of Clinical Investigation, 2018, 128, 2951-2965.	3.9	36
2517	An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/KEAP1/NRF2 relevant subtypes. Molecular Medicine, 2020, 26, 48.	1.9	10
2518	Exploring the multiple roles of guardian of the genome: P53. Egyptian Journal of Medical Human Genetics, 2020, 21, .	0.5	55
2519	Integrated Analysis of Genetic Abnormalities of the Histone Lysine Methyltransferases in Prostate Cancer. Medical Science Monitor, 2019, 25, 193-239.	0.5	18
2520	The "enemies within": regions of the genome that are inherently difficult to replicate. F1000Research, 2017, 6, 666.	0.8	28
2521	P53 at the start of the 21st century: lessons from elephants. F1000Research, 2017, 6, 2041.	0.8	15
2522	Factors targeting MED12 to drive tumorigenesis?. F1000Research, 2018, 7, 359.	0.8	11
2523	Heterogeneity of tumor cells in terms of cancer-initiating cells. Journal of Toxicologic Pathology, 2017, 30, 1-6.	0.3	10
2524	A Gene Gravity Model for the Evolution of Cancer Genomes: A Study of 3,000 Cancer Genomes across 9 Cancer Types. PLoS Computational Biology, 2015, 11, e1004497.	1.5	65
2525	Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap Insertional Mutagenesis. PLoS Computational Biology, 2016, 12, e1005074.	1.5	52
2526	NetNorM: Capturing cancer-relevant information in somatic exome mutation data with gene networks for cancer stratification and prognosis. PLoS Computational Biology, 2017, 13, e1005573.	1.5	27

#	Article	IF	Citations
2527	Inherited Disease Genetics Improves the Identification of Cancer-Associated Genes. PLoS Genetics, 2016, 12, e1006081.	1.5	14
2528	Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity. PLoS Genetics, 2016, 12, e1006279.	1.5	43
2529	Somatic Mutation Patterns in Hemizygous Genomic Regions Unveil Purifying Selection during Tumor Evolution. PLoS Genetics, 2016, 12, e1006506.	1.5	24
2530	Colorectal cancer mutational profiles correlate with defined microbial communities in the tumor microenvironment. PLoS Genetics, 2018, 14, e1007376.	1.5	65
2531	Evolution of Pre-Existing versus Acquired Resistance to Platinum Drugs and PARP Inhibitors in BRCA-Associated Cancers. PLoS ONE, 2014, 9, e105724.	1.1	12
2532	A Novobiocin Derivative, XN4, Inhibits the Proliferation of Chronic Myeloid Leukemia Cells by Inducing Oxidative DNA Damage. PLoS ONE, 2015, 10, e0123314.	1.1	8
2533	Identification of Variants in Primary and Recurrent Glioblastoma Using a Cancer-Specific Gene Panel and Whole Exome Sequencing. PLoS ONE, 2015, 10, e0124178.	1.1	16
2534	Concurrent Mutations in ATM and Genes Associated with Common Î³ Chain Signaling in Peripheral T Cell Lymphoma. PLoS ONE, 2015, 10, e0141906.	1.1	20
2535	Bringing Down Cancer Aircraft: Searching for Essential Hypomutated Proteins in Skin Melanoma. PLoS ONE, 2015, 10, e0142819.	1.1	14
2536	Colorectal Cancer Genetic Heterogeneity Delineated by Multi-Region Sequencing. PLoS ONE, 2016, 11, e0152673.	1.1	25
2537	Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance. PLoS ONE, 2016, 11, e0155840.	1.1	20
2538	A Physical Mechanism and Global Quantification of Breast Cancer. PLoS ONE, 2016, 11, e0157422.	1.1	19
2539	Application of Circulating Tumor DNA as a Non-Invasive Tool for Monitoring the Progression of Colorectal Cancer. PLoS ONE, 2016, 11, e0159708.	1.1	38
2540	Epigenomic annotation of noncoding mutations identifies mutated pathways in primary liver cancer. PLoS ONE, 2017, 12, e0174032.	1.1	9
2541	Correction of PTEN mutations in glioblastoma cell lines via AAV-mediated gene editing. PLoS ONE, 2017, 12, e0176683.	1.1	14
2542	Electronic cigarette aerosols suppress cellular antioxidant defenses and induce significant oxidative DNA damage. PLoS ONE, 2017, 12, e0177780.	1.1	125
2543	Assessment of circulating copy number variant detection for cancer screening. PLoS ONE, 2017, 12, e0180647.	1.1	34
2544	N-Terminal Acetylation-Targeted N-End Rule Proteolytic System: The Ac/N-End Rule Pathway. Molecules and Cells, 2016, 39, 169-178.	1.0	56

#	Article	IF	Citations
2545	A thiolâ€bound drug reservoir enhances APRâ€246â€induced mutant p53 tumor cell death. EMBO Molecular Medicine, 2021, 13, e10852.	3.3	28
2546	p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy. Critical Reviews in Oncogenesis, 2018, 23, 173-187.	0.2	10
2547	The Expanded p53 Interactome as a Predictive Model for Cancer Therapy. Genomics and Computational Biology, 2015, 1, 20.	0.7	3
2548	Integrated multi-omics analysis of genomics, epigenomics, and transcriptomics in ovarian carcinoma. Aging, 2019, 11, 4198-4215.	1.4	17
2549	Genomic landscapes by multiregion sequencing combined with circulation tumor DNA detection contribute to molecular diagnosis in glioblastomas. Aging, 2019, 11, 11224-11243.	1.4	6
2550	Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy. Aging, 2020, 12, 3312-3339.	1.4	103
2551	Construction of immune-related and prognostic lncRNA clusters and identification of their immune and genomic alterations characteristics in lung adenocarcinoma samples. Aging, 2020, 12, 9868-9881.	1.4	9
2552	High expression of UNC5B enhances tumor proliferation, increases metastasis, and worsens prognosis in breast cancer. Aging, 2020, 12, 17079-17098.	1.4	12
2553	Robust genomic copy number predictor of pan cancer metastasis. Genes and Cancer, 2018, 9, 66-77.	0.6	7
2554	The combinatorial complexity of cancer precision medicine. Oncoscience, 2014, 1, 504-509.	0.9	48
2555	A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience, 2014, 1, 614-623.	0.9	26
2556	Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas. Oncotarget, 2016, 7, 47418-47430.	0.8	13
2557	Selective DNA methylation in cancers controls collateral damage induced by large structural variations. Oncotarget, 2017, 8, 71385-71392.	0.8	11
2558	Novel B55Î±-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest. Oncotarget, 2016, 7, 61081-61092.	0.8	23
2559	Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells. Oncotarget, 2016, 7, 61630-61642.	0.8	24
2560	Association mining of mutated cancer genes in different clinical stages across 11 cancer types. Oncotarget, 2016, 7, 68270-68277.	0.8	9
2561	EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells. Oncotarget, 2016, 7, 84453-84467.	0.8	57
2562	inFRank: a ranking-based identification of influential genes in biological networks. Oncotarget, 2017, 8, 43810-43821.	0.8	5

#	Article	IF	Citations
2563	Increased gene expression noise in human cancers is correlated with low p53 and immune activities as well as late stage cancer. Oncotarget, 2016, 7, 72011-72020.	0.8	33
2564	Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients. Oncotarget, 2016, 7, 73876-73887.	0.8	9
2565	Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients. Oncotarget, 2016, 7, 77482-77494.	0.8	33
2566	TP53 mutations, expression and interaction networks in human cancers. Oncotarget, 2017, 8, 624-643.	0.8	105
2567	Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing. Oncotarget, 2017, 8, 8095-8104.	0.8	26
2568	Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing. Oncotarget, 2017, 8, 5349-5360.	0.8	7
2569	The heterogeneous landscape of ALK negative ALCL. Oncotarget, 2017, 8, 18525-18536.	0.8	28
2570	The ribosomal protein gene RPL5 is a haploinsufficient tumor suppressor in multiple cancer types. Oncotarget, 2017, 8, 14462-14478.	0.8	92
2571	Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget, 2017, 8, 33796-33806.	0.8	5
2572	IER5 as a promising predictive marker promotes irradiation-induced apoptosis in cervical cancer tissues from patients undergoing chemoradiotherapy. Oncotarget, 2017, 8, 36438-36448.	0.8	8
2573	RNA sequencing-based cell proliferation analysis across 19 cancers identifies a subset of proliferation-informative cancers with a common survival signature. Oncotarget, 2017, 8, 38668-38681.	0.8	29
2574	p53, p63 and p73 in the wonderland ofS. cerevisiae. Oncotarget, 2017, 8, 57855-57869.	0.8	15
2575	Epigenetic silencing of tumor suppressor candidate 3 confers adverse prognosis in early colorectal cancer. Oncotarget, 2017, 8, 84714-84728.	0.8	5
2576	Lentiviral CRISPR/Cas9 nickase vector mediated BIRC5 editing inhibits epithelial to mesenchymal transition in ovarian cancer cells. Oncotarget, 2017, 8, 94666-94680.	0.8	45
2577	Clinical significance of YAP1 activation in head and neck squamous cell carcinoma. Oncotarget, 2017, 8, 111130-111143.	0.8	34
2578	Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinomaâ€”an aggressive and fatal disease. Oncotarget, 2017, 8, 112313-112329.	0.8	29
2579	PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. Oncotarget, 2017, 8, 113494-113501.	0.8	34
2580	Biphasic regulation of autophagy by miR-96 in prostate cancer cells under hypoxia. Oncotarget, 2014, 5, 9169-9182.	0.8	66

#	Article	IF	Citations
2581	Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells. Oncotarget, 2018, 9, 20508-20523.	0.8	86
2582	Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression. Oncotarget, 2015, 6, 5547-5566.	0.8	41
2583	Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget, 2018, 9, 33232-33243.	0.8	26
2584	Differential gene expression analysis of HNSCC tumors deciphered tobacco dependent and independent molecular signatures. Oncotarget, 2019, 10, 6168-6183.	0.8	18
2585	Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. Oncotarget, 2020, 11, 1-14.	0.8	1
2586	Transcriptome-wide identification and study of cancer-specific splicing events across multiple tumors. Oncotarget, 2015, 6, 6825-6839.	0.8	36
2587	Cisplatin fails to induce puma mediated apoptosis in mucosal melanomas. Oncotarget, 2015, 6, 9887-9896.	0.8	4
2588	Ultra-deep targeted sequencing of advanced oral squamous cell carcinoma identifies a mutation-based prognostic gene signature. Oncotarget, 2015, 6, 18066-18080.	0.8	58
2589	Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers. Oncotarget, 2015, 6, 18641-18652.	0.8	20
2590	Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure. Oncotarget, 2015, 6, 28327-28340.	0.8	24
2591	Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. Oncotarget, 2015, 6, 32161-32168.	0.8	28
2592	Mutually exclusive mutations inNOTCH1andPIK3CAassociated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China. Oncotarget, 2016, 7, 3599-3613.	0.8	29
2593	RPS7 inhibits colorectal cancer growth via decreasing HIF-1Î±-mediated glycolysis. Oncotarget, 2016, 7, 5800-5814.	0.8	32
2594	Transcriptional profiling analysis and functional prediction of long noncoding RNAs in cancer. Oncotarget, 2016, 7, 8131-8142.	0.8	49
2595	Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells. Oncotarget, 2016, 7, 17652-17664.	0.8	44
2596	Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies. Oncotarget, 2016, 7, 27802-27818.	0.8	46
2597	Synonymous mutations in oncogenesis and apoptosis versus survival unveiled by network modeling. Oncotarget, 2016, 7, 34599-34616.	0.8	11
2598	A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas. Oncotarget, 2017, 8, 50489-50499.	0.8	23

#	Article	IF	Citations
2599	Tissue specificity of DNA damage response and tumorigenesis. Cancer Biology and Medicine, 2019, 16, 396-414.	1.4	32
2600	Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma. Annals of Translational Medicine, 2019, 7, 648-648.	0.7	111
2601	Genome-wide association study of the TP53 R249S mutation in hepatocellular carcinoma with aflatoxin B1 exposure and infection with hepatitis B virus. Journal of Gastrointestinal Oncology, 2020, 11, 1333-1349.	0.6	8
2602	Pharmacological targeting of mutant p53. Translational Cancer Research, 2016, 5, 698-706.	0.4	18
2603	The association between genomic variations and histological grade in hepatocellular carcinoma. Translational Cancer Research, 2020, 9, 2424-2433.	0.4	4
2604	Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity. SSRN Electronic Journal, 0, , .	0.4	2
2605	DNA Double Strand Break Repair - Related Synthetic Lethality. Current Medicinal Chemistry, 2019, 26, 1446-1482.	1.2	9
2606	Exploring Dysregulated Signaling Pathways in Cancer. Current Pharmaceutical Design, 2020, 26, 429-445.	0.9	18
2607	Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China. Current Gene Therapy, 2020, 20, 127-141.	0.9	31
2608	Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia. Current Cancer Drug Targets, 2020, 20, 473-489.	0.8	4
2609	Influence of Amino Acid Mutations and Small Molecules on Targeted Inhibition of Proteins Involved in Cancer. Current Topics in Medicinal Chemistry, 2019, 19, 457-466.	1.0	3
2610	Immune Blockade Inhibition in Breast Cancer. Anticancer Research, 2016, 36, 5607-5622.	0.5	37
2611	Molecular and genetic profile of head and neck squamous cell carcinoma. Medical Herald of the South of Russia, 2018, 9, 50-57.	0.2	1
2612	Evaluation of safety of induced pluripotent stem cells by genome integrity. Inflammation and Regeneration, 2014, 34, 087-093.	1.5	2
2613	Immunoediting is not a primary transformation event in a murine model of MLL-ENL AML. Life Science Alliance, 2018, 1, e201800079.	1.3	5
2614	Evaluation of p53 and Its Target Gene Expression as Potential Biomarkers of Cholangiocarcinoma in Thai Patients. Asian Pacific Journal of Cancer Prevention, 2020, 21, 791-798.	0.5	7
2615	The PTENP1 Pseudogene, Unlike the PTEN Gene, Is Methylated in Normal Endometrium, As Well As in Endometrial Hyperplasias and Carcinomas in Middle-Aged and Elderly Females. Acta Naturae, 2018, 10, 43-50.	1.7	15
2616	Emerging epigenetic therapeutics for myeloid leukemia: modulating demethylase activity with ascorbate. Haematologica, 2021, 106, 14-25.	1.7	16

#	Article	IF	Citations
2617	Pediatric High Grade Gliomas in the Context of Cancer Predisposition Syndromes. Journal of Korean Neurosurgical Society, 2018, 61, 319-332.	0.5	30
2618	Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies. Cancers, 2020, 12, 2783.	1.7	64
2619	Histone Demethylases and Their Roles in Cancer Epigenetics. , 2016, 01, .		54
2620	Whole exome sequencing identifies genomic alterations in proximal and distal colorectal cancer. Bulletin of the Geological Society of Malaysia, 2019, 2, .	0.5	1
2621	Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing. World Journal of Gastroenterology, 2016, 22, 2284-2293.	1.4	42
2622	Expression of the epigenetic H3K27me3 modifier genes KDM6A and EZH2 in patients with upper tract urothelial carcinoma. Oncology Letters, 2020, 20, 1-1.	0.8	3
2623	Mechanistic insight of predictive biomarkers for antitumor PDâ€'1/PDâ€'L1 blockade: A paradigm shift towards immunome evaluation (Review). Oncology Reports, 2020, 44, 424-437.	1.2	18
2624	Kevetrin induces apoptosis in TP53 wildâ€'type and mutant acute myeloid leukemia cells. Oncology Reports, 2020, 44, 1561-1573.	1.2	4
2625	Oncogene-tumor suppressor gene feedback interactions and their control. Mathematical Biosciences and Engineering, 2015, 12, 1277-1288.	1.0	1
2626	Genomic-Glycosylation Aberrations in Tumor Initiation, Progression and Management. AIMS Medical Science, 2016, 3, 386-416.	0.2	3
2627	An improved understanding of cancer genomics through massively parallel sequencing. Translational Cancer Research, 2014, 3, 243-259.	0.4	10
2628	Review of Immunogenomics and the Role of Tumor Mutational Burden as a Biomarker for Immunotherapy Response. Journal of Immunotherapy and Precision Oncology, 2019, 2, 144-151.	0.6	4
2629	Statistical analysis of survival models using feature quantification on prostate cancer histopathological images. Journal of Pathology Informatics, 2019, 10, 30.	0.8	5
2630	Molecular and Clinicopathological Features of Gastrointestinal Stromal Tumors in Vietnamese Patients. Journal of Pathology and Translational Medicine, 2019, 53, 361-368.	0.4	2
2631	Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. Cancer Research and Treatment, 2019, 51, 211-222.	1.3	12
2632	Elevated Expression of RIOK1 Is Correlated with Breast Cancer Hormone Receptor Status and Promotes Cancer Progression. Cancer Research and Treatment, 2020, 52, 1067-1083.	1.3	3
2633	Metformin and mTOR Inhibitors: Allies against Ovarian and Breast Cancers. Journal of Carcinogenesis & Mutagenesis, 2017, 08, .	0.3	1
2634	Identification of genomic features associated with immunotherapy response in gastrointestinal cancers. World Journal of Gastrointestinal Oncology, 2019, 11, 270-280.	0.8	8

#	Article	IF	Citations
2635	Lung Cancer Genomics. Acta Medica Academica, 2019, 48, 78.	0.3	19
2636	Expressional Subpopulation of Cancers Determined by G64, a Co-regulated Module. Genomics and Informatics, 2015, 13, 132.	0.4	2
2637	A novel GSK3-regulated APC:Axin interaction regulates Wnt signaling by driving a catalytic cycle of efficient Î²catenin destruction. ELife, 2015, 4, e08022.	2.8	83
2638	Viral factors in influenza pandemic risk assessment. ELife, 2016, 5, .	2.8	82
2639	p27Kip1 promotes invadopodia turnover and invasion through the regulation of the PAK1/Cortactin pathway. ELife, 2017, 6, .	2.8	41
2640	Systematic morphological profiling of human gene and allele function via Cell Painting. ELife, 2017, 6, .	2.8	129
2641	Free-living human cells reconfigure their chromosomes in the evolution back to uni-cellularity. ELife, 2017, 6, .	2.8	31
2642	Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells. ELife, 2018, 7, .	2.8	70
2643	Mismatch repair-signature mutations activate gene enhancers across human colorectal cancer epigenomes. ELife, 2019, 8, .	2.8	19
2644	Somatic mutations in early metazoan genes disrupt regulatory links between unicellular and multicellular genes in cancer. ELife, 2019, 8, .	2.8	50
2645	Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides. ELife, 2020, 9, .	2.8	122
2646	DGPathinter: a novel model for identifying driver genes via knowledge-driven matrix factorization with prior knowledge from interactome and pathways. PeerJ Computer Science, 0, 3, e133.	2.7	4
2647	A pan-cancer analysis of prognostic genes. PeerJ, 2015, 3, e1499.	0.9	32
2648	Identification of Flap endonuclease 1 as a potential core gene in hepatocellular carcinoma by integrated bioinformatics analysis. PeerJ, 2019, 7, e7619.	0.9	11
2649	Cancer spectrum in TP53-deficient golden Syrian hamsters: A new model for li-fraumeni syndrome. Journal of Carcinogenesis, 2021, 20, 18.	2.5	6
2651	The Evolution of Clinically Aggressive Triple-Negative Breast Cancer Shows a Large Mutational Diversity and Early Metastasis to Lymph Nodes. Cancers, 2021, 13, 5091.	1.7	4
2653	Structureâ€“function relationships explain CTCF zinc finger mutation phenotypes in cancer. Cellular and Molecular Life Sciences, 2021, 78, 7519-7536.	2.4	12
2654	Development and Validation of Targeted Gene Sequencing Panel Based Companion Diagnostic for Korean Patients with Solid Tumors. Cancers, 2021, 13, 5112.	1.7	0

#	Article	IF	Citations
2655	Cellular senescence limits translational readthrough. Biology Open, 2021, 10, .	0.6	1
2656	Identification of a DNA Methylation-Driven Genes-Based Prognostic Model and Drug Targets in Breast Cancer: In silico Screening of Therapeutic Compounds and in vitro Characterization. Frontiers in Immunology, 2021, 12, 761326.	2.2	7
2657	Genomic Landscape in Neoplasm-Like Stroma Reveals Distinct Prognostic Subtypes of Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2021, 11, 771247.	1.3	1
2658	Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived Mimetic Nanovesicles to Treat Bladder Cancer. Molecular Pharmaceutics, 2021, 18, 4015-4028.	2.3	24
2659	Computational studies reveal co-occurrence of two mutations in IL7R gene of high-grade serous carcinoma patients. Journal of Biomolecular Structure and Dynamics, 2022, 40, 13310-13324.	2.0	2
2661	p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis. Molecules, 2021, 26, 6215.	1.7	6
2662	Structural and functional analysis of somatic coding and UTR indels in breast and lung cancer genomes. Scientific Reports, 2021, 11, 21178.	1.6	1
2663	A Sensitive PCR-Based Method for Somatic Mutations Enrichment and Screening. Cancer Management and Research, 2021, Volume 13, 8099-8107.	0.9	0
2664	One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies. Epigenomes, 2021, 5, 22.	0.8	3
2667	DNA methylation in genes associated with the evolution of ageing and disease: A critical review. Ageing Research Reviews, 2021, 72, 101488.	5.0	15
2668	Basic Cancer Biology. , 2014, , 1-39.		0
2669	How T Cells Single Out Tumor Cells: â€œAnd That Has Made All the Differenceâ€¦â€•. , 2014, , 13-20.		0
2670	Genomics Meets Cancer Immunotherapy. , 2014, , 229-236.		0
2673	Targeting Histone Lysine Methyltransferases in Cancer. RSC Drug Discovery Series, 2015, , 127-167.	0.2	0
2674	Assessment of Biomarkersâ€™ Predictive Value of Efficacy. , 2015, , 101-112.		0
2675	Targeted Therapies For Intestinal Tumorigenesis. , 2015, , 391-440.		0
2686	Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 509-509.	0.8	0
2688	Radiosensitizing Glioma by Targeting ATM with Small Molecule Inhibitors. , 2016, , 289-305.		0

#	Article	IF	Citations
2689	Molecular Targeted Therapies in Head and Neck Cancer. , 2016, , 349-372.		0
2690	Molecular Pathology of Cancer. , 2016, , 1-54.		0
2691	Graph Centrality Based Prediction of Cancer Genes. Springer Proceedings in Mathematics and Statistics, 2016, , 275-311.	0.1	0
2692	Biomarkers in Head and Neck Cancer. , 2016, , 149-162.		0
2693	Genetics and Epigenetics of Head and Neck Cancer. , 2016, , 115-132.		0
2696	Moving molecular subtypes to the clinic in gastric cancer. Translational Cancer Research, 2016, 5, S25-S30.	0.4	1
2699	Distinct distributions of genomic features of the 5â€™ and 3â€™ partners of coding somatic cancer gene fusions: arising mechanisms and functional implications. Oncotarget, 2017, 8, 66769-66783.	0.8	0
2707	The Role of Cbx Proteins in Human Benign and Malignant Hematopoiesis. Blood, 2016, 128, 2651-2651.	0.6	0
2708	Dynamical Analysis of Drug Efficacy and Mechanism of Action Using GFP Reporters. , 2017, , 1145-1174.		0
2709	Grundprinzipien der Tumorstehung. , 2017, , 1-16.		0
2710	Identifying Heterogeneity Patterns of Allelic Imbalance on Germline Variants to Infer Clonal Architecture. Lecture Notes in Computer Science, 2017, , 286-297.	1.0	3
2711	New Perspectives in Medical Oncology : Molecular Medicine and its Perspectives. International Journal of Medicine and Surgery, 2017, 4, 58-62.	0.0	0
2712	The Molecular Pathology of Serous Endometrial Cancer. Molecular Pathology Library, 2017, , 87-122.	0.1	0
2716	OVA12 promotes tumor growth by regulating p53 expression in human cancer cells. Oncotarget, 2017, 8, 52854-52865.	0.8	0
2726	Change of Title: Microarrays Becomes High-Throughput. High-Throughput, 2017, 6, 1.	4.4	0
2727	Change of Title: Microarrays Becomes High-Throughput. High-Throughput, 2017, 6, 1.	4.4	1
2728	CANcer-specific Evaluation System (CANES): a high-accuracy platform, for preclinical single/multi-biomarker discovery. Oncotarget, 2017, 8, 69808-69822.	0.8	0
2734	DNA Damage Repair. Molecular Pathology Library, 2018, , 405-417.	0.1	0

#	Article	IF	Citations
2737	Immunotherapy in urothelial cancer: recent data and perspectives. Onkourologiya, 2018, 13, 16-24.	0.1	2
2739	Identification of Acquired Notch3 Dependency in Metastatic Head and Neck Cancer. SSRN Electronic Journal, 0, , .	0.4	0
2740	FAK as a Target for Therapy in Head and Neck Cancer. Current Cancer Research, 2018, , 469-490.	0.2	1
2741	Immunotherapy and New Combinations in Muscle-Invasive Bladder Cancer. , 2018, , 91-98.		0
2742	c-MET in Head and Neck Squamous Cell Carcinoma. Current Cancer Research, 2018, , 63-88.	0.2	1
2751	Applying molecular communication theory to estimate information loss in cell signal transduction. , 2018, , .		1
2757	Factors targeting MED12 to drive tumorigenesis?. F1000Research, 2018, 7, 359.	0.8	10
2758	Novel Approaches to Immunotherapy in Triple Negative Breast Cancer. International Journal of Cancer Management, 2018, In Press, .	0.2	1
2762	The Emerging Medical Landscape. Practical Issues in Geriatrics, 2019, , 9-23.	0.3	0
2764	Using Drosophila Models and Tools to Understand the Mechanisms of Novel Human Cancer Driver Gene Function. Advances in Experimental Medicine and Biology, 2019, 1167, 15-35.	0.8	2
2765	Epigenetic Abnormalities in Acute Myeloid Leukemia and Leukemia Stem Cells. Advances in Experimental Medicine and Biology, 2019, 1143, 173-189.	0.8	2
2773	Improved antitumor efficacy of neutrophils stimulated by bacillus Calmetteâ€'Guï¿½rin. Molecular Medicine Reports, 2019, 20, 2909-2915.	1.1	2
2774	High-throughput Exploration of the Network Dependent on AKT1 in Mouse Ovarian Granulosa Cells. Molecular and Cellular Proteomics, 2019, 18, 1307-1319.	2.5	8
2777	Human TP53 gene polymorphisms among patients with hepatocellular carcinoma and chronic hepatitis B in Kenya. F1000Research, 0, 8, 1364.	0.8	0
2780	The complementary effect of rs1042522 in TP53 and rs1805007 in MC1R is associated with an elevated risk of cutaneous melanoma in Latvian population. Oncology Letters, 2019, 18, 5225-5234.	0.8	2
2784	Molecular Biology and Genetics of Renal Cell Carcinoma. , 2020, , 19-33.		0
2787	Modulation of p53 Transactivation Domain Conformations by Ligand Binding and Cancer-Associated Mutations. , 2019, , .		4
2791	Precision Oncology vs Phenotypic Approaches in the Management of Cancer: A Case for the Postmitotic State. Human Perspectives in Health Sciences and Technology, 2020, , 169-201.	0.2	0

#	Article	IF	Citations
2792	Analysis of Circulating Tumor DNA to Predict Neoadjuvant Therapy Effectiveness and Breast Cancer Recurrence. Journal of Breast Cancer, 2020, 23, 373.	0.8	1
2793	CHAPTER 7. Helix-mimetics as Proteinâ€“Protein Interaction Inhibitors. RSC Drug Discovery Series, 2020, , 147-170.	0.2	0
2803	ARID1A/BAF250a is significantly overexpressed in primary invasive breast cancer. Translational Cancer Research, 2020, 9, 3937-3945.	0.4	1
2806	Coupled immune stratification and identification of therapeutic candidates in patients with lung adenocarcinoma. Aging, 2020, 12, 16514-16538.	1.4	10
2809	Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers. Npj Precision Oncology, 2021, 5, 96.	2.3	2
2810	Investigation on the Potential Correlation Between TP53 and Esophageal Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 730337.	1.8	4
2811	A Novel Model Based on Genomic Instability-Associated Long Non-Coding RNAs for Predicting Prognosis and Response to Immunotherapy in Patients With Lung Adenocarcinoma. Frontiers in Genetics, 2021, 12, 720013.	1.1	6
2812	Discovery of MK-4688: an Efficient Inhibitor of the HDM2â€“p53 Proteinâ€“Protein Interaction. Journal of Medicinal Chemistry, 2021, 64, 16213-16241.	2.9	14
2813	Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype. Cancers, 2021, 13, 5348.	1.7	4
2814	Conservation and divergence in gene regulation between mouse and human immune cells deserves equal emphasis. Trends in Immunology, 2021, 42, 1077-1087.	2.9	3
2815	Molecular Basis of Breast Cancer. , 2022, , 3-15.		0
2816	Driver mutations in major lung cancer oncogenes can be analyzed in Drosophila models. ALTEX: Alternatives To Animal Experimentation, 2021, 38, 235-244.	0.9	2
2817	Preoperative assessment of endometrial cancer. Translational Cancer Research, 2020, 9, 7746-7758.	0.4	3
2818	A Mechanistic Investigation on the Anticancer Properties of SYA013, a Homopiperazine Analogue of Haloperidol with Activity against Triple Negative Breast Cancer Cells. ACS Omega, 2020, 5, 32907-32918.	1.6	6
2821	Data Augmentation Using GANs for 3D Applications. Advances in Multimedia and Interactive Technologies Book Series, 2020, , 229-269.	0.1	1
2823	An NAD⁺ dependent/sensitive transcription system: Toward a novel anti-cancer therapy. AIMS Molecular Science, 2020, 7, 12-28.	0.3	3
2825	The Pharmacogenomics â€œSide-effectâ€•of TP53/EGFR in Non-small Cell Lung Cancer Accompanied with Atorvastatin Therapy: A Functional Network Analysis. Anti-Cancer Agents in Medicinal Chemistry, 2020, 19, 2060-2071.	0.9	1
2826	Targeting chromatin remodelers in urological tumors. , 2020, , 179-213.		0

#	Article	IF	Citations
2827	A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma. Euroasian Journal of Hepato-gastroenterology, 2021, 10, 56-63.	0.1	5
2830	Role of Xenobiotic in Autophagy Inflection in Cell Death and Carcinogenesis. , 2020, , 1-34.		0
2834	The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. European Urology, 2022, 81, 95-103.	0.9	158
2835	The role of mutations in <i>NF1</i> gene in sporadic carcinogenesis. Uspehi Molekularnoj Onkologii, 2021, 8, 25-33.	0.1	1
2836	Radiotherapy-Induced Digestive Injury: Diagnosis, Treatment and Mechanisms. Frontiers in Oncology, 2021, 11, 757973.	1.3	17
2837	Molecular Heterogeneity of Cervical Cancer Among Different Ethnic/Racial Populations. Journal of Racial and Ethnic Health Disparities, 2022, 9, 2441-2450.	1.8	3
2838	Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma. Frontiers in Immunology, 2021, 12, 721409.	2.2	17
2839	Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?. International Journal of Molecular Sciences, 2021, 22, 11941.	1.8	27
2840	Clinical and Immunological Effects of p53-Targeting Vaccines. Frontiers in Cell and Developmental Biology, 2021, 9, 762796.	1.8	12
2841	Pan-Cancer Analysis Reveals the Signature of TMC Family of Genes as a Promising Biomarker for Prognosis and Immunotherapeutic Response. Frontiers in Immunology, 2021, 12, 715508.	2.2	9
2842	Discovery of a novel potentially transforming somatic mutation in CSF2RB gene in breast cancer. Cancer Medicine, 2021, 10, 8138-8150.	1.3	6
2846	Dynamical Analysis of Drug Efficacy and Mechanism of Action Using GFP Reporters. Advances in Medical Technologies and Clinical Practice Book Series, 0, , 316-353.	0.3	0
2847	The current and future roles of genomics. , 0, , 79-94.		0
2851	Leukemia Stem Cells: Concept and Implications. Methods in Molecular Biology, 2021, 2185, 25-37.	0.4	2
2852	Genetic Alterations of Malignant Pleural Mesothelima. , 0, , .		0
2853	Identification of Novel Functional Variants of SIN3A and SRSF1 among Somatic Variants in Acute Myeloid Leukemia Patients. Molecules and Cells, 2018, 41, 465-475.	1.0	4
2854	Single-sample expression-based chemo-sensitivity score improves survival associations independently from genomic mutations for ovarian cancer Patients. AMIA Summits on Translational Science Proceedings, 2016, 2016, 94-100.	0.4	1
2855	Histone demethylases and their roles in cancer epigenetics. , 2016, 1, 34-40.		47

#	Article	IF	Citations
2856	haploinsufficiency cooperates with oncogenic to promote an early-onset T-cell acute lymphoblastic leukemia. American Journal of Translational Research (discontinued), 2017, 9, 1326-1334.	0.0	4
2857	Pathways to Genome-targeted Therapies in Serous Ovarian Cancer. Journal of Nature and Science, 2017, 3, .	1.1	0
2858	Loss of ACVRIB leads to increased squamous cell carcinoma aggressiveness through alterations in cell-cell and cell-matrix adhesion proteins. American Journal of Cancer Research, 2017, 7, 2422-2437.	1.4	1
2859	The PTENP1 Pseudogene, Unlike the PTEN Gene, Is Methylated in Normal Endometrium, As Well As in Endometrial Hyperplasias and Carcinomas in Middle-Aged and Elderly Females. Acta Naturae, 2018, 10, 43-50.	1.7	8
2861	Pan-cancer analysis of expressed somatic nucleotide variants in long intergenic non-coding RNA. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2018, 23, 512-523.	0.7	1
2862	A comprehensive investigation using meta-analysis and bioinformatics on miR-34a-5p expression and its potential role in head and neck squamous cell carcinoma. American Journal of Translational Research (discontinued), 2018, 10, 2246-2263.	0.0	5
2864	From genome to phenome: Predicting multiple cancer phenotypes based on somatic genomic alterations via the genomic impact transformer. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2020, 25, 79-90.	0.7	7
2865	Modulation of p53 Transactivation Domain Conformations by Ligand Binding and Cancer-Associated Mutations. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2020, 25, 195-206.	0.7	4
2866	MiR-3196, a p53-responsive microRNA, functions as a tumor suppressor in hepatocellular carcinoma by targeting FOXP4. American Journal of Cancer Research, 2019, 9, 2665-2678.	1.4	3
2867	The extracellular signal-regulated kinase 1/2 modulates the intracellular localization of DNA methyltransferase 3A to regulate erythrocytic differentiation. American Journal of Translational Research (discontinued), 2020, 12, 1016-1030.	0.0	5
2869	Tumor mutation burden associated with miRNA-gene interaction outcome mediates the survival of patients with liver hepatocellular carcinoma. EXCLI Journal, 2020, 19, 861-871.	0.5	1
2870	Positive feedback loop of AKR1B10P1/miR-138/SOX4 promotes cell growth in hepatocellular carcinoma cells. American Journal of Translational Research (discontinued), 2020, 12, 5465-5480.	0.0	3
2871	Assessment of hazard immune-related genes and tumor immune infiltrations in renal cell carcinoma. American Journal of Translational Research (discontinued), 2020, 12, 7096-7113.	0.0	2
2872	Frequent Subgraph Mining of Functional Interaction Patterns Across Multiple Cancers. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2021, 26, 261-272.	0.7	0
2873	TP53, SPOP and PIK3CA Genes Status in Prostate Cancer. Asian Pacific Journal of Cancer Prevention, 2020, 21, 3365-3371.	0.5	1
2874	The WRAP53Î± gene undergoes p53 tumor suppressor-dependent transcriptional regulation in response to DNA damage. Gene Reports, 2022, 26, 101431.	0.4	0
2875	Epigenetic condensates regulate chromatin activity and tumorigenesis. Molecular and Cellular Oncology, 2021, 8, 1997040.	0.3	0
2876	Genetic features of endometrioid-type endometrial carcinoma arising in uterine adenomyosis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 117-123.	1.4	2

#	Article	IF	Citations
2877	What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience. Current Oncology, 2021, 28, 4862-4873.	0.9	0
2878	Precise Identification of Recurrent Somatic Mutations in Oral Cancer Through Whole-Exome Sequencing Using Multiple Mutation Calling Pipelines. Frontiers in Oncology, 2021, 11, 741626.	1.3	7
2879	Liquid biopsies in pediatric oncology: opportunities and obstacles. Current Opinion in Pediatrics, 2022, 34, 39-47.	1.0	5
2880	Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance. Oncology Reports, 2021, 47, .	1.2	3
2881	Targeted Nanotherapeutics Using LACTB Gene Therapy Against Melanoma. International Journal of Nanomedicine, 2021, Volume 16, 7697-7709.	3.3	7
2882	CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer. International Journal of Molecular Sciences, 2021, 22, 12777.	1.8	16
2883	Nature of spontaneously arising single base substitutions in normal cells. Genome Instability & Disease, 2021, 2, 339.	0.5	0
2884	The Genomic Landscape of Pediatric Renal Cell Carcinomas. SSRN Electronic Journal, 0, , .	0.4	0
2885	Comprehensive Molecular Analyses of a Macrophages-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and LASSO Algorithm. SSRN Electronic Journal, 0, , .	0.4	0
2886	Clinical and molecular features of sacrum chordoma in Chinese patients. Annals of Translational Medicine, 2021, 10, 0-0.	0.7	3
2887	Histone Methyltransferase KMT2D Regulates H3K4 Methylation and is Involved in the Pathogenesis of Ovarian Cancer. Cell Transplantation, 2021, 30, 096368972110275.	1.2	3
2888	Targeted next generation sequencing of circulating tumor DNA provides prognostic information for management in breast cancer patients. Annals of Translational Medicine, 2021, 10, 0-0.	0.7	1
2889	Cancer testis antigen XAGE-1 is a promising marker for the diagnosis and treatment of ovarian cancer. Journal of Medicine and Life, 2021, 14, 710-715.	0.4	0
2890	Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas. Biomedicines, 2022, 10, 150.	1.4	11
2891	A survey on graph-based deep learning for computational histopathology. Computerized Medical Imaging and Graphics, 2022, 95, 102027.	3.5	36
2892	<scp>ScalpelSig</scp> Designs Targeted Genomic Panels from Data to Detect Activity of Mutational Signatures. Journal of Computational Biology, 2022, 29, 56-73.	0.8	1
2893	Highly sensitive and quantitative biodetection with lipid-polymer hybrid nanoparticles having organic room-temperature phosphorescence. Biosensors and Bioelectronics, 2022, 199, 113889.	5.3	8
2894	TP53, SPOP and PIK3CA Genes Status in Prostate Cancer. Asian Pacific Journal of Cancer Prevention, 2020, 21, 3365-3371.	0.5	2

#	Article	IF	Citations
2895	Artificial Intelligence and Precision Medicine: A Perspective. Advances in Experimental Medicine and Biology, 2021, , 1-11.	0.8	6
2896	Regulatory patterns analysis of transcription factor binding site clustered regions and identification of key genes in endometrial cancer. Computational and Structural Biotechnology Journal, 2022, 20, 812-823.	1.9	3
2897	A connected network-regularized logistic regression model for feature selection. Applied Intelligence, 0, , 1.	3.3	6
2899	Analysis of histone variant constraint and tissue expression suggests five potential novel human disease genes: H2AFY2, H2AFZ, H2AFY, H2AFV, H1F0. Human Genetics, 2022, 141, 1409-1421.	1.8	3
2900	Comparative assessment of genes driving cancer and somatic evolution in non-cancer tissues: an update of the Network of Cancer Genes (NCG) resource. Genome Biology, 2022, 23, 35.	3.8	38
2901	p53-mediated neurodegeneration in the absence of the nuclear protein Akirin2. IScience, 2022, 25, 103814.	1.9	3
2902	RadSigBench: a framework for benchmarking functional genomics signatures of cancer cell radiosensitivity. Briefings in Bioinformatics, 2022, 23, .	3.2	1
2903	Puf-A promotes cancer progression by interacting with nucleophosmin in nucleolus. Oncogene, 2022, 41, 1155-1165.	2.6	5
2904	An agingâ€related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma. Cancer Science, 2022, 113, 891-903.	1.7	12
2905	Evaluation of exosomal non-coding RNAs in cancer using high-throughput sequencing. Journal of Translational Medicine, 2022, 20, 30.	1.8	22
2906	Loss of NFE2L3 protects against inflammation-induced colorectal cancer through modulation of the tumor microenvironment. Oncogene, 2022, 41, 1563-1575.	2.6	13
2907	Targeting XPO1-Dependent Nuclear Export in Cancer. Biochemistry (Moscow), 2022, 87, S178-S191.	0.7	2
2908	Lysine methyltransferase inhibitors: where we are now. RSC Chemical Biology, 2022, 3, 359-406.	2.0	21
2909	Diffusion kernel-based predictive modeling of KRAS dependency in KRAS wild type cancer cell lines. Npj Systems Biology and Applications, 2022, 8, 2.	1.4	0
2910	Pervasive Conditional Selection of Driver Mutations and Modular Epistasis Networks in Cancer. SSRN Electronic Journal, 0, , .	0.4	0
2911	PIK3CA Mutations in Diffuse Gliomas: An Update on Molecular Stratification, Prognosis, Recurrence, and Aggressiveness. Clinical Medicine Insights: Oncology, 2022, 16, 117955492110688.	0.6	4
2912	Complexity against current cancer research: Are we on the wrong track?. International Journal of Cancer, 2022, 150, 1569-1578.	2.3	7
2913	Integrated Analysis of Ovarian Juvenile Granulosa Cell Tumors Reveals Distinct Epigenetic Signatures and Recurrent TERT Rearrangements. Clinical Cancer Research, 2022, 28, 1724-1733.	3.2	8

#	Article	IF	Citations
2914	Progress and possibilities for patient-derived iPSCs and genetically engineered stem cells in cancer modeling and targeted therapies. , 2022, , 247-288.		1
2915	Neurofibromin and suppression of tumorigenesis: beyond the GAP. Oncogene, 2022, 41, 1235-1251.	2.6	13
2916	Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma. Frontiers in Immunology, 2021, 12, 798474.	2.2	10
2917	Driver mutations in ADGRL3 are involved in the evolution of ependymoma. Laboratory Investigation, 2022, , .	1.7	2
2918	Molecular characteristics of youngâ€onset colorectal cancer in Vietnamese patients. Asia-Pacific Journal of Clinical Oncology, 2022, , .	0.7	3
2920	Big-Hypergraph Factorization Neural Network for Survival Prediction From Whole Slide Image. IEEE Transactions on Image Processing, 2022, 31, 1149-1160.	6.0	17
2921	Precision medicine for metastatic colorectal cancer in clinical practice. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110727.	1.4	23
2923	Immune system changes in the pathogenesis of neurofibromatosis type 1. Oncogematologiya, 2022, 17, 113-120.	0.1	0
2925	Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Scientific Reports, 2022, 12, 1248.	1.6	3
2926	Follicular Helper T-Cell-Based Classification of Endometrial Cancer Promotes Precise Checkpoint Immunotherapy and Provides Prognostic Stratification. Frontiers in Immunology, 2021, 12, 788959.	2.2	9
2927	Histone 3 lysine 4 monomethylation supports activation of transcription in S. cerevisiae during nutrient stress. Current Genetics, 2022, 68, 181-194.	0.8	6
2928	Integrative Modeling of Multiomics Data for Predicting Tumor Mutation Burden in Patients with Lung Cancer. BioMed Research International, 2022, 2022, 1-14.	0.9	7
2929	Liquidambaric acid inhibits Wnt/Î²-catenin signaling and colon cancer via targeting TNF receptor-associated factor 2. Cell Reports, 2022, 38, 110319.	2.9	20
2930	Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends in Pharmacological Sciences, 2022, 43, 136-150.	4.0	294
2931	Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. Journal of Clinical Oncology, 2022, 40, 369-381.	0.8	60
2933	Opportunities for Early Cancer Detection: The Rise of ctDNA Methylation-Based Pan-Cancer Screening Technologies. Epigenomes, 2022, 6, 6.	0.8	14
2934	Activating PIK3CA postzygotic mutations in segmental overgrowth of muscles with bone involvement in the body extremities. Molecular Genetics and Genomics, 2022, 297, 387-396.	1.0	3
2935	A systems genetics approach delineates the role of Bcl2 in leukemia pathogenesis. Leukemia Research, 2022, 114, 106804.	0.4	2

#	Article	IF	Citations
2936	A DNA-Methylation-Driven Genes Based Prognostic Signature Reveals Immune Microenvironment in Pancreatic Cancer. Frontiers in Immunology, 2022, 13, 803962.	2.2	13
2937	In Silico Study to Predict the Structural and Functional Consequences of SNPs on Biomarkers of Ovarian Cancer (OC) and BPA Exposure-Associated OC. International Journal of Molecular Sciences, 2022, 23, 1725.	1.8	4
2938	Large Animal Models of Breast Cancer. Frontiers in Oncology, 2022, 12, 788038.	1.3	13
2939	Multiâ€omics data identified <scp>TP53</scp> and <scp>LRP1B</scp> as key regulatory gene related to immune phenotypes via <scp>EPCAM</scp> in <scp>HCC</scp>. Cancer Medicine, 2022, 11, 2145-2158.	1.3	2
2940	p53 Signaling on Microenvironment and Its Contribution to Tissue Chemoresistance. Membranes, 2022, 12, 202.	1.4	8
2941	Fixing the GAP: The role of RhoGAPs in cancer. European Journal of Cell Biology, 2022, 101, 151209.	1.6	20
2942	DAB2IP suppresses tumor malignancy by inhibiting GRP75-driven p53 ubiquitination in colon cancer. Cancer Letters, 2022, 532, 215588.	3.2	9
2944	Genomic profiling of gallbladder carcinoma: Targetable mutations and pathways involved. Pathology Research and Practice, 2022, 232, 153806.	1.0	4
2945	Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities. European Journal of Pharmacology, 2022, 919, 174807.	1.7	17
2946	Cancer gene mutation frequencies for the U.S. population. Nature Communications, 2021, 12, 5961.	5.8	78
2947	Cancer Precision Drug Discovery Using Big Data and Artificial Intelligence Technologies. Advances in Computational Intelligence and Robotics Book Series, 2022, , 109-136.	0.4	0
2948	Multiomics analysis of altered NRF3 expression reveals poor prognosis in cancer. Informatics in Medicine Unlocked, 2022, 29, 100892.	1.9	0
2949	Conserved Î‘-Helix-3 is Crucial for Structure and Functions of Rad6 E2 Ubiquitin-Conjugating Enzymes. SSRN Electronic Journal, 0, , .	0.4	0
2950	Efficient expression, purification, and visualization by cryo-EM of unliganded near full-length HER3. Methods in Enzymology, 2022, 667, 611-632.	0.4	0
2951	A Novel Risk Defining System for Pediatric T-Cell Acute Lymphoblastic Leukemia From CCCG-ALL-2015 Group. Frontiers in Oncology, 2022, 12, 841179.	1.3	7
2952	Detection of Cancer Mutations by Urine Liquid Biopsy as a Potential Tool in the Clinical Management of Bladder Cancer Patients. Cancers, 2022, 14, 969.	1.7	2
2953	Predicting Mutational Status of Driver and Suppressor Genes Directly from Histopathology With Deep Learning: A Systematic Study Across 23 Solid Tumor Types. Frontiers in Genetics, 2021, 12, 806386.	1.1	14
2954	ATR inhibitor AZD6738 increases the sensitivity of colorectal cancer cells to 5â€fluorouracil by inhibiting repair of DNA damage. Oncology Reports, 2022, 47, .	1.2	9

#	Article	IF	Citations
2955	Systematic illumination of druggable genes in cancer genomes. Cell Reports, 2022, 38, 110400.	2.9	14
2956	Introduction and expression of PIK3CAE545K in a papillary thyroid cancer BRAFV600E cell line leads to a dedifferentiated aggressive phenotype. Journal of Otolaryngology - Head and Neck Surgery, 2022, 51, 7.	0.9	6
2957	Engineering prodrug nanomicelles as pyroptosis inducer for codelivery of PI3K/mTOR and CDK inhibitors to enhance antitumor immunity. Acta Pharmaceutica Sinica B, 2022, 12, 3139-3155.	5.7	13
2958	HepaCAMâ€'PIK3CA axis regulates the reprogramming of glutamine metabolism to inhibit prostate cancer cell proliferation. International Journal of Oncology, 2022, 60, .	1.4	3
2959	An Immune-Related Gene Pair Index Predicts Clinical Response and Survival Outcome of Immune Checkpoint Inhibitors in Melanoma. Frontiers in Immunology, 2022, 13, 839901.	2.2	1
2960	TP53 mutations in head and neck cancer. Molecular Carcinogenesis, 2022, 61, 385-391.	1.3	14
2962	PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?. Frontiers in Oncology, 2022, 12, 819128.	1.3	135
2963	Endothelial Senescence: A New Age in Pulmonary Hypertension. Circulation Research, 2022, 130, 928-941.	2.0	20
2964	Identification of a <scp>DNA</scp> damage repair <scp>geneâ€related</scp> signature for lung squamous cell carcinoma prognosis. Thoracic Cancer, 2022, , .	0.8	4
2965	Cross-Talk between p53 and Wnt Signaling in Cancer. Biomolecules, 2022, 12, 453.	1.8	15
2966	Case Report: A Novel Pathomechanism in PEComa by the Loss of Heterozygosity of TP53. Frontiers in Oncology, 2022, 12, 849004.	1.3	4
2967	Computational investigation of pyrrolidin derivatives as novel GPX4/MDM2â€"p53 inhibitors using 2D/3D-QSAR, ADME/toxicity, molecular docking, molecular dynamics simulations, and MM-GBSA free energy. Structural Chemistry, 2022, 33, 1019-1039.	1.0	17
2968	Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review. Cancer and Metastasis Reviews, 2022, 41, 433-446.	2.7	8
2969	HLA3D: an integrated structure-based computational toolkit for immunotherapy. Briefings in Bioinformatics, 2022, 23, .	3.2	2
2970	Precise tumor immune rewiring via synthetic CRISPRa circuits gated by concurrent gain/loss of transcription factors. Nature Communications, 2022, 13, 1454.	5.8	6
2971	Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression. Scientific Reports, 2022, 12, 5404.	1.6	10
2972	KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis. Molecular Cancer, 2022, 21, 89.	7.9	21
2973	The multifaceted roles of cohesin in cancer. Journal of Experimental and Clinical Cancer Research, 2022, 41, 96.	3.5	11

#	Article	IF	Citations
2976	Histone Methylases and Demethylases Regulating Antagonistic Methyl Marks: Changes Occurring in Cancer. Cells, 2022, 11, 1113.	1.8	12
2977	Homeostasis Imbalance of YY2 and YY1 Promotes Tumor Growth by Manipulating Ferroptosis. Advanced Science, 2022, 9, e2104836.	5.6	15
2978	Curcumin as a Potential Therapeutic Agent in Certain Cancer Types. Cureus, 2022, 14, e22825.	0.2	7
2979	Neddylation is essential for Î²-catenin degradation in Wnt signaling pathway. Cell Reports, 2022, 38, 110538.	2.9	11
2980	The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Cancers, 2022, 14, 1640.	1.7	3
2981	Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia. Frontiers in Immunology, 2022, 13, 867443.	2.2	4
2982	In Silico Bioinformatics Followed by Molecular Validation Using Archival FFPE Tissue Biopsies Identifies a Panel of Transcripts Associated with Severe Asthma and Lung Cancer. Cancers, 2022, 14, 1663.	1.7	2
2983	Prognostic Pathways Guide Drug Indications in Pan-Cancers. Frontiers in Oncology, 2022, 12, 849552.	1.3	0
2984	A general calculus of fitness landscapes finds genes under selection in cancers. Genome Research, 2022, , gr.275811.121.	2.4	7
2985	Bidimensional linked matrix factorization for pan-omics pan-cancer analysis. Annals of Applied Statistics, 2022, 16, 193-215.	0.5	9
2986	FOXO3 Expression in Macrophages Is Lowered by a High-Fat Diet and Regulates Colonic Inflammation and Tumorigenesis. Metabolites, 2022, 12, 250.	1.3	7
2987	Genotypes and phenotypes heterogeneity in PIK3CA-related overgrowth spectrum and overlapping conditions: 150 novel patients and systematic review of 1007 patients with PIK3CA pathogenetic variants. Journal of Medical Genetics, 2023, 60, 163-173.	1.5	15
2988	Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations. Experimental Hematology, 2022, , .	0.2	2
2989	Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2022, 22, 361-370.	1.1	5
2990	Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature Medicine, 2022, 28, 557-567.	15.2	26
2991	Classification of adultâ€type diffuse gliomas: Impact of the World Health Organization 2021 update. Brain Pathology, 2022, 32, e13062.	2.1	53
2992	Bladder Cancer Extracellular Vesicles Elicit a CD8 T Cell-Mediated Antitumor Immunity. International Journal of Molecular Sciences, 2022, 23, 2904.	1.8	7
2993	P53 and taurine upregulated gene 1 promotes the repair of the DeoxyriboNucleic Acid damage induced by bupivacaine in murine primary sensory neurons. Bioengineered, 2022, 13, 7439-7456.	1.4	6

#	Article	IF	Citations
2994	Association of KMT2C Genetic Variants with the Clinicopathologic Development of Oral Cancer. International Journal of Environmental Research and Public Health, 2022, 19, 3974.	1.2	3
2995	Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2022, 23, 3478.	1.8	25
2996	Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematological Oncology, 2022, 40, 491-504.	0.8	0
2997	Small cell lung cancer: Subtypes and therapeutic implications. Seminars in Cancer Biology, 2022, 86, 543-554.	4.3	21
2998	Signalling dynamics, cell decisions, and homeostatic control in health and disease. Current Opinion in Cell Biology, 2022, 75, 102066.	2.6	17
2999	The genomic landscape of pediatric renal cell carcinomas. IScience, 2022, 25, 104167.	1.9	3
3001	Progenitor cells derived from geneâ€engineered human induced pluripotent stem cells as synthetic cancer cell alternatives for in vitro pharmacology. Biotechnology Journal, 2022, , 2100693.	1.8	2
3002	Improving the role of immune checkpoint inhibitors in the management of advanced urothelial carcinoma, where do we stand?. Translational Oncology, 2022, 19, 101387.	1.7	2
3003	Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL). Cellular Signalling, 2022, 93, 110301.	1.7	4
3004	Construction and Clinical Translation of Causal Pan-Cancer Gene Score Across Cancer Types. Frontiers in Genetics, 2021, 12, 784775.	1.1	5
3005	Evaluation of the Role of p53 Tumour Suppressor Posttranslational Modifications and TTC5 Cofactor in Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 13198.	1.8	4
3006	Comprehensive Profiling of Mammalian Tribbles Interactomes Implicates TRIB3 in Gene Repression. Cancers, 2021, 13, 6318.	1.7	7
3007	Identification of m6A Regulator-Associated Methylation Modification Clusters and Immune Profiles in Melanoma. Frontiers in Cell and Developmental Biology, 2021, 9, 761134.	1.8	6
3008	Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer. Cancer, 2022, 128, 1157-1161.	2.0	10
3009	DNA Methylation and mRNA Expression of OX40 (TNFRSF4) and GITR (TNFRSF18, AITR) in Head and Neck Squamous Cell Carcinoma Correlates With HPV Status, Mutational Load, an Interferon-Î³ Signature, Signatures of Immune Infiltrates, and Survival. Journal of Immunotherapy, 2022, 45, 194-206.	1.2	6
3010	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nature Reviews Drug Discovery, 2022, 21, 509-528.	21.5	201
3011	IFI16 inhibits DNA repair that potentiates type-I interferon-induced antitumor effects in triple negative breast cancer. Cell Reports, 2021, 37, 110138.	2.9	24
3012	KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma. Nature Communications, 2021, 12, 7204.	5.8	22

#	Article	IF	Citations
3013	Using amide proton transfer-weighted MRI to non-invasively differentiate mismatch repair deficient and proficient tumors in endometrioid endometrial adenocarcinoma. Insights Into Imaging, 2021, 12, 182.	1.6	3
3015	AMMASurv: Asymmetrical Multi-Modal Attention for Accurate Survival Analysis with Whole Slide Images and Gene Expression Data. , 2021, , .		4
3016	The Current Understanding of and Treatment Paradigm for Newly-Diagnosed TP53-Mutated Acute Myeloid Leukemia. Hemato, 2021, 2, 748-763.	0.2	2
3017	Transâ€cleaving hammerhead ribozyme in specific regions can improve knockdown efficiency in vivo. Journal of Cellular Biochemistry, 2022, , .	1.2	2
3018	Xeroderma Pigmentosum Complementation Group C (XPC): Emerging Roles in Non-Dermatologic Malignancies. Frontiers in Oncology, 2022, 12, 846965.	1.3	6
3019	Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review). International Journal of Oncology, 2022, 60, .	1.4	25
3020	Comprehensive Molecular Profiling of Colorectal Cancer With Situs Inversus Totalis by Next-Generation Sequencing. Frontiers in Oncology, 2022, 12, 813253.	1.3	1
3021	Evaluating Established Roles, Future Perspectives and Methodological Heterogeneity for Wilmsâ€™ Tumor 1 (WT1) Antigen Detection in Adult Renal Cell Carcinoma, Using a Novel N-Terminus Targeted Antibody (Clone WT49). Biomedicines, 2022, 10, 912.	1.4	5
3022	Genomic alterations of dermatofibrosarcoma protuberans revealed by wholeâ€genome sequencing. British Journal of Dermatology, 2022, 186, 997-1009.	1.4	8
3023	Nuclear translocation of p85Î² promotes tumorigenesis of PIK3CA helical domain mutant cancer. Nature Communications, 2022, 13, 1974.	5.8	13
3024	Age-Related Cancer-Associated Microbiota Potentially Promotes Oral Squamous Cell Cancer Tumorigenesis by Distinct Mechanisms. Frontiers in Microbiology, 2022, 13, 852566.	1.5	6
3025	G-Protein Subunit Gamma 4 as a Potential Biomarker for Predicting the Response of Chemotherapy and Immunotherapy in Bladder Cancer. Genes, 2022, 13, 693.	1.0	4
3026	Autophagy modulating therapeutics inhibit ovarian cancer colony generation by polyploid giant cancer cells (PGCCs). BMC Cancer, 2022, 22, 410.	1.1	11
3027	Targeting AML at the intersection of epigenetics and signaling. Science Signaling, 2022, 15, eabo0059.	1.6	1
3028	Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations. Cell Reports, 2022, 39, 110622.	2.9	15
3029	High-throughput functional evaluation of human cancer-associated mutations using base editors. Nature Biotechnology, 2022, 40, 874-884.	9.4	32
3030	Golden Spice Turmeric and Its Health Benefits. , 0, , .		1
3031	The paradigm of drug resistance in cancer: an epigenetic perspective. Bioscience Reports, 2022, 42, .	1.1	21

#	Article	IF	Citations
3032	Identifying common driver modules by equilibrating coverage and mutual exclusivity across pan-cancer data. Neurocomputing, 2022, 492, 408-420.	3.5	1
3046	Interrogating the Cancer Genome to Deliver More Precise Cancer Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e577-e583.	1.8	0
3133	KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming. Nature Cancer, 2022, 3, 753-767.	5.7	41
3138	Design and statistical principles of the SHIVA trial. Chinese Clinical Oncology, 2015, 4, 32.	0.4	1
3139	The roles of E3 ligases in Hepatocellular carcinoma.. American Journal of Cancer Research, 2022, 12, 1179-1214.	1.4	0
3140	Automated causal inference in application to randomized controlled clinical trials. Nature Machine Intelligence, 2022, 4, 436-444.	8.3	8
3141	Dissecting the Genetic and Non-Genetic Heterogeneity of Acute Myeloid Leukemia Using Next-Generation Sequencing and In Vivo Models. Cancers, 2022, 14, 2182.	1.7	4
3143	A Prognostic Gene Signature for Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 841530.	1.3	9
3144	Modulation of Tumor Immune Microenvironment and Prognostic Value of Ferroptosis-Related Genes, and Candidate Target Drugs in Glioblastoma Multiforme. Frontiers in Pharmacology, 2022, 13, 898679.	1.6	7
3145	Transcriptome analysis of clock disrupted cancer cells reveals differential alternative splicing of cancer hallmarks genes. Npj Systems Biology and Applications, 2022, 8, 17.	1.4	4
3146	CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer. Nature Communications, 2022, 13, 2642.	5.8	15
3147	Regulation of developmental hierarchy in Drosophila neural stem cell tumors by COMPASS and Polycomb complexes. Science Advances, 2022, 8, eabi4529.	4.7	2
3148	The Mettl3 epitranscriptomic writer amplifies p53 stress responses. Molecular Cell, 2022, 82, 2370-2384.e10.	4.5	22
3149	Multi-Omic Data Improve Prediction of Personalized Tumor Suppressors and Oncogenes. Frontiers in Genetics, 2022, 13, .	1.1	1
3150	Systematic review of the CUP trials characteristics and perspectives for next-generation studies. Cancer Treatment Reviews, 2022, 107, 102407.	3.4	13
3151	A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecologic Oncology, 2022, 166, 44-49.	0.6	5
3152	The â€˜New (Nu)-clearâ€™ evidence of the tumor-driving role of PI3K. , 2022, 1, .		6
3153	Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?. Cancers, 2022, 14, 2434.	1.7	7

#	Article	IF	Citations
3154	FLG Is a Potential Biomarker of Prognosis and Immunotherapy in Skin Cutaneous Melanoma. Applied Bionics and Biomechanics, 2022, 2022, 1-11.	0.5	3
3155	Chromosome 1 instability in multiple myeloma: Aberrant gene expression, pathogenesis, and potential therapeutic target. FASEB Journal, 2022, 36, e22341.	0.2	7
3156	Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using Bioinformatics. Frontiers in Genetics, 2022, 13, .	1.1	7
3157	The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma. PeerJ, 0, 10, e13473.	0.9	4
3158	Tumor suppressor p53 restrains cancer cell dissemination by modulating mitochondrial dynamics. Oncogenesis, 2022, 11, 26.	2.1	10
3159	Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients. Nature Communications, 2022, 13, 2800.	5.8	21
3160	Individualized discovery of rare cancer drivers in global network context. ELife, 2022, 11, .	2.8	3
3161	Halofuginone micelle nanoparticles eradicate Nrf2-activated lung adenocarcinoma without systemic toxicity. Free Radical Biology and Medicine, 2022, 187, 92-104.	1.3	5
3162	Heritable genomic diversity in breast cancer driver genes and associations with risk in a Chilean population. Biological Research, 2022, 55, .	1.5	1
3163	Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm. Frontiers in Immunology, 0, 13, .	2.2	23
3164	Cancer-related Mutations with Local or Long-range Effects on an Allosteric Loop of p53. Journal of Molecular Biology, 2022, 434, 167663.	2.0	17
3165	Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression. Frontiers in Oncology, 0, 12, .	1.3	11
3166	<scp>Time Resolvedâ€Fluorescence Resonance Energy Transfer</scp> platform for quantitative nucleosome binding and footprinting. Protein Science, 2022, 31, .	3.1	6
3167	Association of Nucleostemin Polymorphisms with Chronic Hepatitis B Virus Infection in Chinese Han Population. Genetic Testing and Molecular Biomarkers, 2022, 26, 255-262.	0.3	1
3168	Calotropin and corotoxigenin 3-O-glucopyranoside from the desert milkweed Asclepias subulata inhibit the Na⁺/K⁺-ATPase activity. PeerJ, 0, 10, e13524.	0.9	3
3169	A Unique Spectrum of Spontaneous Tumors in Dino Knockout Mice Identifies Tissue-Specific Requirements for Tumor Suppression. Cells, 2022, 11, 1818.	1.8	4
3171	On Signaling Dysregulation in Cancer. , 2021, , .		2
3172	DeepGCNMIL: Multi-head Attention Guided Multi-Instance Learning Approach for Whole-Slide Images Survival Analysis Using Graph Convolutional Networks. , 2022, , .		3

#	Article	IF	Citations
3173	A Germline Mutation in ATR Is Associated With Lung Adenocarcinoma in Asian Patients. Frontiers in Oncology, 0, 12, .	1.3	0
3174	Update on prognostic and predictive biomarkers of breast cancer. Seminars in Diagnostic Pathology, 2022, 39, 322-332.	1.0	20
3175	Liver cancer heterogeneity modeled by in situ genome editing of hepatocytes. Science Advances, 2022, 8, .	4.7	15
3176	The dual interaction of antimicrobial peptides on bacteria and cancer cells; mechanism of action and therapeutic strategies of nanostructures. Microbial Cell Factories, 2022, 21, .	1.9	17
3177	Are We Right on Target? Is Comprehensive Genomic Profiling Ready for Prime Time in Resource-Constrained Settings?. JCO Global Oncology, 2022, , .	0.8	2
3178	Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer. Cancer Research, 2022, 82, 2838-2847.	0.4	14
3179	Somatic Mutations in Exon 7 of the TP53 Gene in Index Colorectal Lesions Are Associated with the Early Occurrence of Metachronous Adenoma. Cancers, 2022, 14, 2823.	1.7	0
3180	IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer. Frontiers in Immunology, 0, 13, .	2.2	10
3181	Implications of Chromatin Modifier Mutations in Epigenetic Regulation of Bladder Cancer. , 0, , 45-60.		1
3182	Target-Based Small Molecule Drug Discovery for Colorectal Cancer: A Review of Molecular Pathways and In Silico Studies. Biomolecules, 2022, 12, 878.	1.8	6
3183	Clinical significance of chromosomal integrity in gastric cancers. International Journal of Biological Markers, 0, , 039361552211062.	0.7	1
3184	Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. Cancers, 2022, 14, 2816.	1.7	3
3185	Drug Repurposing by Tumor Tissue Editing. Frontiers in Oncology, 0, 12, .	1.3	5
3186	Current Status, Opportunities, and Challenges of Exosomes in Oral Cancer Diagnosis and Treatment. International Journal of Nanomedicine, 0, Volume 17, 2679-2705.	3.3	13
3187	Treatment Represents a Key Driver of Metastatic Cancer Evolution. Cancer Research, 2022, 82, 2918-2927.	0.4	11
3188	EOCSA: Predicting prognosis of Epithelial ovarian cancer with whole slide histopathological images. Expert Systems With Applications, 2022, 206, 117643.	4.4	8
3189	Molecular vulnerabilities and therapeutic resistance in hormone receptor positive and HER2 dependent breast cancer tumours. Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 487-497.	0.9	1
3190	On mathematical optimization for clustering categories in contingency tables. Advances in Data Analysis and Classification, 2023, 17, 407-429.	0.9	1

#	Article	IF	Citations
3191	The Therapeutic Potential of the Restoration of the p53 Protein Family Members in the EGFR-Mutated Lung Cancer. International Journal of Molecular Sciences, 2022, 23, 7213.	1.8	4
3192	Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma. Frontiers in Oncology, 0, 12, .	1.3	4
3193	The Î²-TrCP-Mediated Pathway Cooperates with the Keap1-Mediated Pathway in Nrf2 Degradation In Vivo. Molecular and Cellular Biology, 2022, 42, .	1.1	13
3194	Identification of TNFAIP6 as a hub gene associated with the progression of glioblastoma by weighted gene coâ€expression network analysis. IET Systems Biology, 2022, 16, 145-156.	0.8	6
3196	Integrated bioinformatics data analysis reveals a risk signature and PKD1 induced progression in endometrial cancer patients with postmenopausal status. Aging, 2022, 14, 5554-5570.	1.4	1
3197	Targeting Streptomyces-Derived Streptenol Derivatives against Gynecological Cancer Target PIK3CA: An In Silico Approach. BioMed Research International, 2022, 2022, 1-15.	0.9	2
3198	What we have learnt from Drosophila model organism: the coordination between insulin signaling pathway and tumor cells. Heliyon, 2022, 8, e09957.	1.4	2
3199	Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	11
3200	Highâ€Resolution Imaging of Human Cancer Proteins Using Microprocessor Materials. ChemBioChem, 2022, 23, .	1.3	8
3201	APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma. Lung Cancer, 2022, , .	0.9	1
3202	AP3S1 is a Novel Prognostic Biomarker and Correlated With an Immunosuppressive Tumor Microenvironment in Pan-Cancer. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	3
3203	Synthesis of MDM2-p53 Inhibitor BI-0282 via a Dipolar Cycloaddition and Late-Stage Davisâ€“Beirut Reaction. Organic Process Research and Development, 2022, 26, 2526-2531.	1.3	2
3204	Comprehensive omics studies of p53 mutants in human cancer. Briefings in Functional Genomics, 2023, 22, 97-108.	1.3	6
3206	Lpt, trr, and Hcf regulate histone mono- and dimethylation that are essential for Drosophila heart development. Developmental Biology, 2022, 490, 53-65.	0.9	4
3207	Chalcones as Anti-Glioblastoma Stem Cell Agent Alone or as Nanoparticle Formulation Using Carbon Dots as Nanocarrier. Pharmaceutics, 2022, 14, 1465.	2.0	7
3208	Cancer Biology and Implications for the Perioperative Period. , 2023, , 24-45.		1
3209	KMT2C-deficient tumors have elevated APOBEC mutagenesis and genomic instability in multiple cancers. NAR Cancer, 2022, 4, .	1.6	2
3210	Activation of the integrated stress response is a vulnerability for multidrugâ€resistant <scp>FBXW7</scp> â€deficient cells. EMBO Molecular Medicine, 2022, 14, .	3.3	12

#	Article	IF	Citations
3211	Association of Pathway Mutations With Survival in Taiwanese Breast Cancers. Frontiers in Oncology, 0, 12, .	1.3	2
3212	High prevalence of p16 staining in malignant tumors. PLoS ONE, 2022, 17, e0262877.	1.1	10
3213	A Generalized Integration Approach to Association Analysis with Multi-category Outcome: An Application to a Tumor Sequencing Study of Colorectal Cancer and Smoking. Journal of the American Statistical Association, 2023, 118, 29-42.	1.8	0
3214	The structural maintenance of chromosomes 5 is a possible biomarker for individualized treatment of colorectal cancer. Cancer Medicine, 0, , .	1.3	0
3215	Molecular Biomarkers in Cancer. Biomolecules, 2022, 12, 1021.	1.8	85
3216	Stochasticity of p53 Protein Expression in Cells of Primary and Transferable Human Lines. Biophysics (Russian Federation), 2022, 67, 427-434.	0.2	0
3217	Loss of TIP60 (KAT5) abolishes H2AZ lysine 7 acetylation and causes p53, INK4A, and ARF-independent cell cycle arrest. Cell Death and Disease, 2022, 13, .	2.7	9
3219	The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligandâ€“dependent Cancer Models. Cancer Research Communications, 2022, 2, 914-928.	0.7	4
3220	Zinc-doped Prussian blue nanoparticles for mutp53-carrying tumor ion interference and photothermal therapy. Asian Journal of Pharmaceutical Sciences, 2022, 17, 767-777.	4.3	7
3221	E2F7 enhances hepatocellular carcinoma growth by preserving the SP1/SOX4/Anillin axis viaÂrepressing miRNAâ€383â€5p transcription. Molecular Carcinogenesis, 2022, 61, 975-988.	1.3	4
3222	Multi-Omic Analysis of Two Common P53 Mutations: Proteins Regulated by Mutated P53 as Potential Targets for Immunotherapy. Cancers, 2022, 14, 3975.	1.7	2
3223	p53 Tumor Suppressor: Functional Regulation and Role in Gene Therapy. , 0, , .		1
3224	Analysis of genetic profiling, pathomics signature, and prognostic features of primary lymphoepitheliomaâ€like carcinoma of the renal pelvis. Molecular Oncology, 0, , .	2.1	1
3225	Clinical applications of mass spectrometryâ€based proteomics in cancer: Where are we?. Proteomics, 2023, 23, .	1.3	20
3226	Nucleolar protein NOC4L inhibits tumorigenesis and progression by attenuating SIRT1-mediated p53 deacetylation. Oncogene, 2022, 41, 4474-4484.	2.6	4
3227	Analysis of the B2M Expression in Colon Adenocarcinoma and Its Correlation with Patient Prognosis. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-13.	0.5	3
3228	Localization-dictated function for METTL3. Nature Cell Biology, 2022, 24, 1188-1189.	4.6	1
3229	PI3K/mTOR inhibitor omipalisib prolongs cardiac repolarization along with a mild proarrhythmic outcome in the AV block dog model. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0

#	Article	IF	Citations
3231	Drosophila melanogaster: A platform for anticancer drug discovery and personalized therapies. Frontiers in Genetics, 0, 13, .	1.1	10
3232	The Creation of the Suppressive Cancer Microenvironment in Patients with HPV-Positive Cervical Cancer. Diagnostics, 2022, 12, 1906.	1.3	3
3233	The Effects of Methanol Extracts of Hyssopus officinalis on Model of Induced Glioblastoma Multiforme (GBM) in Rats. Journal of Molecular Neuroscience, 2022, 72, 2045-2066.	1.1	1
3234	Whole-exome sequencing and bioinformatics analysis of a case of non-alpha-fetoprotein-elevated lung hepatoid adenocarcinoma. Frontiers in Pharmacology, 0, 13, .	1.6	3
3235	Combined evaluation of both WEE1 and phosphorylated cyclin dependent kinase 1 expressions in oral squamous cell carcinomas predicts cancer recurrence and progression. Journal of Dental Sciences, 2022, 17, 1780-1787.	1.2	1
3236	Exploring synthetic lethal network for the precision treatment of clear cell renal cell carcinoma. Scientific Reports, 2022, 12, .	1.6	3
3237	Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy. Genome Medicine, 2022, 14, .	3.6	6
3238	Drosophila as a toolkit to tackle cancer and its metabolism. Frontiers in Oncology, 0, 12, .	1.3	5
3239	Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials. Acta Biomaterialia, 2022, 150, 402-412.	4.1	8
3240	Fatty acid desaturase 1 (FADS1) is a cancer marker for patient survival and a potential novel target for precision cancer treatment. Frontiers in Oncology, 0, 12, .	1.3	10
3241	Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nature Medicine, 2022, 28, 1831-1839.	15.2	47
3242	Aberrant DNA methylation in t(8;21) acute myeloid leukemia. Genome Instability & Disease, 2022, 3, 209-216.	0.5	0
3243	Pervasive conditional selection of driver mutations and modular epistasis networks in cancer. Cell Reports, 2022, 40, 111272.	2.9	4
3244	Genetic, metabolic and immunological features of cancers with <scp>NRF2</scp> addiction. FEBS Letters, 2022, 596, 1981-1993.	1.3	5
3245	Cruciferous vegetables as a treasure of functional foods bioactive compounds: Targeting p53 family in gastrointestinal tract and associated cancers. Frontiers in Nutrition, 0, 9, .	1.6	5
3246	Golden Syrian Hamster Models for Cancer Research. Cells, 2022, 11, 2395.	1.8	7
3247	A novel glycosylated indolocarbazole derivative LCS1269 effectively inhibits growth of human cancer cells in vitro and in vivo through driving of both apoptosis and senescence by inducing of DNA damage and modulating of AKT/mTOR/S6K and ERK pathways. Chemico-Biological Interactions, 2022, 364, 110056.	1.7	3
3248	Identification of cell cycle-associated and -unassociated regulators for expression of a hepatocellular carcinoma oncogene cyclin-dependent kinase inhibitor 3. Biochemical and Biophysical Research Communications, 2022, 625, 46-52.	1.0	1

#	Article	IF	Citations
3250	The role of mixed lineage kinase 3 (MLK3) in cancers. , 2022, 238, 108269.		3
3251	The Role of Mixed Lineage Kinase 3 (MLK3) in Cancers. SSRN Electronic Journal, 0, , .	0.4	0
3252	Fast FF-to-FFPE Whole Slide Image Translation viaÂLaplacian Pyramid andÂContrastive Learning. Lecture Notes in Computer Science, 2022, , 409-419.	1.0	4
3253	Hybrid Cardiac Imaging: The Role of Machine Learning and Artificial Intelligence. , 2022, , 203-222.		0
3254	Enhancers: Encoding Regulation Across Time. Cognitive Systems Monographs, 2022, , 39-57.	0.1	0
3255	Generating Hypergraph-Based High-Order Representations of Whole-Slide Histopathological Images for Survival Prediction. IEEE Transactions on Pattern Analysis and Machine Intelligence, 2022, , 1-16.	9.7	8
3256	Druggable sites/pockets of theÂp53-DNAJA1 proteinâ€“protein interaction: In silico modeling and in vitro/in vivo validation. Methods in Enzymology, 2022, , 83-107.	0.4	0
3257	Genomic Alterations in Lung Cancer. Medical Radiology, 2022, , .	0.0	0
3258	Delineating the Role of PI3K Signaling Pathway in the Stem Cell Therapeutics of ROS-Induced Carcinomas. , 2022, , 2153-2177.		0
3259	A p53 transcriptional signature in primary and metastatic cancers derived using machine learning. Frontiers in Genetics, 0, 13, .	1.1	2
3260	Metabolismâ€Based Molecular Subtyping Endows Effective Ketogenic Therapy in p53â€Mutant Colon Cancer. Advanced Science, 2022, 9, .	5.6	4
3261	The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy. Cancers, 2022, 14, 4255.	1.7	3
3262	The Ferroptosis Molecular Subtype Reveals Characteristics of the Tumor Microenvironment, Immunotherapeutic Response, and Prognosis in Gastric Cancer. International Journal of Molecular Sciences, 2022, 23, 9767.	1.8	2
3263	Mutant p53 Depletion by Novel Inhibitors for HSP40/J-Domain Proteins Derived from the Natural Compound Plumbagin. Cancers, 2022, 14, 4187.	1.7	11
3264	Association between cancer genes and germ layer specificity. , 2022, 39, .		1
3265	Utilization of cytologic cell blocks for targeted sequencing of solid tumors. Cancer Medicine, 2023, 12, 4042-4063.	1.3	3
3266	<scp>DNA</scp> damage response signaling: A common link between cancer and cardiovascular diseases. Cancer Medicine, 2023, 12, 4380-4404.	1.3	6
3267	Empirical single-cell tracking and cell-fate simulation reveal dual roles of p53 in tumor suppression. ELife, 0, 11, .	2.8	1

#	Article	IF	Citations
3268	How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes. Cancers, 2022, 14, 4519.	1.7	7
3269	Towards label-efficient automatic diagnosis and analysis: a comprehensive survey of advanced deep learning-based weakly-supervised, semi-supervised and self-supervised techniques in histopathological image analysis. Physics in Medicine and Biology, 2022, 67, 20TR01.	1.6	17
3271	Dissecting the Kinetic Mechanism of Human Lysine Methyltransferase 2D and Its Interactions with the WRAD2 Complex. Biochemistry, 2022, 61, 1974-1987.	1.2	0
3272	High FLT3 expression indicates favorable prognosis and correlates with clinicopathological parameters and immune infiltration in breast cancer. Frontiers in Genetics, 0, 13, .	1.1	6
3273	Toward Accurate Coarse-Grained Simulations of Disordered Proteins and Their Dynamic Interactions. Journal of Chemical Information and Modeling, 2022, 62, 4523-4536.	2.5	9
3274	DNA damage accumulation and repair defects in FLT3â€ITD acute myeloid leukemia: Implications for clonal evolution and disease progression. Hematological Oncology, 2023, 41, 26-38.	0.8	6
3275	Regulating the p53 Tumor Suppressor Network at PML Biomolecular Condensates. Cancers, 2022, 14, 4549.	1.7	7
3276	Proteasomal deubiquitylase activity enhances cell surface recycling of the epidermal growth factor receptor in non-small cell lung cancer. Cellular Oncology (Dordrecht), 2022, 45, 951-965.	2.1	3
3277	Genomic alterations predictive of poor clinical outcomes in pan-cancer. Oncotarget, 2022, 13, 1069-1077.	0.8	0
3278	Close link between breast cancer & apoptosis. International Journal of Health Sciences, 0, , 10446-10456.	0.0	0
3279	Clone wars: From molecules to cell competition in intestinal stem cell homeostasis and disease. Experimental and Molecular Medicine, 2022, 54, 1367-1378.	3.2	6
3280	Inactivation of <scp>RB1</scp>, <scp>CDKN2A</scp>, and <scp>TP53</scp> have distinct effects on genomic stability at sideâ€byâ€side comparison in karyotypically normal cells. Genes Chromosomes and Cancer, 2023, 62, 93-100.	1.5	4
3283	Herbal Drugs to Targets in the Treatment of Cancer - A Futuristic Approach. Current Cancer Therapy Reviews, 2023, 19, 177-197.	0.2	0
3284	CARM1-mediated methylation of ASXL2 impairs tumor-suppressive function of MLL3/COMPASS. Science Advances, 2022, 8, .	4.7	4
3285	Ribosome biogenesis and ribosome therapy in cancer cells. Research Results in Pharmacology, 2022, 8, 15-24.	0.1	1
3286	Novel <scp>NRF2</scp>â€activated cancer treatments utilizing synthetic lethality. IUBMB Life, 2022, 74, 1209-1231.	1.5	7
3287	lncRNA PVT1: a novel oncogene in multiple cancers. Cellular and Molecular Biology Letters, 2022, 27, .	2.7	15
3288	Reduced expression and activity of patient-derived SHIP1 phosphatase domain mutants. Cellular Signalling, 2023, 101, 110485.	1.7	2

#	Article	IF	Citations
3289	Revisiting a challenging p53 binding site: a diversity-optimized HEFLib reveals diverse binding modes in T-p53C-Y220C. RSC Medicinal Chemistry, 2022, 13, 1575-1586.	1.7	5
3290	Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules. British Journal of Cancer, 0, , .	2.9	0
3291	PIK3CA mutations associated with a poor postoperative prognosis in patients with pulmonary pleomorphic carcinoma: a retrospective cohort study. BMC Cancer, 2022, 22, .	1.1	1
3292	Identification of a New Prediction Model for Bladder Cancer Related to Immune Functions and Chemotherapy Using Gene Sets of Biological Processes. BioMed Research International, 2022, 2022, 1-21.	0.9	0
3293	Dedifferentiation and inÂvivo reprogramming of committed cells in wound repair (Review). Molecular Medicine Reports, 2022, 26, .	1.1	2
3294	DNAJA1- and conformational mutant p53-dependent inhibition of cancer cell migration by a novel compound identified through a virtual screen. Cell Death Discovery, 2022, 8, .	2.0	5
3295	Molecular profiling of patients with cytogenetically normal acute myeloid leukemia and hyperleukocytosis. Cancer, 2022, 128, 4213-4222.	2.0	4
3296	Prime Editing: An Emerging Tool in Cancer Treatment. Molecular Biotechnology, 0, , .	1.3	0
3297	The International Consensus Classification of acute myeloid leukemia. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2023, 482, 27-37.	1.4	17
3298	GOF Mutant p53 in Cancers: A Therapeutic Challenge. Cancers, 2022, 14, 5091.	1.7	11
3300	A Novel Bayesian Framework Infers Driver Activation States and Reveals Pathway-Oriented Molecular Subtypes in Head and Neck Cancer. Cancers, 2022, 14, 4825.	1.7	0
3301	An integrated multi-omics analysis of topoisomerase family in pan-cancer: Friend or foe?. PLoS ONE, 2022, 17, e0274546.	1.1	2
3303	Diabetic Retinopathy: Are lncRNAs New Molecular Players and Targets?. Antioxidants, 2022, 11, 2021.	2.2	5
3305	Tumor-derived ARHGAP35 mutations enhance the GÎ±13-Rho signaling axis in human endometrial cancer. Cancer Gene Therapy, 2023, 30, 313-323.	2.2	1
3306	The <scp>NRF2</scp> antagonist <scp>ML385</scp> inhibits <scp>PI3Kâ€mTOR</scp> signaling and growth of lung squamous cell carcinoma cells. Cancer Medicine, 2023, 12, 5688-5702.	1.3	9
3307	Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches. Journal of Personalized Medicine, 2022, 12, 1651.	1.1	3
3308	Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma. Experimental Hematology and Oncology, 2022, 11, .	2.0	6
3309	How Genetics and Genomics Advances Are Rewriting Pediatric Cancer Research and Clinical Care. Medicina (Lithuania), 2022, 58, 1386.	0.8	2

#	Article	IF	Citations
3310	Novel Expression of Thymine Dimers in Renal Cell Carcinoma, Demonstrated through Immunohistochemistry. Biomedicines, 2022, 10, 2673.	1.4	4
3311	Electrochemical biosensors for analysis of DNA point mutations in cancer research. Analytical and Bioanalytical Chemistry, 2023, 415, 1065-1085.	1.9	11
3312	PIK3CA Mutational Analysis in Patients With Macrodactyly. Pediatric and Developmental Pathology, 2022, 25, 624-634.	0.5	1
3314	A Bioinformatics View on Acute Myeloid Leukemia Surface Molecules by Combined Bayesian and ABC Analysis. Bioengineering, 2022, 9, 642.	1.6	1
3315	Multiregional Sequencing Analysis Reveals Extensive Genetic Heterogeneity in Gastric Tumors from Latinos. Cancer Research Communications, 2022, 2, 1487-1496.	0.7	2
3316	Blood-based DNA methylation signatures in cancer: A systematic review. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2023, 1869, 166583.	1.8	8
3317	Elucidation of genomic origin of synchronous endometrial and ovarian cancer (SEO) by genomic and microsatellite analysis. Journal of Gynecologic Oncology, 2023, 34, .	1.0	6
3318	Contemporary Clinical Definitions, Differential Diagnosis, and Novel Predictive Tools for Renal Cell Carcinoma. Biomedicines, 2022, 10, 2926.	1.4	7
3319	Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	12
3320	The Role of WRAP53 in Cell Homeostasis and Carcinogenesis Onset. Current Issues in Molecular Biology, 2022, 44, 5498-5515.	1.0	2
3321	Low-Carbohydrate High-Fat Diet: A SWOC Analysis. Metabolites, 2022, 12, 1126.	1.3	7
3322	Mechanistic Contributions of lncRNAs to Cellular Signaling Pathways Crucial to the Lifecycle of Human Papillomaviruses. Viruses, 2022, 14, 2439.	1.5	2
3323	Context-Dependent Function of Long Noncoding RNA PURPL in Transcriptome Regulation during p53 Activation. Molecular and Cellular Biology, 2022, 42, .	1.1	4
3325	WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function. Experimental and Molecular Medicine, 2022, 54, 1913-1926.	3.2	0
3326	Very large hidden genetic diversity in one single tumor: evidence for tumors-in-tumor. National Science Review, 2022, 9, .	4.6	2
3327	Dose-effect of polystyrene microplastics on digestive toxicity in chickens (Gallus gallus): Multi-omics reveals critical role of gut-liver axis. Journal of Advanced Research, 2023, 52, 3-18.	4.4	16
3328	Targeting the PI3K Pathway in Gynecologic Malignancies. Current Oncology Reports, 2022, 24, 1669-1676.	1.8	1
3329	High frequency of colorectal neoplasia in patients with sporadic adenomas or adenocarcinomas of the papilla of Vater: The same adenoma-carcinoma sequence?. Digestive and Liver Disease, 2022, , .	0.4	0

#	Article	IF	Citations
3330	Receptor Tyrosine Kinase Pathway and Infiltrating Urothelial Carcinoma. Journal of Environmental Pathology, Toxicology and Oncology, 2023, 42, 65-77.	0.6	0
3331	Turmeric ethanol extract (Curcuma longa L.) reduces apoptosis and promotes canine osteosarcoma cell proliferation. Ciencia Animal Brasileira, 0, 23, .	0.3	0
3332	Cancer Survival Prediction From Whole Slide Images With Self-Supervised Learning and Slide Consistency. IEEE Transactions on Medical Imaging, 2023, 42, 1401-1412.	5.4	8
3333	Extrato etanÃ³lico de aÃ§afrÃ£o (Curcuma longa L.) reduz apoptose e promove proliferaÃ§Ã£o de cÃ©lulas de osteossarcoma canino. Ciencia Animal Brasileira, 0, 23, .	0.3	0
3334	Histone Methyltransferase KMT2B Promotes Metastasis and Angiogenesis of Cervical Cancer by Upregulating EGF Expression. International Journal of Biological Sciences, 2023, 19, 34-49.	2.6	2
3335	Targeting the DNA Damage Response Machinery for Lung Cancer Treatment. Pharmaceuticals, 2022, 15, 1475.	1.7	6
3336	Exploring the mechanism of Tengli Kangliu Decoction in the prevention and treatment of colorectal cancer precancerous based on network pharmacology. Medicine (United States), 2022, 101, e31690.	0.4	0
3337	dTMP imbalance through thymidylate 5â€²-phosphohydrolase activity induces apoptosis in triple-negative breast cancers. Scientific Reports, 2022, 12, .	1.6	1
3338	Translational readthrough of nonsense mutant TP53 by mRNA incorporation of 5-Fluorouridine. Cell Death and Disease, 2022, 13, .	2.7	13
3339	Transcriptional upregulation of <scp>CXCL13</scp> is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma. Cancer Medicine, 2023, 12, 7639-7650.	1.3	3
3340	Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A. Nature Communications, 2022, 13, .	5.8	5
3341	Subclonal mutations in epigenetic regulators bring fitness in times of stress. Cancer Cell, 2023, 41, 7-9.	7.7	1
3342	Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions. Journal of Medicinal Chemistry, 2022, 65, 16033-16061.	2.9	28
3343	Engineering chimeric antigen receptor T cells for solid tumour therapy. Clinical and Translational Medicine, 2022, 12, .	1.7	13
3344	The role of nextâ€generation sequencing in the examination of signaling genes in Brca1/2 â€negative breast cancer cases. Annals of Human Genetics, 0, , .	0.3	0
3345	Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics. ESMO Open, 2022, 7, 100611.	2.0	5
3346	Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program. International Journal of Gynecological Cancer, 2023, 33, 109-117.	1.2	33
3347	Identification of an inhibitory domain in GTPase-activating protein p190RhoGAP responsible for masking its functional GAP domain. Journal of Biological Chemistry, 2022, , 102792.	1.6	0

#	Article	IF	Citations
3348	Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia. Cancer Cell, 2023, 41, 164-180.e8.	7.7	15
3349	Assessments of Somatic Variant Classification Using the Association for Molecular Pathology/American Society of Clinical Oncology/College of American Pathologists Guidelines. Journal of Molecular Diagnostics, 2023, 25, 69-86.	1.2	5
3350	Complete Models of p53 Better Inform the Impact of Hotspot Mutations. International Journal of Molecular Sciences, 2022, 23, 15267.	1.8	2
3351	BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models. Neuro-Oncology, 2023, 25, 913-926.	0.6	9
3352	A Systematic Analysis of the Role of Unc-5 Netrin Receptor A (UNC5A) in Human Cancers. Biomolecules, 2022, 12, 1826.	1.8	0
3353	The R736H cancer mutation in DNMT3A modulates the properties of the FF-subunit interface. Biochimie, 2023, 208, 66-74.	1.3	1
3354	Premature aging in childhood cancer survivors (Review). Oncology Letters, 2022, 25, .	0.8	3
3355	CRAC (Clinical Relevance of Alterations in Cancer): a Knowledge Base for the Selection of Molecularly Matched Therapy for Solid Tumors. Sovremennye Tehnologii V Medicine, 2022, 14, 15.	0.4	0
3356	Identification of a Novel Myc-Regulated Gene Signature for Patients with Kidney Renal Clear Cell Carcinoma. Journal of Oncology, 2022, 2022, 1-21.	0.6	1
3357	MLL3 loss drives metastasis by promoting a hybrid epithelialâ€“mesenchymal transition state. Nature Cell Biology, 2023, 25, 145-158.	4.6	16
3358	Genome-wide DNA methylation profile analysis identifies an individualized predictive signature for melanoma immune response. Journal of Cancer Research and Clinical Oncology, 2023, 149, 343-356.	1.2	2
3359	An IFN-Î³-related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohorts. Frontiers in Genetics, 0, 13, .	1.1	2
3360	Clustered PHD domains in KMT2/MLL proteins are attracted by H3K4me3 and H3 acetylation-rich active promoters and enhancers. Cellular and Molecular Life Sciences, 2023, 80, .	2.4	3
3361	Ras superfamily GTPase activating proteins in cancer: Potential therapeutic targets?. European Journal of Medicinal Chemistry, 2023, 248, 115104.	2.6	3
3362	Self-supervised learning-based Multi-Scale feature Fusion Network for survival analysis from whole slide images. Computers in Biology and Medicine, 2023, 153, 106482.	3.9	6
3363	Trace Analysis of Multiple Tumor Exosomal PDâ€L1 Based on SERS Immunoassay Platform. , 2023, 2, .		2
3364	COOBoostR: An Extreme Gradient Boosting-Based Tool for Robust Tissue or Cell-of-Origin Prediction of Tumors. Life, 2023, 13, 71.	1.1	2
3365	A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. Npj Breast Cancer, 2022, 8, .	2.3	8

#	Article	IF	Citations
3366	Recurrence risk assessment for stage III colorectal cancer based on five methylation biomarkers in plasma cellâ€free DNA. Journal of Pathology, 0, , .	2.1	1
3367	A High-Throughput Sequencing Data-Based Classifier Reveals the Metabolic Heterogeneity of Hepatocellular Carcinoma. Cancers, 2023, 15, 592.	1.7	2
3368	Metabolism-Guided Optimization of Tryptophanol-Derived Isoindolinone p53 Activators. Pharmaceuticals, 2023, 16, 146.	1.7	3
3369	SWI/SNF Blockade Disrupts PU.1-Directed Enhancer Programs in Normal Hematopoietic Cells and Acute Myeloid Leukemia. Cancer Research, 2023, 83, 983-996.	0.4	12
3370	Preclinical Models of Low-Grade Gliomas. Cancers, 2023, 15, 596.	1.7	4
3371	Cell differentiation modifies the p53 transcriptional program through a combination of gene silencing and constitutive transactivation. Cell Death and Differentiation, 2023, 30, 952-965.	5.0	3
3372	Adaptive graph convolutional neural network and its biomedical applications. , 2023, , 105-132.		0
3373	Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. , 2023, , 41-46.		0
3374	Powering Toxicogenomic Studies by Applying Machine Learning to Genomic Sequencing and Variant Detection. Computational Methods in Engineering & the Sciences, 2023, , 611-627.	0.3	0
3375	LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma. Cancer Discovery, 2023, 13, 1002-1025.	7.7	5
3376	Traditional Chinese medicine for colorectal cancer treatment: potential targets and mechanisms of action. Chinese Medicine, 2023, 18, .	1.6	7
3377	Pre-training in Medical Data: A Survey. , 2023, 20, 147-179.		3
3379	Multi-omics analysis of the Indian ovarian cancer cohort revealed histotype-specific mutation and gene expression patterns. Frontiers in Genetics, 0, 14, .	1.1	0
3380	Downregulated KDM6A mediates gastric carcinogenesis via Wnt/Î²-catenin signaling pathway mediated epithelial-to-mesenchymal transition. Pathology Research and Practice, 2023, 245, 154461.	1.0	0
3381	Landscape of chromatin remodeling gene alterations in endometrial carcinoma. Gynecologic Oncology, 2023, 172, 54-64.	0.6	3
3382	Role of histone methylation in skin cancers: Histone methylationâ€“modifying enzymes as a new class of targets for skin cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188865.	3.3	6
3383	Activated Src kinases downstream of BCR-ABL and Flt3 induces proteasomal degradation of SHIP1 by phosphorylation of tyrosine 1021. Biochimica Et Biophysica Acta - Molecular Cell Research, 2023, 1870, 119467.	1.9	2
3384	Implementation of network embedding strategy on proteome datasets from multi-source cancers to demonstrate marker proteins of cancers. Australian Journal of Chemistry, 2023, , .	0.5	1

#	Article	IF	Citations
3385	Risk scoring based on DNA methylation-driven related DEGs for colorectal cancer prognosis with systematic insights. Life Sciences, 2023, 316, 121413.	2.0	3
3386	Phylogenetic analysis of the MCL1 BH3 binding groove and rBH3 sequence motifs in the p53 and INK4 protein families. PLoS ONE, 2023, 18, e0277726.	1.1	1
3387	Telomerase inhibition is an effective therapeutic strategy inTERTpromoter-mutant glioblastoma models with low tumor volume. Neuro-Oncology, 2023, 25, 1275-1285.	0.6	8
3388	Immune Checkpoint Inhibitors in Urological Cancers. , 2023, , 1-25.		0
3389	Searching for DNA methylation in patients triple-negative breast cancer: a liquid biopsy approach. Expert Review of Molecular Diagnostics, 2023, 23, 41-51.	1.5	1
3390	Transcriptome analysis reveals effects of leukemogenic SHP2 mutations in biosynthesis of amino acids signaling. Frontiers in Oncology, 0, 13, .	1.3	1
3391	Prognosis and personalized medicine prediction by integrated whole exome and transcriptome sequencing of hepatocellular carcinoma. Frontiers in Genetics, 0, 14, .	1.1	0
3392	Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS. Blood Advances, 2023, 7, 2952-2956.	2.5	7
3394	TIM-3 signaling hijacks the canonical Wnt/Î²-catenin pathway to maintain cancer stemness in acute myeloid leukemia. Blood Advances, 2023, 7, 2053-2065.	2.5	5
3395	Biological and Genetic Mechanisms of COPD, Its Diagnosis, Treatment, and Relationship with Lung Cancer. Biomedicines, 2023, 11, 448.	1.4	7
3396	Aberrant phase separation and nucleolar dysfunction in rare genetic diseases. Nature, 0, , .	13.7	9
3397	Utility of public knowledge bases for the interpretation of comprehensive tumor molecular profiling results. Clinical and Experimental Medicine, 0, , .	1.9	0
3398	Tissue specificity and spatio-temporal dynamics of the p53 transcriptional program. Cell Death and Differentiation, 2023, 30, 897-905.	5.0	4
3399	The Current Progress and Future Options of Multiple Therapy and Potential Biomarkers for Muscle-Invasive Bladder Cancer. Biomedicines, 2023, 11, 539.	1.4	2
3400	Revisiting the Role of the CXCL13/CXCR5-Associated Immune Axis in Melanoma: Potential Implications for Anti-PD-1-Related Biomarker Research. Life, 2023, 13, 553.	1.1	2
3401	Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer. British Journal of Cancer, 2023, 128, 1582-1591.	2.9	7
3402	Recurrent PIK3CA H1047R-Mutated Congenital Infiltrative Facial Lipomatosis: A Case Report and Review of Literature. Current Issues in Molecular Biology, 2023, 45, 1712-1719.	1.0	2
3403	Long noncoding RNA LINC01088 inhibits esophageal squamous cell carcinoma progression by targeting the NPM1-HDM2-p53 axis. Acta Biochimica Et Biophysica Sinica, 2023, , .	0.9	0

#	Article	IF	Citations
3404	Systems Biology Approaches for the Improvement of Oncolytic Virus-Based Immunotherapies. Cancers, 2023, 15, 1297.	1.7	4
3405	GraphLSurv: A scalable survival prediction network with adaptive and sparse structure learning for histopathological whole-slide images. Computer Methods and Programs in Biomedicine, 2023, 231, 107433.	2.6	1
3406	Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway). Frontiers in Oncology, 0, 13, .	1.3	0
3409	Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	62
3410	SpliceTools, a suite of downstream RNA splicing analysis tools to investigate mechanisms and impact of alternative splicing. Nucleic Acids Research, 2023, 51, e42-e42.	6.5	5
3411	Development and Experimental Validation of a Novel Prognostic Signature for Gastric Cancer. Cancers, 2023, 15, 1610.	1.7	0
3413	Cancer Biology. , 2023, , 1-30.		0
3414	Atypical histone targets of PHD fingers. Journal of Biological Chemistry, 2023, 299, 104601.	1.6	7
3415	The construction and analysis of a prognostic assessment model based on P53-related multi-genes in breast carcinoma. European Journal of Cancer Prevention, 0, Publish Ahead of Print, .	0.6	0
3416	Arsenic causing gallbladder cancer disease in Bihar. Scientific Reports, 2023, 13, .	1.6	6
3417	ITGB1-mediated molecular landscape and cuproptosis phenotype induced the worse prognosis in diffuse gastric cancer. Frontiers in Oncology, 0, 13, .	1.3	0
3418	Wild-type and mutant p53 in cancer-related ferroptosis. A matter of stress management?. Frontiers in Genetics, 0, 14, .	1.1	1
3419	Setd2 inactivation sensitizes lung adenocarcinoma to inhibitors of oxidative respiration and mTORC1 signaling. Communications Biology, 2023, 6, .	2.0	2
3422	Landscape of KRAS, BRAF, and PIK3CA Mutations and Clinical Features of EBV-Associated and Microsatellite Unstable Gastric Cancer. Molecular Biology, 2023, 57, 61-73.	0.4	1
3423	Crosstalk between triple negative breast cancer and microenvironment. Oncotarget, 2023, 14, 284-293.	0.8	2
3424	Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles. Journal of Nanobiotechnology, 2023, 21, .	4.2	4
3425	POP1 promotes the progression of breast cancer through maintaining telomere integrity. Carcinogenesis, 2023, 44, 252-262.	1.3	2
3426	Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties. Science Translational Medicine, 2023, 15, .	5.8	13

#	Article	IF	Citations
3427	Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication. Nature Communications, 2023, 14, .	5.8	5
3428	Sirtuin1-p53: A potential axis for cancer therapy. Biochemical Pharmacology, 2023, 212, 115543.	2.0	3
3429	TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia. Biomedicines, 2023, 11, 1152.	1.4	2
3430	Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis. Cell Death Discovery, 2023, 9, .	2.0	2
3431	Two assembly modes for SIN3 histone deacetylase complexes. Cell Discovery, 2023, 9, .	3.1	6
3432	Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies. Experimental Hematology, 2023, 122, 10-18.	0.2	1
3433	Structure of a SIN3â€“HDAC complex from budding yeast. Nature Structural and Molecular Biology, 2023, 30, 753-760.	3.6	9
3434	Identification of circulating tumour DNA (ctDNA) from the liquid biopsy results: Findings from an observational cohort study. Cancer Treatment and Research Communications, 2023, 35, 100701.	0.7	0
3470	Principles of Monoclonal and Small Molecular Targeting Agents for Pediatric Cancer Management. , 2023, , 1-19.		0
3495	Using Sister Chromatid Exchange Assay to Detect Homologous Recombination Deficiency in Epigenetically Deregulated Urothelial Carcinoma Cells. Methods in Molecular Biology, 2023, , 133-144.	0.4	0
3509	Review on Bladder Cancer Diagnosis. , 0, , .		0
3521	Evolutionary determinants of curability in cancer. Nature Ecology and Evolution, 0, , .	3.4	1
3528	Mechanistic insights into the dual role of CCAR2/DBC1 in cancer. Experimental and Molecular Medicine, 2023, 55, 1691-1701.	3.2	2
3540	Clonal evolution in leukemia: preleukemia, evolutionary models, and clinical implications. Genome Instability & Disease, 2023, 4, 227-238.	0.5	0
3541	LncRNA MALAT1 signaling pathway and clinical applications in overcome on cancers metastasis. Clinical and Experimental Medicine, 2023, 23, 4457-4472.	1.9	2
3582	Incidental detection of FGFR3 fusion via liquid biopsy leading to earlier diagnosis of urothelial carcinoma. Npj Precision Oncology, 2023, 7, .	2.3	0
3590	The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 0, , .	1.4	2
3599	Cancer stem cells and maintenance of tumor heterogeneity/microenvironment. , 2024, , 517-529.		0

#	Article	IF	Citations
3608	Case report: Squamous cell carcinoma of the prostate-a clinicopathological and genomic sequencing-based investigation. Pathology and Oncology Research, 0, 29, .	0.9	1
3614	Pharmacological reactivation of p53 in the era of precision anticancer medicine. Nature Reviews Clinical Oncology, 2024, 21, 106-120.	12.5	2
3616	P53, ROS: Redox Regulation Signaling, Metabolic Reprogramming, and Autophagy in Cancer. , 2023, , 237-268.		0
3649	SAMMS: Multi-modality Deep Learning with the Foundation Model for the Prediction of Cancer Patient Survival. , 2023, , .		0
3652	Hyper-graph learning and its applications for medical image analysis. , 2024, , 153-184.		0
3657	Metabolic alterations in hereditary and sporadic renal cell carcinoma. Nature Reviews Nephrology, 2024, 20, 233-250.	4.1	0
3672	Cellular signaling in glioblastoma: A molecular and clinical perspective. International Review of Cell and Molecular Biology, 2024, , .	1.6	0
3674	Safety Issues Related to Pluripotent Stem Cell-Based Therapies: Tumour Risk. , 2023, , 419-457.		0
3692	Cancer Precision Drug Discovery Using Big Data and Artificial Intelligence Technologies. , 2023, , 400-427.		0